[{"title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"3NEPvLll8SQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)42153-4/abstract","googleCitationCount":1011,"googleAuthor":""},{"title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"XE-ODN-GxesJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31710-7/abstract","googleCitationCount":606,"googleAuthor":""},{"title":"De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of …","googleId":"BTK0UF4IMiEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321817","googleCitationCount":662,"googleAuthor":"","doi":"10.1093/annonc/mdx308","elsevierAuthor":"Pelliccia C.","publicationName":"Virchows Archiv","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":["G Curigliano","H.J. Burstein","E.P. Winer","M. Gnant","P. Dubsky","S. Loibl","M. Colleoni","M.M. Regan","M. Piccart-Gebhart","H.-J. Senn","B. Thürlimann","F. André","J. Baselga","J. Bergh","H. Bonnefoi","S.Y. Brucker","F. Cardoso","L. Carey","E. Ciruelos","J. Cuzick","C. Denkert","A. Di Leo","B. Ejlertsen","P. Francis","V. Galimberti","J. Garber","B. Gulluoglu","P. Goodwin","N. Harbeck","D.F. Hayes","C.-S. Huang","J. Huober","H. Khaled","J. Jassem","Z. Jiang","P. Karlsson","M. Morrow","R. Orecchia","K.C. Osborne","O. Pagani","A.H. Partridge","K. Pritchard","J. Ro","E.J.T. Rutgers","F. Sedlmayer","V. Semiglazov","Z. Shao","I. Smith","M. Toi","A. Tutt","G. Viale","T. Watanabe","T.J. Whelan","B. Xu"],"twitterCount":100,"altmetricId":21261969},{"title":"4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4)","googleId":"OovdHxUh4f4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34113-4/abstract","googleCitationCount":639,"googleAuthor":"F Cardoso"},{"title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"GLg3ND5iWuAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)42150-9/abstract","googleCitationCount":596,"googleAuthor":"PE Postmus"},{"title":"Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"1Dai1BwvSmwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)42152-2/abstract","googleCitationCount":599,"googleAuthor":"R Glynne-Jones"},{"title":"Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 …","googleId":"iH4n8WCRI_gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341055","googleCitationCount":506,"googleAuthor":"","doi":"10.1093/annonc/mdy166","elsevierAuthor":"Haenssle H.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"323","altmetricAuthors":["H.A. Haenssle","C. Fink","R. Schneiderbauer","F. Toberer","T. Buhl","A. Blum","A. Kalloo","A. Ben Hadj Hassen","L. Thomas","A. Enk","L. Uhlmann","Christina Alt","Monika Arenbergerova","Renato Bakos","Anne Baltzer","Ines Bertlich","Andreas Blum","Therezia Bokor-Billmann","Jonathan Bowling","Naira Braghiroli","Ralph Braun","Kristina Buder-Bakhaya","Timo Buhl","Horacio Cabo","Leo Cabrijan","Naciye Cevic","Anna Classen","David Deltgen","Christine Fink","Ivelina Georgieva","Lara-Elena Hakim-Meibodi","Susanne Hanner","Franziska Hartmann","Julia Hartmann","Georg Haus","Elti Hoxha","Raimonds Karls","Hiroshi Koga","Jürgen Kreusch","Aimilios Lallas","Pawel Majenka","Ash Marghoob","Cesare Massone","Lali Mekokishvili","Dominik Mestel","Volker Meyer","Anna Neuberger","Kari Nielsen","Margaret Oliviero","Riccardo Pampena","John Paoli","Erika Pawlik","Barbar Rao","Adriana Rendon","Teresa Russo","Ahmed Sadek","Kinga Samhaber","Roland Schneiderbauer","Anissa Schweizer","Ferdinand Toberer","Lukas Trennheuser","Lyobomira Vlahova","Alexander Wald","Julia Winkler","Priscila Wölbing","Iris Zalaudek"],"twitterCount":744,"altmetricId":42877749},{"title":"Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"E_R-TgfQFuQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31692-8/abstract","googleCitationCount":346,"googleAuthor":""},{"title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR …","googleId":"V6aPgr8tkZwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321350","googleCitationCount":455,"googleAuthor":"B Lueza","doi":"10.1093/annonc/mdx175","elsevierAuthor":"Mineur L.","publicationName":"PLoS ONE","elsevierCoverDate":"2021-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"0","altmetricAuthors":["D. Arnold","B. Lueza","J.-Y. Douillard","M. Peeters","H.-J. Lenz","A. Venook","V. Heinemann","E. Van Cutsem","J.-P. Pignon","J. Tabernero","A. Cervantes","F. Ciardiello"],"twitterCount":14,"altmetricId":18763468},{"title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","googleId":"whLdzWN07sUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324317","googleCitationCount":403,"googleAuthor":"P Lepage","doi":"10.1093/annonc/mdx108","elsevierAuthor":"Wang F.","publicationName":"Frontiers in Oncology","elsevierCoverDate":"2020-10-20","elsevierCoverDisplayDate":"20 October 2020","elsevierCitationCount":"0","altmetricAuthors":["N. Chaput","P. Lepage","C. Coutzac","E. Soularue","K. Le Roux","C. Monot","L. Boselli","E. Routier","L. Cassard","M. Collins","T. Vaysse","L. Marthey","A. Eggermont","V. Asvatourian","E. Lanoy","C. Mateus","C. Robert","F. Carbonnel"],"twitterCount":52,"altmetricId":18481829},{"title":"Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"oIQVuQDeP1EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31711-9/abstract","googleCitationCount":237,"googleAuthor":"A Vogel"},{"title":"Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer","googleId":"rPeA_3if0MYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348938","googleCitationCount":283,"googleAuthor":"L Derosa","doi":"10.1093/annonc/mdy103","elsevierAuthor":"Derosa L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"214","altmetricAuthors":["L. Derosa","M.D. Hellmann","M. Spaziano","D. Halpenny","M. Fidelle","H. Rizvi","N. Long","A.J. Plodkowski","K.C. Arbour","J.E. Chaft","J.A. Rouche","L. Zitvogel","G. Zalcman","L. Albiges","B. Escudier","B. Routy"],"twitterCount":93,"altmetricId":35016882},{"title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety …","googleId":"dfrhxNec43MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322707","googleCitationCount":369,"googleAuthor":"GV Long","doi":"10.1093/annonc/mdx176","elsevierAuthor":"Granados K.","publicationName":"International Journal of Molecular Sciences","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"1 November 2020","elsevierCitationCount":"1","altmetricAuthors":["G.V. Long","K.T. Flaherty","D. Stroyakovskiy","H. Gogas","E. Levchenko","F. de Braud","J. Larkin","C. Garbe","T. Jouary","A. Hauschild","V. Chiarion-Sileni","C. Lebbe","M. Mandalà","M. Millward","A. Arance","I. Bondarenko","J.B.A.G. Haanen","J. Hansson","J. Utikal","V. Ferraresi","P. Mohr","V. Probachai","D. Schadendorf","P. Nathan","C. Robert","A. Ribas","M.A. Davies","S.R. Lane","J.J. Legos","B. Mookerjee","J.-J. Grob"],"twitterCount":24,"altmetricId":19981217},{"title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"973T08Eu4qYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)42145-5/abstract","googleCitationCount":518,"googleAuthor":"P Moreau"},{"title":"Comprehensive analysis of the clinical immuno-oncology landscape","googleId":"JMxuRntBcUIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350203","googleCitationCount":301,"googleAuthor":"J Tang","doi":"10.1093/annonc/mdx755","elsevierAuthor":"Tang J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"212","altmetricAuthors":["J. Tang","A. Shalabi","V.M. Hubbard-Lucey"],"twitterCount":390,"altmetricId":30115438},{"title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","googleId":"s_s_PGmenvcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321933","googleCitationCount":468,"googleAuthor":"AM Menzies","doi":"10.1093/annonc/mdw443","elsevierAuthor":"Menzies A.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"348","altmetricAuthors":["A.M. Menzies","D.B. Johnson","S. Ramanujam","V.G. Atkinson","A.N.M. Wong","J.J. Park","J.L. McQuade","A.N. Shoushtari","K.K. Tsai","Z. Eroglu","O. Klein","J.C. Hassel","J.A. Sosman","A. Guminski","R.J. Sullivan","A. Ribas","M.S. Carlino","M.A. Davies","S.K. Sandhu","G.V. Long"],"twitterCount":33,"altmetricId":12298245},{"title":"Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma","googleId":"kSUFFxCzMCUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322720","googleCitationCount":303,"googleAuthor":"","doi":"10.1093/annonc/mdx178","elsevierAuthor":"Perlstein D.","publicationName":"PLoS ONE","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"5","altmetricAuthors":["E. Saâda-Bouzid","C. Defaucheux","A. Karabajakian","V.P. Coloma","V. Servois","X. Paoletti","C. Even","J. Fayette","J. Guigay","D. Loirat","F. Peyrade","M. Alt","J. Gal","C. Le Tourneau"],"twitterCount":50,"altmetricId":18814625},{"title":"Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"RmK6BhSdorEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)42148-0/abstract","googleCitationCount":287,"googleAuthor":"S Mahner"},{"title":"Tumour-and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","googleId":"lpwU8nhhn9QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349269","googleCitationCount":268,"googleAuthor":"LL Siu","doi":"10.1093/annonc/mdx286","elsevierAuthor":"Khoja L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"197","altmetricAuthors":["L. Khoja","D. Day","T. Wei-Wu Chen","L.L. Siu","A.R. Hansen"],"twitterCount":105,"altmetricId":23508315},{"title":"Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial","googleId":"Nn_pEWNVQQwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322227","googleCitationCount":286,"googleAuthor":"EH Tan","doi":"10.1093/annonc/mdw611","elsevierAuthor":"Paz-Ares L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"222","altmetricAuthors":["L. Paz-Ares","E.-H. Tan","K. O’Byrne","L. Zhang","V. Hirsh","M. Boyer","J.C.-H. Yang","T. Mok","K.H. Lee","S. Lu","Y. Shi","D.H. Lee","J. Laskin","D.-W. Kim","S.A. Laurie","K. Kölbeck","J. Fan","N. Dodd","A. Märten","K. Park"],"twitterCount":64,"altmetricId":16241360},{"title":"Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes …","googleId":"HVMLQS5nSUsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454859","googleCitationCount":229,"googleAuthor":"L Horn","doi":"10.1093/annonc/mdy041","elsevierAuthor":"Vokes E.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"180","altmetricAuthors":["E.E. Vokes","N. Ready","E. Felip","L. Horn","M.A. Burgio","S.J. Antonia","O. Arén Frontera","S. Gettinger","E. Holgado","D. Spigel","D. Waterhouse","M. Domine","M. Garassino","L.Q.M. Chow","G. Blumenschein","F. Barlesi","B. Coudert","J. Gainor","O. Arrieta","J. Brahmer","C. Butts","M. Steins","W.J. Geese","A. Li","D. Healey","L. Crinò"],"twitterCount":55,"altmetricId":32647455},{"title":"ESMO-magnitude of clinical benefit scale version 1.1","googleId":"jIFgK4FbpqoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349324","googleCitationCount":259,"googleAuthor":"NI Cherny","doi":"10.1093/annonc/mdx310","elsevierAuthor":"Cherny N.I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"174","altmetricAuthors":["N.I. Cherny","U. Dafni","J. Bogaerts","N.J. Latino","G. Pentheroudakis","J.-Y. Douillard","J. Tabernero","C. Zielinski","M.J. Piccart","E.G.E. de Vries"],"twitterCount":56,"altmetricId":24615945},{"title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2 …","googleId":"KUsvv8xkoKIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321052","googleCitationCount":240,"googleAuthor":"SM Stemmer","doi":"10.1093/annonc/mdy155","elsevierAuthor":"Ribelles N.","publicationName":"European Journal of Cancer","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0","altmetricAuthors":["G.N. Hortobagyi","S.M. Stemmer","H.A. Burris","Y.S. Yap","G.S. Sonke","S. Paluch-Shimon","M. Campone","K. Petrakova","K.L. Blackwell","E.P. Winer","W. Janni","S. Verma","P. Conte","C.L. Arteaga","D.A. Cameron","S. Mondal","F. Su","M. Miller","M. Elmeliegy","C. Germa","J. O’Shaughnessy"],"twitterCount":83,"altmetricId":39386777},{"title":"Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro …","googleId":"xgZdBbeTMhwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341936","googleCitationCount":187,"googleAuthor":"KW Lee","doi":"10.1093/annonc/mdy264","elsevierAuthor":"Bang Y.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"138","altmetricAuthors":["Y.-J Bang","E.Yañez Ruiz","E. Van Cutsem","K.-W Lee","L. Wyrwicz","M. Schenker","M. Alsina","M.-H Ryu","H.-C Chung","L. Evesque","S.-E Al-Batran","S.H. Park","M. Lichinitser","N. Boku","M.H. Moehler","J. Hong","H. Xiong","R. Hallwachs","I. Conti","J. Taieb"],"twitterCount":72,"altmetricId":45508230},{"title":"Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"pNNlJJvhfpgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31691-6/abstract","googleCitationCount":220,"googleAuthor":""},{"title":"Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by …","googleId":"n1aDxA3wLe8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350173","googleCitationCount":198,"googleAuthor":"G Pentheroudakis","doi":"10.1093/annonc/mdx738","elsevierAuthor":"Yoshino T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"154","altmetricAuthors":["T. Yoshino","D. Arnold","H. Taniguchi","G. Pentheroudakis","K. Yamazaki","R.-H. Xu","T.W. Kim","F. Ismail","I.B. Tan","K.-H. Yeh","A. Grothey","S. Zhang","J.B. Ahn","M.Y. Mastura","D. Chong","L.-T. Chen","S. Kopetz","T. Eguchi-Nakajima","H. Ebi","A. Ohtsu","A. Cervantes","K. Muro","J. Tabernero","H. Minami","F. Ciardiello","J.-Y. Douillard"],"twitterCount":37,"altmetricId":29047821},{"title":"Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology","googleId":"-9AxJsn5Uh0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324123","googleCitationCount":232,"googleAuthor":"EJ Limkin","doi":"10.1093/annonc/mdx034","elsevierAuthor":"Noortman W.A.","publicationName":"PLoS ONE","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"0","altmetricAuthors":["E.J. Limkin","R. Sun","L. Dercle","E.I. Zacharaki","C. Robert","S. Reuzé","A. Schernberg","N. Paragios","E. Deutsch","C. Ferté"],"twitterCount":21,"altmetricId":16196737},{"title":"Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"VWEZuMEIBLoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31712-0/abstract","googleCitationCount":154,"googleAuthor":""},{"title":"Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines","googleId":"GCroUoe4INgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31698-9/abstract","googleCitationCount":220,"googleAuthor":"R Giusti"},{"title":"Selective RET kinase inhibition for patients with RET-altered cancers","googleId":"BK7Pn-ZJLqwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341043","googleCitationCount":153,"googleAuthor":"V Subbiah","doi":"10.1093/annonc/mdy137","elsevierAuthor":"Subbiah V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"114","altmetricAuthors":["V. Subbiah","V. Velcheti","B.B. Tuch","K. Ebata","N.L. Busaidy","M.E. Cabanillas","L.J. Wirth","S. Stock","S. Smith","V. Lauriault","S. Corsi-Travali","D. Henry","M. Burkard","R. Hamor","K. Bouhana","S. Winski","R.D. Wallace","D. Hartley","S. Rhodes","M. Reddy","B.J. Brandhuber","S. Andrews","S.M. Rothenberg","A. Drilon"],"twitterCount":158,"altmetricId":37998552},{"title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","googleId":"4OIdLzBp2PYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319593","googleCitationCount":278,"googleAuthor":"JC Osorio","doi":"10.1093/annonc/mdw640","elsevierAuthor":"Osorio J.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"221","altmetricAuthors":["J.C. Osorio","A. Ni","J.E. Chaft","R. Pollina","M.K. Kasler","D. Stephens","C. Rodriguez","L. Cambridge","H. Rizvi","J.D. Wolchok","T. Merghoub","C.M. Rudin","S. Fish","M.D. Hellmann"],"twitterCount":34,"altmetricId":14927389},{"title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"UEw7iOVaJsIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)42147-9/abstract","googleCitationCount":192,"googleAuthor":""},{"title":"European cancer mortality predictions for the year 2017, with focus on lung cancer","googleId":"hhQuz1hvJhoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320125","googleCitationCount":201,"googleAuthor":"M Malvezzi","doi":"10.1093/annonc/mdx033","elsevierAuthor":"Zhou J.","publicationName":"Bioscience Reports","elsevierCoverDate":"2019-08-02","elsevierCoverDisplayDate":"2 August 2019","elsevierCitationCount":"12","altmetricAuthors":["M. Malvezzi","G. Carioli","P. Bertuccio","P. Boffetta","F. Levi","C. La Vecchia","E. Negri"],"twitterCount":274,"altmetricId":17781670},{"title":"High prevalence of mutantKRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients","googleId":"n0kEd1gUlI8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320691","googleCitationCount":212,"googleAuthor":"FA San Lucas","doi":"10.1093/annonc/mdx004","elsevierAuthor":"Pofali P.","publicationName":"Current Cancer Drug Targets","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"2","altmetricAuthors":["K. Allenson","J. Castillo","F.A. San Lucas","G. Scelo","D.U. Kim","V. Bernard","G. Davis","T. Kumar","M. Katz","M.J. Overman","L. Foretova","E. Fabianova","I. Holcatova","V. Janout","F. Meric-Bernstam","P. Gascoyne","I. Wistuba","G. Varadhachary","P. Brennan","S. Hanash","D. Li","A. Maitra","H. Alvarez"],"twitterCount":49,"altmetricId":15586791},{"title":"Foods and beverages and colorectal cancer risk: a systematic review and meta-analysis of cohort studies, an update of the evidence of the WCRF-AICR …","googleId":"b9rdYFR6Z1cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321337","googleCitationCount":193,"googleAuthor":"L Abar","doi":"10.1093/annonc/mdx171","elsevierAuthor":"Nimptsch K.","publicationName":"British Journal of Cancer","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":["A.R. Vieira","L. Abar","D.S.M. Chan","S. Vingeliene","E. Polemiti","C. Stevens","D. Greenwood","T. Norat"],"twitterCount":30,"altmetricId":18789349},{"title":"Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study","googleId":"mCTvC-S32QoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50454-9/abstract","googleCitationCount":145,"googleAuthor":""},{"title":"Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors","googleId":"BtloFdMWIG8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316692","googleCitationCount":161,"googleAuthor":"CM Lovly","doi":"10.1093/annonc/mdx703","elsevierAuthor":"Westover D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"124","altmetricAuthors":[],"twitterCount":0},{"title":"Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"7JMTnEptucgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31690-4/abstract","googleCitationCount":136,"googleAuthor":""},{"title":"Glioblastoma targeted therapy: updated approaches from recent biological insights","googleId":"SYyIipepKswJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322483","googleCitationCount":176,"googleAuthor":"M Touat","doi":"10.1093/annonc/mdx106","elsevierAuthor":"Mishinov S.V.","publicationName":"Sovremennye Tehnologii v Medicine","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":["M. Touat","A. Idbaih","M. Sanson","K.L. Ligon"],"twitterCount":26,"altmetricId":21068513},{"title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","googleId":"CWHiydiOzTkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345326","googleCitationCount":153,"googleAuthor":"MK McConechy","doi":"10.1093/annonc/mdy058","elsevierAuthor":"Kommoss S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"103","altmetricAuthors":["S. Kommoss","M.K. McConechy","F. Kommoss","S. Leung","A. Bunz","J. Magrill","H. Britton","F. Kommoss","F. Grevenkamp","A. Karnezis","W. Yang","A. Lum","B. Krämer","F. Taran","A. Staebler","S. Lax","S.Y. Brucker","D.G. Huntsman","C.B. Gilks","J.N. McAlpine","A. Talhouk."],"twitterCount":10,"altmetricId":32815487},{"title":"ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up","googleId":"Z5_4ivDLP68J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934133X","googleCitationCount":120,"googleAuthor":"D Berney","doi":"10.1093/annonc/mdy217","elsevierAuthor":"Honecker F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"83","altmetricAuthors":["F. Honecker","J. Aparicio","D. Berney","J. Beyer","C. Bokemeyer","R. Cathomas","N. Clarke","G. Cohn-Cedermark","G. Daugaard","K.-P. Dieckmann","K. Fizazi","S. Fosså","J.R. Germa-Lluch","P. Giannatempo","J.A. Gietema","S. Gillessen","H.S. Haugnes","A. Heidenreich","K. Hemminki","R. Huddart","M.A.S. Jewett","F. Joly","J. Lauritsen","A. Lorch","A. Necchi","N. Nicolai","C. Oing","J. Oldenburg","D. Ondruš","A. Papachristofilou","T. Powles","A. Sohaib","O. Ståhl","T. Tandstad","G. Toner","A. Horwich"],"twitterCount":54,"altmetricId":45994890},{"title":"Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study","googleId":"Z2g9gYxJEgoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341468","googleCitationCount":131,"googleAuthor":"AR Hansen","doi":"10.1093/annonc/mdy232","elsevierAuthor":"Hansen A.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"92","altmetricAuthors":["A.R. Hansen","C. Massard","P.A. Ott","N.B. Haas","J.S. Lopez","S. Ejadi","J.M. Wallmark","B. Keam","J.-P. Delord","R. Aggarwal","M. Gould","P. Yang","S.M. Keefe","S.A. Piha-Paul"],"twitterCount":42,"altmetricId":44741209},{"title":"European cancer mortality predictions for the year 2018 with focus on colorectal cancer","googleId":"9X7u_Z26O6QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341945477X","googleCitationCount":138,"googleAuthor":"M Malvezzi","doi":"10.1093/annonc/mdy033","elsevierAuthor":"Malvezzi M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"90","altmetricAuthors":["M. Malvezzi","G. Carioli","P. Bertuccio","P. Boffetta","F. Levi","C. La Vecchia","E. Negri"],"twitterCount":158,"altmetricId":34495957},{"title":"Human papillomavirus-related oropharyngeal cancer","googleId":"4V7Cy1WI_lUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349300","googleCitationCount":165,"googleAuthor":"M Mena","doi":"10.1093/annonc/mdx304","elsevierAuthor":"Taberna M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"109","altmetricAuthors":["M. Taberna","M. Mena","M.A. Pavón","L. Alemany","M.L. Gillison","R. Mesía"],"twitterCount":20,"altmetricId":21191230},{"title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","googleId":"rGRTXs2Y9gIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934997X","googleCitationCount":156,"googleAuthor":"A Betof","doi":"10.1093/annonc/mdx642","elsevierAuthor":"Pollack M.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"130","altmetricAuthors":["M.H. Pollack","A. Betof","H. Dearden","K. Rapazzo","I. Valentine","A.S. Brohl","K.K. Ancell","G.V. Long","A.M. Menzies","Z. Eroglu","D.B. Johnson","A.N. Shoushtari"],"twitterCount":46,"altmetricId":27511607},{"title":"Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma","googleId":"VhPcvkOL7Q8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320058","googleCitationCount":167,"googleAuthor":"JH Lee","doi":"10.1093/annonc/mdx026","elsevierAuthor":"Strudel M.","publicationName":"Current Medicinal Chemistry","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":["J.H. Lee","G.V. Long","S. Boyd","S. Lo","A.M. Menzies","V. Tembe","A. Guminski","V. Jakrot","R.A. Scolyer","G.J. Mann","R.F. Kefford","M.S. Carlino","H. Rizos"],"twitterCount":81,"altmetricId":15743618},{"title":"Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board","googleId":"whg1ImT-CS8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350720","googleCitationCount":138,"googleAuthor":"","doi":"10.1093/annonc/mdx781","elsevierAuthor":"Somashekhar S.P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"89","altmetricAuthors":["S.P. Somashekhar","M.-J. Sepúlveda","S. Puglielli","A.D. Norden","E.H. Shortliffe","C. Rohit Kumar","A. Rauthan","N. Arun Kumar","P. Patil","K. Rhee","Y. Ramya"],"twitterCount":132,"altmetricId":31502934},{"title":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage …","googleId":"CKBbpFfqB9MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345417","googleCitationCount":127,"googleAuthor":"MR Sydes","doi":"10.1093/annonc/mdy072","elsevierAuthor":"Sydes M.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"91","altmetricAuthors":["M.R. Sydes","M.R. Spears","M.D. Mason","N.W. Clarke","D.P. Dearnaley","J.S. de Bono","G. Attard","S. Chowdhury","W. Cross","S. Gillessen","Z.I. Malik","R. Jones","C.C. Parker","A.W.S. Ritchie","J.M. Russell","R. Millman","D. Matheson","C. Amos","C. Gilson","A. Birtle","S. Brock","L. Capaldi","P. Chakraborti","A. Choudhury","L. Evans","D. Ford","J. Gale","S. Gibbs","D.C. Gilbert","R. Hughes","D. McLaren","J.F. Lester","A. Nikapota","J. O’Sullivan","O. Parikh","C. Peedell","A. Protheroe","S.M. Rudman","R. Shaffer","D. Sheehan","M. Simms","N. Srihari","R. Strebel","S. Sundar","S. Tolan","D. Tsang","M. Varughese","J. Wagstaff","M.K.B. Parmar","N.D. James"],"twitterCount":138,"altmetricId":33684368},{"title":"KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)","googleId":"8lloK8EpRN8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50436-7/abstract","googleCitationCount":117,"googleAuthor":"R Greil"},{"title":"Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients","googleId":"9t2ppcGDgfsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321386","googleCitationCount":149,"googleAuthor":"JL Perez-Gracia","doi":"10.1093/annonc/mdx190","elsevierAuthor":"Yang H.j.","publicationName":"Molecular Genetics and Genomic Medicine","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"1 June 2020","elsevierCitationCount":"2","altmetricAuthors":["M.F. Sanmamed","J.L. Perez-Gracia","K.A. Schalper","J.P. Fusco","A. Gonzalez","M.E. Rodriguez-Ruiz","C. Oñate","G. Perez","C. Alfaro","S. Martín-Algarra","M.P. Andueza","A. Gurpide","M. Morgado","J. Wang","A. Bacchiocchi","R. Halaban","H. Kluger","L. Chen","M. Sznol","I. Melero"],"twitterCount":35,"altmetricId":20912137},{"title":"An update on the management of sporadic desmoid-type fibromatosis: a European consensus initiative between Sarcoma Patients EuroNet (SPAEN) and …","googleId":"bz1ZHAiiHV4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934935X","googleCitationCount":146,"googleAuthor":"J Garcia","doi":"10.1093/annonc/mdx323","elsevierAuthor":"Kasper B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"102","altmetricAuthors":["B. Kasper","C. Baumgarten","J. Garcia","S. Bonvalot","R. Haas","F. Haller","P. Hohenberger","N. Penel","C. Messiou","W.T. van der Graaf","A. Gronchi","S. Bauer","J.Y. Blay","F. van Coevorden","P. Dileo","H.R. Dürr","M. Fiore","V. Grünwald","R. Jones","I. Judson","C. Kettelhack","K. Kopeckova","A. Lazar","L.H. Lindner","J. Martin-Broto","P. Rutkowski","S. Stacchiotti","E. Stoeckle","C. Valverde","K. Verhoef","E. Wardelmann","M. Wartenberg"],"twitterCount":22,"altmetricId":26882622},{"title":"Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients","googleId":"ZgSR3-cC5XQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320101","googleCitationCount":157,"googleAuthor":"AR Mato","doi":"10.1093/annonc/mdx031","elsevierAuthor":"Rogers B.B.","publicationName":"Clinical Journal of Oncology Nursing","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"0","altmetricAuthors":["A.R. Mato","B.T. Hill","N. Lamanna","P.M. Barr","C.S. Ujjani","D.M. Brander","C. Howlett","A.P. Skarbnik","B.D. Cheson","C.S. Zent","J.J. Pu","P. Kiselev","K. Foon","J. Lenhart","S. Henick Bachow","A.M. Winter","A.-L. Cruz","D.F. Claxton","A. Goy","C. Daniel","K. Isaac","K.H. Kennard","C. Timlin","M. Fanning","L. Gashonia","M. Yacur","J. Svoboda","S.J. Schuster","C. Nabhan"],"twitterCount":4,"altmetricId":16811438},{"title":"Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis","googleId":"2orw7pHP3CsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320988","googleCitationCount":115,"googleAuthor":"M Bruzzone","doi":"10.1093/annonc/mdy127","elsevierAuthor":"Poggio F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"81","altmetricAuthors":["F. Poggio","M. Bruzzone","M. Ceppi","N.F. Pondé","G. La Valle","L. Del Mastro","E. de Azambuja","M. Lambertini"],"twitterCount":121,"altmetricId":43356739},{"title":"Mechanisms regulating T-cell infiltration and activity in solid tumors","googleId":"s_m2z9sXZAsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419541473","googleCitationCount":138,"googleAuthor":"M Irving","doi":"10.1093/annonc/mdx238","elsevierAuthor":"Lanitis E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"105","altmetricAuthors":["E. Lanitis","D. Dangaj","M. Irving","G. Coukos"],"twitterCount":98,"altmetricId":27639497},{"title":"BET inhibitors: a novel epigenetic approach","googleId":"5AB-EvjYCFQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321313","googleCitationCount":140,"googleAuthor":"DB Doroshow","doi":"10.1093/annonc/mdx157","elsevierAuthor":"Frame S.","publicationName":"PLoS ONE","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"2","altmetricAuthors":["D.B. Doroshow","J.P. Eder","P.M. LoRusso"],"twitterCount":13,"altmetricId":22281514},{"title":"RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer","googleId":"M20N-uY9ucwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345569","googleCitationCount":117,"googleAuthor":"S Gutiérrez-Enríquez","doi":"10.1093/annonc/mdy099","elsevierAuthor":"Cruz C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"84","altmetricAuthors":["C. Cruz","M. Castroviejo-Bermejo","S. Gutiérrez-Enríquez","A. Llop-Guevara","Y.H. Ibrahim","A. Gris-Oliver","S. Bonache","B. Morancho","A. Bruna","O.M. Rueda","Z. Lai","U.M. Polanska","G.N. Jones","P. Kristel","L. de Bustos","M. Guzman","O. Rodríguez","J. Grueso","G. Montalban","G. Caratú","F. Mancuso","R. Fasani","J. Jiménez","W.J. Howat","B. Dougherty","A. Vivancos","P. Nuciforo","X. Serres-Créixams","I.T. Rubio","A. Oaknin","E. Cadogan","J.C. Barrett","C. Caldas","J. Baselga","C. Saura","J. Cortés","J. Arribas","J. Jonkers","O. Díez","M.J. O’Connor","J. Balmaña","V. Serra"],"twitterCount":44,"altmetricId":35366205},{"title":"Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy","googleId":"TcW2JC9xwwsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350069","googleCitationCount":137,"googleAuthor":"V Lemaire","doi":"10.1093/annonc/mdx686","elsevierAuthor":"Rotte A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"89","altmetricAuthors":["A. Rotte","J.Y. Jin","V. Lemaire"],"twitterCount":13,"altmetricId":27879820},{"title":"Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi …","googleId":"W4Svblm1hmAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322550","googleCitationCount":154,"googleAuthor":"","doi":"10.1093/annonc/mdx155","elsevierAuthor":"Conteduca V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-07-01","elsevierCoverDisplayDate":"July 2017","elsevierCitationCount":"118","altmetricAuthors":["V. Conteduca","D. Wetterskog","M.T.A. Sharabiani","E. Grande","M.P. Fernandez-Perez","A. Jayaram","S. Salvi","D. Castellano","A. Romanel","C. Lolli","V. Casadio","G. Gurioli","D. Amadori","A. Font","S. Vazquez-Estevez","A. González del Alba","B. Mellado","O. Fernandez-Calvo","M.J. Méndez-Vidal","M.A. Climent","I. Duran","E. Gallardo","A. Rodriguez","C. Santander","M.I. Sáez","J. Puente","D. Gasi Tandefelt","A. Wingate","D. Dearnaley","F. Demichelis","U. De Giorgi","E. Gonzalez-Billalabeitia","G. Attard"],"twitterCount":57,"altmetricId":19840937},{"title":"Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX …","googleId":"jmz885CC1e8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318848","googleCitationCount":105,"googleAuthor":"S Peters","doi":"10.1093/annonc/mdy405","elsevierAuthor":"Gadgeel S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"83","altmetricAuthors":["S. Gadgeel","S. Peters","T. Mok","A.T. Shaw","D.W. Kim","S.I. Ou","M. Pérol","A. Wrona","S. Novello","R. Rosell","A. Zeaiter","T. Liu","E. Nüesch","B. Balas","D.R. Camidge"],"twitterCount":50,"altmetricId":48197357},{"title":"Surgical resection versus watchful waiting in low-grade gliomas","googleId":"rkQkqgAfhtMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321611","googleCitationCount":143,"googleAuthor":"AS Jakola","doi":"10.1093/annonc/mdx230","elsevierAuthor":"Mato D.","publicationName":"Neurosurgery","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"1 February 2021","elsevierCitationCount":"0","altmetricAuthors":["A.S. Jakola","A.J. Skjulsvik","K.S. Myrmel","K. Sjåvik","G. Unsgård","S.H. Torp","K. Aaberg","T. Berg","H.Y. Dai","K. Johnsen","R. Kloster","O. Solheim"],"twitterCount":20,"altmetricId":19952597},{"title":"Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients","googleId":"Oew1KAYCj8oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324445","googleCitationCount":150,"googleAuthor":"J Vidal","doi":"10.1093/annonc/mdx125","elsevierAuthor":"Zou D.","publicationName":"Carcinogenesis","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"1 November 2020","elsevierCitationCount":"0","altmetricAuthors":["J. Vidal","L. Muinelo","A. Dalmases","F. Jones","D. Edelstein","M. Iglesias","M. Orrillo","A. Abalo","C. Rodríguez","E. Brozos","Y. Vidal","S. Candamio","F. Vázquez","J. Ruiz","M. Guix","L. Visa","V. Sikri","J. Albanell","B. Bellosillo","R. López","C. Montagut"],"twitterCount":19,"altmetricId":18789061},{"title":"Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature","googleId":"UT6vsWS8DcsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322069","googleCitationCount":146,"googleAuthor":"L Spain","doi":"10.1093/annonc/mdw558","elsevierAuthor":"Spain L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"108","altmetricAuthors":["L. Spain","G. Walls","M. Julve","K. O’Meara","T. Schmid","E. Kalaitzaki","S. Turajlic","M. Gore","J. Rees","J. Larkin"],"twitterCount":6,"altmetricId":13061338},{"title":"Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease …","googleId":"KopIl4fMbmUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322756","googleCitationCount":143,"googleAuthor":"","doi":"10.1093/annonc/mdx183","elsevierAuthor":"Haratani K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-07-01","elsevierCoverDisplayDate":"July 2017","elsevierCitationCount":"118","altmetricAuthors":["K. Haratani","H. Hayashi","T. Tanaka","H. Kaneda","Y. Togashi","K. Sakai","K. Hayashi","S. Tomida","Y. Chiba","K. Yonesaka","Y. Nonagase","T. Takahama","J. Tanizaki","K. Tanaka","T. Yoshida","K. Tanimura","M. Takeda","H. Yoshioka","T. Ishida","T. Mitsudomi","K. Nishio","K. Nakagawa"],"twitterCount":14,"altmetricId":18812306},{"title":"Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program","googleId":"y3PaGTiJQdIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350379","googleCitationCount":129,"googleAuthor":"F Cardoso","doi":"10.1093/annonc/mdx651","elsevierAuthor":"Cardoso F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"91","altmetricAuthors":["F. Cardoso","J.M.S. Bartlett","L. Slaets","C.H.M. van Deurzen","E. van Leeuwen-Stok","P. Porter","B. Linderholm","I. Hedenfalk","C. Schröder","J. Martens","J. Bayani","C. van Asperen","M. Murray","C. Hudis","L. Middleton","J. Vermeij","K. Punie","J. Fraser","M. Nowaczyk","I.T. Rubio","S. Aebi","C. Kelly","K.J. Ruddy","E. Winer","C. Nilsson","L. Dal Lago","L. Korde","K. Benstead","O. Bogler","T. Goulioti","A. Peric","S. Litière","K.C. Aalders","C. Poncet","K. Tryfonidis","S.H. Giordano"],"twitterCount":12,"altmetricId":28052076},{"title":"Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer","googleId":"WqKlO74zAvMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454641","googleCitationCount":123,"googleAuthor":"","doi":"10.1093/annonc/mdy014","elsevierAuthor":"Adam J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"107","altmetricAuthors":["J. Adam","N. Le Stang","I. Rouquette","A. Cazes","C. Badoual","H. Pinot-Roussel","L. Tixier","C. Danel","F. Damiola","D. Damotte","F. Penault-Llorca","S. Lantuéjoul"],"twitterCount":31,"altmetricId":31801996},{"title":"Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer","googleId":"bME61RUdIk4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354985","googleCitationCount":129,"googleAuthor":"","doi":"10.1093/annonc/mdx784","elsevierAuthor":"Condorelli R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"102","altmetricAuthors":["R. Condorelli","L. Spring","J. O’Shaughnessy","L. Lacroix","C. Bailleux","V. Scott","J. Dubois","R.J. Nagy","R.B. Lanman","A.J. Iafrate","F. Andre","A. Bardia"],"twitterCount":27,"altmetricId":30299072},{"title":"Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial","googleId":"nxKUezNOicQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320733","googleCitationCount":142,"googleAuthor":"NB Leighl","doi":"10.1093/annonc/mdx008","elsevierAuthor":"Song P.","publicationName":"Thoracic Cancer","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"1 September 2020","elsevierCitationCount":"1","altmetricAuthors":["R. Hui","E.B. Garon","J.W. Goldman","N.B. Leighl","M.D. Hellmann","A. Patnaik","L. Gandhi","J.P. Eder","M.-J. Ahn","L. Horn","E. Felip","E. Carcereny","R. Rangwala","G.M. Lubiniecki","J. Zhang","K. Emancipator","C. Roach","N.A. Rizvi"],"twitterCount":36,"altmetricId":16250897},{"title":"Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines","googleId":"Rq1p5-uN4eMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31688-6/abstract","googleCitationCount":99,"googleAuthor":"M Dicato"},{"title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"AaYqT9WkkDUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)42151-0/abstract","googleCitationCount":134,"googleAuthor":"M Dreyling"},{"title":"Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma","googleId":"U9Hmo_iY_D8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352482","googleCitationCount":135,"googleAuthor":"M Dreyling","doi":"10.1093/annonc/mdx289","elsevierAuthor":"Dreyling M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"107","altmetricAuthors":["M. Dreyling","F. Morschhauser","K. Bouabdallah","D. Bron","D. Cunningham","S.E. Assouline","G. Verhoef","K. Linton","C. Thieblemont","U. Vitolo","F. Hiemeyer","M. Giurescu","J. Garcia-Vargas","I. Gorbatchevsky","L. Liu","K. Koechert","C. Peña","M. Neves","B.H. Childs","P.L. Zinzani"],"twitterCount":2,"altmetricId":25004009},{"title":"Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR …","googleId":"DYKqcjdUTUwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349014","googleCitationCount":116,"googleAuthor":"J Mazières","doi":"10.1093/annonc/mdy121","elsevierAuthor":"Griesinger F.","publicationName":"Oncotarget","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"1 October 2018","elsevierCitationCount":"6","altmetricAuthors":["S. Novello","J. Mazières","I.-J. Oh","J. de Castro","M.R. Migliorino","Å. Helland","R. Dziadziuszko","F. Griesinger","A. Kotb","A. Zeaiter","A. Cardona","B. Balas","H.K. Johannsdottir","A. Das-Gupta","J. Wolf"],"twitterCount":63,"altmetricId":37135325},{"title":"Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic …","googleId":"NR80ytPApcMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341341","googleCitationCount":104,"googleAuthor":"TR Cottrell","doi":"10.1093/annonc/mdy218","elsevierAuthor":"Cottrell T.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"74","altmetricAuthors":["T.R. Cottrell","E.D. Thompson","P.M. Forde","J.E. Stein","A.S. Duffield","V. Anagnostou","N. Rekhtman","R.A. Anders","J.D. Cuda","P.B. Illei","E. Gabrielson","F.B. Askin","N. Niknafs","K.N. Smith","M.J. Velez","J.L. Sauter","J.M. Isbell","D.R. Jones","R.J. Battafarano","S.C. Yang","L. Danilova","J.D. Wolchok","S.L. Topalian","V.E. Velculescu","D.M. Pardoll","J.R. Brahmer","M.D. Hellmann","J.E. Chaft","A. Cimino-Mathews","J.M. Taube"],"twitterCount":88,"altmetricId":44717108},{"title":"Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study","googleId":"sZmT8SYUz0sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321532","googleCitationCount":127,"googleAuthor":"L Cabel","doi":"10.1093/annonc/mdx212","elsevierAuthor":"Yang S.","publicationName":"Journal of Cellular Physiology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"1 February 2020","elsevierCitationCount":"25","altmetricAuthors":["L. Cabel","F. Riva","V. Servois","A. Livartowski","C. Daniel","A. Rampanou","O. Lantz","E. Romano","M. Milder","B. Buecher","S. Piperno-Neumann","V. Bernard","S. Baulande","I. Bieche","J.Y. Pierga","C. Proudhon","F.-C. Bidard"],"twitterCount":44,"altmetricId":19778420},{"title":"Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study","googleId":"sOhBQzXEP1cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349439","googleCitationCount":126,"googleAuthor":"J Larkin","doi":"10.1093/annonc/mdx339","elsevierAuthor":"Chapman P.B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"85","altmetricAuthors":["P.B. Chapman","C. Robert","J. Larkin","J.B. Haanen","A. Ribas","D. Hogg","O. Hamid","P.A. Ascierto","A. Testori","P.C. Lorigan","R. Dummer","J.A. Sosman","K.T. Flaherty","I. Chang","S. Coleman","I. Caro","A. Hauschild","G.A. McArthur"],"twitterCount":42,"altmetricId":23386285},{"title":"CheckMate 214: efficacy and safety of nivolumab+ ipilimumab (N+ I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC) …","googleId":"YwcXZMNYlHIJ","googleLink":"https://www.researchgate.net/profile/Toni_Choueiri/publication/320350214_LBA5CheckMate_214_Efficacy_and_safety_of_nivolumab_ipilimumab_NI_v_sunitinib_S_for_treatment-naive_advanced_or_metastatic_renal_cell_carcinoma_mRCC_including_IMDC_risk_and_PD-L1_expression_subgroups/links/5a888e5caca272017e5f5d25/LBA5CheckMate-214-Efficacy-and-safety-of-nivolumab-ipilimumab-N-I-v-sunitinib-S-for-treatment-naive-advanced-or-metastatic-renal-cell-carcinoma-mRCC-including-IMDC-risk-and-PD-L1-expression-subgrou.pdf","googleCitationCount":126,"googleAuthor":""},{"title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","googleId":"MboC3oFoRkkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320083","googleCitationCount":130,"googleAuthor":"P Munster","doi":"10.1093/annonc/mdx029","elsevierAuthor":"Bucau M.","publicationName":"Oncotarget","elsevierCoverDate":"2020-09-29","elsevierCoverDisplayDate":"29 September 2020","elsevierCitationCount":"0","altmetricAuthors":["P.A. Ott","S.A. Piha-Paul","P. Munster","M.J. Pishvaian","E.M.J. van Brummelen","R.B. Cohen","C. Gomez-Roca","S. Ejadi","M. Stein","E. Chan","M. Simonelli","A. Morosky","S. Saraf","K. Emancipator","M. Koshiji","J. Bennouna"],"twitterCount":29,"altmetricId":16219851},{"title":"Osimertinib benefit inEGFR-mutant NSCLC patients withT790M-mutation detected by circulating tumour DNA","googleId":"EM1xZd7VyuMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320800","googleCitationCount":131,"googleAuthor":"J Remon","doi":"10.1093/annonc/mdx017","elsevierAuthor":"Abate R.E.","publicationName":"Cancers","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"0","altmetricAuthors":["J. Remon","C. Caramella","C. Jovelet","L. Lacroix","A. Lawson","S. Smalley","K. Howarth","D. Gale","E. Green","V. Plagnol","N. Rosenfeld","D. Planchard","M.V. Bluthgen","A. Gazzah","C. Pannet","C. Nicotra","E. Auclin","J.C. Soria","B. Besse"],"twitterCount":18,"altmetricId":15635603},{"title":"Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy","googleId":"f1jkyjFeOmsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316795","googleCitationCount":102,"googleAuthor":"","doi":"10.1093/annonc/mdx810","elsevierAuthor":"Baracos V.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"71","altmetricAuthors":["V.E. Baracos","L. Arribas"],"twitterCount":53,"altmetricId":33923037},{"title":"Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma","googleId":"4vLEiRxJlBAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322665","googleCitationCount":127,"googleAuthor":"MA Qazi","doi":"10.1093/annonc/mdx169","elsevierAuthor":"Qazi M.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-07-01","elsevierCoverDisplayDate":"July 2017","elsevierCitationCount":"78","altmetricAuthors":["M.A. Qazi","P. Vora","C. Venugopal","S.S. Sidhu","J. Moffat","C. Swanton","S.K. Singh"],"twitterCount":17,"altmetricId":18755665},{"title":"Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results …","googleId":"tPKKWUyHOLoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342462","googleCitationCount":85,"googleAuthor":"S Loibl","doi":"10.1093/annonc/mdy460","elsevierAuthor":"Loibl S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"58","altmetricAuthors":["S. Loibl","K.E. Weber","K.M. Timms","E.P. Elkin","E. Hahnen","P.A. Fasching","B. Lederer","C. Denkert","A. Schneeweiss","S. Braun","C.T. Salat","M. Rezai","J.U. Blohmer","D.M. Zahm","C. Jackisch","B. Gerber","P. Klare","S. Kümmel","C. Schem","S. Paepke","R. Schmutzler","K. Rhiem","S. Penn","J. Reid","V. Nekljudova","A.-R. Hartman","G. von Minckwitz","M. Untch"],"twitterCount":28,"altmetricId":49913934},{"title":"Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy","googleId":"KqQPr9qeJKYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419541461","googleCitationCount":109,"googleAuthor":"AR Sánchez-Paulete","doi":"10.1093/annonc/mdx237","elsevierAuthor":"To J.","publicationName":"Communications Biology","elsevierCoverDate":"2021-12-01","elsevierCoverDisplayDate":"December 2021","elsevierCitationCount":"0","altmetricAuthors":["A.R. Sánchez-Paulete","A. Teijeira","F.J. Cueto","S. Garasa","J.L. Pérez-Gracia","A. Sánchez-Arráez","D. Sancho","I. Melero"],"twitterCount":14,"altmetricId":26590720},{"title":"Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC","googleId":"zRwJzoFqamIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32762-0/abstract","googleCitationCount":86,"googleAuthor":"NA Rizvi"},{"title":"Causes of death among cancer patients","googleId":"TmSXqBV4QdsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322161","googleCitationCount":166,"googleAuthor":"NG Zaorsky","doi":"10.1093/annonc/mdw604","elsevierAuthor":"Zaorsky N.G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"121","altmetricAuthors":["N.G. Zaorsky","T.M. Churilla","B.L. Egleston","S.G. Fisher","J.A. Ridge","E.M. Horwitz","J.E. Meyer"],"twitterCount":75,"altmetricId":13493880},{"title":"BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives","googleId":"ZK3QRnJ9VaYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345867","googleCitationCount":113,"googleAuthor":"","doi":"10.1093/annonc/mdx401","elsevierAuthor":"Sanz-Garcia E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"77","altmetricAuthors":["E. Sanz-Garcia","G. Argiles","E. Elez","J. Tabernero"],"twitterCount":25,"altmetricId":22303499},{"title":"Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line …","googleId":"I4W3gQF9OwEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932126X","googleCitationCount":121,"googleAuthor":"C Rolfo","doi":"10.1093/annonc/mdx119","elsevierAuthor":"Xie Y.H.","publicationName":"Signal Transduction and Targeted Therapy","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"1 December 2020","elsevierCitationCount":"46","altmetricAuthors":["N. Boeckx","R. Koukakis","K. Op de Beeck","C. Rolfo","G. Van Camp","S. Siena","J. Tabernero","J.-Y. Douillard","T. André","M. Peeters"],"twitterCount":6,"altmetricId":19663596},{"title":"Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer","googleId":"kZCcStisSwAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318861","googleCitationCount":80,"googleAuthor":"GV Long","doi":"10.1093/annonc/mdy408","elsevierAuthor":"Long G.V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"58","altmetricAuthors":["G.V. Long","S.S. Tykodi","J.G. Schneider","C. Garbe","G. Gravis","M. Rashford","S. Agrawal","E. Grigoryeva","A. Bello","A. Roy","L. Rollin","X. Zhao"],"twitterCount":62,"altmetricId":48227872},{"title":"Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors","googleId":"JM3oYibCnAIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934966X","googleCitationCount":113,"googleAuthor":"I Sloma","doi":"10.1093/annonc/mdx416","elsevierAuthor":"Izumchenko E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"87","altmetricAuthors":["E. Izumchenko","K. Paz","D. Ciznadija","I. Sloma","A. Katz","D. Vasquez-Dunddel","I. Ben-Zvi","J. Stebbing","W. McGuire","W. Harris","R. Maki","A. Gaya","A. Bedi","S. Zacharoulis","R. Ravi","L.H. Wexler","M.O. Hoque","C. Rodriguez-Galindo","H. Pass","N. Peled","A. Davies","R. Morris","M. Hidalgo","D. Sidransky"],"twitterCount":10,"altmetricId":26150407},{"title":"Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"roYk1TxvdXIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31689-8/abstract","googleCitationCount":81,"googleAuthor":"I Ray-Coquard"},{"title":"Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial","googleId":"KZvArhuaafoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342413","googleCitationCount":89,"googleAuthor":"TG Kwon","doi":"10.1093/annonc/mdy454","elsevierAuthor":"Gross-Goupil M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"58","altmetricAuthors":["M. Gross-Goupil","T.G. Kwon","M. Eto","D. Ye","H. Miyake","S.I. Seo","S.-S. Byun","J.L. Lee","V. Master","J. Jin","R. DeBenedetto","R. Linke","M. Casey","B. Rosbrook","M. Lechuga","O. Valota","E. Grande","D.I. Quinn"],"twitterCount":38,"altmetricId":49972708},{"title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","googleId":"5eX2SfV5OHkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341791","googleCitationCount":110,"googleAuthor":"J Mateo","doi":"10.1093/annonc/mdy263","elsevierAuthor":"Mateo J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"75","altmetricAuthors":["J. Mateo","D. Chakravarty","R. Dienstmann","S. Jezdic","A. Gonzalez-Perez","N. Lopez-Bigas","C.K.Y. Ng","P.L. Bedard","G. Tortora","J.-Y. Douillard","E.M. Van Allen","N. Schultz","C. Swanton","F. André","L. Pusztai"],"twitterCount":248,"altmetricId":46756092},{"title":"Intratumoral immunotherapy: using the tumor as the remedy","googleId":"fjXgSwnZdxUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419541515","googleCitationCount":100,"googleAuthor":"L Tselikas","doi":"10.1093/annonc/mdx683","elsevierAuthor":"Marabelle A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"73","altmetricAuthors":["A. Marabelle","L. Tselikas","T. de Baere","R. Houot"],"twitterCount":75,"altmetricId":30659554},{"title":"Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples","googleId":"-JfQrlb8rssJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319076","googleCitationCount":148,"googleAuthor":"LA Renfro","doi":"10.1093/annonc/mdw413","elsevierAuthor":"Renfro L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"103","altmetricAuthors":["L.A. Renfro","D.J. Sargent"],"twitterCount":11,"altmetricId":12601573},{"title":"PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers","googleId":"ZLv0BPO-6RcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342073","googleCitationCount":84,"googleAuthor":"","doi":"10.1093/annonc/mdy334","elsevierAuthor":"Sabari J.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"60","altmetricAuthors":["J.K. Sabari","G.C. Leonardi","C.A. Shu","R. Umeton","J. Montecalvo","A. Ni","R. Chen","J. Dienstag","C. Mrad","I. Bergagnini","W.V. Lai","M. Offin","K.C. Arbour","A.J. Plodkowski","D.F. Halpenny","P.K. Paik","B.T. Li","G.J. Riely","M.G. Kris","C.M. Rudin","L.M. Sholl","M. Nishino","M.D. Hellmann","N. Rekhtman","M.M. Awad","A. Drilon"],"twitterCount":50,"altmetricId":47331018},{"title":"First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma …","googleId":"QAaz4pRUNj4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349579","googleCitationCount":105,"googleAuthor":"CM Ding","doi":"10.1093/annonc/mdx359","elsevierAuthor":"Shi Y.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"91","altmetricAuthors":["Y.K. Shi","L. Wang","B.H. Han","W. Li","P. Yu","Y.P. Liu","C.M. Ding","X. Song","Z.Y. Ma","X.L. Ren","J.F. Feng","H.L. Zhang","G.Y. Chen","X.H. Han","N. Wu","C. Yao","Y. Song","S.C. Zhang","W. Song","X.Q. Liu","S.J. Zhao","Y.C. Lin","X.Q. Ye","K. Li","Y.Q. Shu","L.M. Ding","F.L. Tan","Y. Sun"],"twitterCount":13,"altmetricId":24246270},{"title":"Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study","googleId":"5HT_3DNQlooJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50455-0/abstract","googleCitationCount":84,"googleAuthor":""},{"title":"European Society for Medical Oncology (ESMO) position paper on supportive and palliative care","googleId":"ZRjJkyqwv_8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350215","googleCitationCount":99,"googleAuthor":"F Scotté","doi":"10.1093/annonc/mdx757","elsevierAuthor":"Jordan K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"68","altmetricAuthors":["K. Jordan","M. Aapro","S. Kaasa","C.I. Ripamonti","F. Scotté","F. Strasser","A. Young","E. Bruera","J. Herrstedt","D. Keefe","B. Laird","D. Walsh","J.Y. Douillard","A. Cervantes"],"twitterCount":185,"altmetricId":30460851},{"title":"Improved survival using specialized multidisciplinary board in sarcoma patients","googleId":"EeWwvLBbDmYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346046","googleCitationCount":98,"googleAuthor":"JY Blay","doi":"10.1093/annonc/mdx484","elsevierAuthor":"Blay J.Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"86","altmetricAuthors":["J.-Y. Blay","P. Soibinet","N. Penel","E. Bompas","F. Duffaud","E. Stoeckle","O. Mir","J. Adam","C. Chevreau","S. Bonvalot","M. Rios","P. Kerbrat","D. Cupissol","P. Anract","F. Gouin","J. -E. Kurtz","C. Lebbe","N. Isambert","F. Bertucci","M. Toumonde","A. Thyss","S. Piperno-Neumann","P. Dubray-Longeras","P. Meeus","F. Ducimetière","A. Giraud","J. -M. Coindre","I. Ray-Coquard","A. Italiano","A. Le Cesne"],"twitterCount":41,"altmetricId":24446445},{"title":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","googleId":"xG-NnAYhDXAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454707","googleCitationCount":102,"googleAuthor":"Y Bareche","doi":"10.1093/annonc/mdy024","elsevierAuthor":"Bareche Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"63","altmetricAuthors":["Y. Bareche","D. Venet","M. Ignatiadis","P. Aftimos","M. Piccart","F. Rothe","C. Sotiriou"],"twitterCount":41,"altmetricId":32072934},{"title":"Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer","googleId":"eu1SFmu76QYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35043-4/abstract","googleCitationCount":96,"googleAuthor":"AG Marcelin"},{"title":"Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): results from CheckMate 331","googleId":"U2QG0fxaBlAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32761-9/abstract","googleCitationCount":75,"googleAuthor":""},{"title":"Immunotherapy in ovarian cancer","googleId":"W2LDurrEmjkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342034655X","googleCitationCount":93,"googleAuthor":"K Odunsi","doi":"10.1093/annonc/mdx444","elsevierAuthor":"Odunsi K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"1 November 2017","elsevierCitationCount":"68","altmetricAuthors":["K. Odunsi"],"twitterCount":1,"altmetricId":30376829},{"title":"Do patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS Cancer Drugs Fund","googleId":"1zDO6V11IKcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321258","googleCitationCount":100,"googleAuthor":"","doi":"10.1093/annonc/mdx110","elsevierAuthor":"Ushkalova E.A.","publicationName":"Farmakoekonomika","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":["A. Aggarwal","T. Fojo","C. Chamberlain","C. Davis","R. Sullivan"],"twitterCount":474,"altmetricId":19652984},{"title":"Alpelisib (ALP)+ fulvestrant (FUL) for advanced breast cancer (ABC): results of the phase III SOLAR-1 trial","googleId":"9zOYoaMAvCwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50401-X/abstract","googleCitationCount":79,"googleAuthor":"F André"},{"title":"Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma","googleId":"znmBens0W60J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321490","googleCitationCount":102,"googleAuthor":"A Strati","doi":"10.1093/annonc/mdx206","elsevierAuthor":"Hofman P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"34","altmetricAuthors":["A. Strati","G. Koutsodontis","G. Papaxoinis","I. Angelidis","M. Zavridou","P. Economopoulou","I. Kotsantis","M. Avgeris","M. Mazel","C. Perisanidis","C. Sasaki","C. Alix-Panabières","E. Lianidou","A. Psyrri"],"twitterCount":14,"altmetricId":21513573},{"title":"Updated safety and clinical activity results from a phase Ib study of atezolizumab+ bevacizumab in hepatocellular carcinoma (HCC)","googleId":"vBdmkqm1QqQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50419-7/abstract","googleCitationCount":78,"googleAuthor":""},{"title":"Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC)","googleId":"uSBIuWlxEokJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38546-X/abstract","googleCitationCount":97,"googleAuthor":""},{"title":"Real-world evidence in the treatment of ovarian cancer","googleId":"bkc_3fnAHb4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420346548","googleCitationCount":90,"googleAuthor":"","doi":"10.1093/annonc/mdx443","elsevierAuthor":"Eisenhauer E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"1 November 2017","elsevierCitationCount":"70","altmetricAuthors":[],"twitterCount":0},{"title":"Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma","googleId":"xnFuV0ZuYnkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354900","googleCitationCount":94,"googleAuthor":"","doi":"10.1093/annonc/mdx765","elsevierAuthor":"Krug A.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"67","altmetricAuthors":["A.K. Krug","D. Enderle","C. Karlovich","T. Priewasser","S. Bentink","A. Spiel","K. Brinkmann","J. Emenegger","D.G. Grimm","E. Castellanos-Rizaldos","J.W. Goldman","L.V. Sequist","J.-C. Soria","D.R. Camidge","S.M. Gadgeel","H.A. Wakelee","M. Raponi","M. Noerholm","J. Skog"],"twitterCount":49,"altmetricId":30341671},{"title":"Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced …","googleId":"pO5kBYhk4FkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348926","googleCitationCount":83,"googleAuthor":"","doi":"10.1093/annonc/mdy101","elsevierAuthor":"Abou-Alfa G.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"64","altmetricAuthors":["G.K. Abou-Alfa","S. Qin","B.-Y. Ryoo","S.-N. Lu","C.-J. Yen","Y.-H. Feng","H.Y. Lim","F. Izzo","M. Colombo","D. Sarker","L. Bolondi","G. Vaccaro","W.P. Harris","Z. Chen","R.A. Hubner","T. Meyer","W. Sun","J.J. Harding","E.M. Hollywood","J. Ma","P.J. Wan","M. Ly","J. Bomalaski","A. Johnston","C.-C. Lin","Y. Chao","L.-T. Chen"],"twitterCount":9,"altmetricId":36755011},{"title":"Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study","googleId":"2T6KSY8r_ooJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319684","googleCitationCount":101,"googleAuthor":"","doi":"10.1093/annonc/mdw651","elsevierAuthor":"Kelley R.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"68","altmetricAuthors":["R.K. Kelley","C. Verslype","A.L. Cohn","T.-S. Yang","W.-C. Su","H. Burris","F. Braiteh","N. Vogelzang","A. Spira","P. Foster","Y. Lee","E. Van Cutsem"],"twitterCount":10,"altmetricId":17333910},{"title":"Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors","googleId":"_HM1ZnpeLuQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321660","googleCitationCount":100,"googleAuthor":"","doi":"10.1093/annonc/mdx235","elsevierAuthor":"Navani V.","publicationName":"British Journal of Clinical Pharmacology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"1 September 2020","elsevierCitationCount":"1","altmetricAuthors":["X. Zhao","S. Suryawanshi","M. Hruska","Y. Feng","X. Wang","J. Shen","H.E. Vezina","M.B. McHenry","I.M. Waxman","A. Achanta","A. Bello","A. Roy","S. Agrawal"],"twitterCount":47,"altmetricId":20295976},{"title":"Concordance of blood-and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer","googleId":"6P1_W9eWCZEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324342","googleCitationCount":103,"googleAuthor":"","doi":"10.1093/annonc/mdx112","elsevierAuthor":"Vera R.","publicationName":"Clinical and Translational Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":["J. Grasselli","E. Elez","G. Caratù","J. Matito","C. Santos","T. Macarulla","J. Vidal","M. Garcia","J.M. Viéitez","D. Paéz","E. Falcó","C. Lopez Lopez","E. Aranda","F. Jones","V. Sikri","P. Nuciforo","R. Fasani","J. Tabernero","C. Montagut","D. Azuara","R. Dienstmann","R. Salazar","A. Vivancos"],"twitterCount":3,"altmetricId":18485839},{"title":"Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer","googleId":"nNtHp7zSw7oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349919","googleCitationCount":94,"googleAuthor":"M Ilié","doi":"10.1093/annonc/mdx636","elsevierAuthor":"Ilié M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"65","altmetricAuthors":["M. Ilié","E. Szafer-Glusman","V. Hofman","E. Chamorey","S. Lalvée","E. Selva","S. Leroy","C.-H. Marquette","M. Kowanetz","P. Hedge","E. Punnoose","P. Hofman"],"twitterCount":51,"altmetricId":27232644},{"title":"CCAT1 and CCAT2 long noncoding RNAs, located within the 8q. 24.21 'gene desert', serve as important prognostic biomarkers in colorectal cancer","googleId":"H_O6jWyUlE8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321696","googleCitationCount":94,"googleAuthor":"","doi":"10.1093/annonc/mdx248","elsevierAuthor":"Gong T.","publicationName":"Aging","elsevierCoverDate":"2020-06-30","elsevierCoverDisplayDate":"30 June 2020","elsevierCitationCount":"0","altmetricAuthors":["T. Ozawa","T. Matsuyama","Y. Toiyama","N. Takahashi","T. Ishikawa","H. Uetake","Y. Yamada","M. Kusunoki","G. Calin","A. Goel"],"twitterCount":2,"altmetricId":24356054},{"title":"First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid …","googleId":"KEeidmV8NrwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320678","googleCitationCount":100,"googleAuthor":"","doi":"10.1093/annonc/mdx002","elsevierAuthor":"Derakhshani A.","publicationName":"Journal of Cellular Physiology","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"1 April 2020","elsevierCitationCount":"9","altmetricAuthors":["Y.J. Bang","G. Giaccone","S.A. Im","D.Y. Oh","T.M. Bauer","J.L. Nordstrom","H. Li","G.R. Chichili","P.A. Moore","S. Hong","S.J. Stewart","J.E. Baughman","R.J. Lechleider","H.A. Burris"],"twitterCount":1,"altmetricId":16006722},{"title":"Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study","googleId":"liXDPg06Gw8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320241","googleCitationCount":94,"googleAuthor":"AI Phipps","doi":"10.1093/annonc/mdx052","elsevierAuthor":"Nkune N.W.","publicationName":"Anti-Cancer Agents in Medicinal Chemistry","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"1","altmetricAuthors":["R. Dienstmann","M.J. Mason","F.A. Sinicrope","A.I. Phipps","S. Tejpar","A. Nesbakken","S.A. Danielsen","A. Sveen","D.D. Buchanan","M. Clendenning","C. Rosty","B. Bot","S.R. Alberts","J. Milburn Jessup","R.A. Lothe","M. Delorenzi","P.A. Newcomb","D. Sargent","J. Guinney"],"twitterCount":11,"altmetricId":16305020},{"title":"Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study","googleId":"xnbz4U15er0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931960X","googleCitationCount":120,"googleAuthor":"GA McArthur","doi":"10.1093/annonc/mdw641","elsevierAuthor":"McArthur G.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"85","altmetricAuthors":["G.A. McArthur","M. Maio","A. Arance","P. Nathan","C. Blank","M.-F. Avril","C. Garbe","A. Hauschild","D. Schadendorf","O. Hamid","M. Fluck","M. Thebeau","J. Schachter","R. Kefford","M. Chamberlain","M. Makrutzki","S. Robson","R. Gonzalez","K. Margolin"],"twitterCount":3,"altmetricId":14865523},{"title":"Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of …","googleId":"hjfkNGjS19sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454604","googleCitationCount":85,"googleAuthor":"JJ Yang","doi":"10.1093/annonc/mdy009","elsevierAuthor":"Li Y.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"65","altmetricAuthors":["Y.S. Li","B.Y. Jiang","J.J. Yang","X.C. Zhang","Z. Zhang","J.Y. Ye","W.Z. Zhong","H.Y. Tu","H.J. Chen","Z. Wang","C.R. Xu","B.C. Wang","H.J. Du","S. Chuai","H. Han-Zhang","J. Su","Q. Zhou","X.N. Yang","W.B. Guo","H.H. Yan","Y.H. Liu","L.X. Yan","B. Huang","M.M. Zheng","Y.L. Wu"],"twitterCount":3,"altmetricId":31726445},{"title":"Immunological differences between primary and metastatic breast cancer","googleId":"YMCvlmhyiV8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318782","googleCitationCount":73,"googleAuthor":"X Li","doi":"10.1093/annonc/mdy399","elsevierAuthor":"Szekely B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"51","altmetricAuthors":["B. Szekely","V. Bossuyt","X. Li","V.B. Wali","G.A. Patwardhan","C. Frederick","A. Silber","T. Park","M. Harigopal","V. Pelekanou","M. Zhang","Q. Yan","D.L. Rimm","G. Bianchini","C. Hatzis","L. Pusztai"],"twitterCount":138,"altmetricId":48087768},{"title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"GNA4kIAX048J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31693-X/abstract","googleCitationCount":63,"googleAuthor":"PL Zinzani"},{"title":"An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium …","googleId":"KsHU8XswW04J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320186","googleCitationCount":91,"googleAuthor":"O Sartor","doi":"10.1093/annonc/mdx044","elsevierAuthor":"Sartor O.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-05-01","elsevierCoverDisplayDate":"May 2017","elsevierCitationCount":"69","altmetricAuthors":["O. Sartor","R.E. Coleman","S. Nilsson","D. Heinrich","S.I. Helle","J.M. O’Sullivan","N.J. Vogelzang","Ø. Bruland","S. Kobina","S. Wilhelm","L. Xu","M. Shan","M.W. Kattan","C. Parker"],"twitterCount":9,"altmetricId":16509567},{"title":"Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines","googleId":"n-RV3PkMrBYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31697-7/abstract","googleCitationCount":63,"googleAuthor":"NI Cherny"},{"title":"Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): results …","googleId":"W2CN8WOhwPUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39105-5/abstract","googleCitationCount":89,"googleAuthor":"S Loi"},{"title":"International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)","googleId":"Ac6sX81ICFkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932246X","googleCitationCount":128,"googleAuthor":"P Hilden","doi":"10.1093/annonc/mdx097","elsevierAuthor":"Berzaczy D.","publicationName":"PLoS ONE","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"March 2019","elsevierCitationCount":"1","altmetricAuthors":["A. Younes","P. Hilden","B. Coiffier","A. Hagenbeek","G. Salles","W. Wilson","J.F. Seymour","K. Kelly","J. Gribben","M. Pfreunschuh","F. Morschhauser","H. Schoder","A.D. Zelenetz","J. Rademaker","R. Advani","N. Valente","C. Fortpied","T.E. Witzig","L.H. Sehn","A. Engert","R.I. Fisher","P.-L. Zinzani","M. Federico","M. Hutchings","C. Bollard","M. Trneny","Y.A. Elsayed","K. Tobinai","J.S. Abramson","N. Fowler","A. Goy","M. Smith","S. Ansell","J. Kuruvilla","M. Dreyling","C. Thieblemont","R.F. Little","I. Aurer","M.H.J. Van Oers","K. Takeshita","A. Gopal","S. Rule","S. de Vos","I. Kloos","M.S. Kaminski","M. Meignan","L.H. Schwartz","J.P. Leonard","S.J. Schuster","V.E. Seshan"],"twitterCount":95,"altmetricId":18526924},{"title":"Treatment of recurrent ovarian cancer","googleId":"irGrI6z5oVkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420346524","googleCitationCount":76,"googleAuthor":"S Pignata","doi":"10.1093/annonc/mdx441","elsevierAuthor":"Pignata S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"1 November 2017","elsevierCitationCount":"55","altmetricAuthors":[],"twitterCount":0},{"title":"Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial","googleId":"y5Dmny7hSl0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322070","googleCitationCount":116,"googleAuthor":"SH Lee","doi":"10.1093/annonc/mdw559","elsevierAuthor":"Lee S.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"87","altmetricAuthors":["S.-H. Lee","J.-K. Lee","M.-J. Ahn","D.-W. Kim","J.-M. Sun","B. Keam","T.M. Kim","D.S. Heo","J.S. Ahn","Y.-L. Choi","H.-S. Min","Y.K. Jeon","K. Park"],"twitterCount":13,"altmetricId":13264859},{"title":"Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: recurrent disease","googleId":"gikE_afqJsEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320459","googleCitationCount":112,"googleAuthor":"MR Mirza","doi":"10.1093/annonc/mdw663","elsevierAuthor":"Wilson M.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-04-01","elsevierCoverDisplayDate":"1 April 2017","elsevierCitationCount":"93","altmetricAuthors":["M.K. Wilson","E. Pujade-Lauraine","D. Aoki","M.R. Mirza","D. Lorusso","A.M. Oza","A. du Bois","I. Vergote","A. Reuss","M. Bacon","M. Friedlander","D. Gallardo-Rincon","F. Joly","S.-J. Chang","A.M. Ferrero","R.J. Edmondson","P. Wimberger","J. Maenpaa","D. Gaffney","R. Zang","A. Okamoto","G. Stuart","K. Ochiai"],"twitterCount":4,"altmetricId":14865500},{"title":"Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy","googleId":"Gc26OX2gqiQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352366","googleCitationCount":85,"googleAuthor":"","doi":"10.1093/annonc/mdx271","elsevierAuthor":"Bozzetti F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"65","altmetricAuthors":["F. Bozzetti"],"twitterCount":7,"altmetricId":20701061},{"title":"Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients","googleId":"hUIjPQsLEXAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934983X","googleCitationCount":82,"googleAuthor":"V Bernard","doi":"10.1093/annonc/mdx542","elsevierAuthor":"Castillo J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"66","altmetricAuthors":["J. Castillo","V. Bernard","F.A. San Lucas","K Allenson","M. Capello","D.U. Kim","P. Gascoyne","F.C. Mulu","B.M. Stephens","J. Huang","H. Wang","A.A. Momin","R.O. Jacamo","M. Katz","R. Wolff","M. Javle","G. Varadhachary","I.I. Wistuba","S. Hanash","A. Maitra","H. Alvarez"],"twitterCount":28,"altmetricId":26558717},{"title":"IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin+ nab-paclitaxel (CnP) with or without atezolizumab …","googleId":"dpDeks1nvgEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50456-2/abstract","googleCitationCount":69,"googleAuthor":"F Cappuzzo"},{"title":"CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials","googleId":"TMTicSZFpmQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355115","googleCitationCount":112,"googleAuthor":"G Goss","doi":"10.1093/annonc/mdx820","elsevierAuthor":"Goss G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"86","altmetricAuthors":["G. Goss","C.-M. Tsai","F.A. Shepherd","M.-J. Ahn","L. Bazhenova","L. Crinò","F. de Marinis","E. Felip","A. Morabito","R. Hodge","M. Cantarini","M. Johnson","T. Mitsudomi","P.A. Jänne","J.C.-H. Yang"],"twitterCount":21,"altmetricId":30831463},{"title":"Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast …","googleId":"j9n3rYkfiOUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349798","googleCitationCount":84,"googleAuthor":"M Robson","doi":"10.1093/annonc/mdx505","elsevierAuthor":"Han H.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"74","altmetricAuthors":["H.S. Han","V. Diéras","M. Robson","M. Palácová","P.K. Marcom","A. Jager","I. Bondarenko","D. Citrin","M. Campone","M.L. Telli","S.M. Domchek","M. Friedlander","B. Kaufman","J.E. Garber","Y. Shparyk","E. Chmielowska","E.H. Jakobsen","V. Kaklamani","W. Gradishar","C.K. Ratajczak","C. Nickner","Q. Qin","J. Qian","S.P. Shepherd","S.J. Isakoff","S. Puhalla"],"twitterCount":1,"altmetricId":27031791},{"title":"Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer","googleId":"EAJljg9-vMgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345570","googleCitationCount":66,"googleAuthor":"S Siena","doi":"10.1093/annonc/mdy100","elsevierAuthor":"Siena S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"51","altmetricAuthors":["S. Siena","A. Sartore-Bianchi","S. Marsoni","H.I. Hurwitz","S.J. McCall","F. Penault-Llorca","S. Srock","A. Bardelli","L. Trusolino"],"twitterCount":38,"altmetricId":35755731},{"title":"Long-term toxicity of cisplatin in germ-cell tumor survivors","googleId":"iDfg2GfwZHYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345855","googleCitationCount":81,"googleAuthor":"M Chovanec","doi":"10.1093/annonc/mdx360","elsevierAuthor":"Chovanec M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"59","altmetricAuthors":["M. Chovanec","M. Abu Zaid","N. Hanna","N. El-Kouri","L.H. Einhorn","C. Albany"],"twitterCount":8,"altmetricId":22211606},{"title":"RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study","googleId":"z2Eb6009_PUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934534X","googleCitationCount":77,"googleAuthor":"JB Bachet","doi":"10.1093/annonc/mdy061","elsevierAuthor":"Bachet J.B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"56","altmetricAuthors":["J.B. Bachet","O. Bouché","J. Taieb","O. Dubreuil","M.L. Garcia","A. Meurisse","C. Normand","J.M. Gornet","P. Artru","S. Louafi","F. Bonnetain","A. Thirot-Bidault","I. Baumgaertner","R. Coriat","D. Tougeron","T. Lecomte","F. Mary","T. Aparicio","L. Marthey","V. Taly","H. Blons","D. Vernerey","P. Laurent-Puig"],"twitterCount":9,"altmetricId":33197535},{"title":"EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours","googleId":"9evIP-N-k5UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)42149-2/abstract","googleCitationCount":112,"googleAuthor":""},{"title":"Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the …","googleId":"Y_hyrbStDjMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319829","googleCitationCount":110,"googleAuthor":"GM Wulf","doi":"10.1093/annonc/mdw672","elsevierAuthor":"Matulonis U.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"86","altmetricAuthors":["U.A. Matulonis","G.M. Wulf","W.T. Barry","M. Birrer","S.N. Westin","S. Farooq","K.M. Bell-McGuinn","E. Obermayer","C. Whalen","T. Spagnoletti","W. Luo","H. Liu","R.C. Hok","C. Aghajanian","D.B. Solit","G.B. Mills","B.S. Taylor","H. Won","M.F. Berger","S. Palakurthi","J. Liu","L.C. Cantley","E. Winer"],"twitterCount":2,"altmetricId":18212067},{"title":"Differential protein stability and clinical responses ofEML4-ALK fusion variants to various ALK inhibitors in advancedALK-rearranged non-small cell lung …","googleId":"Wpw1kl--lYYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320630","googleCitationCount":108,"googleAuthor":"","doi":"10.1093/annonc/mdw693","elsevierAuthor":"Elsayed M.","publicationName":"Pharmaceuticals","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0","altmetricAuthors":["C.G. Woo","S. Seo","S.W. Kim","S.J. Jang","K.S. Park","J.Y. Song","B. Lee","M.W. Richards","R. Bayliss","D.H. Lee","J. Choi"],"twitterCount":9,"altmetricId":15212945},{"title":"Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H …","googleId":"9MWA4VyBm4kJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50410-0/abstract","googleCitationCount":64,"googleAuthor":"HJJ Lenz"},{"title":"Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer","googleId":"oWfOuyjvNCYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349774","googleCitationCount":81,"googleAuthor":"IG Murillas","doi":"10.1093/annonc/mdx483","elsevierAuthor":"Fribbens C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"53","altmetricAuthors":["C. Fribbens","I. Garcia Murillas","M. Beaney","S. Hrebien","B. O’Leary","L. Kilburn","K. Howarth","M. Epstein","E. Green","N. Rosenfeld","A. Ring","S. Johnston","N. Turner"],"twitterCount":19,"altmetricId":27031736},{"title":"Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II–III trial","googleId":"cBIkLJ3XgVwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352512","googleCitationCount":84,"googleAuthor":"D Alterio","doi":"10.1093/annonc/mdx299","elsevierAuthor":"Ghi M.G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"66","altmetricAuthors":["M.G. Ghi","A. Paccagnella","D. Ferrari","P. Foa","D. Alterio","C. Codecà","F. Nolè","E. Verri","R. Orecchia","F. Morelli","S. Parisi","C. Mastromauro","C.A. Mione","C. Rossetto","M. Polsinelli","H. Koussis","L. Loreggian","A. Bonetti","F. Campostrini","G. Azzarello","C. D’Ambrosio","F. Bertoni","C. Casanova","E. Emiliani","M. Guaraldi","F. Bunkheila","P. Bidoli","R.M. Niespolo","A. Gava","E. Massa","A. Frattegiani","F. Valduga","G. Pieri","T. Cipani","D. Da Corte","F. Chiappa","E. Rulli"],"twitterCount":10,"altmetricId":21516966},{"title":"FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma","googleId":"HOtsu9gEikcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342036","googleCitationCount":54,"googleAuthor":"L Emmett","doi":"10.1093/annonc/mdy330","elsevierAuthor":"Tan A.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"50","altmetricAuthors":["A.C. Tan","L. Emmett","S. Lo","V. Liu","R. Kapoor","M.S. Carlino","A.D. Guminski","G.V. Long","A.M. Menzies"],"twitterCount":9,"altmetricId":46879649},{"title":"Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study","googleId":"K-gyFUrJvL0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322082","googleCitationCount":104,"googleAuthor":"P Hammel","doi":"10.1093/annonc/mdw561","elsevierAuthor":"Faivre S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"70","altmetricAuthors":["S. Faivre","P. Niccoli","D. Castellano","J.W. Valle","P. Hammel","J.-L. Raoul","A. Vinik","E. Van Cutsem","Y.-J. Bang","S.-H. Lee","I. Borbath","C. Lombard-Bohas","P. Metrakos","D. Smith","J.-S. Chen","P. Ruszniewski","J.-F. Seitz","S. Patyna","D.R. Lu","K.J. Ishak","E. Raymond"],"twitterCount":3,"altmetricId":13520702},{"title":"Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a …","googleId":"-CbF1tPfjc0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320745","googleCitationCount":87,"googleAuthor":"","doi":"10.1093/annonc/mdx009","elsevierAuthor":"Jiang D.M.","publicationName":"Oncology (Switzerland)","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0","altmetricAuthors":["J. Liang","N. Bi","S. Wu","M. Chen","C. Lv","L. Zhao","A. Shi","W. Jiang","Y. Xu","Z. Zhou","W. Wang","D. Chen","Z. Hui","J. Lv","H. Zhang","Q. Feng","Z. Xiao","X. Wang","L. Liu","T. Zhang","L. Du","W. Chen","Y. Shyr","W. Yin","J. Li","J. He","L. Wang"],"twitterCount":30,"altmetricId":15968947},{"title":"Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized …","googleId":"7U4PJZR1zDwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319830","googleCitationCount":104,"googleAuthor":"F Khosrow-Khavar","doi":"10.1093/annonc/mdw673","elsevierAuthor":"Khosrow-Khavar F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"62","altmetricAuthors":["F. Khosrow-Khavar","K.B. Filion","S. Al-Qurashi","N. Torabi","N. Bouganim","S. Suissa","L. Azoulay"],"twitterCount":11,"altmetricId":14898822},{"title":"Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206","googleId":"4XrLOEF45I4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350033","googleCitationCount":75,"googleAuthor":"N Adra","doi":"10.1093/annonc/mdx680","elsevierAuthor":"Adra N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"66","altmetricAuthors":["N. Adra","L.H. Einhorn","S.K. Althouse","N.R. Ammakkanavar","D. Musapatika","C. Albany","D. Vaughn","N.H. Hanna"],"twitterCount":12,"altmetricId":27569023},{"title":"Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015","googleId":"Gr_-4cpYDBsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320253","googleCitationCount":83,"googleAuthor":"","doi":"10.1093/annonc/mdx053","elsevierAuthor":"Hilal T.","publicationName":"JAMA Internal Medicine","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"3","altmetricAuthors":["A. Vivot","J. Jacot","J.-D. Zeitoun","P. Ravaud","P. Crequit","R. Porcher"],"twitterCount":125,"altmetricId":16221375},{"title":"Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer","googleId":"9j0uvrbDQh4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50438-0/abstract","googleCitationCount":59,"googleAuthor":""},{"title":"A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma …","googleId":"vX0hz0VkgKoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324305","googleCitationCount":78,"googleAuthor":"RD Petty","doi":"10.1093/annonc/mdx107","elsevierAuthor":"Ishii T.","publicationName":"International Journal of Clinical Oncology","elsevierCoverDate":"2019-07-12","elsevierCoverDisplayDate":"12 July 2019","elsevierCitationCount":"5","altmetricAuthors":["E. Van Cutsem","Y.-J. Bang","W. Mansoor","R.D. Petty","Y. Chao","D. Cunningham","D.R. Ferry","N.R. Smith","P. Frewer","J. Ratnayake","P.K. Stockman","E. Kilgour","D. Landers"],"twitterCount":4,"altmetricId":21165469},{"title":"Latest clinical evidence and further development of PARP inhibitors in ovarian cancer","googleId":"P6jyX2doe-4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349178","googleCitationCount":59,"googleAuthor":"MR Mirza","doi":"10.1093/annonc/mdy174","elsevierAuthor":"Mirza M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"46","altmetricAuthors":["M.R. Mirza","S. Pignata","J.A. Ledermann"],"twitterCount":1,"altmetricId":58307152},{"title":"Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)","googleId":"VH2wnWYIDlAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318964","googleCitationCount":52,"googleAuthor":"","doi":"10.1093/annonc/mdy423","elsevierAuthor":"Marabelle A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"43","altmetricAuthors":["A. Marabelle","R. Andtbacka","K. Harrington","I. Melero","R. Leidner","T. de Baere","C. Robert","P.A. Ascierto","J -F Baurain","M. Imperiale","S. Rahimian","D. Tersago","E. Klumper","M. Hendriks","R. Kumar","M. Stern","K. Öhrling","C. Massacesi","I. Tchakov","A. Tse","J -Y Douillard","J. Tabernero","J. Haanen","J. Brody"],"twitterCount":42,"altmetricId":49381781},{"title":"Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) tumors: pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001","googleId":"2jn2ehTMEpUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50408-2/abstract","googleCitationCount":61,"googleAuthor":""},{"title":"Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer","googleId":"f9GG1JvXz9wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454586","googleCitationCount":72,"googleAuthor":"N Feeney","doi":"10.1093/annonc/mdy005","elsevierAuthor":"Guibert N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"55","altmetricAuthors":["N. Guibert","Y. Hu","N. Feeney","Y. Kuang","V. Plagnol","G. Jones","K. Howarth","J.F. Beeler","C.P. Paweletz","G.R. Oxnard"],"twitterCount":51,"altmetricId":31455638},{"title":"Safety and dose modification for patients receiving niraparib","googleId":"iqtQSV85LXkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341092","googleCitationCount":64,"googleAuthor":"","doi":"10.1093/annonc/mdy181","elsevierAuthor":"Banerjee S.","publicationName":"ESMO Open","elsevierCoverDate":"2020-12-11","elsevierCoverDisplayDate":"11 December 2020","elsevierCitationCount":"1","altmetricAuthors":["J.S. Berek","U.A. Matulonis","U. Peen","P. Ghatage","S. Mahner","A. Redondo","A. Lesoin","N. Colombo","I. Vergote","O. Rosengarten","J. Ledermann","M. Pineda","S. Ellard","J. Sehouli","A. Gonzalez-Martin","D. Berton-Rigaud","R. Madry","A. Reinthaller","S. Hazard","W. Guo","M.R. Mirza"],"twitterCount":14,"altmetricId":41973859},{"title":"A randomized trial of induction docetaxel–cisplatin–5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma …","googleId":"LqvwrgRiaU0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354936","googleCitationCount":74,"googleAuthor":"","doi":"10.1093/annonc/mdx770","elsevierAuthor":"Frikha M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"51","altmetricAuthors":["M. Frikha","A. Auperin","Y. Tao","F. Elloumi","N. Toumi","P. Blanchard","P. Lang","S. Sun","S. Racadot","J. Thariat","M. Alfonsi","C. Tuchais","A. Cornely","A. Moussa","J. Guigay","J. Daoud","J. Bourhis"],"twitterCount":7,"altmetricId":30375563},{"title":"Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): phase 3 KEYNOTE-040 trial","googleId":"dHFBcK4DYAMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39140-7/abstract","googleCitationCount":76,"googleAuthor":"EE Cohen"},{"title":"Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma","googleId":"WVQ8RRu2S3gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346010","googleCitationCount":74,"googleAuthor":"","doi":"10.1093/annonc/mdx479","elsevierAuthor":"Schlumberger M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"54","altmetricAuthors":["M. Schlumberger","R. Elisei","S. Müller","P. Schöffski","M. Brose","M. Shah","L. Licitra","J. Krajewska","M.C. Kreissl","B. Niederle","E.E.W. Cohen","L. Wirth","H. Ali","D.O. Clary","Y. Yaron","M. Mangeshkar","D. Ball","B. Nelkin","S. Sherman"],"twitterCount":30,"altmetricId":26504569},{"title":"Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions","googleId":"EgUSBwBNP0MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322513","googleCitationCount":77,"googleAuthor":"MB Atkins","doi":"10.1093/annonc/mdx151","elsevierAuthor":"Ghiringhelli F.","publicationName":"Bulletin du Cancer","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"0","altmetricAuthors":["M.B. Atkins","J.I. Clark","D.I. Quinn"],"twitterCount":5,"altmetricId":18585268},{"title":"Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions","googleId":"f7sVN9C17pUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352470","googleCitationCount":73,"googleAuthor":"","doi":"10.1093/annonc/mdx288","elsevierAuthor":"Mayo-de-las-Casas C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"61","altmetricAuthors":["C. Mayo-de-las-Casas","N. Jordana-Ariza","M. Garzón-Ibañez","A. Balada-Bel","J. Bertrán-Alamillo","S. Viteri-Ramírez","N. Reguart","M.A. Muñoz-Quintana","P. Lianes-Barragan","C. Camps","E. Jantús","J. Remon-Massip","S. Calabuig","D. Aguiar","M.L. Gil","N. Viñolas","A.K. Santos-Rodríguez","M. Majem","B. García-Peláez","S. Villatoro","A. Pérez-Rosado","J.C. Monasterio","E. Ovalle","M.J. Catalán","R. Campos","D. Morales-Espinosa","A. Martínez-Bueno","M. González-Cao","X. González","I. Moya-Horno","A.E. Sosa","N. Karachaliou","R. Rosell","M.A. Molina-Vila"],"twitterCount":9,"altmetricId":22294349},{"title":"Delirium in adult cancer patients: ESMO Clinical Practice Guidelines","googleId":"g7JkhZhsFgMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31696-5/abstract","googleCitationCount":53,"googleAuthor":"SH Bush"},{"title":"Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo (radio) therapy: current …","googleId":"vmXWzOuDY_EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345661","googleCitationCount":56,"googleAuthor":"A Laviano","doi":"10.1093/annonc/mdy114","elsevierAuthor":"de van der Schueren M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"49","altmetricAuthors":["M.A.E. de van der Schueren","A. Laviano","H. Blanchard","M. Jourdan","J. Arends","V.E. Baracos"],"twitterCount":40,"altmetricId":38062521},{"title":"The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting","googleId":"zR9Z-sTCGYoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324299","googleCitationCount":79,"googleAuthor":"A Molassiotis","doi":"10.1093/annonc/mdx100","elsevierAuthor":"Aapro M.","publicationName":"Cancer Reports","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"9","altmetricAuthors":["G. Dranitsaris","A. Molassiotis","M. Clemons","E. Roeland","L. Schwartzberg","P. Dielenseger","K. Jordan","A. Young","M. Aapro"],"twitterCount":68,"altmetricId":18601578},{"title":"Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in the Netherlands and the importance of additional …","googleId":"YkOYFko8N-EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345338","googleCitationCount":66,"googleAuthor":"","doi":"10.1093/annonc/mdy060","elsevierAuthor":"Nauta I.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"60","altmetricAuthors":["I.H. Nauta","M.M. Rietbergen","A.A.J.D. van Bokhoven","E. Bloemena","B.I. Lissenberg-Witte","D.A.M. Heideman","R.J. Baatenburg de Jong","R.H. Brakenhoff","C.R. Leemans"],"twitterCount":3,"altmetricId":33162595},{"title":"Molecular correlates differentiate response to atezolizumab (atezo)+ bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated …","googleId":"z6r8M_03wBAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50428-8/abstract","googleCitationCount":59,"googleAuthor":"BI Rini"},{"title":"Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group","googleId":"ADqejP7k9eIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324147","googleCitationCount":78,"googleAuthor":"A Gronchi","doi":"10.1093/annonc/mdx054","elsevierAuthor":"Traylor J.I.","publicationName":"Neurosurgery","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"1 February 2021","elsevierCitationCount":"1","altmetricAuthors":["S. Stacchiotti","A. Gronchi","P. Fossati","T. Akiyama","C. Alapetite","M. Baumann","J.Y. Blay","S. Bolle","S. Boriani","P. Bruzzi","R. Capanna","A. Caraceni","R. Casadei","V. Colia","J. Debus","T. Delaney","A. Desai","P. Dileo","S. Dijkstra","F. Doglietto","A. Flanagan","S. Froelich","P.A. Gardner","H. Gelderblom","Z.L. Gokaslan","R. Haas","C. Heery","N. Hindi","P. Hohenberger","F. Hornicek","R. Imai","L. Jeys","R.L. Jones","B. Kasper","A. Kawai","M. Krengli","A. Leithner","I. Logowska","J. Martin Broto","D. Mazzatenta","C. Morosi","P. Nicolai","O.J. Norum","S. Patel","N. Penel","P. Picci","S. Pilotti","S. Radaelli","F. Ricchini","P. Rutkowski","S. Scheipl","C. Sen","E. Tamborini","K.A. Thornton","B. Timmermann","V. Torri","P.U. Tunn","M. Uhl","Y. Yamada","D.C. Weber","D. Vanel","P.P. Varga","C.L.A. Vleggeert-Lankamp","P.G. Casali","J. Sommer"],"twitterCount":12,"altmetricId":16463816},{"title":"Blood-based biomarkers for cancer immunotherapy: tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ …","googleId":"ZIZg79FE5DAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38544-6/abstract","googleCitationCount":72,"googleAuthor":""},{"title":"Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer","googleId":"n3ncIXWoiqsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934904X","googleCitationCount":57,"googleAuthor":"","doi":"10.1093/annonc/mdy126","elsevierAuthor":"Wang H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"43","altmetricAuthors":["H. Wang","J. Agulnik","G. Kasymjanova","A. Wang","P. Jiménez","V. Cohen","D. Small","C. Pepe","L. Sakr","P.O. Fiset","M. Auger","S. Camilleri-Broet","M. Alam El Din","G. Chong","L. van Kempen","A. Spatz"],"twitterCount":33,"altmetricId":37820613},{"title":"Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma","googleId":"7HpsXiZd5nEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350501","googleCitationCount":67,"googleAuthor":"RJ Lee","doi":"10.1093/annonc/mdx717","elsevierAuthor":"Lee R.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"52","altmetricAuthors":["R.J. Lee","G. Gremel","A. Marshall","K.A. Myers","N. Fisher","J.A. Dunn","N. Dhomen","P.G. Corrie","M.R. Middleton","P. Lorigan","R. Marais"],"twitterCount":118,"altmetricId":28480893},{"title":"GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial","googleId":"hKoB9Dhlh0cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321374","googleCitationCount":75,"googleAuthor":"","doi":"10.1093/annonc/mdx184","elsevierAuthor":"Leonard R.C.F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-08-01","elsevierCoverDisplayDate":"1 August 2017","elsevierCitationCount":"56","altmetricAuthors":["R.C.F. Leonard","D.J.A. Adamson","G. Bertelli","J. Mansi","A. Yellowlees","J. Dunlop","G.A. Thomas","R.E. Coleman","R.A. Anderson"],"twitterCount":4,"altmetricId":19870941},{"title":"Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer","googleId":"c4_Mxz0sCQ8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342061","googleCitationCount":57,"googleAuthor":"M Scheffler","doi":"10.1093/annonc/mdy333","elsevierAuthor":"Kron A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"44","altmetricAuthors":["A. Kron","C. Alidousty","M. Scheffler","S. Merkelbach-Bruse","D. Seidel","R. Riedel","M.A. Ihle","S. Michels","L. Nogova","J. Fassunke","C. Heydt","F. Kron","F. Ueckeroth","M. Serke","S. Krüger","C. Grohe","D. Koschel","J. Benedikter","B. Kaminsky","B. Schaaf","J. Braess","M. Sebastian","K -O Kambartel","R. Thomas","T. Zander","A.M. Schultheis","R. Büttner","J. Wolf"],"twitterCount":37,"altmetricId":47182351},{"title":"PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non …","googleId":"pwsxNfKR6bIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932068X","googleCitationCount":76,"googleAuthor":"MS Tsao","doi":"10.1093/annonc/mdx003","elsevierAuthor":"Yotsukura M.","publicationName":"Japanese Journal of Clinical Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"1 January 2021","elsevierCitationCount":"0","altmetricAuthors":["M.-S. Tsao","G. Le Teuff","F.A. Shepherd","C. Landais","P. Hainaut","M. Filipits","R. Pirker","T. Le Chevalier","S. Graziano","R. Kratze","J.-C. Soria","J.-P. Pignon","L. Seymour","E. Brambilla"],"twitterCount":70,"altmetricId":15953816},{"title":"Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study","googleId":"aH6AkxVOh1AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342310","googleCitationCount":69,"googleAuthor":"AA Brandes","doi":"10.1093/annonc/mdy414","elsevierAuthor":"Conte P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"49","altmetricAuthors":["P. Conte","A. Frassoldati","G. Bisagni","A.A. Brandes","M. Donadio","O. Garrone","F. Piacentini","L. Cavanna","F. Giotta","M. Aieta","V. Gebbia","A. Molino","A. Musolino","A. Ferro","R. Maltoni","S. Danese","C. Zamagni","A. Rimanti","K. Cagossi","A. Russo","P. Pronzato","F. Giovanardi","G. Moretti","L. Lombardo","A. Schirone","A. Beano","L. Amaducci","E.A. Bajardi","R. Vicini","S. Balduzzi","R. D’Amico","V. Guarneri"],"twitterCount":74,"altmetricId":48446077},{"title":"ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia","googleId":"7l4AWkNT6SAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321398","googleCitationCount":70,"googleAuthor":"D Currow","doi":"10.1093/annonc/mdx192","elsevierAuthor":"Wakabayashi H.","publicationName":"Journal of Cachexia, Sarcopenia and Muscle","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"1","altmetricAuthors":["D. Currow","J.S. Temel","A. Abernethy","J. Milanowski","J. Friend","K.C. Fearon"],"twitterCount":11,"altmetricId":19853072},{"title":"Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies","googleId":"G38FIF-DPwAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345879","googleCitationCount":65,"googleAuthor":"M Collins","doi":"10.1093/annonc/mdx403","elsevierAuthor":"Collins M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"46","altmetricAuthors":["M. Collins","J.M. Michot","F.X. Danlos","C. Mussini","E. Soularue","C. Mateus","D. Loirat","A. Buisson","I. Rosa","O. Lambotte","S. Laghouati","N. Chaput","C. Coutzac","A.L. Voisin","J.C. Soria","A. Marabelle","S. Champiat","C. Robert","F. Carbonnel"],"twitterCount":9,"altmetricId":27861404},{"title":"Practical guidance for mismatch repair-deficiency testing in endometrial cancer","googleId":"8z34RnYa-VsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319325","googleCitationCount":93,"googleAuthor":"AML Jansen","doi":"10.1093/annonc/mdw542","elsevierAuthor":"Stelloo E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"68","altmetricAuthors":["E. Stelloo","A.M.L. Jansen","E.M. Osse","R.A. Nout","C.L. Creutzberg","D. Ruano","D.N. Church","H. Morreau","V.T.H.B.M. Smit","T. van Wezel","T. Bosse"],"twitterCount":31,"altmetricId":12691919},{"title":"A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2–advanced breast cancer …","googleId":"_Ir6wXQwHMAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322094","googleCitationCount":89,"googleAuthor":"L Dirix","doi":"10.1093/annonc/mdw562","elsevierAuthor":"Martín M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"67","altmetricAuthors":["M. Martín","A. Chan","L. Dirix","J. O’Shaughnessy","R. Hegg","A. Manikhas","M. Shtivelband","P. Krivorotko","N. Batista López","M. Campone","M. Ruiz Borrego","Q.J. Khan","J.T. Beck","M. Ramos Vázquez","P. Urban","S. Goteti","E. Di Tomaso","C. Massacesi","S. Delaloge"],"twitterCount":4,"altmetricId":13264710},{"title":"First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer","googleId":"VFnIN_ezYA0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341651","googleCitationCount":52,"googleAuthor":"C Massard","doi":"10.1093/annonc/mdy244","elsevierAuthor":"Massard C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"40","altmetricAuthors":["C. Massard","A. Azaro","J.-C. Soria","U. Lassen","C. Le Tourneau","D. Sarker","C. Smith","U. Ohnmacht","G. Oakley","B.K.R. Patel","E.S.M. Yuen","K.A. Benhadji","J. Rodon"],"twitterCount":1,"altmetricId":51241828},{"title":"Preclinical and clinical development of neoantigen vaccines","googleId":"joryDcGfW_sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419541497","googleCitationCount":64,"googleAuthor":"","doi":"10.1093/annonc/mdx681","elsevierAuthor":"Li L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"49","altmetricAuthors":["L. Li","S.P. Goedegebuure","W.E. Gillanders"],"twitterCount":19,"altmetricId":30655459},{"title":"Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in PTS with melanoma who …","googleId":"YcTlNYnQpMgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39111-0/abstract","googleCitationCount":69,"googleAuthor":"PA Ascierto"},{"title":"Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient …","googleId":"8UMUDp2Gh8IJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341766","googleCitationCount":56,"googleAuthor":"","doi":"10.1093/annonc/mdy257","elsevierAuthor":"Ettl J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"32","altmetricAuthors":["J. Ettl","R.G.W. Quek","K.-H. Lee","H.S. Rugo","S. Hurvitz","A. Gonçalves","L. Fehrenbacher","R. Yerushalmi","L.A. Mina","M. Martin","H. Roché","Y.-H. Im","D. Markova","H. Bhattacharyya","A.L. Hannah","W. Eiermann","J.L. Blum","J.K. Litton"],"twitterCount":36,"altmetricId":46565446},{"title":"Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody …","googleId":"bSDvFNFrInAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353840","googleCitationCount":64,"googleAuthor":"","doi":"10.1093/annonc/mdx514","elsevierAuthor":"Arnold D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"44","altmetricAuthors":["D. Arnold","C.S. Fuchs","J. Tabernero","A. Ohtsu","A.X. Zhu","E.B. Garon","J.R. Mackey","L. Paz-Ares","A.D. Baron","T. Okusaka","T. Yoshino","H.H. Yoon","M. Das","D. Ferry","Y. Zhang","Y. Lin","P. Binder","A. Sashegyi","I. Chau"],"twitterCount":5,"altmetricId":31557523},{"title":"Pembrolizumab for advanced biliary adenocarcinoma: results from the multicohort, phase II KEYNOTE-158 study","googleId":"-BvgtB7RN94J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49087-X/abstract","googleCitationCount":52,"googleAuthor":"A Nagrial"},{"title":"Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution","googleId":"hFVONvIPuWwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355152","googleCitationCount":60,"googleAuthor":"S Venkatesan","doi":"10.1093/annonc/mdy003","elsevierAuthor":"Venkatesan S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"41","altmetricAuthors":["S. Venkatesan","R. Rosenthal","N. Kanu","N. McGranahan","J. Bartek","S.A. Quezada","J. Hare","R.S. Harris","C. Swanton"],"twitterCount":31,"altmetricId":31398642},{"title":"Understanding personal risk of oropharyngeal cancer: risk-groups for oncogenic oral HPV infection and oropharyngeal cancer","googleId":"FSY7ZBOy77oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353979","googleCitationCount":64,"googleAuthor":"G D'Souza","doi":"10.1093/annonc/mdx535","elsevierAuthor":"D'Souza G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"47","altmetricAuthors":["G. D’Souza","T.S. McNeel","C. Fakhry"],"twitterCount":110,"altmetricId":27666704},{"title":"Impact of early palliative care on caregivers of patients with advanced cancer: cluster randomised trial","googleId":"_7KmT2NiuQkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319118","googleCitationCount":88,"googleAuthor":"C Lo","doi":"10.1093/annonc/mdw438","elsevierAuthor":"McDonald J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"55","altmetricAuthors":["J. McDonald","N. Swami","B. Hannon","C. Lo","A. Pope","A. Oza","N. Leighl","M.K. Krzyzanowska","G. Rodin","L.W. Le","C. Zimmermann"],"twitterCount":40,"altmetricId":12384404},{"title":"Pertuzumab, trastuzumab, and standard anthracycline-and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive …","googleId":"ySGaJ99_7m0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341935495X","googleCitationCount":63,"googleAuthor":"SM Swain","doi":"10.1093/annonc/mdx773","elsevierAuthor":"Swain S.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"49","altmetricAuthors":["S.M. Swain","M.S. Ewer","G. Viale","S. Delaloge","J.-M. Ferrero","M. Verrill","R. Colomer","C. Vieira","T.L. Werner","H. Douthwaite","D. Bradley","M. Waldron-Lynch","A. Kiermaier","J. Eng-Wong","C. Dang"],"twitterCount":11,"altmetricId":30501274},{"title":"Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial","googleId":"V0mTyQeYmDsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454513","googleCitationCount":64,"googleAuthor":"B Allard","doi":"10.1093/annonc/mdx730","elsevierAuthor":"Buisseret L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"50","altmetricAuthors":["L. Buisseret","S. Pommey","B. Allard","S. Garaud","M. Bergeron","I. Cousineau","L. Ameye","Y. Bareche","M. Paesmans","J.P.A. Crown","A. Di Leo","S. Loi","M. Piccart-Gebhart","K. Willard-Gallo","C. Sotiriou","J. Stagg"],"twitterCount":22,"altmetricId":29285356},{"title":"LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors","googleId":"IssF7hstf1cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354754","googleCitationCount":63,"googleAuthor":"SK Chia","doi":"10.1093/annonc/mdx557","elsevierAuthor":"Burugu S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"48","altmetricAuthors":[],"twitterCount":0},{"title":"A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary …","googleId":"UmMY_-3_bgYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454525","googleCitationCount":61,"googleAuthor":"H Takahashi","doi":"10.1093/annonc/mdx771","elsevierAuthor":"Fushimi C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"49","altmetricAuthors":["C. Fushimi","Y. Tada","H. Takahashi","T. Nagao","H. Ojiri","T. Masubuchi","T. Matsuki","K. Miura","D. Kawakita","H. Hirai","E. Hoshino","S. Kamata","T. Saotome"],"twitterCount":13,"altmetricId":29890796},{"title":"Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment","googleId":"BytWdQvYgigJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352652","googleCitationCount":67,"googleAuthor":"AR Thierry","doi":"10.1093/annonc/mdx330","elsevierAuthor":"Thierry A.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"51","altmetricAuthors":["A.R. Thierry","S. El Messaoudi","C. Mollevi","J.L. Raoul","R. Guimbaud","D. Pezet","P. Artru","E. Assenat","C. Borg","M. Mathonnet","C. De La Fouchardière","O. Bouché","C. Gavoille","C. Fiess","B. Auzemery","R. Meddeb","E. Lopez-Crapez","C. Sanchez","B. Pastor","M. Ychou"],"twitterCount":54,"altmetricId":21509005},{"title":"Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: first-line interventions","googleId":"FfE-jHZ106gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320769","googleCitationCount":68,"googleAuthor":"JA Ledermann","doi":"10.1093/annonc/mdx011","elsevierAuthor":"Karam A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-04-01","elsevierCoverDisplayDate":"April 2017","elsevierCitationCount":"61","altmetricAuthors":["A. Karam","J.A. Ledermann","J.-W. Kim","J. Sehouli","K. Lu","C. Gourley","N. Katsumata","R.A. Burger","B.-H. Nam","M. Bacon","C. Ng","J. Pfisterer","R.L.M. Bekkers","A. Casado Herráez","A. Redondo","H. Fujiwara","N. Gleeson","O. Rosengarten","G. Scambia","J. Zhu","A. Okamoto","G. Stuart","K. Ochiai"],"twitterCount":8,"altmetricId":17063046},{"title":"International cancer seminars: a focus on esophageal squamous cell carcinoma","googleId":"a-VgWBvwgMcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341935241X","googleCitationCount":61,"googleAuthor":"G Murphy","doi":"10.1093/annonc/mdx279","elsevierAuthor":"Murphy G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"49","altmetricAuthors":["G. Murphy","V. McCormack","B. Abedi-Ardekani","M. Arnold","M.C. Camargo","N.A. Dar","S.M. Dawsey","A. Etemadi","R.C. Fitzgerald","D.E. Fleischer","N.D. Freedman","A.M. Goldstein","S. Gopal","M. Hashemian","N. Hu","P.L. Hyland","B. Kaimila","F. Kamangar","R. Malekzadeh","C.G. Mathew","D. Menya","G. Mulima","M.M. Mwachiro","A. Mwasamwaja","N. Pritchett","Y.-L. Qiao","L.F. Ribeiro-Pinto","M. Ricciardone","J. Schüz","F. Sitas","P.R. Taylor","K. Van Loon","S.-M. Wang","W.-Q. Wei","C.P. Wild","C. Wu","C.C. Abnet","S.J. Chanock","P. Brennan"],"twitterCount":3,"altmetricId":21126975},{"title":"Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial","googleId":"XDSDHP500vwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324238","googleCitationCount":69,"googleAuthor":"RD Carvajal","doi":"10.1093/annonc/mdx079","elsevierAuthor":"Khachigian L.M.","publicationName":"Current Medicinal Chemistry","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"1","altmetricAuthors":[],"twitterCount":0},{"title":"Overview of current systemic management of EGFR-mutant NSCLC","googleId":"vFBC2Khe6MkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316680","googleCitationCount":58,"googleAuthor":"HH Loong","doi":"10.1093/annonc/mdx702","elsevierAuthor":"Hsu W.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"44","altmetricAuthors":["W.-H. Hsu","J.C.-H. Yang","T.S. Mok","H.H. Loong"],"twitterCount":5,"altmetricId":33367601},{"title":"Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer","googleId":"rzSFX2XnlxIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353876","googleCitationCount":61,"googleAuthor":"E Pleasance","doi":"10.1093/annonc/mdx523","elsevierAuthor":"Jones M.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"45","altmetricAuthors":["M.R. Jones","H. Lim","Y. Shen","E. Pleasance","C. Ch'ng","C. Reisle","S. Leelakumari","C. Zhao","S. Yip","J. Ho","E. Zhong","T. Ng","D. Ionescu","D.F. Schaeffer","A.J. Mungall","K.L. Mungall","Y. Zhao","R.A. Moore","Y. Ma","S. Chia","C. Ho","D.J. Renouf","K. Gelmon","S.J.M. Jones","M.A. Marra","J. Laskin"],"twitterCount":8,"altmetricId":26271680},{"title":"Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up","googleId":"BVO2fy8qa4EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931909X","googleCitationCount":81,"googleAuthor":"H Kadara","doi":"10.1093/annonc/mdw436","elsevierAuthor":"Wang F.","publicationName":"Frontiers in Oncology","elsevierCoverDate":"2020-10-20","elsevierCoverDisplayDate":"20 October 2020","elsevierCitationCount":"0","altmetricAuthors":["H Kadara","M Choi","J. Zhang","E.R. Parra","J. Rodriguez-Canales","S.G. Gaffney","Z. Zhao","C. Behrens","J. Fujimoto","C. Chow","Y. Yoo","N. Kalhor","C. Moran","D. Rimm","S. Swisher","D.L. Gibbons","J. Heymach","E. Kaftan","J.P. Townsend","T.J. Lynch","J. Schlessinger","J. Lee","R.P. Lifton","I.I. Wistuba","R.S. Herbst"],"twitterCount":11,"altmetricId":12561835},{"title":"ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal …","googleId":"bChMFevPuykJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39139-0/abstract","googleCitationCount":64,"googleAuthor":"I McNeish"},{"title":"Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma …","googleId":"WgrkaTwq-SUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934952X","googleCitationCount":64,"googleAuthor":"HM Prince","doi":"10.1093/annonc/mdx352","elsevierAuthor":"Alhusayen R.","publicationName":"Dermatology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":["P. Quaglino","M. Maule","H.M. Prince","P. Porcu","S. Horwitz","M. Duvic","R. Talpur","M. Vermeer","M. Bagot","J. Guitart","E. Papadavid","J.A. Sanches","E. Hodak","M. Sugaya","E. Berti","P. Ortiz-Romero","N. Pimpinelli","O. Servitje","A. Pileri","P.L. Zinzani","T. Estrach","R. Knobler","R. Stadler","M.T. Fierro","S. Alberti Violetti","I. Amitay-Laish","C. Antoniou","C. Astrua","S. Chaganti","F. Child","A. Combalia","S. Fabbro","P. Fava","V. Grandi","C. Jonak","E. Martinez-Escala","M. Kheterpal","E.J. Kim","C. McCormack","T. Miyagaki","D. Miyashiro","S. Morris","C. Muniesa","V. Nikolaou","G. Ognibene","F. Onida","S. Osella-Abate","S. Porkert","C. Postigo-Llorente","C. Ram-Wolff","S. Ribero","K. Rogers","M. Sanlorenzo","R. Stranzenbach","N. Spaccarelli","A. Stevens","D. Zugna","A.H. Rook","L.J. Geskin","R. Willemze","S. Whittaker","R. Hoppe","J. Scarisbrick","Y. Kim"],"twitterCount":3,"altmetricId":26836949},{"title":"Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study","googleId":"S5lXFX-HE2cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353864","googleCitationCount":66,"googleAuthor":"RW Joseph","doi":"10.1093/annonc/mdx518","elsevierAuthor":"Necchi A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"53","altmetricAuthors":["A. Necchi","R.W. Joseph","Y. Loriot","J. Hoffman-Censits","J.L. Perez-Gracia","D.P. Petrylak","C.L. Derleth","D. Tayama","Q. Zhu","B. Ding","C. Kaiser","J.E. Rosenberg"],"twitterCount":6,"altmetricId":25032236},{"title":"The European society for medical oncology (ESMO) precision medicine glossary","googleId":"16uKHIZmFr0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350112","googleCitationCount":61,"googleAuthor":"LL Siu","doi":"10.1093/annonc/mdx707","elsevierAuthor":"Yates L.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"35","altmetricAuthors":["L.R. Yates","J. Seoane","C. Le Tourneau","L.L. Siu","R. Marais","S. Michiels","J.C. Soria","P. Campbell","N. Normanno","A. Scarpa","J.S. Reis-Filho","J. Rodon","C. Swanton","F. Andre"],"twitterCount":99,"altmetricId":28839354},{"title":"Cancer deaths and cases attributable to lifestyle factors and infections in China, 2013","googleId":"UBKIYXH_QgQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349464","googleCitationCount":60,"googleAuthor":"F Islami","doi":"10.1093/annonc/mdx342","elsevierAuthor":"Islami F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"43","altmetricAuthors":["F. Islami","W. Chen","X.Q. Yu","J. Lortet-Tieulent","R. Zheng","W.D. Flanders","C. Xia","M.J. Thun","S.M. Gapstur","M. Ezzati","A. Jemal"],"twitterCount":8,"altmetricId":21538291},{"title":"The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular …","googleId":"x5G1gAdb-PgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318885","googleCitationCount":54,"googleAuthor":"CK Lee","doi":"10.1093/annonc/mdy410","elsevierAuthor":"Mooi J.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"37","altmetricAuthors":["J.K. Mooi","P. Wirapati","R. Asher","C.K. Lee","P. Savas","T.J. Price","A. Townsend","J. Hardingham","D. Buchanan","D. Williams","S. Tejpar","J.M. Mariadason","N.C. Tebbutt"],"twitterCount":11,"altmetricId":48780676},{"title":"Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind …","googleId":"iVoGQe7utRMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354912","googleCitationCount":57,"googleAuthor":"","doi":"10.1093/annonc/mdx767","elsevierAuthor":"Tabernero J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"41","altmetricAuthors":["J. Tabernero","R.R. Hozak","T. Yoshino","A.L. Cohn","R. Obermannova","G. Bodoky","R. Garcia-Carbonero","T.-E. Ciuleanu","D.C. Portnoy","J. Prausová","K. Muro","R.W. Siegel","R.J. Konrad","H. Ouyang","S.A. Melemed","D. Ferry","F. Nasroulah","E. Van Cutsem"],"twitterCount":17,"altmetricId":30375879},{"title":"Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with …","googleId":"nd2kB4tfcM4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50406-9/abstract","googleCitationCount":53,"googleAuthor":"J Brody"},{"title":"Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) young oncologists committee burnout …","googleId":"59EQj5YOZIwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322811","googleCitationCount":63,"googleAuthor":"R Califano","doi":"10.1093/annonc/mdx196","elsevierAuthor":"Phillips C.S.","publicationName":"Journal of Advanced Nursing","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"1 November 2019","elsevierCitationCount":"5","altmetricAuthors":["S. Banerjee","R. Califano","J. Corral","E. de Azambuja","L. De Mattos-Arruda","V. Guarneri","M. Hutka","K. Jordan","E. Martinelli","G. Mountzios","M.A. Ozturk","M. Petrova","S. Postel-Vinay","M. Preusser","C. Qvortrup","M.N.M. Volkov","J. Tabernero","D. Olmos","M.H. Strijbos"],"twitterCount":69,"altmetricId":19544027},{"title":"ClonEvol: clonal ordering and visualization in cancer sequencing","googleId":"Nk1etyO1BTcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353852","googleCitationCount":59,"googleAuthor":"HX Dang","doi":"10.1093/annonc/mdx517","elsevierAuthor":"Dang H.X.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"41","altmetricAuthors":["H.X. Dang","B.S. White","S.M. Foltz","C.A. Miller","J. Luo","R.C. Fields","C.A. Maher"],"twitterCount":27,"altmetricId":25116848},{"title":"Development of an integrated electronic platform for patient self-report and management of adverse events during cancer treatment","googleId":"fDV3rOx_GwIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352597","googleCitationCount":59,"googleAuthor":"P Holch","doi":"10.1093/annonc/mdx317","elsevierAuthor":"Holch P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"35","altmetricAuthors":["P. Holch","L. Warrington","L.C.A. Bamforth","A. Keding","L.E. Ziegler","K. Absolom","C. Hector","C. Harley","O. Johnson","G. Hall","C. Morris","G. Velikova"],"twitterCount":33,"altmetricId":21304945},{"title":"JAVELIN renal 101: a randomized, Phase III study of avelumab+ axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)","googleId":"7ycuXzG_e7YJ","googleLink":"https://researchers.mq.edu.au/files/117842959/Publisher_version_open_access_.pdf","googleCitationCount":48,"googleAuthor":"K Penkov"},{"title":"Pertuzumab (P)+ trastuzumab (H)+ chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC/GEJC): final analysis of a …","googleId":"EiiSpPr7zd4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37890-X/abstract","googleCitationCount":59,"googleAuthor":"PM Hoff"},{"title":"Corrections to “Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”","googleId":"ya4axIpRsIQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31702-8/abstract","googleCitationCount":55,"googleAuthor":"S Mahner"},{"title":"Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information","googleId":"BxJyYr852YUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454689","googleCitationCount":55,"googleAuthor":"S Kim","doi":"10.1093/annonc/mdy022","elsevierAuthor":"Kim S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"44","altmetricAuthors":["S. Kim","H.S. Kim","E. Kim","M.G. Lee","E.-C. Shin","S. Paik","S. Kim"],"twitterCount":11,"altmetricId":31969911},{"title":"Molecular tumor boards: current practice and future needs","googleId":"5Mz-lPEyZO8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353918","googleCitationCount":55,"googleAuthor":"","doi":"10.1093/annonc/mdx528","elsevierAuthor":"van der Velden D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"38","altmetricAuthors":["D.L. van der Velden","C.M.L. van Herpen","H.W.M. van Laarhoven","E.F. Smit","H.J.M. Groen","S.M. Willems","P.M. Nederlof","M.H.G. Langenberg","E. Cuppen","S. Sleijfer","N. Steeghs","E.E. Voest"],"twitterCount":4,"altmetricId":26737200},{"title":"Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial","googleId":"V7m10H-CD6EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454628","googleCitationCount":59,"googleAuthor":"","doi":"10.1093/annonc/mdy012","elsevierAuthor":"Rugo H.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"44","altmetricAuthors":["H.S. Rugo","V. Diéras","K.A. Gelmon","R.S. Finn","D.J. Slamon","M. Martin","P. Neven","Y. Shparyk","A. Mori","D.R. Lu","H. Bhattacharyya","C.H.u.a.n.g. Bartlett","S. Iyer","S. Johnston","J. Ettl","N. Harbeck"],"twitterCount":14,"altmetricId":32034272},{"title":"Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East …","googleId":"-cL_0UV2Vn8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345958","googleCitationCount":54,"googleAuthor":"S Lu","doi":"10.1093/annonc/mdx419","elsevierAuthor":"Nokihara H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"42","altmetricAuthors":["H. Nokihara","S. Lu","T.S.K. Mok","K. Nakagawa","N. Yamamoto","Y.K. Shi","L. Zhang","R.A. Soo","J.C. Yang","S. Sugawara","M. Nishio","T. Takahashi","K. Goto","J. Chang","M. Maemondo","Y. Ichinose","Y. Cheng","W.T. Lim","S. Morita","T. Tamura"],"twitterCount":7,"altmetricId":29209439},{"title":"Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)","googleId":"X-TX3qZNWXkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319556","googleCitationCount":78,"googleAuthor":"","doi":"10.1093/annonc/mdw625","elsevierAuthor":"Mesnage S.J.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"65","altmetricAuthors":["S.J.L. Mesnage","A. Auguste","C. Genestie","A. Dunant","E. Pain","F. Drusch","S. Gouy","P. Morice","E. Bentivegna","C. Lhomme","P. Pautier","J. Michels","A. Le Formal","B. Cheaib","J. Adam","A.F. Leary"],"twitterCount":21,"altmetricId":13778193},{"title":"Primary PFS and safety analyses of a randomized phase III study of carboplatin+ paclitaxel+/− bevacizumab, with or without atezolizumab in 1L non-squamous …","googleId":"tW_SKT_2ZGIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32868-6/abstract","googleCitationCount":55,"googleAuthor":"F Cappuzzo"},{"title":"Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA","googleId":"Xn_fzJLlcP0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39150-X/abstract","googleCitationCount":57,"googleAuthor":""},{"title":"Investigating the poor outcomes ofBRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials","googleId":"8i5eZ_PLMVMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319623","googleCitationCount":73,"googleAuthor":"CG Smith","doi":"10.1093/annonc/mdw645","elsevierAuthor":"Fanelli G.N.","publicationName":"Cancer Cell International","elsevierCoverDate":"2020-01-29","elsevierCoverDisplayDate":"29 January 2020","elsevierCitationCount":"7","altmetricAuthors":["J.F. Seligmann","D. Fisher","C.G. Smith","S.D. Richman","F. Elliott","S. Brown","R. Adams","T. Maughan","P. Quirke","J. Cheadle","M. Seymour","G. Middleton"],"twitterCount":0,"altmetricId":15558865},{"title":"Subjective and objective taste and smell changes in cancer","googleId":"FYPektw0N9wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320009","googleCitationCount":56,"googleAuthor":"CA Corish","doi":"10.1093/annonc/mdx018","elsevierAuthor":"Azzam P.","publicationName":"ecancermedicalscience","elsevierCoverDate":"2020-05-16","elsevierCoverDisplayDate":"16 May 2020","elsevierCitationCount":"0","altmetricAuthors":["L.E. Spotten","C.A. Corish","C.M. Lorton","P.M. Ui Dhuibhir","N.C. O’Donoghue","B. O’Connor","T.D. Walsh"],"twitterCount":6,"altmetricId":17163832},{"title":"Fluoropyrimidine (FP)+ bevacizumab (BEV)+ atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL–a …","googleId":"CnozItgixTkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50411-2/abstract","googleCitationCount":44,"googleAuthor":"A Grothey"},{"title":"Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic …","googleId":"_TruGkshOrMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342334","googleCitationCount":44,"googleAuthor":"F Diehl","doi":"10.1093/annonc/mdy417","elsevierAuthor":"Kruger S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"27","altmetricAuthors":["S. Kruger","V. Heinemann","C. Ross","F. Diehl","D. Nagel","S. Ormanns","S. Liebmann","I. Prinz-Bravin","C.B. Westphalen","M. Haas","A. Jung","T. Kirchner","M. von Bergwelt-Baildon","S. Boeck","S. Holdenrieder"],"twitterCount":60,"altmetricId":50019933},{"title":"The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC","googleId":"Q0RqKI0np2oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341935255X","googleCitationCount":57,"googleAuthor":"PN Aguiar Jr","doi":"10.1093/annonc/mdx305","elsevierAuthor":"Bravaccini S.","publicationName":"Lung Cancer","elsevierCoverDate":"2019-06-01","elsevierCoverDisplayDate":"June 2019","elsevierCitationCount":"3","altmetricAuthors":["P N Aguiar","L A Perry","J Penny-Dimri","H Babiker","H Tadokoro","R A de Mello","G L Lopes"],"twitterCount":11,"altmetricId":21094200},{"title":"Pattern recognition receptors: immune targets to enhance cancer immunotherapy","googleId":"g4dxCRjrbT8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321362","googleCitationCount":57,"googleAuthor":"J Brody","doi":"10.1093/annonc/mdx179","elsevierAuthor":"Bai L.","publicationName":"Pharmacological Research","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"1","altmetricAuthors":["T. Shekarian","S. Valsesia-Wittmann","J. Brody","M.C. Michallet","S. Depil","C. Caux","A. Marabelle"],"twitterCount":98,"altmetricId":19233747},{"title":"Larotrectinib efficacy and safety in TRK fusion cancer: an expanded clinical dataset showing consistency in an age and tumor agnostic approach","googleId":"08Pe7nwlSfEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48876-5/abstract","googleCitationCount":43,"googleAuthor":"UN Lassen"},{"title":"Infection-related complications during treatment for childhood acute lymphoblastic leukemia","googleId":"qsJjY-GcvoEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322057","googleCitationCount":62,"googleAuthor":"SC Howard","doi":"10.1093/annonc/mdw557","elsevierAuthor":"Inaba H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"29","altmetricAuthors":["H. Inaba","D. Pei","J. Wolf","S.C. Howard","R.T. Hayden","M. Go","O. Varechtchouk","T. Hahn","J. Buaboonnam","M.L. Metzger","J.E. Rubnitz","R.C. Ribeiro","J.T. Sandlund","S. Jeha","C. Cheng","W.E. Evans","M.V. Relling","C.-H. Pui"],"twitterCount":3,"altmetricId":13062085},{"title":"Mapping unmet supportive care needs, quality-of-life perceptions and current symptoms in cancer survivors across the Asia-Pacific region: results from the …","googleId":"O3snlcxwf78J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349506","googleCitationCount":54,"googleAuthor":"A Molassiotis","doi":"10.1093/annonc/mdx350","elsevierAuthor":"Molassiotis A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"0","altmetricAuthors":["A. Molassiotis","P. Yates","Q. Li","W.K.W. So","K. Pongthavornkamol","P. Pittayapan","H. Komatsu","M. Thandar","M. Yi","S. Titus Chacko","V. Lopez","J. Butcon","D. Wyld","R.J. Chan","Melissa Doolan","Maria Estrella Litam","Rubiliza Onofre","Conchitina Lluch","Rosebe Nacion","Maria Luisa Ombao","Zaw Wai Soe","Theingi Myint","Emily Ang","Harue Arao","Kaori Yagasaki","Vinitha Ravindran","Roselin V. Rhenius","Amalorpavamari Lucas","Lillian Percy Kujur","Abijah Princy","Kai-chow Choi","Yin-ping Choy","Yan-pui Lee","Chun-yip Shiu","Yinghua Xu"],"twitterCount":1,"altmetricId":27911651},{"title":"Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma","googleId":"1Gdv-h0Gr3gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341407","googleCitationCount":50,"googleAuthor":"","doi":"10.1093/annonc/mdy226","elsevierAuthor":"Tetzlaff M.T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"39","altmetricAuthors":["M.T. Tetzlaff","J.L. Messina","J.E. Stein","X. Xu","R.N. Amaria","C.U. Blank","B.A. van de Wiel","P.M. Ferguson","R.V. Rawson","M.I. Ross","A.J. Spillane","J.E. Gershenwald","R.P.M. Saw","A.C.J. van Akkooi","W.J. van Houdt","T.C. Mitchell","A.M. Menzies","G.V. Long","J.A. Wargo","M.A. Davies","V.G. Prieto","J.M. Taube","R.A. Scolyer"],"twitterCount":40,"altmetricId":44119329},{"title":"Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers","googleId":"7YMm8uDyEfEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37805-4/abstract","googleCitationCount":54,"googleAuthor":"TW Kim"},{"title":"Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone …","googleId":"q-aW8DuuEI0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341705","googleCitationCount":47,"googleAuthor":"","doi":"10.1093/annonc/mdy249","elsevierAuthor":"Hong R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"35","altmetricAuthors":["R.L. Hong","C.F. Hsiao","L.L. Ting","J.Y. Ko","C.W. Wang","J.T.C. Chang","P.J. Lou","H.M. Wang","M.H. Tsai","S.C. Lai","T.W. Liu"],"twitterCount":7,"altmetricId":45571496},{"title":"Periodontal disease, edentulism, and pancreatic cancer: a meta-analysis","googleId":"leiMMexwTX8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320010","googleCitationCount":61,"googleAuthor":"P Maisonneuve","doi":"10.1093/annonc/mdx019","elsevierAuthor":"Chen Y.","publicationName":"Journal of Clinical Periodontology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"1 September 2020","elsevierCitationCount":"0","altmetricAuthors":["P. Maisonneuve","S. Amar","A.B. Lowenfels"],"twitterCount":5,"altmetricId":15919531},{"title":"A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive …","googleId":"zU4jRRRngCAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324226","googleCitationCount":56,"googleAuthor":"MH Kulke","doi":"10.1093/annonc/mdx078","elsevierAuthor":"Kulke M.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"0","altmetricAuthors":["M.H. Kulke","P. Ruszniewski","E. Van Cutsem","C. Lombard-Bohas","J.W. Valle","W.W. De Herder","M. Pavel","E. Degtyarev","J.C. Brase","L. Bubuteishvili-Pacaud","M. Voi","R. Salazar","I. Borbath","N. Fazio","D. Smith","J. Capdevila","R.P. Riechelmann","J.C. Yao"],"twitterCount":8,"altmetricId":18066297},{"title":"Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer","googleId":"_JHsuXugQlAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346095","googleCitationCount":52,"googleAuthor":"AB Schrock","doi":"10.1093/annonc/mdx490","elsevierAuthor":"Chung J.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"40","altmetricAuthors":["J.H. Chung","D. Pavlick","R. Hartmaier","A.B. Schrock","L. Young","B. Forcier","P. Ye","M.K. Levin","M. Goldberg","H. Burris","L.M. Gay","A.D. Hoffman","P.J. Stephens","G.M. Frampton","D.M. Lipson","D.M. Nguyen","S. Ganesan","B.H. Park","L.T. Vahdat","B. Leyland-Jones","T.I. Mughal","L. Pusztai","J. O’Shaughnessy","V.A. Miller","J.S. Ross","S.M. Ali"],"twitterCount":15,"altmetricId":26591011},{"title":"Second primary malignancies in multiple myeloma: an overview and IMWG consensus","googleId":"I4f4osDJABEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322185","googleCitationCount":69,"googleAuthor":"","doi":"10.1093/annonc/mdw606","elsevierAuthor":"Zhao Y.","publicationName":"Cell Biology and Toxicology","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0","altmetricAuthors":["P. Musto","K.C. Anderson","M. Attal","P.G. Richardson","A. Badros","J. Hou","R. Comenzo","J. Du","B.G.M. Durie","J. San Miguel","H. Einsele","W.M. Chen","L. Garderet","G. Pietrantuono","J. Hillengass","R.A. Kyle","P. Moreau","J.J. Lahuerta","O. Landgren","H. Ludwig","A. Larocca","A. Mahindra","M. Cavo","A. Mazumder","P.L. McCarthy","A. Nouel","S.V. Rajkumar","A. Reiman","E. Riva","O. Sezer","E. Terpos","I. Turesson","S. Usmani","B.M. Weiss","A. Palumbo"],"twitterCount":24,"altmetricId":13794337},{"title":"Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for …","googleId":"5s9MQ2NMZO4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50458-6/abstract","googleCitationCount":42,"googleAuthor":"V Velcheti"},{"title":"Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic …","googleId":"trGJOyDGiK0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349476","googleCitationCount":56,"googleAuthor":"J Siveke","doi":"10.1093/annonc/mdx343","elsevierAuthor":"Schultheis B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"39","altmetricAuthors":["B. Schultheis","D. Reuter","M.P. Ebert","J. Siveke","A. Kerkhoff","W.E. Berdel","R. Hofheinz","D.M. Behringer","W.E. Schmidt","E. Goker","S. De Dosso","M. Kneba","S. Yalcin","F. Overkamp","F. Schlegel","M. Dommach","R. Rohrberg","T. Steinmetz","M. Bulitta","D. Strumberg"],"twitterCount":5,"altmetricId":22387607},{"title":"Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer","googleId":"cJDlrTiTRyMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454719","googleCitationCount":51,"googleAuthor":"N Priedigkeit","doi":"10.1093/annonc/mdy025","elsevierAuthor":"Hartmaier R.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"37","altmetricAuthors":["R.J. Hartmaier","S.E. Trabucco","N. Priedigkeit","J.H. Chung","C.A. Parachoniak","P. Vanden Borre","S. Morley","M. Rosenzweig","L.M. Gay","M.E. Goldberg","J. Suh","S.M. Ali","J. Ross","B. Leyland-Jones","B. Young","C. Williams","B. Park","M. Tsai","B. Haley","J. Peguero","R.D. Callahan","I. Sachelarie","J. Cho","J.M. Atkinson","A. Bahreini","A.M. Nagle","S.L. Puhalla","R.J. Watters","Z. Erdogan-Yildirim","L. Cao","S. Oesterreich","A. Mathew","P.C. Lucas","N.E. Davidson","A.M. Brufsky","G.M. Frampton","P.J. Stephens","J. Chmielecki","A.V. Lee"],"twitterCount":55,"altmetricId":31937265},{"title":"Acquired chemotherapy resistance in ovarian cancer","googleId":"kRQ7nHL9jb8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420346573","googleCitationCount":50,"googleAuthor":"EL Christie","doi":"10.1093/annonc/mdx446","elsevierAuthor":"Christie E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"1 November 2017","elsevierCitationCount":"35","altmetricAuthors":[],"twitterCount":0},{"title":"Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative …","googleId":"y_Hwm3sXs-kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320460","googleCitationCount":67,"googleAuthor":"J Brown","doi":"10.1093/annonc/mdw665","elsevierAuthor":"Tufano A.M.","publicationName":"Clinical Breast Cancer","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0","altmetricAuthors":["R. Bell","J. Brown","M. Parmar","M. Toi","T. Suter","G.G. Steger","X. Pivot","J. Mackey","C. Jackisch","R. Dent","P. Hall","N. Xu","L. Morales","L. Provencher","R. Hegg","L. Vanlemmens","A. Kirsch","A. Schneeweiss","N. Masuda","F. Overkamp","D. Cameron"],"twitterCount":2,"altmetricId":14865535},{"title":"Nivolumab induced radiation recall pneumonitis after two years of radiotherapy","googleId":"LwcPSS7YNk0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32437-8/abstract","googleCitationCount":57,"googleAuthor":""},{"title":"Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA …","googleId":"yhogiUBXn4kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354997","googleCitationCount":48,"googleAuthor":"","doi":"10.1093/annonc/mdx787","elsevierAuthor":"Fossard G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"36","altmetricAuthors":["G. Fossard","F. Broussais","I. Coelho","S. Bailly","E. Nicolas-Virelizier","E. Toussaint","C. Lancesseur","F. Le Bras","E. Willems","E. Tchernonog","T. Chalopin","R. Delarue","R. Gressin","A. Chauchet","E. Gyan","G. Cartron","C. Bonnet","C. Haioun","G. Damaj","P. Gaulard","L. Fornecker","H. Ghesquières","O. Tournilhac","M. Gomes da Silva","R. Bouabdallah","G. Salles","E. Bachy"],"twitterCount":35,"altmetricId":30681455},{"title":"Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study","googleId":"uc12gvuaon4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320162","googleCitationCount":54,"googleAuthor":"A Ribas","doi":"10.1093/annonc/mdx040","elsevierAuthor":"Cohen-Aubart F.","publicationName":"Annals of the Rheumatic Diseases","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":["B. Dréno","A. Ribas","J. Larkin","P.A. Ascierto","A. Hauschild","L. Thomas","J.-J. Grob","D.O. Koralek","I. Rooney","J.J. Hsu","E.F. McKenna","G.A. McArthur"],"twitterCount":5,"altmetricId":19494337},{"title":"Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the …","googleId":"0MebEzG64wIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321015","googleCitationCount":47,"googleAuthor":"C Cremolini","doi":"10.1093/annonc/mdy140","elsevierAuthor":"Cremolini C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"40","altmetricAuthors":["C. Cremolini","C. Antoniotti","S. Lonardi","F. Bergamo","E. Cortesi","G. Tomasello","R. Moretto","M. Ronzoni","P. Racca","F. Loupakis","A. Zaniboni","G. Tonini","A. Buonadonna","F. Marmorino","G. Allegrini","C. Granetto","G. Masi","V. Zagonel","E. Sensi","G. Fontanini","L. Boni","A. Falcone"],"twitterCount":23,"altmetricId":39288798},{"title":"Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients","googleId":"3GpLyzqtnMoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345521","googleCitationCount":42,"googleAuthor":"JL Perez-Gracia","doi":"10.1093/annonc/mdy089","elsevierAuthor":"Rodríguez-Ruiz M.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"34","altmetricAuthors":["M.E. Rodríguez-Ruiz","J.L. Perez-Gracia","I. Rodríguez","C. Alfaro","C. Oñate","G. Pérez","I. Gil-Bazo","A. Benito","S. Inogés","A. López-Diaz de Cerio","M. Ponz-Sarvise","L. Resano","P. Berraondo","B. Barbés","S. Martin-Algarra","A. Gúrpide","M.F. Sanmamed","C. de Andrea","A.M. Salazar","I. Melero"],"twitterCount":11,"altmetricId":34632490},{"title":"Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study","googleId":"gFl3-e4UZEYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341754","googleCitationCount":41,"googleAuthor":"","doi":"10.1093/annonc/mdy256","elsevierAuthor":"De Vos S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"33","altmetricAuthors":["S. de Vos","L.J. Swinnen","D. Wang","E. Reid","N. Fowler","J. Cordero","M. Dunbar","S.H. Enschede","C. Nolan","A.M. Petrich","J.A. Ross","A.H. Salem","M. Verdugo","S. Agarwal","L. Zhou","M. Kozloff","L.J. Nastoupil","C.R. Flowers"],"twitterCount":16,"altmetricId":45809351},{"title":"Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative …","googleId":"Tmzq_-ul8E0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341328","googleCitationCount":43,"googleAuthor":"L Malorni","doi":"10.1093/annonc/mdy214","elsevierAuthor":"Malorni L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"37","altmetricAuthors":["L. Malorni","G. Curigliano","A.M. Minisini","S. Cinieri","C.A. Tondini","K. D’Hollander","G. Arpino","A. Bernardo","A. Martignetti","C. Criscitiello","F. Puglisi","M. Pestrin","G. Sanna","E. Moretti","E. Risi","C. Biagioni","A. McCartney","L. Boni","M. Buyse","I. Migliaccio","L. Biganzoli","A. Di Leo"],"twitterCount":35,"altmetricId":43586983},{"title":"Velour trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity","googleId":"QKpKRxgqzG8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)66216-2/abstract","googleCitationCount":54,"googleAuthor":""},{"title":"Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2 …","googleId":"hNWw21fKSlEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352561","googleCitationCount":53,"googleAuthor":"AS Hamy","doi":"10.1093/annonc/mdx309","elsevierAuthor":"Hamy A.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"34","altmetricAuthors":["A.-S. Hamy","J.-Y. Pierga","A. Sabaila","E. Laas","H. Bonsang-Kitzis","C. Laurent","A. Vincent-Salomon","P. Cottu","F. Lerebours","R. Rouzier","M. Lae","F. Reyal"],"twitterCount":21,"altmetricId":21098561},{"title":"Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer","googleId":"cArXuAfWad4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342358","googleCitationCount":38,"googleAuthor":"P Cottu","doi":"10.1093/annonc/mdy448","elsevierAuthor":"Cottu P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"30","altmetricAuthors":["P. Cottu","V. D'Hondt","S. Dureau","F. Lerebours","I. Desmoulins","P.-E. Heudel","F.P. Duhoux","C. Levy","M.-A. Mouret-Reynier","F. Dalenc","J.-S. Frenel","C. Jouannaud","L. Venat-Bouvet","S. Nguyen","J.-M. Ferrero","J.-L. Canon","J. Grenier","C. Callens","D. Gentien","J. Lemonnier","A. Vincent-Salomon","S. Delaloge"],"twitterCount":49,"altmetricId":49515809},{"title":"Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer","googleId":"wjQPzV-QDo0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316710","googleCitationCount":49,"googleAuthor":"L Friboulet","doi":"10.1093/annonc/mdx705","elsevierAuthor":"Favazza L.A.","publicationName":"Modern Pathology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"1 September 2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0},{"title":"The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast","googleId":"M2YUfbqT4RgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932229X","googleCitationCount":53,"googleAuthor":"M Lazzeroni","doi":"10.1093/annonc/mdw623","elsevierAuthor":"Pruneri G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"41","altmetricAuthors":["G. Pruneri","M. Lazzeroni","V. Bagnardi","G.B. Tiburzio","N. Rotmensz","A. DeCensi","A. Guerrieri-Gonzaga","A. Vingiani","G. Curigliano","S. Zurrida","F. Bassi","R. Salgado","G. Van den Eynden","S. Loi","C. Denkert","B. Bonanni","G. Viale"],"twitterCount":25,"altmetricId":13613683},{"title":"nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast …","googleId":"39qHxHyYTlMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341225","googleCitationCount":43,"googleAuthor":"R Coleman","doi":"10.1093/annonc/mdy201","elsevierAuthor":"Yardley D.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"37","altmetricAuthors":["D.A. Yardley","R. Coleman","P. Conte","J. Cortes","A. Brufsky","M. Shtivelband","R. Young","C. Bengala","H. Ali","J. Eakel","A. Schneeweiss","L. de la Cruz-Merino","S. Wilks","J. O’Shaughnessy","S. Glück","H. Li","J. Miller","D. Barton","N. Harbeck"],"twitterCount":46,"altmetricId":43409127},{"title":"Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients","googleId":"Saws194IJzUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349944","googleCitationCount":49,"googleAuthor":"M Lambertini","doi":"10.1093/annonc/mdx639","elsevierAuthor":"Lambertini M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"37","altmetricAuthors":["M. Lambertini","O. Goldrat","A.R. Ferreira","J. Dechene","H.A. Azim Jr","J. Desir","A. Delbaere","M.-D. t’Kint de Roodenbeke","E. de Azambuja","M. Ignatiadis","I. Demeestere"],"twitterCount":43,"altmetricId":27248526},{"title":"Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?","googleId":"p0LeEFdraUAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353839","googleCitationCount":47,"googleAuthor":"IH Sahin","doi":"10.1093/annonc/mdx503","elsevierAuthor":"Sahin I.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"30","altmetricAuthors":["I.H. Sahin","G. Askan","Z.I. Hu","E.M. O’Reilly"],"twitterCount":29,"altmetricId":24770236},{"title":"What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis","googleId":"2o93TR0d-F4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345405","googleCitationCount":45,"googleAuthor":"IR White","doi":"10.1093/annonc/mdy071","elsevierAuthor":"Vale C.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"34","altmetricAuthors":["C.L. Vale","D.J. Fisher","I.R. White","J.R. Carpenter","S. Burdett","N.W. Clarke","K. Fizazi","G. Gravis","N.D. James","M.D. Mason","M.K.B. Parmar","L.H. Rydzewska","C.J. Sweeney","M.R. Spears","M.R. Sydes","J.F. Tierney"],"twitterCount":17,"altmetricId":33680499},{"title":"Impact of zumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: exploratory analysis of the phase ii checkmate 275 study","googleId":"4bFbq6yoz74J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38122-9/abstract","googleCitationCount":49,"googleAuthor":""},{"title":"Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma","googleId":"zpHVKPgqZhEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350070","googleCitationCount":48,"googleAuthor":"E Ghorani","doi":"10.1093/annonc/mdx687","elsevierAuthor":"Ghorani E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"37","altmetricAuthors":["E. Ghorani","R. Rosenthal","N. McGranahan","J.L. Reading","M. Lynch","K.S. Peggs","C. Swanton","S.A. Quezada"],"twitterCount":16,"altmetricId":28237091},{"title":"Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions","googleId":"GJWU25bDTYkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345582","googleCitationCount":41,"googleAuthor":"EEW Cohen","doi":"10.1093/annonc/mdy102","elsevierAuthor":"Haddad R.I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"30","altmetricAuthors":["R.I. Haddad","M. Posner","R. Hitt","E.E.W. Cohen","J. Schulten","J.-L. Lefebvre","J.B. Vermorken"],"twitterCount":40,"altmetricId":35366342},{"title":"Addressing the quality of life needs of older patients with cancer: a SIOG consensus paper and practical guide","googleId":"w99YVEXzsH0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341420","googleCitationCount":38,"googleAuthor":"F Scotté","doi":"10.1093/annonc/mdy228","elsevierAuthor":"Scotté F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"30","altmetricAuthors":["F. Scotté","P. Bossi","E. Carola","T. Cudennec","P. Dielenseger","F. Gomes","S. Knox","F. Strasser"],"twitterCount":63,"altmetricId":45079755},{"title":"CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer","googleId":"BRzdf1031OUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345491","googleCitationCount":41,"googleAuthor":"","doi":"10.1093/annonc/mdy085","elsevierAuthor":"Smeby J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"31","altmetricAuthors":["J. Smeby","A. Sveen","M.A. Merok","S.A. Danielsen","I.A. Eilertsen","M.G. Guren","R. Dienstmann","A. Nesbakken","R.A. Lothe"],"twitterCount":10,"altmetricId":34279367},{"title":"Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm","googleId":"KdzBP6cnKjAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31971-4/abstract","googleCitationCount":62,"googleAuthor":"N Shenoy"},{"title":"Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients","googleId":"_nzkQ6SAG-0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454781","googleCitationCount":43,"googleAuthor":"E Pectasides","doi":"10.1093/annonc/mdy034","elsevierAuthor":"Kim S.T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"35","altmetricAuthors":["S.T. Kim","K.C. Banks","E. Pectasides","S.Y. Kim","K. Kim","R.B. Lanman","A. Talasaz","J. An","M.G. Choi","J.H. Lee","T.S. Sohn","J.M. Bae","S. Kim","S.H. Park","J.O. Park","Y.S. Park","H.Y. Lim","N.K.D. Kim","W. Park","H. Lee","A.J. Bass","K. Kim","W.K. Kang","J. Lee"],"twitterCount":14,"altmetricId":32543953},{"title":"Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic","googleId":"hXWDpA0TieUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32420-2/abstract","googleCitationCount":48,"googleAuthor":""},{"title":"Do contemporary randomized controlled trials meet ESMO thresholds for meaningful clinical benefit?","googleId":"h12xVhUjB-sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319301","googleCitationCount":63,"googleAuthor":"R Sullivan","doi":"10.1093/annonc/mdw538","elsevierAuthor":"Del Paggio J.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"38","altmetricAuthors":["J.C. Del Paggio","B. Azariah","R. Sullivan","W.M. Hopman","F.V. James","S. Roshni","I.F. Tannock","C.M. Booth"],"twitterCount":110,"altmetricId":12636703},{"title":"Waldenström's macroglobulinaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","googleId":"iUFI1cMahvEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31695-3/abstract","googleCitationCount":35,"googleAuthor":"E Kastritis"},{"title":"Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma","googleId":"_TamHOAeuMwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345302","googleCitationCount":43,"googleAuthor":"W Jurczak","doi":"10.1093/annonc/mdy056","elsevierAuthor":"Jurczak W.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"32","altmetricAuthors":["W. Jurczak","P.L. Zinzani","G. Gaidano","A. Goy","M. Provencio","Z. Nagy","T. Robak","K. Maddocks","C. Buske","S. Ambarkhane","M. Winderlich","M. Dirnberger-Hertweck","R. Korolkiewicz","K.A. Blum"],"twitterCount":11,"altmetricId":33203750},{"title":"Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE …","googleId":"Rfgoqy9ugfkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349002","googleCitationCount":42,"googleAuthor":"HG Wirsching","doi":"10.1093/annonc/mdy120","elsevierAuthor":"Wirsching H.G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"34","altmetricAuthors":["H.-G. Wirsching","G. Tabatabai","U. Roelcke","A.F. Hottinger","F. Jörger","A. Schmid","L. Plasswilm","D. Schrimpf","C. Mancao","D. Capper","K. Conen","T. Hundsberger","F. Caparrotti","R. von Moos","C. Riklin","J. Felsberg","P. Roth","D.T.W. Jones","S. Pfister","E.J. Rushing","L. Abrey","G. Reifenberger","L. Held","A. von Deimling","A. Ochsenbein","M. Weller"],"twitterCount":13,"altmetricId":36244143},{"title":"Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors","googleId":"OcT33W3-ynMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350525","googleCitationCount":47,"googleAuthor":"C Albany","doi":"10.1093/annonc/mdx731","elsevierAuthor":"Albany C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"44","altmetricAuthors":["C. Albany","N. Adra","A.C. Snavely","C. Cary","T.A. Masterson","R.S. Foster","K. Kesler","T.M. Ulbright","L. Cheng","M. Chovanec","F. Taza","K. Ku","M.J. Brames","N.H. Hanna","L.H. Einhorn"],"twitterCount":8,"altmetricId":28803336},{"title":"Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue","googleId":"0m4C53yZBWQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342371","googleCitationCount":35,"googleAuthor":"MC Vegliante","doi":"10.1093/annonc/mdy450","elsevierAuthor":"Wei T.","publicationName":"Journal of Cancer Research and Clinical Oncology","elsevierCoverDate":"2021-03-01","elsevierCoverDisplayDate":"March 2021","elsevierCitationCount":"0","altmetricAuthors":["S. Ciavarella","M.C. Vegliante","M. Fabbri","S. De Summa","F. Melle","G. Motta","V. De Iuliis","G. Opinto","A. Enjuanes","S. Rega","A. Gulino","C. Agostinelli","A. Scattone","S. Tommasi","A. Mangia","F. Mele","G. Simone","A.F. Zito","G. Ingravallo","U. Vitolo","A. Chiappella","C. Tarella","A.M. Gianni","A. Rambaldi","P.L. Zinzani","B. Casadei","E. Derenzini","G. Loseto","A. Pileri","V. Tabanelli","S. Fiori","A. Rivas-Delgado","A. López-Guillermo","T. Venesio","A. Sapino","E. Campo","C. Tripodo","A. Guarini","S.A. Pileri"],"twitterCount":8,"altmetricId":49565840},{"title":"A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance)","googleId":"kWE4dmgWkqwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346150","googleCitationCount":49,"googleAuthor":"","doi":"10.1093/annonc/mdx496","elsevierAuthor":"Martin P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"39","altmetricAuthors":["P. Martin","S.-H. Jung","B. Pitcher","N.L. Bartlett","K.A. Blum","T. Shea","E.D. Hsi","J. Ruan","S.E. Smith","J.P. Leonard","B.D. Cheson"],"twitterCount":4,"altmetricId":25701101},{"title":"Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) …","googleId":"exQLpop4URMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49923-7/abstract","googleCitationCount":43,"googleAuthor":""},{"title":"Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the …","googleId":"UappUNCpm50J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932280X","googleCitationCount":52,"googleAuthor":"","doi":"10.1093/annonc/mdx193","elsevierAuthor":"Jin C.","publicationName":"Cardiology (Switzerland)","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0","altmetricAuthors":["M.E. Pavel","E. Baudin","K.E. Öberg","J.D. Hainsworth","M. Voi","N. Rouyrre","M. Peeters","D.J. Gross","J.C. Yao"],"twitterCount":1,"altmetricId":21410412},{"title":"Epacadostat plus pembrolizumab in patients with advanced melanoma: phase 1 and 2 efficacy and safety results from ECHO-202/KEYNOTE-037","googleId":"qRmyrEsZRyEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38477-5/abstract","googleCitationCount":48,"googleAuthor":"TF Gajewski"},{"title":"Use of chemotherapy near the end of life: what factors matter?","googleId":"rcVUW7N3zWUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320435","googleCitationCount":58,"googleAuthor":"P Rochigneux","doi":"10.1093/annonc/mdw654","elsevierAuthor":"Kaasa S.","publicationName":"The Lancet Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"130","altmetricAuthors":["P. Rochigneux","J.L. Raoul","Y. Beaussant","R. Aubry","F. Goldwasser","C. Tournigand","L. Morin"],"twitterCount":37,"altmetricId":14865545},{"title":"Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy","googleId":"Wl0K-q-jCVMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320095","googleCitationCount":48,"googleAuthor":"R Douard","doi":"10.1093/annonc/mdx030","elsevierAuthor":"Yang Y.","publicationName":"Aging","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"0","altmetricAuthors":["E. Auclin","A. Zaanan","D. Vernerey","R. Douard","C. Gallois","P. Laurent-Puig","F. Bonnetain","J. Taieb"],"twitterCount":1,"altmetricId":20782562},{"title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA)","googleId":"2YoX13n8AQIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49078-9/abstract","googleCitationCount":39,"googleAuthor":""},{"title":"Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of …","googleId":"l7Z2984aA-EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349646","googleCitationCount":50,"googleAuthor":"PC Barata","doi":"10.1093/annonc/mdx405","elsevierAuthor":"Barata P.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"39","altmetricAuthors":["P.C. Barata","V.S. Koshkin","P. Funchain","D. Sohal","A. Pritchard","S. Klek","T. Adamowicz","D. Gopalakrishnan","J. Garcia","B. Rini","P. Grivas"],"twitterCount":11,"altmetricId":26591190},{"title":"OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant …","googleId":"0tsNO6QGSpkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350641","googleCitationCount":43,"googleAuthor":"DM Provencher","doi":"10.1093/annonc/mdx754","elsevierAuthor":"Provencher D.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"26","altmetricAuthors":["D.M. Provencher","C.J. Gallagher","W.R. Parulekar","J.A. Ledermann","D.K. Armstrong","M. Brundage","C. Gourley","I. Romero","A. Gonzalez-Martin","M. Feeney","P. Bessette","M. Hall","J.I. Weberpals","G. Hall","S.K. Lau","P. Gauthier","M. Fung-Kee-Fung","E.A. Eisenhauer","C. Winch","D. Tu","H.J. MacKay"],"twitterCount":31,"altmetricId":29362902},{"title":"Nivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged …","googleId":"pghwK1aDCbEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38550-1/abstract","googleCitationCount":46,"googleAuthor":""},{"title":"Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: A joint study of the EAU-Young …","googleId":"XzgWREbE7kQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38138-2/abstract","googleCitationCount":44,"googleAuthor":"L Mariani"},{"title":"A polymorphic MYC response element in KBTBD11 influences colorectal cancer risk, especially in interaction with an MYC-regulated SNP rs6983267","googleId":"lgJq764m2EkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355012","googleCitationCount":42,"googleAuthor":"J Gong","doi":"10.1093/annonc/mdx789","elsevierAuthor":"Gong J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"39","altmetricAuthors":[],"twitterCount":0},{"title":"IMpower132: efficacy of atezolizumab (atezo)+ carboplatin (carbo)/cisplatin (cis)+ pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous …","googleId":"sXw_bfOpDGsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50457-4/abstract","googleCitationCount":37,"googleAuthor":""},{"title":"Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+ cobimetinib and atezolizumab monotherapy vs regorafenib in …","googleId":"g6KV-0HjOu8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34066-9/abstract","googleCitationCount":44,"googleAuthor":"F Ciardiello"},{"title":"Alcohol and cigarette consumption predict mortality in patients with head and neck cancer: a pooled analysis within the International Head and Neck Cancer …","googleId":"KEeyRXUZMAEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346058","googleCitationCount":45,"googleAuthor":"V Wünsch-Filho","doi":"10.1093/annonc/mdx486","elsevierAuthor":"Giraldi L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"34","altmetricAuthors":["L. Giraldi","E. Leoncini","R. Pastorino","V. Wünsch-Filho","M. de Carvalho","R. Lopez","G. Cadoni","D. Arzani","L. Petrelli","K. Matsuo","C. Bosetti","C. La Vecchia","W. Garavello","J. Polesel","D. Serraino","L. Simonato","C. Canova","L. Richiardi","P. Boffetta","M. Hashibe","Y.C.A. Lee","S. Boccia"],"twitterCount":27,"altmetricId":51501949},{"title":"Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001","googleId":"EM4ODdMcr88J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43453-4/abstract","googleCitationCount":34,"googleAuthor":""},{"title":"ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe","googleId":"-6G_-cztLikJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346204","googleCitationCount":44,"googleAuthor":"NI Cherny","doi":"10.1093/annonc/mdx521","elsevierAuthor":"Cherny N.I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"27","altmetricAuthors":["N.I. Cherny","R. Sullivan","J. Torode","M. Saar","A. Eniu"],"twitterCount":89,"altmetricId":25182786},{"title":"Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in …","googleId":"KA396dkhjk4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324196","googleCitationCount":50,"googleAuthor":"JJ Knox","doi":"10.1093/annonc/mdx075","elsevierAuthor":"Zhou F.","publicationName":"Drug Design, Development and Therapy","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"2019","elsevierCitationCount":"9","altmetricAuthors":["J.J. Knox","C.H. Barrios","T.M. Kim","T. Cosgriff","V. Srimuninnimit","K. Pittman","R. Sabbatini","S.Y. Rha","T.W. Flaig","R.D. Page","J.T. Beck","F. Cheung","S. Yadav","P. Patel","L. Geoffrois","J. Niolat","N. Berkowitz","M. Marker","D. Chen","R.J. Motzer"],"twitterCount":14,"altmetricId":17630443},{"title":"Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms","googleId":"thQg4b1NgbUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350756","googleCitationCount":39,"googleAuthor":"F Blackhall","doi":"10.1093/annonc/mdx790","elsevierAuthor":"Kordbacheh T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"35","altmetricAuthors":["T. Kordbacheh","J. Honeychurch","F. Blackhall","C. Faivre-Finn","T. Illidge"],"twitterCount":48,"altmetricId":32847099},{"title":"RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI …","googleId":"hg-h3xCw_0EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349762","googleCitationCount":48,"googleAuthor":"N Normanno","doi":"10.1093/annonc/mdx417","elsevierAuthor":"Normanno N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"40","altmetricAuthors":["N. Normanno","R. Esposito Abate","M. Lambiase","L. Forgione","C. Cardone","A. Iannaccone","A. Sacco","A.M. Rachiglio","E. Martinelli","D. Rizzi","S. Pisconti","M. Biglietto","R. Bordonaro","T. Troiani","T.P. Latiano","F. Giuliani","S. Leo","A. Rinaldi","E. Maiello","F. Ciardiello"],"twitterCount":12,"altmetricId":27413261},{"title":"Human papillomavirus (HPV) and somatic EGFR mutations are essential, mutually exclusive oncogenic mechanisms for inverted sinonasal papillomas and …","googleId":"nGtxw5h62GgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350549","googleCitationCount":39,"googleAuthor":"AM Udager","doi":"10.1093/annonc/mdx736","elsevierAuthor":"Udager A.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"32","altmetricAuthors":["A.M. Udager","J.B. McHugh","C.M. Goudsmit","H.C. Weigelin","M.S. Lim","K.S.J Elenitoba-Johnson","B.L. Betz","T.E. Carey","N.A. Brown"],"twitterCount":10,"altmetricId":29108386},{"title":"Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer","googleId":"tJRXb-T0tc0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349592","googleCitationCount":42,"googleAuthor":"AA Sahin","doi":"10.1093/annonc/mdx397","elsevierAuthor":"Fujii T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"31","altmetricAuthors":["T. Fujii","T. Kogawa","W. Dong","A.A. Sahin","S. Moulder","J.K. Litton","D. Tripathy","T. Iwamoto","K.K. Hunt","L. Pusztai","B. Lim","Y. Shen","N.T. Ueno"],"twitterCount":16,"altmetricId":23134125},{"title":"KEYNOTE-059 update: efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G …","googleId":"Pliwvuq75hEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39120-1/abstract","googleCitationCount":45,"googleAuthor":""},{"title":"Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC …","googleId":"JlSB7lImorUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321106","googleCitationCount":35,"googleAuthor":"J Mateo","doi":"10.1093/annonc/mdy172","elsevierAuthor":"Lorente D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"30","altmetricAuthors":["D. Lorente","D. Olmos","J. Mateo","D. Dolling","D. Bianchini","G. Seed","P. Flohr","M. Crespo","I. Figueiredo","S. Miranda","H.I. Scher","L.W.M.M. Terstappen","J.S. de Bono"],"twitterCount":43,"altmetricId":40868638},{"title":"Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were …","googleId":"7VJCiuB1Y_UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33687-7/abstract","googleCitationCount":37,"googleAuthor":"F Meric-Bernstam"},{"title":"Impact of physical activity on fatigue and quality of life in people with advanced lung cancer: a randomized controlled trial","googleId":"omcSF3epBc8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321489","googleCitationCount":44,"googleAuthor":"HM Dhillon","doi":"10.1093/annonc/mdx205","elsevierAuthor":"Ma R.C.","publicationName":"Oncology Nursing Forum","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"1 May 2020","elsevierCitationCount":"0","altmetricAuthors":["H.M. Dhillon","M.L. Bell","H.P. van der Ploeg","J.D. Turner","M. Kabourakis","L. Spencer","C. Lewis","R. Hui","P. Blinman","S.J. Clarke","M.J. Boyer","J.L. Vardy"],"twitterCount":18,"altmetricId":19772113},{"title":"Front-line therapy of advanced epithelial ovarian cancer: standard treatment","googleId":"HAj8cjAzVcAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420346615","googleCitationCount":40,"googleAuthor":"","doi":"10.1093/annonc/mdx450","elsevierAuthor":"Marth C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"1 November 2017","elsevierCitationCount":"32","altmetricAuthors":[],"twitterCount":0},{"title":"Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines","googleId":"u-98sAqANuAJ","googleLink":"https://www.researchgate.net/profile/Fabio_Trippa/publication/325949870_Diarrhoea_in_adult_cancer_patients_ESMO_Clinical_Practice_Guidelines/links/5c9a73c545851506d72d9cff/Diarrhoea-in-adult-cancer-patients-ESMO-Clinical-Practice-Guidelines.pdf","googleCitationCount":37,"googleAuthor":"NI Cherny"},{"title":"Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck …","googleId":"1q63F7Ca7cAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349488","googleCitationCount":45,"googleAuthor":"EEW Cohen","doi":"10.1093/annonc/mdx344","elsevierAuthor":"Brisson R.J.","publicationName":"Head and Neck","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"1 November 2019","elsevierCitationCount":"3","altmetricAuthors":["E.E.W. Cohen","L.F. Licitra","B. Burtness","J. Fayette","T. Gauler","P.M. Clement","J.J. Grau","J.M. del Campo","A. Mailliez","R.I. Haddad","J.B. Vermorken","M. Tahara","J. Guigay","L. Geoffrois","M.C. Merlano","N. Dupuis","N. Krämer","X.J. Cong","N. Gibson","F. Solca","E. Ehrnrooth","J.-P.H. Machiels"],"twitterCount":4,"altmetricId":21996050},{"title":"Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy","googleId":"HTHb-EUC7EEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353761","googleCitationCount":42,"googleAuthor":"F Dhermain","doi":"10.1093/annonc/mdx408","elsevierAuthor":"Tallet A.V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"32","altmetricAuthors":["A.V. Tallet","F. Dhermain","E. Le Rhun","G. Noël","Y.M. Kirova"],"twitterCount":4,"altmetricId":23397991},{"title":"RET fusions in a small subset of advanced colorectal cancers at risk of being neglected","googleId":"d9nlJM-GtpkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348902","googleCitationCount":40,"googleAuthor":"F Pietrantonio","doi":"10.1093/annonc/mdy090","elsevierAuthor":"Pietrantonio F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"35","altmetricAuthors":["F. Pietrantonio","F. Di Nicolantonio","A.B. Schrock","J. Lee","F. Morano","G. Fucà","P. Nikolinakos","A. Drilon","J.F. Hechtman","J. Christiansen","K. Gowen","G.M. Frampton","P. Gasparini","D. Rossini","C. Gigliotti","S.T. Kim","M. Prisciandaro","J. Hodgson","A. Zaniboni","V.K. Chiu","M. Milione","R. Patel","V. Miller","A. Bardelli","L. Novara","L. Wang","S.M. Pupa","G. Sozzi","J. Ross","M. Di Bartolomeo","A. Bertotti","S. Ali","L. Trusolino","A. Falcone","F. de Braud","C. Cremolini"],"twitterCount":9,"altmetricId":34417765},{"title":"Epigenetic modifiers as new immunomodulatory therapies in solid tumours","googleId":"nO4muLjCS34J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454884","googleCitationCount":33,"googleAuthor":"S Aspeslagh","doi":"10.1093/annonc/mdy050","elsevierAuthor":"Aspeslagh S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"27","altmetricAuthors":["S. Aspeslagh","D. Morel","J.-C. Soria","S. Postel-Vinay"],"twitterCount":54,"altmetricId":32856905},{"title":"The evolution of chemotherapy for the treatment of prostate cancer","googleId":"EAjfhsqX_GQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345831","googleCitationCount":40,"googleAuthor":"HM Sandler","doi":"10.1093/annonc/mdx348","elsevierAuthor":"Quinn D.I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"30","altmetricAuthors":["D.I. Quinn","H.M. Sandler","L.G. Horvath","A. Goldkorn","J.A. Eastham"],"twitterCount":27,"altmetricId":22004462},{"title":"A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant …","googleId":"H9PCtq6DUYgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350446","googleCitationCount":44,"googleAuthor":"","doi":"10.1093/annonc/mdx698","elsevierAuthor":"Zhang L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"23","altmetricAuthors":["L. Zhang","S. Lu","J. Feng","A. Dechaphunkul","J. Chang","D. Wang","S. Chessari","C. Lanzarotti","K. Jordan","M. Aapro"],"twitterCount":3,"altmetricId":28074108},{"title":"Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case–control study","googleId":"BXaC7ic5pTcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354729","googleCitationCount":42,"googleAuthor":"C Cremolini","doi":"10.1093/annonc/mdx546","elsevierAuthor":"Cremolini C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"33","altmetricAuthors":["C. Cremolini","F. Morano","R. Moretto","R. Berenato","E. Tamborini","F. Perrone","D. Rossini","A. Gloghini","A. Busico","G. Zucchelli","C. Baratelli","E. Tamburini","M. Tampellini","E. Sensi","G. Fucà","C. Volpi","M. Milione","M. Di Maio","G. Fontanini","F. De Braud","A. Falcone","F. Pietrantonio"],"twitterCount":5,"altmetricId":31039527},{"title":"Predictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI)–analysis of somatic alterations (SAs)","googleId":"5MkdF4a3rg4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38408-8/abstract","googleCitationCount":46,"googleAuthor":"S Menon"},{"title":"DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update","googleId":"kOVhdOZ_aJgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353773","googleCitationCount":45,"googleAuthor":"LM Henricks","doi":"10.1093/annonc/mdx411","elsevierAuthor":"Henricks L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"28","altmetricAuthors":["L.M. Henricks","F.L. Opdam","J.H. Beijnen","A. Cats","J H M Schellens"],"twitterCount":68,"altmetricId":27411564},{"title":"ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with …","googleId":"NcEKQkK9BeMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354821","googleCitationCount":39,"googleAuthor":"M Hutchings","doi":"10.1093/annonc/mdx413","elsevierAuthor":"Buske C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"29","altmetricAuthors":["C. Buske","M. Hutchings","M. Ladetto","V. Goede","U. Mey","P. Soubeyran","M. Spina","R. Stauder","M. Trněný","U. Wedding","P. Fields","Christian Buske","Martin Dreyling","Andrés J M Ferreri","Paul Fields","Gianluca Gaidano","Valentin Goede","Martin Hutchings","Marco Ladetto","Steven Le Gouill","Stefano Luminari","Ulrich Mey","Peter de Nully Brown","Michael Pfreundschuh","Christiane Pott","Norbert Schmitz","Pierre Soubeyran","Michele Spina","Reinhard Stauder","Anna Sureda Balari","Marek Trněný","Gustaaf van Imhoff","Jan Walewski","Ulrich Wedding","Alberto Zamò","Emanuele Zucca"],"twitterCount":51,"altmetricId":29621864},{"title":"Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients","googleId":"vi7JoLHDtUMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35399-2/abstract","googleCitationCount":42,"googleAuthor":"TK Eigentler"},{"title":"CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair","googleId":"p71vDR8bcIAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322628","googleCitationCount":54,"googleAuthor":"W Guo","doi":"10.1093/annonc/mdx165","elsevierAuthor":"Shenoy T.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-07-01","elsevierCoverDisplayDate":"July 2017","elsevierCitationCount":"44","altmetricAuthors":["T.R. Shenoy","G. Boysen","M.Y. Wang","Q.Z. Xu","W. Guo","F.M. Koh","C. Wang","L.Z. Zhang","Y. Wang","V. Gil","S. Aziz","R. Christova","D.N. Rodrigues","M. Crespo","P. Rescigno","N. Tunariu","R. Riisnaes","Z. Zafeiriou","P. Flohr","W. Yuan","E. Knight","A. Swain","M. Ramalho-Santos","D.Y. Xu","J. de Bono","H. Wu"],"twitterCount":15,"altmetricId":18584207},{"title":"Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma","googleId":"je1M02-5dCEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324160","googleCitationCount":45,"googleAuthor":"","doi":"10.1093/annonc/mdx072","elsevierAuthor":"von Tresckow B.","publicationName":"Hematologic Malignancies","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":["P.J. Bröckelmann","H. Müller","O. Casasnovas","M. Hutchings","B. von Tresckow","M. Jürgens","S.J. McCall","F. Morschhauser","M. Fuchs","P. Borchmann","C.H. Moskowitz","A. Engert"],"twitterCount":4,"altmetricId":17825273},{"title":"Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a …","googleId":"g2A1yxVoo3MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341298","googleCitationCount":33,"googleAuthor":"M Ignatiadis","doi":"10.1093/annonc/mdy211","elsevierAuthor":"Ignatiadis M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"28","altmetricAuthors":["M. Ignatiadis","S. Litière","F. Rothe","S. Riethdorf","C. Proudhon","T. Fehm","K. Aalders","H. Forstbauer","P.A. Fasching","E. Brain","P. Vuylsteke","E. Guardiola","R. Lorenz","K. Pantel","K. Tryfonidis","W. Janni","M. Piccart","C. Sotiriou","B. Rack","J.-Y. Pierga"],"twitterCount":24,"altmetricId":43599217},{"title":"Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?","googleId":"sSPFbNDwv74J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350689","googleCitationCount":38,"googleAuthor":"PC Chou","doi":"10.1093/annonc/mdx766","elsevierAuthor":"Yang M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"32","altmetricAuthors":["M. Yang","M.E. Forbes","R.L. Bitting","S.S. O'Neill","P -C Chou","U. Topaloglu","L.D. Miller","G.A. Hawkins","S.C. Grant","B.R. DeYoung","W.J. Petty","K. Chen","B.C. Pasche","W. Zhang"],"twitterCount":113,"altmetricId":30295626},{"title":"A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups","googleId":"km6xLrSaOFgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322562","googleCitationCount":44,"googleAuthor":"S Michiels","doi":"10.1093/annonc/mdx156","elsevierAuthor":"Lindsay C.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-07-01","elsevierCoverDisplayDate":"July 2017","elsevierCitationCount":"40","altmetricAuthors":["C.R. Lindsay","V. Faugeroux","S. Michiels","E. Pailler","F. Facchinetti","D. Ou","M.V. Bluthgen","C. Pannet","M. Ngo-Camus","G. Bescher","C. Caramella","F. Billiot","J. Remon","D. Planchard","J.-C. Soria","B. Besse","F. Farace"],"twitterCount":26,"altmetricId":21170835},{"title":"A randomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable …","googleId":"83ZYG67gc8oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50420-3/abstract","googleCitationCount":37,"googleAuthor":""},{"title":"Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma","googleId":"MtliDix5DsMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346149","googleCitationCount":42,"googleAuthor":"M Reni","doi":"10.1093/annonc/mdx495","elsevierAuthor":"Reni M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"34","altmetricAuthors":["M. Reni","S. Zanon","G. Balzano","S. Nobile","C.C. Pircher","M. Chiaravalli","P. Passoni","P.G. Arcidiacono","R. Nicoletti","S. Crippa","N. Slim","C. Doglioni","M. Falconi","L. Gianni"],"twitterCount":3,"altmetricId":26590363},{"title":"Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy …","googleId":"yQ1PPO77ELEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345934","googleCitationCount":43,"googleAuthor":"","doi":"10.1093/annonc/mdx414","elsevierAuthor":"McCoach C.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"1","altmetricAuthors":["C.E. McCoach","G.M. Blumenthal","L. Zhang","A. Myers","S. Tang","R. Sridhara","P. Keegan","R. Pazdur","R.C. Doebele","D. Kazandjian"],"twitterCount":72,"altmetricId":23519834},{"title":"Are liquid biopsies a surrogate for tissue EGFR testing?","googleId":"dZ0zv7H09PoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316722","googleCitationCount":35,"googleAuthor":"J Remon","doi":"10.1093/annonc/mdx706","elsevierAuthor":"Goldman J.W.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"29","altmetricAuthors":["J.W. Goldman","Z.S. Noor","J. Remon","B. Besse","N. Rosenfeld"],"twitterCount":81,"altmetricId":33296231},{"title":"Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification","googleId":"rF_cAGb2yhYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348999","googleCitationCount":36,"googleAuthor":"","doi":"10.1093/annonc/mdy119","elsevierAuthor":"Liu L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"27","altmetricAuthors":["L. Liu","J.M. Toung","A.F. Jassowicz","R. Vijayaraghavan","H. Kang","R. Zhang","K.M. Kruglyak","H.J. Huang","T. Hinoue","H. Shen","N.S. Salathia","D.S. Hong","A. Naing","V. Subbiah","S.A. Piha-Paul","M. Bibikova","G. Granger","B. Barnes","R. Shen","K. Gutekunst","S. Fu","A.M. Tsimberidou","C. Lu","C. Eng","S.L. Moulder","E.S. Kopetz","R.N. Amaria","F. Meric-Bernstam","P.W. Laird","J.-B. Fan","F. Janku"],"twitterCount":11,"altmetricId":36466262},{"title":"Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular …","googleId":"yvbIEGOb5ysJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320575","googleCitationCount":49,"googleAuthor":"TM Kim","doi":"10.1093/annonc/mdw685","elsevierAuthor":"Johnson M.L.","publicationName":"JAMA Oncology","elsevierCoverDate":"2019-07-01","elsevierCoverDisplayDate":"July 2019","elsevierCitationCount":"13","altmetricAuthors":["M. Rummel","T.M. Kim","F. Aversa","W. Brugger","E. Capochiani","C. Plenteda","F. Re","P. Trask","S. Osborne","R. Smith","A. Grigg"],"twitterCount":5,"altmetricId":15121113},{"title":"Pembrolizumab for patients with PD-L1–positive advanced carcinoid or pancreatic neuroendocrine tumors: results from the KEYNOTE-028 study","googleId":"1ssg-TvfRGMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37844-3/abstract","googleCitationCount":39,"googleAuthor":"JM Mehnert"},{"title":"An open-label, multicohort, phase 1/2 study in patients with virus-associated cancers (CheckMate 358): safety and efficacy of neoadjuvant nivolumab in squamous cell …","googleId":"46IO_PuxTQUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39141-9/abstract","googleCitationCount":38,"googleAuthor":"RL Ferris"},{"title":"Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized …","googleId":"h-KmQLwSnKUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348951","googleCitationCount":37,"googleAuthor":"S Hayoz","doi":"10.1093/annonc/mdy105","elsevierAuthor":"Ruhstaller T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"31","altmetricAuthors":["T. Ruhstaller","P. Thuss-Patience","S. Hayoz","S. Schacher","J.R. Knorrenschild","A. Schnider","L. Plasswilm","W. Budach","W. Eisterer","H. Hawle","C. Mariette","V. Hess","W. Mingrone","M. Montemurro","M. Girschikofsky","S.C. Schmidt","M. Bitzer","L. Bedenne","P. Brauchli","M. Stahl"],"twitterCount":24,"altmetricId":35366906},{"title":"Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of …","googleId":"1idKyaNWjBsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353906","googleCitationCount":40,"googleAuthor":"","doi":"10.1093/annonc/mdx527","elsevierAuthor":"Pu X.","publicationName":"Pathology Research and Practice","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"0","altmetricAuthors":["P. Schöffski","A. Wozniak","S. Stacchiotti","P. Rutkowski","J.-Y. Blay","L.H. Lindner","S.J. Strauss","A. Anthoney","F. Duffaud","S. Richter","V. Grünwald","M.G. Leahy","P. Reichardt","J. Sufliarsky","W.T. van der Graaf","R. Sciot","M. Debiec-Rychter","T. van Cann","S. Marréaud","M. Lia","T. Raveloarivahy","L. Collette","S. Bauer"],"twitterCount":4,"altmetricId":40681126},{"title":"Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience","googleId":"tSZAFQ5nggoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349452","googleCitationCount":40,"googleAuthor":"S Paydaş","doi":"10.1093/annonc/mdx341","elsevierAuthor":"Beköz H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"31","altmetricAuthors":["H. Beköz","N. Karadurmuş","S. Paydaş","A. Türker","T. Toptaş","T. Fıratlı Tuğlular","M. Sönmez","Z. Gülbaş","E. Tekgündüz","A.H. Kaya","M. Özbalak","N. Taştemir","L. Kaynar","R. Yıldırım","I. Karadoğan","M. Arat","F. Pepedil Tanrıkulu","V. Özkocaman","H. Abalı","M. Turgut","M. Kurt Yüksel","M. Özcan","M.H. Doğu","S. Kabukçu Hacıoğlu","I. Barışta","M. Demirkaya","F.D. Köseoğlu","S.K. Toprak","M. Yılmaz","H.C. Demirkürek","O. Demirkol","B. Ferhanoğlu"],"twitterCount":6,"altmetricId":21522899},{"title":"Observation as the initial management strategy in patients with mantle cell lymphoma","googleId":"WFSZjObmnsQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349415","googleCitationCount":40,"googleAuthor":"C Steidl","doi":"10.1093/annonc/mdx333","elsevierAuthor":"Abrisqueta P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"32","altmetricAuthors":["P. Abrisqueta","D.W. Scott","G.W. Slack","C. Steidl","A. Mottok","R.D. Gascoyne","J.M. Connors","L.H. Sehn","K.J. Savage","A.S. Gerrie","D. Villa"],"twitterCount":6,"altmetricId":21371404},{"title":"Updated results from KEYNOTE-021 cohort G: a randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line …","googleId":"h8zY8M_XCR8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39152-3/abstract","googleCitationCount":40,"googleAuthor":""},{"title":"Lifestyle factors and risk of sporadic colorectal cancer by microsatellite instability status: a systematic review and meta-analyses","googleId":"EO2boc02XogJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454938","googleCitationCount":32,"googleAuthor":"PR Carr","doi":"10.1093/annonc/mdy059","elsevierAuthor":"Carr P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"23","altmetricAuthors":["P.R. Carr","E. Alwers","S. Bienert","J. Weberpals","M. Kloor","H. Brenner","M. Hoffmeister"],"twitterCount":15,"altmetricId":32964714},{"title":"Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review","googleId":"s4cp_xMB0UQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353815","googleCitationCount":37,"googleAuthor":"E Díaz-Rubio","doi":"10.1093/annonc/mdx501","elsevierAuthor":"Garciá-Foncillas J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"30","altmetricAuthors":["J. García-Foncillas","E. Alba","E. Aranda","E. Díaz-Rubio","R. López-López","J. Tabernero","A. Vivancos"],"twitterCount":13,"altmetricId":25151666},{"title":"Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide","googleId":"8JlsI3G0ZmUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352433","googleCitationCount":46,"googleAuthor":"","doi":"10.1093/annonc/mdx283","elsevierAuthor":"Rathkopf D.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"35","altmetricAuthors":["D.E. Rathkopf","M.R. Smith","C.J. Ryan","W.R. Berry","N.D. Shore","G. Liu","C.S. Higano","J.J. Alumkal","R. Hauke","R.F. Tutrone","M. Saleh","E. Chow Maneval","S. Thomas","D.S. Ricci","M.K. Yu","C.J. de Boer","A. Trinh","T. Kheoh","R. Bandekar","H.I. Scher","E.S. Antonarakis"],"twitterCount":6,"altmetricId":21288215},{"title":"Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as …","googleId":"koPW_5KxlBkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931912X","googleCitationCount":49,"googleAuthor":"M Yamasaki","doi":"10.1093/annonc/mdw439","elsevierAuthor":"Yamasaki M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"42","altmetricAuthors":["M. Yamasaki","T. Yasuda","M. Yano","M. Hirao","K. Kobayashi","K. Fujitani","S. Tamura","Y. Kimura","H. Miyata","M. Motoori","O. Shiraishi","T. Makino","T. Satoh","M. Mori","Y. Doki"],"twitterCount":1,"altmetricId":15094966},{"title":"Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and …","googleId":"Aze7hvTc_BQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32760-7/abstract","googleCitationCount":29,"googleAuthor":"RS Herbst"},{"title":"Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases","googleId":"zgADMXTMMgQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355085","googleCitationCount":38,"googleAuthor":"","doi":"10.1093/annonc/mdx797","elsevierAuthor":"Turner N.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"31","altmetricAuthors":["N.C. Turner","R.S. Finn","M. Martin","S.-A. Im","A. DeMichele","J. Ettl","V. Diéras","S. Moulder","O. Lipatov","M. Colleoni","M. Cristofanilli","D.R. Lu","A. Mori","C. Giorgetti","S. Iyer","C. Huang Bartlett","K.A. Gelmon"],"twitterCount":52,"altmetricId":31577212},{"title":"Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function","googleId":"ctPU4Fz7_GcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319106","googleCitationCount":49,"googleAuthor":"M Choi","doi":"10.1093/annonc/mdw437","elsevierAuthor":"Choi M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"40","altmetricAuthors":["M. Choi","H. Kadara","J. Zhang","E.R. Parra","J. Rodriguez-Canales","S.G. Gaffney","Z. Zhao","C. Behrens","J. Fujimoto","C. Chow","K. Kim","N. Kalhor","C. Moran","D. Rimm","S. Swisher","D.L. Gibbons","J. Heymach","E. Kaftan","J.P. Townsend","T.J. Lynch","J. Schlessinger","J. Lee","R.P. Lifton","R.S. Herbst","I.I. Wistuba"],"twitterCount":1,"altmetricId":13315839},{"title":"Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in …","googleId":"ZX63eOfznqoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352408","googleCitationCount":39,"googleAuthor":"Q Wei","doi":"10.1093/annonc/mdx278","elsevierAuthor":"Wei Q.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"36","altmetricAuthors":["Q. Wei","Z. Ye","X. Zhong","L. Li","C. Wang","R.E. Myers","J.P. Palazzo","D. Fortuna","A. Yan","S.A. Waldman","X. Chen","J.A. Posey","A. Basu-Mallick","B.H. Jiang","L. Hou","J. Shu","Y. Sun","J. Xing","B. Li","H. Yang"],"twitterCount":6,"altmetricId":26128476},{"title":"De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and …","googleId":"uwXf1v2qix4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346137","googleCitationCount":37,"googleAuthor":"","doi":"10.1093/annonc/mdx494","elsevierAuthor":"Nitz U.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"34","altmetricAuthors":[],"twitterCount":0},{"title":"Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO","googleId":"Y28UjvI_tF8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454574","googleCitationCount":39,"googleAuthor":"C Cremolini","doi":"10.1093/annonc/mdy004","elsevierAuthor":"Dell'Aquila E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"30","altmetricAuthors":[],"twitterCount":0},{"title":"Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial","googleId":"oX-EbV8o7XwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350495","googleCitationCount":37,"googleAuthor":"","doi":"10.1093/annonc/mdx716","elsevierAuthor":"Ek L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"30","altmetricAuthors":["L. Ek","E. Gezelius","B. Bergman","P.O. Bendahl","H. Anderson","J. Sundberg","M. Wallberg","U. Falkmer","S. Verma","M. Belting"],"twitterCount":33,"altmetricId":28283539},{"title":"Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study","googleId":"4-jXpDH9DOEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350586","googleCitationCount":38,"googleAuthor":"","doi":"10.1093/annonc/mdx742","elsevierAuthor":"Pettersson A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"30","altmetricAuthors":["A. Pettersson","D. Robinson","H. Garmo","L. Holmberg","P. Stattin"],"twitterCount":3,"altmetricId":29584000},{"title":"CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced …","googleId":"LVeXIPO3xTgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)56553-X/abstract","googleCitationCount":39,"googleAuthor":""},{"title":"Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study","googleId":"GkKbfCLYZvkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349567","googleCitationCount":39,"googleAuthor":"E Calvo","doi":"10.1093/annonc/mdx357","elsevierAuthor":"Calvo E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"33","altmetricAuthors":["E. Calvo","V. Moreno","M. Flynn","E. Holgado","M.E. Olmedo","M.P. Lopez Criado","C. Kahatt","J.A. Lopez-Vilariño","M. Siguero","C. Fernandez-Teruel","M. Cullell-Young","A. Soto Matos-Pita","M. Forster"],"twitterCount":40,"altmetricId":21904455},{"title":"Clinical and molecular characterization of patients with cancer of unknown primary in the modern era","googleId":"eXD5xaipjaAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354717","googleCitationCount":40,"googleAuthor":"A Arora","doi":"10.1093/annonc/mdx545","elsevierAuthor":"Varghese A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"34","altmetricAuthors":["A.M. Varghese","A. Arora","M. Capanu","N. Camacho","H.H. Won","A. Zehir","J. Gao","D. Chakravarty","N. Schultz","D.S. Klimstra","M. Ladanyi","D.M. Hyman","D.B. Solit","M.F. Berger","L.B. Saltz"],"twitterCount":11,"altmetricId":26615695},{"title":"Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 …","googleId":"V69ZH4S1hYsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39130-4/abstract","googleCitationCount":41,"googleAuthor":"A Bex"},{"title":"Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury","googleId":"j5-5f6DMHNUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31966-0/abstract","googleCitationCount":46,"googleAuthor":"A D'Errico"},{"title":"Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 …","googleId":"eLDZdL4LwFsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934236X","googleCitationCount":29,"googleAuthor":"L Marandino","doi":"10.1093/annonc/mdy449","elsevierAuthor":"Marandino L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"24","altmetricAuthors":["L. Marandino","A. La Salvia","C. Sonetto","E. De Luca","D. Pignataro","C. Zichi","R.F. Di Stefano","E. Ghisoni","P. Lombardi","A. Mariniello","M.L. Reale","E. Trevisi","G. Leone","L. Muratori","M. Marcato","P. Bironzo","S. Novello","M. Aglietta","G.V. Scagliotti","F. Perrone","M. Di Maio"],"twitterCount":181,"altmetricId":49480452},{"title":"Results of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC)","googleId":"ZtJkQMEl428J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38535-5/abstract","googleCitationCount":39,"googleAuthor":""},{"title":"A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic …","googleId":"0KzyXGxgWQcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934596X","googleCitationCount":36,"googleAuthor":"","doi":"10.1093/annonc/mdx439","elsevierAuthor":"Bossi P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"28","altmetricAuthors":["P. Bossi","R. Miceli","L.D. Locati","D. Ferrari","S. Vecchio","G. Moretti","N. Denaro","F. Caponigro","M. Airoldi","C. Moro","E. Vaccher","A. Sponghini","A. Caldara","G. Rinaldi","F. Ferrau","F. Nolè","S. Lo Vullo","F. Tettamanzi","L. Hollander","L. Licitra"],"twitterCount":1,"altmetricId":60657640},{"title":"InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly …","googleId":"22-PQuHEO-8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50413-6/abstract","googleCitationCount":30,"googleAuthor":"S Rao"},{"title":"Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the …","googleId":"eZA3ClSM_PYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341997","googleCitationCount":28,"googleAuthor":"","doi":"10.1093/annonc/mdy326","elsevierAuthor":"Thomas M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"21","altmetricAuthors":["M. Thomas","S. Ponce-Aix","A. Navarro","J. Riera-Knorrenschild","M. Schmidt","E. Wiegert","K. Kapp","B. Wittig","C. Mauri","M. Dómine Gómez","J. Kollmeier","P. Sadjadian","K -P Fröhling","R.M. Huber","M. Wolf","Georg Pall","Veerle Surmont","Léon Bosquee","Paul Germonpré","Wolfgang Brückl","Christina Grah","Christian Herzmann","Rumo Leistner","Andreas Meyer","Lothar Müller","Oliver Schmalz","Christian Scholz","Michael Schröder","Monika Serke","Claas Wesseler","Christian Brandts","Hans-Georg Kopp","Wolfgang Blau","Frank Griesinger","Maria Rosario Garcia Campelo","Yolanda Garcia Garcia","José Manuel Trigo Perez"],"twitterCount":23,"altmetricId":46819165},{"title":"Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study","googleId":"Sl_YwOfw4wsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934548X","googleCitationCount":34,"googleAuthor":"CKY Ng","doi":"10.1093/annonc/mdy083","elsevierAuthor":"Ng C.K.Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"28","altmetricAuthors":["C.K.Y. Ng","G.G. Di Costanzo","N. Tosti","V. Paradiso","M. Coto-Llerena","G. Roscigno","V. Perrina","C. Quintavalle","T. Boldanova","S. Wieland","G. Marino-Marsilia","M. Lanzafame","L. Quagliata","G. Condorelli","M.S. Matter","R. Tortora","M.H. Heim","L.M. Terracciano","S. Piscuoglio"],"twitterCount":3,"altmetricId":34225863},{"title":"The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients","googleId":"Jda9ZZYFvBoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320642","googleCitationCount":46,"googleAuthor":"","doi":"10.1093/annonc/mdw694","elsevierAuthor":"Lian B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-04-01","elsevierCoverDisplayDate":"1 April 2017","elsevierCitationCount":"27","altmetricAuthors":["B. Lian","C.L. Cui","L. Zhou","X. Song","X.S. Zhang","D. Wu","L. Si","Z.H. Chi","X.N. Sheng","L.L. Mao","X. Wang","B.X. Tang","X.Q. Yan","Y. Kong","J. Dai","S.M. Li","X. Bai","N. Zheng","C.M. Balch","J. Guo"],"twitterCount":1,"altmetricId":15230088},{"title":"Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?","googleId":"PS_v6m2GZ6kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420346627","googleCitationCount":35,"googleAuthor":"","doi":"10.1093/annonc/mdx451","elsevierAuthor":"Monk B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"1 November 2017","elsevierCitationCount":"28","altmetricAuthors":["B.J. Monk","J.K. Chan"],"twitterCount":0,"altmetricId":42621099},{"title":"Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group …","googleId":"90vZAZD8tU4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321702","googleCitationCount":37,"googleAuthor":"JY Blay","doi":"10.1093/annonc/mdx250","elsevierAuthor":"Salas S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-08-01","elsevierCoverDisplayDate":"1 August 2017","elsevierCitationCount":"30","altmetricAuthors":[],"twitterCount":0},{"title":"Insulin resistance and body composition in cancer patients","googleId":"NSShSoL3hKMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316801","googleCitationCount":35,"googleAuthor":"","doi":"10.1093/annonc/mdx815","elsevierAuthor":"Dev R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"23","altmetricAuthors":["R Dev","E. Bruera","S. Dalal"],"twitterCount":47,"altmetricId":33923088},{"title":"Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted …","googleId":"mioz49VZr5UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349610","googleCitationCount":37,"googleAuthor":"","doi":"10.1093/annonc/mdx399","elsevierAuthor":"Ross J.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"32","altmetricAuthors":["J.S. Ross","L.M. Gay","K. Wang","J.A. Vergilio","J. Suh","S. Ramkissoon","H. Somerset","J.M. Johnson","J. Russell","S. Ali","A.B. Schrock","D. Fabrizio","G. Frampton","V. Miller","P.J. Stephens","J.A. Elvin","D.W. Bowles"],"twitterCount":13,"altmetricId":23447247},{"title":"Joint adolescent–adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform …","googleId":"f-zpVhV9gsoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35514-0/abstract","googleCitationCount":32,"googleAuthor":"R Herold"},{"title":"Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study","googleId":"-q2ZBmdIUsQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348963","googleCitationCount":33,"googleAuthor":"","doi":"10.1093/annonc/mdy106","elsevierAuthor":"Gramatzki D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"20","altmetricAuthors":["D. Gramatzki","P. Roth","E.J. Rushing","J. Weller","N. Andratschke","S. Hofer","D. Korol","L. Regli","A. Pangalu","M. Pless","J. Oberle","R. Bernays","H. Moch","S. Rohrmann","M. Weller"],"twitterCount":25,"altmetricId":35024177},{"title":"Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors—Guideline of the Infectious Diseases Working Party (AGIHO) of …","googleId":"nKloUUhDlH4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348975","googleCitationCount":28,"googleAuthor":"","doi":"10.1093/annonc/mdy117","elsevierAuthor":"Rieger C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"20","altmetricAuthors":["C.T. Rieger","B. Liss","S. Mellinghoff","D. Buchheidt","O.A. Cornely","G. Egerer","W.J. Heinz","M. Hentrich","G. Maschmeyer","K. Mayer","M. Sandherr","G. Silling","A. Ullmann","M.J.G.T. Vehreschild","M. von Lilienfeld-Toal","H.H. Wolf","N. Lehners"],"twitterCount":55,"altmetricId":39155698},{"title":"Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial","googleId":"8P5jNf2i44cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318897","googleCitationCount":34,"googleAuthor":"AD Colevas","doi":"10.1093/annonc/mdy411","elsevierAuthor":"Colevas A.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"30","altmetricAuthors":["A.D. Colevas","R. Bahleda","F. Braiteh","A. Balmanoukian","I. Brana","N.G. Chau","I. Sarkar","L. Molinero","W. Grossman","F. Kabbinavar","M. Fassò","C. O’Hear","J. Powderly"],"twitterCount":2,"altmetricId":48517974},{"title":"Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters","googleId":"2vU0-sR64q8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349555","googleCitationCount":38,"googleAuthor":"G Goh","doi":"10.1093/annonc/mdx355","elsevierAuthor":"Linch M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"30","altmetricAuthors":["M. Linch","G. Goh","C. Hiley","Y. Shanmugabavan","N. McGranahan","A. Rowan","Y.N.S. Wong","H. King","A. Furness","A. Freeman","J. Linares","A. Akarca","J. Herrero","R. Rosenthal","N. Harder","G. Schmidt","G.A. Wilson","N.J. Birkbak","R. Mitter","S. Dentro","P. Cathcart","M. Arya","E. Johnston","R. Scott","M. Hung","M. Emberton","G. Attard","Z. Szallasi","S. Punwani","S.A. Quezada","T. Marafioti","M. Gerlinger","H.U. Ahmed","C. Swanton"],"twitterCount":24,"altmetricId":22525285},{"title":"Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast …","googleId":"bjzJO7dvF_sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352457","googleCitationCount":37,"googleAuthor":"MM Regan","doi":"10.1093/annonc/mdx285","elsevierAuthor":"Regan M.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"29","altmetricAuthors":[],"twitterCount":0},{"title":"Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer","googleId":"oT5RrFs8UbYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349786","googleCitationCount":37,"googleAuthor":"S Siena","doi":"10.1093/annonc/mdx504","elsevierAuthor":"Siena S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"27","altmetricAuthors":["S. Siena","A. Sartore-Bianchi","R. Garcia-Carbonero","M. Karthaus","D. Smith","J. Tabernero","E. Van Cutsem","X. Guan","M. Boedigheimer","A. Ang","B. Twomey","B.A. Bach","A.S. Jung","A. Bardelli"],"twitterCount":14,"altmetricId":24770149},{"title":"Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine","googleId":"vEDBX5kP0tQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319532","googleCitationCount":44,"googleAuthor":"A Mitra","doi":"10.1093/annonc/mdw619","elsevierAuthor":"Fantappiè G.","publicationName":"Anti-Cancer Drugs","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":["I.S. Batth","A. Mitra","S. Manier","I.M. Ghobrial","D. Menter","S. Kopetz","S. Li"],"twitterCount":32,"altmetricId":14927372},{"title":"Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer","googleId":"Au9RDXHm_cMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341729","googleCitationCount":32,"googleAuthor":"","doi":"10.1093/annonc/mdy251","elsevierAuthor":"Hanna G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"26","altmetricAuthors":["G.J. Hanna","J.G. Supplee","Y. Kuang","U. Mahmood","C.J. Lau","R.I. Haddad","P.A. Jänne","C.P. Paweletz"],"twitterCount":8,"altmetricId":45298596},{"title":"Research needs in breast cancer","googleId":"bfGg9tfaLWMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322148","googleCitationCount":44,"googleAuthor":"F Cardoso","doi":"10.1093/annonc/mdw571","elsevierAuthor":"Cardoso F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"35","altmetricAuthors":["F. Cardoso","N. Harbeck","C.H. Barrios","J. Bergh","J. Cortés","N. El Saghir","P.A. Francis","C.A. Hudis","S. Ohno","A.H. Partridge","G.W. Sledge","I.E. Smith","K.A. Gelmon"],"twitterCount":40,"altmetricId":13520729},{"title":"Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma","googleId":"b10x_crRrCIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320071","googleCitationCount":37,"googleAuthor":"","doi":"10.1093/annonc/mdx028","elsevierAuthor":"Sadasivan C.","publicationName":"Clinical Science","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"0","altmetricAuthors":["A.K. Gopal","M.A. Fanale","C.H. Moskowitz","A.R. Shustov","S. Mitra","W. Ye","A. Younes","A.J. Moskowitz"],"twitterCount":18,"altmetricId":15793765},{"title":"Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients","googleId":"vxP9MCH8BvEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316709","googleCitationCount":37,"googleAuthor":"J Remon","doi":"10.1093/annonc/mdx704","elsevierAuthor":"Remon J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"21","altmetricAuthors":["J. Remon","C.E. Steuer","S.S. Ramalingam","E. Felip"],"twitterCount":3,"altmetricId":33489658},{"title":"Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro)","googleId":"2loUKQP38moJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50466-5/abstract","googleCitationCount":29,"googleAuthor":"RS Herbst"},{"title":"Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial","googleId":"RtZCCORwjCwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49797-4/abstract","googleCitationCount":30,"googleAuthor":"K Brock"},{"title":"Nanoscale extracellular vesicle-derived DNA is superior to circulating cell-free DNA for mutation detection in early-stage non-small-cell lung cancer","googleId":"9FTG-ZVFNYEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342450","googleCitationCount":23,"googleAuthor":"Y Wan","doi":"10.1093/annonc/mdy458","elsevierAuthor":"Wan Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"17","altmetricAuthors":["Y. Wan","B. Liu","H. Lei","B. Zhang","Y. Wang","H. Huang","S. Chen","Y. Feng","L. Zhu","Y. Gu","Q. Zhang","H. Ma","S.-Y. Zheng"],"twitterCount":8,"altmetricId":50127108},{"title":"Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung …","googleId":"e56AvpARhZYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319234","googleCitationCount":44,"googleAuthor":"","doi":"10.1093/annonc/mdw531","elsevierAuthor":"Iwama E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"40","altmetricAuthors":["E. Iwama","K. Sakai","K. Azuma","T. Harada","D. Harada","K. Nosaki","K. Hotta","F. Ohyanagi","T. Kurata","T. Fukuhara","H. Akamatsu","K. Goto","T. Shimose","J. Kishimoto","Y. Nakanishi","K. Nishio","I. Okamoto"],"twitterCount":5,"altmetricId":16235750},{"title":"DualMET andERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)","googleId":"otBre9AvaqYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349580","googleCitationCount":34,"googleAuthor":"A Martinez-Marti","doi":"10.1093/annonc/mdx396","elsevierAuthor":"Martinez-Marti A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"32","altmetricAuthors":["A. Martinez-Marti","E. Felip","J. Matito","E. Mereu","A. Navarro","S. Cedrés","N. Pardo","A. Martinez de Castro","J. Remon","J.M. Miquel","A. Guillaumet-Adkins","E. Nadal","G. Rodriguez-Esteban","O. Arqués","R. Fasani","P. Nuciforo","H. Heyn","A. Villanueva","H.G. Palmer","A. Vivancos"],"twitterCount":37,"altmetricId":22281524},{"title":"A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma","googleId":"l3k7W4_bGXIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38121-7/abstract","googleCitationCount":37,"googleAuthor":"V Makker"},{"title":"Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of …","googleId":"TfuAuQSE-FUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354961","googleCitationCount":35,"googleAuthor":"","doi":"10.1093/annonc/mdx774","elsevierAuthor":"Schöffski P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"23","altmetricAuthors":["P. Schöffski","A. Wozniak","B. Kasper","S. Aamdal","M.G. Leahy","P. Rutkowski","S. Bauer","H. Gelderblom","A. Italiano","L.H. Lindner","I. Hennig","S. Strauss","B. Zakotnik","A. Anthoney","L. Albiges","J.-Y. Blay","P. Reichardt","J. Sufliarsky","W.T.A. van der Graaf","M. Debiec-Rychter","R. Sciot","T. Van Cann","S. Marréaud","T. Raveloarivahy","S. Collette","S. Stacchiotti"],"twitterCount":11,"altmetricId":34764069},{"title":"Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group","googleId":"_4X3FR_x6HcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320563","googleCitationCount":43,"googleAuthor":"P Coppo","doi":"10.1093/annonc/mdw684","elsevierAuthor":"Tchernonog E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-04-01","elsevierCoverDisplayDate":"1 April 2017","elsevierCitationCount":"25","altmetricAuthors":["E. Tchernonog","P. Faurie","P. Coppo","H. Monjanel","A. Bonnet","M. Algarte Génin","M. Mercier","J. Dupuis","F. Bijou","C. Herbaux","A. Delmer","B. Fabiani","C. Besson","S. Le Gouill","E. Gyan","C. Laurent","H. Ghesquieres","G. Cartron"],"twitterCount":1,"altmetricId":15122240},{"title":"New agents on the horizon in gastric cancer","googleId":"t_Ekt80dJTYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321234","googleCitationCount":39,"googleAuthor":"F Lordick","doi":"10.1093/annonc/mdx051","elsevierAuthor":"Yang Z.","publicationName":"Aging","elsevierCoverDate":"2020-12-31","elsevierCoverDisplayDate":"31 December 2020","elsevierCitationCount":"0","altmetricAuthors":["F. Lordick","K. Shitara","Y.Y. Janjigian"],"twitterCount":4,"altmetricId":16332844},{"title":"Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification","googleId":"btks4kwFrWQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352263","googleCitationCount":37,"googleAuthor":"","doi":"10.1093/annonc/mdx180","elsevierAuthor":"Gilbert J.W.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"29","altmetricAuthors":["J.W. Gilbert","B. Wolpin","T. Clancy","J. Wang","H. Mamon","A.B. Shinagare","J. Jagannathan","M. Rosenthal"],"twitterCount":8,"altmetricId":18755199},{"title":"Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and …","googleId":"c1H9oTITIU8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355127","googleCitationCount":32,"googleAuthor":"AK Godwin","doi":"10.1093/annonc/mdx821","elsevierAuthor":"Sharma P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"25","altmetricAuthors":["P. Sharma","W.E. Barlow","A.K. Godwin","H. Pathak","K. Isakova","D. Williams","K.M. Timms","A.R. Hartman","R.J. Wenstrup","H.M. Linden","D. Tripathy","G.N. Hortobagyi","D.F. Hayes"],"twitterCount":26,"altmetricId":30831608},{"title":"Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup …","googleId":"kL0IoWRrwCsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352639","googleCitationCount":37,"googleAuthor":"H van Tinteren","doi":"10.1093/annonc/mdx322","elsevierAuthor":"Goey K.K.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"28","altmetricAuthors":["K.K.H. Goey","S.G. Elias","H. van Tinteren","M.M. Laclé","S.M. Willems","G.J.A. Offerhaus","W.W.J. de Leng","E. Strengman","A.J. ten Tije","G.-J. M. Creemers","A. van der Velden","F.E. de Jongh","F.L.G. Erdkamp","B.C. Tanis","C.J.A. Punt","M. Koopman"],"twitterCount":5,"altmetricId":25097384},{"title":"Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review","googleId":"3JFW5E76ihgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454823","googleCitationCount":29,"googleAuthor":"A Quintela","doi":"10.1093/annonc/mdy038","elsevierAuthor":"Arnold D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"24","altmetricAuthors":["D. Arnold","G.W. Prager","A. Quintela","A. Stein","S. Moreno Vera","N. Mounedji","J. Taieb"],"twitterCount":30,"altmetricId":33212369},{"title":"Front-line therapy of advanced ovarian cancer: new approaches","googleId":"2tVKzhhRo4UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420346639","googleCitationCount":31,"googleAuthor":"JA Ledermann","doi":"10.1093/annonc/mdx452","elsevierAuthor":"Ledermann J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"1 November 2017","elsevierCitationCount":"27","altmetricAuthors":["J.A. Ledermann"],"twitterCount":1,"altmetricId":52264907},{"title":"Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach","googleId":"Gxcr7M-j_jsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342395","googleCitationCount":26,"googleAuthor":"J Guigay","doi":"10.1093/annonc/mdy452","elsevierAuthor":"Galot R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"22","altmetricAuthors":["R. Galot","C. Le Tourneau","J. Guigay","L. Licitra","I. Tinhofer","A. Kong","C. Caballero","C. Fortpied","J. Bogaerts","A.-S. Govaerts","D. Staelens","T. Raveloarivahy","L. Rodegher","J.-F. Laes","E. Saada-Bouzid","J.-P. Machiels"],"twitterCount":7,"altmetricId":49785509},{"title":"Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized …","googleId":"59XRyXBbRwcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341249","googleCitationCount":28,"googleAuthor":"MJ Maurer","doi":"10.1093/annonc/mdy203","elsevierAuthor":"Maurer M.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"23","altmetricAuthors":["M.J. Maurer","T.M. Habermann","Q. Shi","N. Schmitz","D. Cunningham","M. Pfreundschuh","J.F. Seymour","U. Jaeger","C. Haioun","H. Tilly","H. Ghesquieres","F. Merli","M. Ziepert","R. Herbrecht","J. Flament","T. Fu","C.R. Flowers","B. Coiffier"],"twitterCount":40,"altmetricId":43631582},{"title":"Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III …","googleId":"xFcYQPgPLGMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319507","googleCitationCount":41,"googleAuthor":"S Loibl","doi":"10.1093/annonc/mdw610","elsevierAuthor":"Loibl S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"39","altmetricAuthors":["S. Loibl","C. Jackisch","A. Schneeweiss","S. Schmatloch","B. Aktas","C. Denkert","H. Wiebringhaus","S. Kümmel","M. Warm","S. Paepke","M. Just","C. Hanusch","J. Hackmann","J.-U. Blohmer","M. Clemens","S. Dan Costa","B. Gerber","K. Engels","V. Nekljudova","G. von Minckwitz","M. Untch"],"twitterCount":23,"altmetricId":13493859},{"title":"A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with …","googleId":"U-CCvi3pCCsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350380","googleCitationCount":34,"googleAuthor":"L Wang","doi":"10.1093/annonc/mdx689","elsevierAuthor":"Wang L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"31","altmetricAuthors":["L. Wang","S.M. Dehm","D.W. Hillman","H. Sicotte","W. Tan","M. Gormley","V. Bhargava","R. Jimenez","F. Xie","P. Yin","S. Qin","F. Quevedo","B.A. Costello","H.C. Pitot","T. Ho","A.H. Bryce","Z. Ye","Y. Li","P. Eiken","P.T. Vedell","P. Barman","B.P. McMenomy","T.D. Atwell","R.E. Carlson","M. Ellingson","B.W. Eckloff","R. Qin","F. Ou","S.N. Hart","H. Huang","J. Jen","E.D. Wieben","K.R. Kalari","R.M. Weinshilboum","L. Wang","M. Kohli"],"twitterCount":9,"altmetricId":27843262},{"title":"The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical …","googleId":"uIgZ33ZMljQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321519","googleCitationCount":36,"googleAuthor":"","doi":"10.1093/annonc/mdx210","elsevierAuthor":"Lenouvel D.","publicationName":"Oral Diseases","elsevierCoverDate":"2021-03-01","elsevierCoverDisplayDate":"March 2021","elsevierCitationCount":"1","altmetricAuthors":["J.-P. Foy","C. Bertolus","M.-C. Michallet","S. Deneuve","R. Incitti","N. Bendriss-Vermare","M.-A. Albaret","S. Ortiz-Cuaran","E. Thomas","A. Colombe","C. Py","N. Gadot","J.-P. Michot","J. Fayette","A. Viari","B. Van den Eynde","P. Goudot","M. Devouassoux-Shisheboran","A. Puisieux","C. Caux","P. Zrounba","S. Lantuejoul","P. Saintigny"],"twitterCount":4,"altmetricId":19777757},{"title":"From hepatitis C virus infection to B-cell lymphoma","googleId":"Rlx4XBGYNr0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349907","googleCitationCount":32,"googleAuthor":"E Bachy","doi":"10.1093/annonc/mdx635","elsevierAuthor":"Couronné L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"24","altmetricAuthors":["L. Couronné","E. Bachy","S. Roulland","B. Nadel","F. Davi","M. Armand","D. Canioni","J.M. Michot","C. Visco","L. Arcaini","C. Besson","O. Hermine"],"twitterCount":9,"altmetricId":27410156},{"title":"Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma","googleId":"S2k0Z1pUAEAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320976","googleCitationCount":28,"googleAuthor":"J Lewin","doi":"10.1093/annonc/mdy124","elsevierAuthor":"Lewin J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"19","altmetricAuthors":["J. Lewin","L. Sayers","D. Kee","I. Walpole","A. Sanelli","L. te Marvelde","A. Herschtal","J. Spillane","D. Gyorki","D. Speakman","V. Estall","S. Donahoe","M. Pohl","K. Pope","M. Chua","S. Sandhu","G.A. McArthur","C.J. McCormack","M. Henderson","R.J. Hicks","M. Shackleton"],"twitterCount":10,"altmetricId":36747028},{"title":"Epstein–Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations","googleId":"5MAT3tTumroJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320204","googleCitationCount":34,"googleAuthor":"","doi":"10.1093/annonc/mdx047","elsevierAuthor":"Schoop I.","publicationName":"Human Pathology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"0","altmetricAuthors":["C. Böger","S. Krüger","H.M. Behrens","S. Bock","J. Haag","H. Kalthoff","C. Röcken"],"twitterCount":12,"altmetricId":20684524},{"title":"Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study","googleId":"ddH5awlIvk8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319489","googleCitationCount":40,"googleAuthor":"SR Markar","doi":"10.1093/annonc/mdw560","elsevierAuthor":"Markar S.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"27","altmetricAuthors":["S.R. Markar","B.J. Noordman","H. Mackenzie","J.M. Findlay","P.R. Boshier","M. Ni","E.W. Steyerberg","A. van der Gaast","M.C.C.M. Hulshof","N. Maynard","M.I. van Berge Henegouwen","B.P.L. Wijnhoven","J.V. Reynolds","J.J.B. Van Lanschot","G.B. Hanna"],"twitterCount":9,"altmetricId":18349037},{"title":"Early evolutionary divergence between papillary and anaplastic thyroid cancers","googleId":"bZoPXsZwPtMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349026","googleCitationCount":26,"googleAuthor":"FM Mancuso","doi":"10.1093/annonc/mdy123","elsevierAuthor":"Capdevila J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"0","altmetricAuthors":["J. Capdevila","R. Mayor","F.M. Mancuso","C. Iglesias","G. Caratù","I. Matos","C. Zafón","J. Hernando","A. Petit","P. Nuciforo","J.M. Cameselle-Teijeiro","C. Álvarez","J.A. Recio","J. Tabernero","X. Matias-Guiu","A. Vivancos","J. Seoane"],"twitterCount":10,"altmetricId":36688683},{"title":"Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma","googleId":"75IlyciclcEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32271-9/abstract","googleCitationCount":37,"googleAuthor":"J Larkin"},{"title":"An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients","googleId":"GVf8_uJnZRoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345971","googleCitationCount":33,"googleAuthor":"KA Tomaszewski","doi":"10.1093/annonc/mdx453","elsevierAuthor":"Koller M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"21","altmetricAuthors":["M. Koller","M.J. Hjermstad","K.A. Tomaszewski","I.M. Tomaszewska","K. Hornslien","A. Harle","J.I. Arraras","O. Morag","C. Pompili","G. Ioannidis","M. Georgiou","C. Navarra","W.-C. Chie","C.D. Johnson","A. Himpel","C. Schulz","T. Bohrer","A. Janssens","D. Kuliś","A. Bottomley"],"twitterCount":1,"altmetricId":26590216},{"title":"Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer","googleId":"nHN3cfhjJGYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50424-0/abstract","googleCitationCount":28,"googleAuthor":"ND James"},{"title":"Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell …","googleId":"l182jcdz9uMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349440","googleCitationCount":33,"googleAuthor":"M Moorhead","doi":"10.1093/annonc/mdx340","elsevierAuthor":"Takamatsu H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"22","altmetricAuthors":["H. Takamatsu","N. Takezako","J. Zheng","M. Moorhead","V.E.H. Carlton","K.A. Kong","R. Murata","S. Ito","T. Miyamoto","K. Yokoyama","K. Matsue","T. Sato","T. Kurokawa","H. Yagi","Y. Terasaki","K. Ohata","M. Matsumoto","T. Yoshida","M. Faham","S. Nakao"],"twitterCount":5,"altmetricId":26647930},{"title":"Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection","googleId":"B_BuGIWqMwkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34190-0/abstract","googleCitationCount":27,"googleAuthor":"EP Scully"},{"title":"Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical–pathological features and intratumor …","googleId":"G97EY5ClyK8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345508","googleCitationCount":32,"googleAuthor":"F Lunardi","doi":"10.1093/annonc/mdy086","elsevierAuthor":"Pasello G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"24","altmetricAuthors":["G. Pasello","G. Zago","F. Lunardi","L. Urso","I. Kern","G. Vlacic","F. Grosso","M. Mencoboni","G.L. Ceresoli","M. Schiavon","F. Pezzuto","A. Pavan","S.E. Vuljan","P. Del Bianco","P. Conte","F. Rea","F. Calabrese"],"twitterCount":3,"altmetricId":34084842},{"title":"Bevacizumab+ chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial …","googleId":"r8X0HbEgJzEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419351312","googleCitationCount":31,"googleAuthor":"J Taieb","doi":"10.1093/annonc/mdx529","elsevierAuthor":"Gilabert M.","publicationName":"Journal of Geriatric Oncology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"0","altmetricAuthors":["T. Aparicio","O. Bouché","J. Taieb","E. Maillard","S. Kirscher","P.-L. Etienne","R. Faroux","F. Khemissa Akouz","F. El Hajbi","C. Locher","Y. Rinaldi","T. Lecomte","S. Lavau-Denes","M. Baconnier","A. Oden-Gangloff","D. Genet","E. Paillaud","F. Retornaz","E. François","L. Bedenne"],"twitterCount":9,"altmetricId":26718707},{"title":"Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial","googleId":"cJUUvTTpos0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341432","googleCitationCount":26,"googleAuthor":"","doi":"10.1093/annonc/mdy229","elsevierAuthor":"Corrie P.G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"0","altmetricAuthors":["P.G. Corrie","A. Marshall","P.D. Nathan","P. Lorigan","M. Gore","S. Tahir","G. Faust","C.G. Kelly","M. Marples","S.J. Danson","E. Marshall","S.J. Houston","R.E. Board","A.M. Waterston","J.P. Nobes","M. Harries","S. Kumar","A. Goodman","A. Dalgleish","A. Martin-Clavijo","S. Westwell","R. Casasola","D. Chao","A. Maraveyas","P.M. Patel","C.H. Ottensmeier","D. Farrugia","A. Humphreys","B. Eccles","G. Young","E.O. Barker","C. Harman","M. Weiss","K.A. Myers","A. Chhabra","S.H. Rodwell","J.A. Dunn","M.R. Middleton","Paul Nathan","Paul Lorigan","Peter Dziewulski","Sonja Holikova","Udaiveer Panwar","Saad Tahir","Guy Faust","Anne Thomas","Pippa Corrie","Bhawna Sirohi","Charles Kelly","Mark Middleton","Maria Marples","Sarah Danson","James Lester","Ernest Marshall","Mazhar Ajaz","Stephen Houston","Ruth Board","David Eaton","Ashita Waterston","Jenny Nobes","Suat Loo","Gill Gray","Helen Stubbings","Martin Gore","Mark Harries","Satish Kumar","Andrew Goodman","Angus Dalgleish","Agustin Martin-Clavijo","Jerry Marsden","Sarah Westwell","Richard Casasola","David Chao","Anthony Maraveyas","Ernest Marshall","Poulam Patel","Christian Ottensmeier","David Farrugia","Alison Humphreys","Bryony Eccles","Renata Dega","Chris Herbert","Christopher Price","Murray Brunt","Martin Scott-Brown","Joanna Hamilton","Richard Larry Hayward","John Smyth","Pamela Woodings","Neena Nayak","Lorna Burrows","Virginia Wolstenholme","John Wagstaff","Marianne Nicolson","Andrew Wilson","Clare Barlow","Christopher Scrase","Timothy Podd","Michael Gonzalez","John Stewart","Martin Highley","Virginia Wolstenholme","Simon Grumett","Andrew Goodman","Toby Talbot","Kannon Nathan","Robert Coltart","Bruce Gee","Martin Gore","David Farrugia","Agustin Martin-Clavijo","Jerry Marsden","Christopher Price","David Farrugia","Kannon Nathan","Robert Coltart","Kannon Nathan","Robert Coltart"],"twitterCount":22,"altmetricId":45079668},{"title":"Progestin-associated shift of meningioma mutational landscape","googleId":"V90YADzxXlkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354882","googleCitationCount":30,"googleAuthor":"","doi":"10.1093/annonc/mdx763","elsevierAuthor":"Peyre M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"20","altmetricAuthors":["M. Peyre","S. Gaillard","C. de Marcellus","M. Giry","F. Bielle","C. Villa","A.L. Boch","H. Loiseau","B. Baussart","L. Cazabat","M.L. Raffin-Sanson","M. Sanson","M. Kalamarides"],"twitterCount":4,"altmetricId":30071339},{"title":"Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial","googleId":"toe2baYlDKkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419343042","googleCitationCount":39,"googleAuthor":"T Jiang","doi":"10.1093/annonc/mdw434","elsevierAuthor":"Oshi M.","publicationName":"Cancers","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"0","altmetricAuthors":["W. Shi","T. Jiang","P. Nuciforo","C. Hatzis","E. Holmes","N. Harbeck","C. Sotiriou","L. Peña","S. Loi","D.D. Rosa","S. Chia","A. Wardley","T. Ueno","J. Rossari","H. Eidtmann","A. Armour","M. Piccart-Gebhart","D.L. Rimm","J. Baselga","L. Pusztai"],"twitterCount":20,"altmetricId":12390977},{"title":"Artificial intelligence for melanoma diagnosis: how can we deliver on the promise?","googleId":"e8u8DQgTCh0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34114-6/abstract","googleCitationCount":29,"googleAuthor":"VJ Mar"},{"title":"Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma","googleId":"8LRIf0ULqEYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324275","googleCitationCount":31,"googleAuthor":"HR Kim","doi":"10.1093/annonc/mdx098","elsevierAuthor":"Kim H.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-06-01","elsevierCoverDisplayDate":"1 June 2017","elsevierCitationCount":"26","altmetricAuthors":["H.R. Kim","H.N. Kang","H.S. Shim","E.Y. Kim","J. Kim","D.J. Kim","J.G. Lee","C.Y. Lee","M.H. Hong","S.-M. Kim","H. Kim","K.-H. Pyo","M.R. Yun","H.J. Park","J.Y. Han","H.A. Youn","M.-J. Ahn","S. Paik","T.-M. Kim","B.C. Cho"],"twitterCount":1,"altmetricId":19778205},{"title":"Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies","googleId":"g106dAwUM6gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320551","googleCitationCount":36,"googleAuthor":"H Tang","doi":"10.1093/annonc/mdw683","elsevierAuthor":"Richard M.","publicationName":"PLoS Computational Biology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"1 May 2020","elsevierCitationCount":"0","altmetricAuthors":["H. Tang","S. Wang","G. Xiao","J. Schiller","V. Papadimitrakopoulou","J. Minna","I.I. Wistuba","Y. Xie"],"twitterCount":9,"altmetricId":18480139},{"title":"Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer","googleId":"GXc84oeMHbEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321441","googleCitationCount":31,"googleAuthor":"H Mamiya","doi":"10.1093/annonc/mdx201","elsevierAuthor":"Cersosimo R.J.","publicationName":"American Journal of Health-System Pharmacy","elsevierCoverDate":"2019-08-15","elsevierCoverDisplayDate":"15 August 2019","elsevierCitationCount":"2","altmetricAuthors":["H. Mamiya","R.K. Tahara","S.M. Tolaney","N.K. Choudhry","M. Najafzadeh"],"twitterCount":58,"altmetricId":19870370},{"title":"Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma","googleId":"M50iwsWEVSoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352469","googleCitationCount":32,"googleAuthor":"BS Hoppe","doi":"10.1093/annonc/mdx287","elsevierAuthor":"Hoppe B.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"24","altmetricAuthors":["B.S. Hoppe","C.E. Hill-Kayser","Y.D. Tseng","S. Flampouri","H.M. Elmongy","O. Cahlon","N.P. Mendenhall","A. Maity","L.A. McGee","J.P. Plastaras"],"twitterCount":5,"altmetricId":23784935},{"title":"Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the …","googleId":"rDvJA9goAgYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350513","googleCitationCount":30,"googleAuthor":"MGE Verdam","doi":"10.1093/annonc/mdx726","elsevierAuthor":"Noordman B.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"18","altmetricAuthors":["B.J. Noordman","M.G.E Verdam","S.M. Lagarde","J. Shapiro","M.C.C.M. Hulshof","M.I. van Berge Henegouwen","B.P.L. Wijnhoven","G.A.P. Nieuwenhuijzen","J.J. Bonenkamp","M.A. Cuesta","J.Th.M. Plukker","E.J. Spillenaar Bilgen","E.W. Steyerberg","A. van der Gaast","M.A.G. Sprangers","J.J.B. van Lanschot"],"twitterCount":9,"altmetricId":29850778},{"title":"IMpower131: progression-free survival (PFS) and overall survival (OS) analysis of a randomised Phase III study of atezolizumab+ carboplatin+ paclitaxel or nab …","googleId":"qtda6Fnh9u8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50468-9/abstract","googleCitationCount":25,"googleAuthor":""},{"title":"Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for …","googleId":"yHTKOTGcRe4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349518","googleCitationCount":31,"googleAuthor":"J Doyen","doi":"10.1093/annonc/mdx351","elsevierAuthor":"Azria D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"26","altmetricAuthors":[],"twitterCount":0},{"title":"Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials","googleId":"IOb38PUvRtMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34240-1/abstract","googleCitationCount":25,"googleAuthor":"K Hess"},{"title":"Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 …","googleId":"GVLn-T6xUn4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38315-0/abstract","googleCitationCount":34,"googleAuthor":""},{"title":"Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium","googleId":"MWkCKOn1BfYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341547","googleCitationCount":27,"googleAuthor":"","doi":"10.1093/annonc/mdy210","elsevierAuthor":"Kenis C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"21","altmetricAuthors":["C. Kenis","L. Decoster","J. Flamaing","P.R. Debruyne","I. De Groof","C. Focan","F. Cornélis","V. Verschaeve","C. Bachmann","D. Bron","S. Luce","G. Debugne","H. Van den Bulck","J.-C. Goeminne","D. Schrijvers","K. Geboers","B. Petit","C. Langenaeken","R. Van Rijswijk","P. Specenier","G. Jerusalem","J.-P. Praet","K. Vandenborre","J.-P. Lobelle","M. Lycke","K. Milisen","H. Wildiers"],"twitterCount":29,"altmetricId":43728969},{"title":"Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes","googleId":"uPUgWMKvfD8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319696","googleCitationCount":38,"googleAuthor":"M Parasramka","doi":"10.1093/annonc/mdw652","elsevierAuthor":"Ho T.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"32","altmetricAuthors":["T.H. Ho","D.J. Serie","M. Parasramka","J.C. Cheville","B.M. Bot","W. Tan","L. Wang","R.W. Joseph","T. Hilton","B.C. Leibovich","A.S. Parker","J.E. Eckel-Passow"],"twitterCount":0,"altmetricId":99979252},{"title":"The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation","googleId":"6Z2UXopOlXYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349981","googleCitationCount":31,"googleAuthor":"M Riester","doi":"10.1093/annonc/mdx645","elsevierAuthor":"Riester M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"19","altmetricAuthors":["M. Riester","Q. Xu","A. Moreira","J. Zheng","F. Michor","R.J. Downey"],"twitterCount":1,"altmetricId":27642341},{"title":"Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer …","googleId":"IMjY1NOb16MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324421","googleCitationCount":37,"googleAuthor":"","doi":"10.1093/annonc/mdx122","elsevierAuthor":"Aparicio T.","publicationName":"Digestive and Liver Disease","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"2","altmetricAuthors":["J.J.M. Kwakman","L.H.J. Simkens","J.M. van Rooijen","A.J. van de Wouw","A.J. ten Tije","G.J.M. Creemers","M.P. Hendriks","M. Los","R.J. van Alphen","M.B. Polée","E.W. Muller","A.M.T. van der Velden","T. van Voorthuizen","M. Koopman","L. Mol","E. van Werkhoven","C.J.A. Punt"],"twitterCount":3,"altmetricId":18693716},{"title":"Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism","googleId":"SdRMXIw4JvUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322008","googleCitationCount":39,"googleAuthor":"JC Soria","doi":"10.1093/annonc/mdw552","elsevierAuthor":"Morel D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"29","altmetricAuthors":["D. Morel","G. Almouzni","J.-C. Soria","S. Postel-Vinay"],"twitterCount":18,"altmetricId":13495927},{"title":"CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification","googleId":"jW8SE8n0BekJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320277","googleCitationCount":33,"googleAuthor":"C Pilati","doi":"10.1093/annonc/mdx066","elsevierAuthor":"Hirano D.","publicationName":"PLoS ONE","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"February 2019","elsevierCitationCount":"2","altmetricAuthors":["C. Pilati","J. Taieb","R. Balogoun","L. Marisa","A. de Reyniès","P. Laurent-Puig"],"twitterCount":7,"altmetricId":16898553},{"title":"MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial","googleId":"MgUtRlll7l4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322252","googleCitationCount":34,"googleAuthor":"G Brown","doi":"10.1093/annonc/mdw616","elsevierAuthor":"Patel U.B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"24","altmetricAuthors":[],"twitterCount":0},{"title":"Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force","googleId":"d4OQfN9_EnQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321969","googleCitationCount":38,"googleAuthor":"","doi":"10.1093/annonc/mdw547","elsevierAuthor":"Stauder R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"27","altmetricAuthors":["R. Stauder","B. Eichhorst","M.E. Hamaker","K. Kaplanov","V.A. Morrison","A. Österborg","I. Poddubnaya","J.A. Woyach","T. Shanafelt","L. Smolej","L. Ysebaert","V. Goede"],"twitterCount":21,"altmetricId":13264706},{"title":"Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy—results from the ACOSOG Z1041 …","googleId":"1ZYJ4cMtTF0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320216","googleCitationCount":33,"googleAuthor":"R Lesurf","doi":"10.1093/annonc/mdx048","elsevierAuthor":"Buzdar A.","publicationName":"JAMA Oncology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"January 2019","elsevierCitationCount":"6","altmetricAuthors":["R. Lesurf","O.L. Griffith","M. Griffith","J. Hundal","L. Trani","M.A. Watson","R. Aft","M.J. Ellis","D. Ota","V.J. Suman","F. Meric-Bernstam","A.M. Leitch","J.C. Boughey","G. Unzeitig","A.U. Buzdar","K.K. Hunt","E.R. Mardis"],"twitterCount":5,"altmetricId":18048696},{"title":"Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant …","googleId":"3r3mww53iX8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454690","googleCitationCount":26,"googleAuthor":"MJ Birrer","doi":"10.1093/annonc/mdy023","elsevierAuthor":"Banerjee S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"20","altmetricAuthors":["S. Banerjee","A.M. Oza","M.J. Birrer","E.P. Hamilton","J. Hasan","A. Leary","K.N. Moore","B. Mackowiak-Matejczyk","J. Pikiel","I. Ray-Coquard","P. Trask","K. Lin","E. Schuth","A. Vaze","Y. Choi","J.C. Marsters","D.J. Maslyar","V. Lemahieu","Y. Wang","E.W. Humke","J.F. Liu"],"twitterCount":8,"altmetricId":32502144},{"title":"Muscle protein anabolism in advanced cancer patients: response to protein and amino acids support, and to physical activity","googleId":"CGr03QMpcLUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316783","googleCitationCount":27,"googleAuthor":"","doi":"10.1093/annonc/mdx809","elsevierAuthor":"Antoun S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"16","altmetricAuthors":["S Antoun","B Raynard"],"twitterCount":179,"altmetricId":33934740},{"title":"mFOLFOXIRI+ panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m (CRC): a randomized phase II …","googleId":"qBi0mbbSJAwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38962-6/abstract","googleCitationCount":31,"googleAuthor":""},{"title":"Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel …","googleId":"8Qn_gJzMCMsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321672","googleCitationCount":30,"googleAuthor":"K Nishikawa","doi":"10.1093/annonc/mdx236","elsevierAuthor":"Ke J.","publicationName":"Gastroenterology Report","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"1 June 2020","elsevierCitationCount":"2","altmetricAuthors":[],"twitterCount":0},{"title":"First-onset mental disorders after cancer diagnosis and cancer-specific mortality: a nationwide cohort study","googleId":"Mn7OnArOv-sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321738","googleCitationCount":31,"googleAuthor":"F Fang","doi":"10.1093/annonc/mdx265","elsevierAuthor":"Binnal A.","publicationName":"Oral Diseases","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":["J. Zhu","F. Fang","A. Sjölander","K. Fall","H.O. Adami","U. Valdimarsdóttir"],"twitterCount":2,"altmetricId":20517851},{"title":"Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory …","googleId":"irZnmOPv8HgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319787","googleCitationCount":39,"googleAuthor":"","doi":"10.1093/annonc/mdw666","elsevierAuthor":"Belin L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"30","altmetricAuthors":["L. Belin","M. Kamal","C. Mauborgne","C. Plancher","F. Mulot","J.-P. Delord","A. Gonçalves","C. Gavoille","C. Dubot","N. Isambert","M. Campone","O. Trédan","F. Ricci","M. Alt","D. Loirat","M.-P. Sablin","X. Paoletti","V. Servois","C. Le Tourneau"],"twitterCount":1,"altmetricId":14865499},{"title":"Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma","googleId":"9CuomzqcLNAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320046","googleCitationCount":33,"googleAuthor":"","doi":"10.1093/annonc/mdx025","elsevierAuthor":"Teckie S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-05-01","elsevierCoverDisplayDate":"May 2017","elsevierCitationCount":"19","altmetricAuthors":["S. Teckie","S. Qi","M. Chelius","S. Lovie","M. Hsu","A. Noy","C. Portlock","J. Yahalom"],"twitterCount":1,"altmetricId":18049274},{"title":"Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial","googleId":"pvXM_NAmOz8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321040","googleCitationCount":28,"googleAuthor":"E Fokas","doi":"10.1093/annonc/mdy143","elsevierAuthor":"Fokas E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"20","altmetricAuthors":["E. Fokas","R. Fietkau","A. Hartmann","W. Hohenberger","R. Grützmann","M. Ghadimi","T. Liersch","P. Ströbel","G.G. Grabenbauer","U. Graeven","R -D Hofheinz","C -H Köhne","C. Wittekind","R. Sauer","M. Kaufmann","T. Hothorn","C. Rödel"],"twitterCount":16,"altmetricId":39964932},{"title":"Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC …","googleId":"E4XkErDxfX8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49289-2/abstract","googleCitationCount":24,"googleAuthor":""},{"title":"The antibody–drug conjugate target landscape across a broad range of tumour types","googleId":"hnt3cInNXa0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354705","googleCitationCount":30,"googleAuthor":"DJA de Groot","doi":"10.1093/annonc/mdx541","elsevierAuthor":"Moek K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"23","altmetricAuthors":["K.L. Moek","D.J.A. de Groot","E.G.E. de Vries","R.S.N. Fehrmann"],"twitterCount":25,"altmetricId":28196396},{"title":"The use of antidepressants in oncology: a review and practical tips for oncologists","googleId":"qU1Vmn_j-c4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349804","googleCitationCount":29,"googleAuthor":"L Grassi","doi":"10.1093/annonc/mdx526","elsevierAuthor":"Grassi L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"15","altmetricAuthors":["L. Grassi","M.G. Nanni","G. Rodin","M. Li","R. Caruso"],"twitterCount":21,"altmetricId":27194596},{"title":"Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types","googleId":"crLgaWCIdLwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342085","googleCitationCount":23,"googleAuthor":"T Pascual","doi":"10.1093/annonc/mdy335","elsevierAuthor":"Paré L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"19","altmetricAuthors":["L. Paré","T. Pascual","E. Seguí","C. Teixidó","M. Gonzalez-Cao","P. Galván","A. Rodríguez","B. González","M. Cuatrecasas","E. Pineda","A. Torné","G. Crespo","S. Martin-Algarra","E. Pérez-Ruiz","Ò Reig","M. Viladot","C. Font","B. Adamo","M. Vidal","L. Gaba","M. Muñoz","I. Victoria","G. Ruiz","N. Viñolas","B. Mellado","J. Maurel","J. Garcia-Corbacho","M Á Molina-Vila","M. Juan","J.M. Llovet","N. Reguart","A. Arance","A. Prat"],"twitterCount":43,"altmetricId":47143494},{"title":"Cancer mortality predictions for 2017 in Latin America","googleId":"0YBUv7yyAwkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352536","googleCitationCount":31,"googleAuthor":"C La Vecchia","doi":"10.1093/annonc/mdx301","elsevierAuthor":"Carioli G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"25","altmetricAuthors":["G. Carioli","C. La Vecchia","P. Bertuccio","T. Rodriguez","F. Levi","P. Boffetta","E. Negri","M. Malvezzi"],"twitterCount":4,"altmetricId":21348318},{"title":"Midostaurin: a magic bullet that blocks mast cell expansion and activation","googleId":"GMpLz0ZU4yQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349270","googleCitationCount":31,"googleAuthor":"K Hartmann","doi":"10.1093/annonc/mdx290","elsevierAuthor":"Valent P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"27","altmetricAuthors":["P. Valent","C. Akin","K. Hartmann","T.I. George","K. Sotlar","B. Peter","K.V. Gleixner","K. Blatt","W.R. Sperr","P.W. Manley","O. Hermine","H.C. Kluin-Nelemans","M. Arock","H.-P. Horny","A. Reiter","J. Gotlib"],"twitterCount":3,"altmetricId":25044814},{"title":"Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated …","googleId":"IuOrI65imtcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319799","googleCitationCount":36,"googleAuthor":"SJ Klempner","doi":"10.1093/annonc/mdw669","elsevierAuthor":"Kim S.T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"26","altmetricAuthors":[],"twitterCount":0},{"title":"Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers","googleId":"_dRf8jrRj6UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322045","googleCitationCount":36,"googleAuthor":"HA Yu","doi":"10.1093/annonc/mdw556","elsevierAuthor":"Yu H.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"27","altmetricAuthors":["H.A. Yu","C. Sima","D. Feldman","L.L. Liu","B. Vaitheesvaran","J. Cross","C.M. Rudin","M.G. Kris","W. Pao","F. Michor","G.J. Riely"],"twitterCount":12,"altmetricId":13286734},{"title":"Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer","googleId":"_VYZDZroF5kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354973","googleCitationCount":29,"googleAuthor":"BS Sørensen","doi":"10.1093/annonc/mdx778","elsevierAuthor":"Schou J.V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"24","altmetricAuthors":["J.V. Schou","F.O. Larsen","B.S. Sørensen","R. Abrantes","A.K. Boysen","J.S. Johansen","B.V. Jensen","D.L. Nielsen","K.L. Spindler"],"twitterCount":18,"altmetricId":30605052},{"title":"A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with …","googleId":"eXb0Pb9DxDEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350008","googleCitationCount":33,"googleAuthor":"P Nuciforo","doi":"10.1093/annonc/mdx647","elsevierAuthor":"Nuciforo P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"22","altmetricAuthors":["P. Nuciforo","T. Pascual","J. Cortés","A. Llombart-Cussac","R. Fasani","L. Paré","M. Oliveira","P. Galvan","N. Martínez","B. Bermejo","M. Vidal","S. Pernas","R. López","M. Muñoz","I. Garau","L. Manso","J. Alarcón","E. Martínez","V. Rodrik-Outmezguine","J.C. Brase","P. Villagrasa","A. Prat","E. Holgado"],"twitterCount":51,"altmetricId":27348669},{"title":"A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma","googleId":"b-Q4gNG1tvAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346125","googleCitationCount":28,"googleAuthor":"B Keam","doi":"10.1093/annonc/mdx493","elsevierAuthor":"Voss M.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"24","altmetricAuthors":[],"twitterCount":0},{"title":"The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study","googleId":"NYZW8hEGzo8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322100","googleCitationCount":37,"googleAuthor":"","doi":"10.1093/annonc/mdw563","elsevierAuthor":"Mangili G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"23","altmetricAuthors":["G. Mangili","C. Sigismondi","D. Lorusso","G. Cormio","M. Candiani","G. Scarfone","F. Mascilini","A. Gadducci","A.M. Mosconi","P. Scollo","C. Cassani","S. Pignata","G. Ferrandina"],"twitterCount":1,"altmetricId":13521570},{"title":"A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors","googleId":"JoRsCB8XTA8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932109X","googleCitationCount":25,"googleAuthor":"","doi":"10.1093/annonc/mdy171","elsevierAuthor":"Ferrarotto R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"21","altmetricAuthors":["R. Ferrarotto","G. Eckhardt","A. Patnaik","P. LoRusso","L. Faoro","J.V. Heymach","A.M. Kapoun","L. Xu","P. Munster"],"twitterCount":7,"altmetricId":41052902},{"title":"Body mass index and 20 specific cancers: re-analyses of dose–response meta-analyses of observational studies","googleId":"fJG7prhy-BoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355103","googleCitationCount":29,"googleAuthor":"EK Choi","doi":"10.1093/annonc/mdx819","elsevierAuthor":"Choi E.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"19","altmetricAuthors":["E.K. Choi","H.B. Park","K.H. Lee","J.H. Park","M. Eisenhut","H.J. van der Vliet","G. Kim","J.I. Shin"],"twitterCount":28,"altmetricId":30992091},{"title":"Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies","googleId":"9TpQ6Fb66VsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931926X","googleCitationCount":37,"googleAuthor":"SJ Moschos","doi":"10.1093/annonc/mdw534","elsevierAuthor":"Salama A.K.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"31","altmetricAuthors":["A.K.S. Salama","S.J. Moschos"],"twitterCount":36,"altmetricId":16294560},{"title":"Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial","googleId":"Tdh15v7VFQcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321751","googleCitationCount":30,"googleAuthor":"","doi":"10.1093/annonc/mdx268","elsevierAuthor":"Dong S.","publicationName":"Molecular Genetics and Genomic Medicine","elsevierCoverDate":"2020-03-01","elsevierCoverDisplayDate":"1 March 2020","elsevierCitationCount":"1","altmetricAuthors":["P. Christopoulos","W. Engel-Riedel","C. Grohé","C. Kropf-Sanchen","J. von Pawel","S. Gütz","J. Kollmeier","W. Eberhardt","D. Ukena","V. Baum","I. Nimmrich","C. Sieder","P.A. Schnabel","M. Serke","M. Thomas"],"twitterCount":1,"altmetricId":20490232},{"title":"Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non …","googleId":"doO7r7oysoQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50481-1/abstract","googleCitationCount":23,"googleAuthor":"N Reguart"},{"title":"Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support","googleId":"TxgNThEKQucJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934181X","googleCitationCount":24,"googleAuthor":"GH Lyman","doi":"10.1093/annonc/mdy311","elsevierAuthor":"Lyman G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"14","altmetricAuthors":["G.H. Lyman","L. Yau","R. Nakov","A. Krendyukov"],"twitterCount":72,"altmetricId":46234257},{"title":"Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial","googleId":"4NQc1m_sS90J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354894","googleCitationCount":26,"googleAuthor":"TE Witzig","doi":"10.1093/annonc/mdx764","elsevierAuthor":"Witzig T.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"19","altmetricAuthors":["T.E. Witzig","K. Tobinai","L. Rigacci","T. Ikeda","A. Vanazzi","M. Hino","Y. Shi","J. Mayer","L.J. Costa","C.D. Bermudez Silva","J. Zhu","D. Belada","K. Bouabdallah","J.G. Kattan","J. Kuruvilla","W.S. Kim","J.-F. Larouche","M. Ogura","M. Ozcan","L. Fayad","C. Wu","J. Fan","A.-L. Louveau","M. Voi","F. Cavalli"],"twitterCount":17,"altmetricId":30534021},{"title":"Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint …","googleId":"mkCY1Q_9AlUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34579-X/abstract","googleCitationCount":30,"googleAuthor":"D Sueta"},{"title":"Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States","googleId":"3XHxrVI-rawJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320174","googleCitationCount":31,"googleAuthor":"BA Mahal","doi":"10.1093/annonc/mdx041","elsevierAuthor":"Mahal B.A.","publicationName":"Annals of oncology : official journal of the European Society for Medical Oncology","elsevierCoverDate":"2017-05-01","elsevierCoverDisplayDate":"1 May 2017","elsevierCitationCount":"18","altmetricAuthors":["B.A. Mahal","Y.-W. Chen","V. Muralidhar","A.R. Mahal","T.K. Choueiri","K.E. Hoffman","J.C. Hu","C.J. Sweeney","J.B. Yu","F.Y. Feng","S.P. Kim","C.J. Beard","N.E. Martin","Q.-D. Trinh","P.L. Nguyen"],"twitterCount":23,"altmetricId":16452430},{"title":"Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma","googleId":"rbSkmHINoksJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350045","googleCitationCount":31,"googleAuthor":"SJ Kim","doi":"10.1093/annonc/mdx684","elsevierAuthor":"Kwong Y.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"22","altmetricAuthors":["Y.L. Kwong","S.J. Kim","E. Tse","S.Y. Oh","J.Y. Kwak","H.S. Eom","Y.R. Do","Y.C. Mun","S.R. Lee","H.J. Shin","C. Suh","S.S. Chuang","Y.S. Lee","S.T. Lim","K. Izutsu","R. Suzuki","T. Relander","F. d’Amore","N. Schmitz","A. Jaccard","W.S. Kim"],"twitterCount":2,"altmetricId":28046339},{"title":"Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A …","googleId":"G_kf_BTjScMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49394-0/abstract","googleCitationCount":26,"googleAuthor":""},{"title":"Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): preliminary results from a single-arm, phase 2 study","googleId":"EJZsifuAIV4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38314-9/abstract","googleCitationCount":32,"googleAuthor":"A Algazi"},{"title":"Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid …","googleId":"okyGDd6cp2EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322549","googleCitationCount":32,"googleAuthor":"G Leone","doi":"10.1093/annonc/mdx154","elsevierAuthor":"Leone G.","publicationName":"Mediterranean Journal of Hematology and Infectious Diseases","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"2018","elsevierCitationCount":"1","altmetricAuthors":[],"twitterCount":0},{"title":"Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma …","googleId":"-gH0bvWgbwEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50421-5/abstract","googleCitationCount":23,"googleAuthor":"S Roychowdhury"},{"title":"T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression","googleId":"Sep5QdX7cBoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321003","googleCitationCount":27,"googleAuthor":"A Draghi","doi":"10.1093/annonc/mdy139","elsevierAuthor":"Andersen R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"19","altmetricAuthors":["R. Andersen","T.H. Borch","A. Draghi","A. Gokuldass","M.A.H. Rana","M. Pedersen","M. Nielsen","P. Kongsted","J.W. Kjeldsen","M.C.W. Westergaard","H.D. Radic","C.A. Chamberlain","L.R. Hölmich","H.W. Hendel","M.S. Larsen","Ö Met","I.M. Svane","M. Donia"],"twitterCount":76,"altmetricId":39272539},{"title":"Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically …","googleId":"B4fBIsU9Q1oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49217-X/abstract","googleCitationCount":22,"googleAuthor":"A Hollebecque"},{"title":"A mutational signature associated with alcohol consumption and prognostically significantly mutated driver genes in esophageal squamous cell carcinoma","googleId":"pTJeizM-EmQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454616","googleCitationCount":24,"googleAuthor":"MY Wang","doi":"10.1093/annonc/mdy011","elsevierAuthor":"Li X.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"22","altmetricAuthors":["X.C. Li","M.Y. Wang","M. Yang","H.J. Dai","B.F. Zhang","W. Wang","X.L. Chu","X. Wang","H. Zheng","R.F. Niu","W. Zhang","K.X. Chen"],"twitterCount":2,"altmetricId":32039916},{"title":"A phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)","googleId":"Sg0McIKl18MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49397-6/abstract","googleCitationCount":24,"googleAuthor":"CM Annunziata"},{"title":"PD-1 blockade in HIV-infected patients with lung cancer: a new challenge or already a strategy?","googleId":"jQUHhjHLuOEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)45455-0/abstract","googleCitationCount":27,"googleAuthor":"O Lambotte"},{"title":"S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer …","googleId":"t7rM46hJoHcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355097","googleCitationCount":28,"googleAuthor":"","doi":"10.1093/annonc/mdx816","elsevierAuthor":"Yamada Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"21","altmetricAuthors":["Y. Yamada","T. Denda","M. Gamoh","I. Iwanaga","S. Yuki","H. Shimodaira","M. Nakamura","T. Yamaguchi","H. Ohori","K. Kobayashi","M. Tsuda","Y. Kobayashi","Y. Miyamoto","M. Kotake","K. Shimada","A. Sato","S. Morita","S. Takahashi","Y. Komatsu","C. Ishioka"],"twitterCount":14,"altmetricId":30978825},{"title":"Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of …","googleId":"0NM7X_V7ugsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353980","googleCitationCount":29,"googleAuthor":"J Martin-Broto","doi":"10.1093/annonc/mdx536","elsevierAuthor":"Martin-Broto J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"22","altmetricAuthors":["J. Martin-Broto","A. Redondo","C. Valverde","M.A. Vaz","J. Mora","X. Garcia del Muro","A. Gutierrez","C. Tous","A. Carnero","D. Marcilla","A. Carranza","P. Sancho","J. Martinez-Trufero","R. Diaz-Beveridge","J. Cruz","V. Encinas","M. Taron","D.S. Moura","P. Luna","N. Hindi","A. Lopez-Pousa"],"twitterCount":18,"altmetricId":33569233},{"title":"Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only …","googleId":"PSMJHz_g9HYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934205X","googleCitationCount":26,"googleAuthor":"","doi":"10.1093/annonc/mdy332","elsevierAuthor":"Yang B.","publicationName":"Acta Biochimica Polonica","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":["A. Dietz","G. Wichmann","T. Kuhnt","L. Pfreundner","R. Hagen","M. Scheich","O. Kölbl","M.G. Hautmann","J. Strutz","F. Schreiber","U. Bockmühl","V. Schilling","P. Feyer","M. de Wit","G. Maschmeyer","M. Jungehülsing","U. Schroeder","B. Wollenberg","C. Sittel","M. Münter","T. Lenarz","J.P. Klussmann","O. Guntinas-Lichius","C. Rudack","H.T. Eich","T. Foerg","S. Preyer","M. Westhofen","H.J. Welkoborsky","D. Esser","D. Thurnher","S. Remmert","H. Sudhoff","M. Görner","J. Bünzel","V. Budach","S. Held","M. Knödler","F. Lordick","S. Wiegand","K. Vogel","A. Boehm","M. Flentje","U. Keilholz"],"twitterCount":12,"altmetricId":47338731},{"title":"Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions","googleId":"gyxyVqAau4YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342097","googleCitationCount":24,"googleAuthor":"DB Costa","doi":"10.1093/annonc/mdy336","elsevierAuthor":"Piotrowska Z.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"20","altmetricAuthors":["Z. Piotrowska","D.B. Costa","G.R. Oxnard","M. Huberman","J.F. Gainor","I.T. Lennes","A. Muzikansky","A.T. Shaw","C.G. Azzoli","R.S. Heist","L.V. Sequist"],"twitterCount":18,"altmetricId":50256024},{"title":"A phase 2, randomized, double-blind, placebo-controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin …","googleId":"_al17P_WNw4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320228","googleCitationCount":32,"googleAuthor":"C Aghajanian","doi":"10.1093/annonc/mdx049","elsevierAuthor":"Monk B.J.","publicationName":"Annals of oncology : official journal of the European Society for Medical Oncology","elsevierCoverDate":"2017-05-01","elsevierCoverDisplayDate":"1 May 2017","elsevierCitationCount":"26","altmetricAuthors":["B.J. Monk","M.F. Brady","C. Aghajanian","H.A. Lankes","T. Rizack","J. Leach","J.M. Fowler","R. Higgins","P. Hanjani","M. Morgan","R. Edwards","W. Bradley","T. Kolevska","P. Foukas","E.M. Swisher","K.S. Anderson","R. Gottardo","J.K. Bryan","M. Newkirk","K.L. Manjarrez","R.S. Mannel","R.M. Hershberg","G. Coukos"],"twitterCount":6,"altmetricId":16749478},{"title":"Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International …","googleId":"xQbj7CEj29kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350392","googleCitationCount":26,"googleAuthor":"A Bamias","doi":"10.1093/annonc/mdx692","elsevierAuthor":"Bamias A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"0","altmetricAuthors":["A. Bamias","K. Tzannis","L.C. Harshman","S.J. Crabb","Y.-N. Wong","S. Kumar Pal","U. De Giorgi","S. Ladoire","N. Agarwal","E.Y. Yu","G. Niegisch","A. Necchi","C.N. Sternberg","S. Srinivas","A. Alva","U. Vaishampayan","L. Cerbone","M. Liontos","J. Rosenberg","T. Powles","J. Bellmunt","M.D. Galsky"],"twitterCount":4,"altmetricId":27922268},{"title":"A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting …","googleId":"SKOljdoOUJkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349348","googleCitationCount":29,"googleAuthor":"","doi":"10.1093/annonc/mdx315","elsevierAuthor":"Bossi P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"12","altmetricAuthors":["P. Bossi","D. Cortinovis","S. Fatigoni","M. Cossu Rocca","A. Fabi","P. Seminara","C. Ripamonti","S. Alfieri","R. Granata","C. Bergamini","F. Agustoni","P. Bidoli","F. Nolè","M.A. Pessi","F. Macchi","L. Michellini","F. Montanaro","F. Roila"],"twitterCount":13,"altmetricId":21393357},{"title":"Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two …","googleId":"a6fkvMnSQ3wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319271","googleCitationCount":33,"googleAuthor":"FC Bidard","doi":"10.1093/annonc/mdw535","elsevierAuthor":"Pierga J.Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"26","altmetricAuthors":["J.-Y. Pierga","F.-C. Bidard","A. Autret","T. Petit","F. Andre","F. Dalenc","C. Levy","J.-M. Ferrero","G. Romieu","J. Bonneterre","F. Lerebours","T. Bachelot","P. Kerbrat","M. Campone","J.-C. Eymard","M.-A. Mouret-Reynier","J. Gligorov","A.-C. Hardy-Bessard","A. Lortholary","P. Soulie","J.-M. Boher","C. Proudhon","E. Charafe-Jaufret","J. Lemonnier","F. Bertucci","P. Viens"],"twitterCount":6,"altmetricId":13054821},{"title":"Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours","googleId":"otCL_yHIrecJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322173","googleCitationCount":33,"googleAuthor":"","doi":"10.1093/annonc/mdw605","elsevierAuthor":"Heidenreich A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"26","altmetricAuthors":[],"twitterCount":0},{"title":"Emerging treatment paradigms for brain metastasis in non-small-cell lung cancer: an overview of the current landscape and challenges ahead","googleId":"1ClRTULh6LIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353785","googleCitationCount":24,"googleAuthor":"C Faivre-Finn","doi":"10.1093/annonc/mdx481","elsevierAuthor":"Ulahannan D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"18","altmetricAuthors":["D. Ulahannan","J. Khalifa","C. Faivre-Finn","S -M Lee"],"twitterCount":18,"altmetricId":30189704},{"title":"Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial","googleId":"XkJC-HzspRsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342024","googleCitationCount":21,"googleAuthor":"","doi":"10.1093/annonc/mdy329","elsevierAuthor":"Staehler M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"16","altmetricAuthors":["M. Staehler","R.J. Motzer","D.J. George","H.S. Pandha","F. Donskov","B. Escudier","A.J. Pantuck","A. Patel","L. DeAnnuntis","H. Bhattacharyya","K. Ramaswamy","G. Zanotti","X. Lin","M. Lechuga","L. Serfass","J. Paty","A. Ravaud"],"twitterCount":7,"altmetricId":47890809},{"title":"A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer","googleId":"xFuVGlEqvyYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350100","googleCitationCount":27,"googleAuthor":"","doi":"10.1093/annonc/mdx691","elsevierAuthor":"Criscitiello C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"19","altmetricAuthors":["C. Criscitiello","M.A. Bayar","G. Curigliano","F.W. Symmans","C. Desmedt","H. Bonnefoi","B. Sinn","G. Pruneri","C. Vicier","J.Y. Pierga","C. Denkert","S. Loibl","C. Sotiriou","S. Michiels","F. André"],"twitterCount":22,"altmetricId":27917420},{"title":"Advances in the systemic treatment of melanoma brain metastases","googleId":"8Eis8SZnbawJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321143","googleCitationCount":20,"googleAuthor":"","doi":"10.1093/annonc/mdy185","elsevierAuthor":"Glitza Oliva I.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"16","altmetricAuthors":["I.C. Glitza Oliva","G. Schvartsman","H. Tawbi"],"twitterCount":20,"altmetricId":42361582},{"title":"Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative …","googleId":"Xs-QNUTCpUsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345880","googleCitationCount":29,"googleAuthor":"JP Merlio","doi":"10.1093/annonc/mdx404","elsevierAuthor":"Leduc C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"28","altmetricAuthors":["C. Leduc","J.P. Merlio","B. Besse","H. Blons","D. Debieuvre","P.P. Bringuier","I. Monnet","I. Rouquette","S. Fraboulet-Moreau","A. Lemoine","D. Pouessel","J. Mosser","F. Vaylet","A. Langlais","P. Missy","F. Morin","D. Moro-Sibilot","J. Cadranel","F. Barlesi","M. Beau-Faller"],"twitterCount":15,"altmetricId":28617445},{"title":"KEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma","googleId":"77JmKaZARXEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38479-9/abstract","googleCitationCount":29,"googleAuthor":"A Ribas"},{"title":"Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC)","googleId":"fHDXumLgQIMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39158-4/abstract","googleCitationCount":28,"googleAuthor":"J Mazieres"},{"title":"HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?","googleId":"AYg7pe0SmcUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34119-5/abstract","googleCitationCount":26,"googleAuthor":"S Mahner"},{"title":"Results of COLUMBUS part 2: a phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma","googleId":"sRRZKnmxh-MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38478-7/abstract","googleCitationCount":27,"googleAuthor":"PA Ascierto"},{"title":"Clinical and genetic predictors of paclitaxel neurotoxicity based on patient-versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial","googleId":"Xrj_W2ZIPnEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346101","googleCitationCount":28,"googleAuthor":"SB Park","doi":"10.1093/annonc/mdx491","elsevierAuthor":"Park S.B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"21","altmetricAuthors":["S.B. Park","J.B. Kwok","R. Asher","C.K. Lee","P. Beale","F. Selle","M. Friedlander"],"twitterCount":5,"altmetricId":24928607},{"title":"Impact of prediagnostic smoking and smoking cessation on colorectal cancer prognosis: a meta-analysis of individual patient data from cohorts within the …","googleId":"hohreMbynu8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350665","googleCitationCount":26,"googleAuthor":"JM Ordóñez-Mena","doi":"10.1093/annonc/mdx761","elsevierAuthor":"Ordóñez-Mena J.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"19","altmetricAuthors":["J.M. Ordóñez-Mena","V. Walter","B. Schöttker","M. Jenab","M.G. O’Doherty","F. Kee","B. Bueno-de-Mesquita","P.H.M. Peeters","B.H. Stricker","R. Ruiter","A. Hofman","S. Söderberg","P. Jousilahti","K. Kuulasmaa","N.D. Freedman","T. Wilsgaard","A. Wolk","L.M. Nilsson","A. Tjønneland","J.R. Quirós","F J B van Duijnhoven","P.D. Siersema","P. Boffetta","A. Trichopoulou","H. Brenner"],"twitterCount":33,"altmetricId":30378629},{"title":"Hyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO)","googleId":"UzMapHEWsLUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38553-7/abstract","googleCitationCount":28,"googleAuthor":"R Ferrara"},{"title":"Adjuvant FOLFOX+/− cetuximab in fullRAS andBRAF wildtype stage III colon cancer patients","googleId":"D7yq5-gMH7MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320599","googleCitationCount":37,"googleAuthor":"J Taieb","doi":"10.1093/annonc/mdw687","elsevierAuthor":"Taieb J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-04-01","elsevierCoverDisplayDate":"1 April 2017","elsevierCitationCount":"20","altmetricAuthors":["J. Taieb","R. Balogoun","K. Le Malicot","J. Tabernero","E. Mini","G. Folprecht","J.-L. Van Laethem","J.-F. Emile","C. Mulot","S. Fratté","C.-B. Levaché","L. Saban-Roche","J. Thaler","L.N. Petersen","J. Bridgewater","G. Perkins","C. Lepage","E. Van Cutsem","A. Zaanan","P. Laurent-Puig"],"twitterCount":15,"altmetricId":15112788},{"title":"A phase Ib/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC)","googleId":"7opP6sVHBi8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50430-6/abstract","googleCitationCount":22,"googleAuthor":"C Albany"},{"title":"Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools","googleId":"XT4SqkBsB4gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346162","googleCitationCount":27,"googleAuthor":"E Giovannetti","doi":"10.1093/annonc/mdx499","elsevierAuthor":"Giovannetti E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"21","altmetricAuthors":["E. Giovannetti","P.A. Zucali","Y.G. Assaraf","N. Funel","M. Gemelli","M. Stark","E. Thunnissen","Z. Hou","I.B. Muller","E.A. Struys","M. Perrino","G. Jansen","L.H. Matherly","G.J. Peters"],"twitterCount":4,"altmetricId":24615129},{"title":"Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer","googleId":"hB-3gVRFOsgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322197","googleCitationCount":33,"googleAuthor":"TRJ Evans","doi":"10.1093/annonc/mdw607","elsevierAuthor":"Evans J.T.R.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"29","altmetricAuthors":["T.R.J. Evans","E. Van Cutsem","M.J. Moore","I.S. Bazin","A. Rosemurgy","G. Bodoky","G. Deplanque","M. Harrison","B. Melichar","D. Pezet","A. Elekes","E. Rock","C. Lin","L. Strauss","P.J. O’Dwyer"],"twitterCount":7,"altmetricId":14898928},{"title":"What treatment in 2017 for inoperable pancreatic cancers?","googleId":"P8FHuyPv_9MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322690","googleCitationCount":27,"googleAuthor":"J Taieb","doi":"10.1093/annonc/mdx174","elsevierAuthor":"Taieb J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-07-01","elsevierCoverDisplayDate":"July 2017","elsevierCitationCount":"18","altmetricAuthors":["J. Taieb","A.-L. Pointet","J.L. Van Laethem","B. Laquente","S. Pernot","F. Lordick","M. Reni"],"twitterCount":3,"altmetricId":19777861},{"title":"Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer","googleId":"BbjhiPIAHV0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931885X","googleCitationCount":22,"googleAuthor":"AJ Armstrong","doi":"10.1093/annonc/mdy406","elsevierAuthor":"Armstrong A.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"12","altmetricAuthors":["A.J. Armstrong","P. Lin","C.S. Higano","C.N. Sternberg","G. Sonpavde","B. Tombal","A.J. Templeton","K. Fizazi","D. Phung","E.K. Wong","A. Krivoshik","T.M. Beer"],"twitterCount":17,"altmetricId":48064297},{"title":"Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses: a …","googleId":"NlNpiQoGMuUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349403","googleCitationCount":26,"googleAuthor":"","doi":"10.1093/annonc/mdx332","elsevierAuthor":"Churilla T.","publicationName":"Current Oncology Reports","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"6","altmetricAuthors":["T.M. Churilla","E. Handorf","S. Collette","L. Collette","Y. Dong","A.A. Aizer","M. Kocher","R. Soffietti","B.M. Alexander","S.E. Weiss"],"twitterCount":13,"altmetricId":21380142},{"title":"Physical activity in relation to risk of prostate cancer: a systematic review and meta-analysis","googleId":"jIjfB10CDSEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345429","googleCitationCount":20,"googleAuthor":"","doi":"10.1093/annonc/mdy073","elsevierAuthor":"Benke I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"14","altmetricAuthors":["I.N. Benke","M.F. Leitzmann","G. Behrens","D. Schmid"],"twitterCount":3,"altmetricId":33803990},{"title":"Novel tools to assist neoepitope targeting in personalized cancer immunotherapy","googleId":"PAN7PWIsxDcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419541485","googleCitationCount":24,"googleAuthor":"SK Saini","doi":"10.1093/annonc/mdx544","elsevierAuthor":"Saini S.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"21","altmetricAuthors":["S.K. Saini","N. Rekers","S.R. Hadrup"],"twitterCount":27,"altmetricId":28289827},{"title":"PD-1 blockade with nivolumab in endemic Kaposi sarcoma","googleId":"reD3H_rI-_sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)45459-8/abstract","googleCitationCount":25,"googleAuthor":""},{"title":"Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 …","googleId":"p08HsWEwvcEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321726","googleCitationCount":27,"googleAuthor":"JRB Dyck","doi":"10.1093/annonc/mdx264","elsevierAuthor":"Li C.","publicationName":"Bioscience Reports","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"0","altmetricAuthors":["G. Spera","R. Fresco","H. Fung","J.R.B. Dyck","E. Pituskin","I. Paterson","J.R. Mackey"],"twitterCount":24,"altmetricId":20292148},{"title":"Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a surveillance, epidemiology, and end results …","googleId":"YaFal-HnnPYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341935389X","googleCitationCount":24,"googleAuthor":"A Oseledchyk","doi":"10.1093/annonc/mdx525","elsevierAuthor":"Oseledchyk A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"23","altmetricAuthors":["A. Oseledchyk","M.M. Leitao","J. Konner","R.E. O’Cearbhaill","D. Zamarin","Y. Sonoda","G.J. Gardner","K. Long Roche","C.A. Aghajanian","R.N. Grisham","C.L. Brown","A. Snyder","D.S. Chi","R.A. Soslow","N.R. Abu-Rustum","O. Zivanovic"],"twitterCount":2,"altmetricId":27704221},{"title":"JET-HCC: A phase 3 randomized, double-blind, placebo-controlled study of tivantinib as a second-line therapy in patients with c-Met high hepatocellular carcinoma","googleId":"IFHXCUTanNEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37893-5/abstract","googleCitationCount":26,"googleAuthor":""},{"title":"Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial","googleId":"bKa4yZJDllgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349531","googleCitationCount":28,"googleAuthor":"D Cunningham","doi":"10.1093/annonc/mdx353","elsevierAuthor":"Gleeson M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"20","altmetricAuthors":["M. Gleeson","N. Counsell","D. Cunningham","N. Chadwick","A. Lawrie","E.A. Hawkes","A. McMillan","K.M. Ardeshna","A. Jack","P. Smith","P. Mouncey","C. Pocock","J.A. Radford","J. Davies","D. Turner","A. Kruger","P. Johnson","J. Gambell","D. Linch"],"twitterCount":16,"altmetricId":22220722},{"title":"Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer","googleId":"2-7H6KWmKREJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345442","googleCitationCount":20,"googleAuthor":"","doi":"10.1093/annonc/mdy075","elsevierAuthor":"Liang F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"16","altmetricAuthors":["F. Liang","S. Zhang","Q. Wang","W. Li"],"twitterCount":3,"altmetricId":42261595},{"title":"Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors","googleId":"0iSGPa6fywQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320757","googleCitationCount":29,"googleAuthor":"I McNeish","doi":"10.1093/annonc/mdx010","elsevierAuthor":"Tran K.B.","publicationName":"Current Pharmaceutical Design","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"3","altmetricAuthors":["J. McGee","M. Bookman","P. Harter","C. Marth","I. McNeish","K.N. Moore","A. Poveda","F. Hilpert","K. Hasegawa","M. Bacon","C. Gatsonis","A. Brand","F. Kridelka","J. Berek","N. Ottevanger","T. Levy","S. Silverberg","B.-G. Kim","H. Hirte","A. Okamoto","G. Stuart","K. Ochiai"],"twitterCount":9,"altmetricId":15793784},{"title":"The 'critical mass' survey of palliative care programme at ESMO designated centres of integrated oncology and palliative care","googleId":"gwFICm3vJvsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352421","googleCitationCount":25,"googleAuthor":"D Hui","doi":"10.1093/annonc/mdx280","elsevierAuthor":"Hui D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"14","altmetricAuthors":["D. Hui","N. Cherny","N. Latino","F. Strasser"],"twitterCount":2,"altmetricId":22193736},{"title":"Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: updated results from multicenter, randomized Phase 3 FLOT4-AIO …","googleId":"6eZXkXQ5s9oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39119-5/abstract","googleCitationCount":26,"googleAuthor":"SE Al-Batran"},{"title":"Stevens–Johnson syndrome during nivolumab treatment of NSCLC","googleId":"uAc3wAiT0LgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34995-6/abstract","googleCitationCount":26,"googleAuthor":"F Bertolini"},{"title":"MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2-advanced breast cancer","googleId":"0UmrZUDGfqIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39108-0/abstract","googleCitationCount":28,"googleAuthor":"A Di Leo"},{"title":"Preliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations","googleId":"vlUUT8WS6uYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49503-3/abstract","googleCitationCount":22,"googleAuthor":"AL Ho"},{"title":"Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line …","googleId":"ez8qmwSqUAkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341286","googleCitationCount":20,"googleAuthor":"","doi":"10.1093/annonc/mdy209","elsevierAuthor":"Zhang J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"16","altmetricAuthors":["J. Zhang","Y. Lin","X.J. Sun","B.Y. Wang","Z.H. Wang","J.F. Luo","L.P. Wang","S. Zhang","J. Cao","Z.H. Tao","J. Wu","Z.M. Shao","W.T. Yang","X.C. Hu"],"twitterCount":14,"altmetricId":43716698},{"title":"A phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma","googleId":"oKawZ9q_OwUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32642-0/abstract","googleCitationCount":25,"googleAuthor":"J Abramson"},{"title":"An unknown reaction to pembrolizumab: giant cell arteritis","googleId":"k7FA-cv9YocJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34931-2/abstract","googleCitationCount":28,"googleAuthor":""},{"title":"Pembrolizumab for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial","googleId":"7VrYy7MOOYEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49253-3/abstract","googleCitationCount":20,"googleAuthor":""},{"title":"A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer","googleId":"YjsZe06k-poJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49398-8/abstract","googleCitationCount":21,"googleAuthor":""},{"title":"Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled …","googleId":"5MK2c0hYhzkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341626","googleCitationCount":19,"googleAuthor":"HJ Lenz","doi":"10.1093/annonc/mdy241","elsevierAuthor":"Van Cutsem E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"12","altmetricAuthors":["E. Van Cutsem","T. Yoshino","H.J. Lenz","S. Lonardi","A. Falcone","M.L. Limón","M. Saunders","A. Sobrero","Y.S. Park","R. Ferreiro","Y.S. Hong","J. Tomasek","H. Taniguchi","F. Ciardiello","J. Stoehr","Z. Oum’Hamed","S. Vlassak","M. Studeny","G. Argiles"],"twitterCount":27,"altmetricId":45079730},{"title":"Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm A of the phase II BALTIC study","googleId":"6-m33z3H0nkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50050-3/abstract","googleCitationCount":18,"googleAuthor":"I Bondarenko"},{"title":"Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial","googleId":"EhDdfqjpsBcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320307","googleCitationCount":27,"googleAuthor":"W Eberhardt","doi":"10.1093/annonc/mdx069","elsevierAuthor":"Atkins K.M.","publicationName":"JAMA Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"1","altmetricAuthors":["M. Guberina","W. Eberhardt","M. Stuschke","T. Gauler","F. Heinzelmann","D. Cheufou","M. Kimmich","G. Friedel","H. Schmidberger","K. Darwiche","V. Jendrossek","M. Schuler","G. Stamatis","C. Pöttgen"],"twitterCount":0,"altmetricId":22533281},{"title":"Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final …","googleId":"3pBPcxo6FFwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350094","googleCitationCount":25,"googleAuthor":"A du Bois","doi":"10.1093/annonc/mdx690","elsevierAuthor":"Möbus V.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"16","altmetricAuthors":["V. Möbus","C. Jackisch","H.J. Lück","A. du Bois","C. Thomssen","W. Kuhn","U. Nitz","A. Schneeweiss","J. Huober","N. Harbeck","G. von Minckwitz","I.B. Runnebaum","A. Hinke","G.E. Konecny","M. Untch","C. Kurbacher"],"twitterCount":7,"altmetricId":27878158},{"title":"Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for …","googleId":"MkjwHflhoEEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352585","googleCitationCount":25,"googleAuthor":"JY Hong","doi":"10.1093/annonc/mdx316","elsevierAuthor":"Lim S.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"16","altmetricAuthors":["S.H. Lim","J.Y. Hong","S.T. Lim","H. Hong","J. Arnoud","W. Zhao","D.H. Yoon","T. Tang","J. Cho","S. Park","Y.H. Ko","S.J. Kim","C. Suh","T. Lin","W.S. Kim"],"twitterCount":2,"altmetricId":25436593},{"title":"Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer","googleId":"RusJqw5o9F4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348987","googleCitationCount":19,"googleAuthor":"T Murata","doi":"10.1093/annonc/mdy118","elsevierAuthor":"Katakami N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"9","altmetricAuthors":["N. Katakami","T. Harada","T. Murata","K. Shinozaki","M. Tsutsumi","T. Yokota","M. Arai","Y. Tada","M. Narabayashi","N. Boku"],"twitterCount":5,"altmetricId":44340026},{"title":"A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the …","googleId":"nI_nTyI351kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342309","googleCitationCount":17,"googleAuthor":"EC Smyth","doi":"10.1093/annonc/mdy407","elsevierAuthor":"Smyth E.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"15","altmetricAuthors":["E.C. Smyth","G. Nyamundanda","D. Cunningham","E. Fontana","C. Ragulan","I.B. Tan","S.J. Lin","A. Wotherspoon","M. Nankivell","M. Fassan","A. Lampis","J.C. Hahne","A.R. Davies","J. Lagergren","J.A. Gossage","N. Maisey","M. Green","J.L. Zylstra","W.H. Allum","R.E. Langley","P. Tan","N. Valeri","A. Sadanandam"],"twitterCount":24,"altmetricId":51805870},{"title":"Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their …","googleId":"6EwgpzkqDNsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341559","googleCitationCount":23,"googleAuthor":"Z Sztupinszki","doi":"10.1093/annonc/mdy216","elsevierAuthor":"Diossy M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"0","altmetricAuthors":["M. Diossy","L. Reiniger","Z. Sztupinszki","M. Krzystanek","K.M. Timms","C. Neff","C. Solimeno","D. Pruss","A.C. Eklund","E. Tóth","O. Kiss","O. Rusz","G. Cserni","T. Zombori","B. Székely","J. Kulka","J. Tímár","I. Csabai","Z. Szallasi"],"twitterCount":31,"altmetricId":43908309},{"title":"Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial","googleId":"R7Zbo3ROuJwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341237","googleCitationCount":20,"googleAuthor":"V Scott","doi":"10.1093/annonc/mdy202","elsevierAuthor":"Arnedos M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"16","altmetricAuthors":["M. Arnedos","M.A. Bayar","B. Cheaib","V. Scott","I. Bouakka","A. Valent","J. Adam","V. Leroux-Kozal","V. Marty","A. Rapinat","C. Mazouni","B. Sarfati","I. Bieche","C. Balleyguier","D. Gentien","S. Delaloge","M. Lacroix-Triki","S. Michiels","F. Andre"],"twitterCount":12,"altmetricId":43587846},{"title":"Oncologist use and perception of large panel next-generation tumor sequencing","googleId":"sZQggFA455MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352500","googleCitationCount":25,"googleAuthor":"","doi":"10.1093/annonc/mdx294","elsevierAuthor":"Schram A.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"20","altmetricAuthors":["A.M. Schram","D. Reales","J. Galle","R. Cambria","R. Durany","D. Feldman","E. Sherman","J. Rosenberg","G. D’Andrea","S. Baxi","Y. Janjigian","W. Tap","M. Dickler","J. Baselga","B.S. Taylor","D. Chakravarty","J. Gao","N. Schultz","D.B. Solit","M.F. Berger","D.M. Hyman"],"twitterCount":34,"altmetricId":21620769},{"title":"Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL)","googleId":"hIOAYowlqdcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322604","googleCitationCount":28,"googleAuthor":"P Jain","doi":"10.1093/annonc/mdx163","elsevierAuthor":"Jain P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-07-01","elsevierCoverDisplayDate":"July 2017","elsevierCitationCount":"15","altmetricAuthors":["P. Jain","E. Aoki","M. Keating","W.G. Wierda","S. O’Brien","G.N. Gonzalez","A. Ferrajoli","N. Jain","P.A. Thompson","E. Jabbour","R. Kanagal-Shamanna","S. Pierce","A. Alousi","C. Hosing","I. Khouri","Z. Estrov","J. Cortes","H. Kantarjian","F. Ravandi","T.M. Kadia"],"twitterCount":9,"altmetricId":18550710},{"title":"Mutational mechanisms of amplifications revealed by analysis of clustered rearrangements in breast cancers","googleId":"3CGS3IsilM4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318836","googleCitationCount":17,"googleAuthor":"D Głodzik","doi":"10.1093/annonc/mdy404","elsevierAuthor":"Głodzik D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"10","altmetricAuthors":["D. Głodzik","C. Purdie","I.H. Rye","P.T. Simpson","J. Staaf","P.N. Span","H.G. Russnes","S. Nik-Zainal"],"twitterCount":34,"altmetricId":48917975},{"title":"Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequentBAP1, PIK3CA, and other actionable genomic alterations","googleId":"BR0zAAUdFA8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320617","googleCitationCount":27,"googleAuthor":"AB Schrock","doi":"10.1093/annonc/mdw689","elsevierAuthor":"Wang K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-04-01","elsevierCoverDisplayDate":"1 April 2017","elsevierCitationCount":"16","altmetricAuthors":["K. Wang","J.D. McDermott","A.B. Schrock","J.A. Elvin","L. Gay","S.D. Karam","D. Raben","H. Somerset","S.M. Ali","J.S. Ross","D.W. Bowles"],"twitterCount":2,"altmetricId":15537995},{"title":"Fast progression in patients treated with a checkpoint inhibitor (cpi) vs chemotherapy in OAK, a phase III trial of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC","googleId":"dnFv8ZEF0TcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32757-7/abstract","googleCitationCount":16,"googleAuthor":""},{"title":"ARCTIC: Durvalumab+ tremelimumab and durvalumab monotherapy vs SoC in≥ 3L advanced NSCLC treatment","googleId":"kdfctA5xk9MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49791-3/abstract","googleCitationCount":18,"googleAuthor":"SV Orlov"},{"title":"Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation","googleId":"k7UyrTgk3mUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341183","googleCitationCount":18,"googleAuthor":"","doi":"10.1093/annonc/mdy197","elsevierAuthor":"Morano F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"16","altmetricAuthors":["F. Morano","S. Corallo","M. Niger","L. Barault","M. Milione","R. Berenato","R. Moretto","G. Randon","M. Antista","A. Belfiore","A. Raimondi","F. Nichetti","A. Martinetti","L. Battaglia","F. Perrone","G. Pruneri","A. Falcone","M. Di Bartolomeo","F. de Braud","F. Di Nicolantonio","C. Cremolini","F. Pietrantonio"],"twitterCount":9,"altmetricId":43246899},{"title":"Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab","googleId":"NJdRB17ZVmwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320654","googleCitationCount":28,"googleAuthor":"SM Swain","doi":"10.1093/annonc/mdw695","elsevierAuthor":"Swain S.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"0","altmetricAuthors":["S.M. Swain","A. Schneeweiss","L. Gianni","J.J. Gao","A. Stein","M. Waldron-Lynch","S. Heeson","M.S. Beattie","B. Yoo","J. Cortes","J. Baselga"],"twitterCount":9,"altmetricId":15251193},{"title":"Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer","googleId":"2vLiOdJhwxUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320502","googleCitationCount":26,"googleAuthor":"","doi":"10.1093/annonc/mdw678","elsevierAuthor":"M-Rabet M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-04-01","elsevierCoverDisplayDate":"1 April 2017","elsevierCitationCount":"21","altmetricAuthors":["M. M-Rabet","O. Cabaud","E. Josselin","P. Finetti","R. Castellano","A. Farina","E. Agavnian-Couquiaud","G. Saviane","Y. Collette","P. Viens","A. Gonçalves","C. Ginestier","E. Charafe-Jauffret","D. Birnbaum","D. Olive","F. Bertucci","M. Lopez"],"twitterCount":4,"altmetricId":14927347},{"title":"Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer","googleId":"QRoFFWkU-ZMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932112X","googleCitationCount":17,"googleAuthor":"L Horn","doi":"10.1093/annonc/mdy177","elsevierAuthor":"Gerber D.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"13","altmetricAuthors":["D.E. Gerber","L. Horn","M. Boyer","R. Sanborn","R. Natale","R. Palmero","P. Bidoli","I. Bondarenko","P. Germonpre","D. Ghizdavescu","A. Kotsakis","H. Lena","G. Losonczy","K. Park","W -C Su","M. Tang","J. Lai","N.L. Kallinteris","J.S. Shan","M. Reck","D.R. Spigel"],"twitterCount":15,"altmetricId":41458627},{"title":"MultiplexKRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase …","googleId":"uCKj8i0ndMwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319805","googleCitationCount":26,"googleAuthor":"HJ Huang","doi":"10.1093/annonc/mdw670","elsevierAuthor":"Janku F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"23","altmetricAuthors":[],"twitterCount":0},{"title":"Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC in LUX-Lung (LL) 3, 6 and 7","googleId":"b7HRtUOqqZ8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38595-1/abstract","googleCitationCount":22,"googleAuthor":"T Kato"},{"title":"HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma","googleId":"z4JXtcybchQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35382-7/abstract","googleCitationCount":24,"googleAuthor":"B Toka"},{"title":"The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?","googleId":"g8tUvyl-4UYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345375","googleCitationCount":22,"googleAuthor":"A Grothey","doi":"10.1093/annonc/mdy064","elsevierAuthor":"Sobrero A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"18","altmetricAuthors":["A. Sobrero","A. Grothey","T. Iveson","R. Labianca","T. Yoshino","J. Taieb","T. Maughan","M. Buyse","T. André","J. Meyerhardt","A.F. Shields","I. Souglakos","J.-Y. Douillard","A. Cervantes"],"twitterCount":40,"altmetricId":32964727},{"title":"Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the …","googleId":"lRNtKpufmv0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349889","googleCitationCount":20,"googleAuthor":"","doi":"10.1093/annonc/mdx630","elsevierAuthor":"Nabieva N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"18","altmetricAuthors":["N. Nabieva","S. Kellner","T. Fehm","L. Häberle","J. de Waal","M. Rezai","B. Baier","G. Baake","H.-C. Kolberg","M. Guggenberger","M. Warm","N. Harbeck","R. Wuerstlein","J.-U. Deuker","P. Dall","B. Richter","G. Wachsmann","C. Brucker","J.W. Siebers","N. Fersis","T. Kuhn","C. Wolf","H.-W. Vollert","G.-P. Breitbach","W. Janni","R. Landthaler","A. Kohls","D. Rezek","T. Noesselt","G. Fischer","S. Henschen","T. Praetz","V. Heyl","T. Kühn","T. Krauss","C. Thomssen","A. Hohn","H. Tesch","C. Mundhenke","A. Hein","C. Rauh","C.M. Bayer","A. Jacob","K. Schmidt","E. Belleville","S.Y. Brucker","S. Kümmel","M.W. Beckmann","D. Wallwiener","P. Hadji","P.A. Fasching"],"twitterCount":2,"altmetricId":31915496},{"title":"Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone …","googleId":"n1U8-4NkyvEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349397","googleCitationCount":25,"googleAuthor":"O Sartor","doi":"10.1093/annonc/mdx331","elsevierAuthor":"Sartor O.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"18","altmetricAuthors":["O. Sartor","D. Heinrich","N. Mariados","M.J. Méndez Vidal","D. Keizman","C. Thellenberg Karlsson","A. Peer","G. Procopio","S.J. Frank","K. Pulkkanen","E. Rosenbaum","S. Severi","J.M. Trigo Perez","V. Wagner","R. Li","L.T. Nordquist"],"twitterCount":16,"altmetricId":22211579},{"title":"High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy","googleId":"rmoEHL7KA_UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31964-7/abstract","googleCitationCount":28,"googleAuthor":""},{"title":"Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer","googleId":"71ltQAxZVHgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341935063X","googleCitationCount":20,"googleAuthor":"","doi":"10.1093/annonc/mdx753","elsevierAuthor":"de Boer S.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"18","altmetricAuthors":["S.M. de Boer","B.G. Wortman","T. Bosse","M.E. Powell","N. Singh","H. Hollema","G. Wilson","M.N. Chowdhury","L. Mileshkin","J. Pyman","D. Katsaros","S. Carinelli","A. Fyles","C.M. McLachlin","C. Haie-Meder","P. Duvillard","R.A. Nout","K.W. Verhoeven-Adema","H. Putter","C.L. Creutzberg","V.T.H.B.M. Smit"],"twitterCount":16,"altmetricId":29621993},{"title":"Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy","googleId":"aQLpEN6nrDgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32267-7/abstract","googleCitationCount":24,"googleAuthor":""},{"title":"Translational insights into gastrointestinal stromal tumor and current clinical advances","googleId":"zuZ7BhGK_6oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341961","googleCitationCount":14,"googleAuthor":"MC Heinrich","doi":"10.1093/annonc/mdy309","elsevierAuthor":"Hemming M.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"9","altmetricAuthors":["M.L. Hemming","M.C. Heinrich","S. Bauer","S. George"],"twitterCount":2,"altmetricId":46473287},{"title":"New treatments in ovarian cancer","googleId":"e8IkU5VoO7cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420346536","googleCitationCount":21,"googleAuthor":"","doi":"10.1093/annonc/mdx442","elsevierAuthor":"Pujade-Lauraine E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"1 November 2017","elsevierCitationCount":"18","altmetricAuthors":["E. Pujade-Lauraine"],"twitterCount":3,"altmetricId":30378144},{"title":"Unmet needs in the first-line treatment of follicular lymphoma","googleId":"8ufkvoo-DhsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352275","googleCitationCount":22,"googleAuthor":"","doi":"10.1093/annonc/mdx189","elsevierAuthor":"Casulo C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"16","altmetricAuthors":["C. Casulo","L. Nastoupil","N.H. Fowler","J.W. Friedberg","C.R. Flowers"],"twitterCount":1,"altmetricId":19458136},{"title":"Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients","googleId":"2ZkMv8lgAx8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934164X","googleCitationCount":17,"googleAuthor":"J Fredsøe","doi":"10.1093/annonc/mdy243","elsevierAuthor":"Schmidt L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"13","altmetricAuthors":["L. Schmidt","J. Fredsøe","H. Kristensen","S.H. Strand","A. Rasmussen","S. Høyer","M. Borre","P. Mouritzen","T. Ørntoft","K.D. Sørensen"],"twitterCount":8,"altmetricId":45102965},{"title":"A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study","googleId":"wXszS5LgJm4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346034","googleCitationCount":20,"googleAuthor":"P Ferrari","doi":"10.1093/annonc/mdx482","elsevierAuthor":"Chajès V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"16","altmetricAuthors":["V. Chajès","N. Assi","C. Biessy","P. Ferrari","S. Rinaldi","N. Slimani","G.M. Lenoir","L. Baglietto","M. His","M.C. Boutron-Ruault","A. Trichopoulou","P. Lagiou","M. Katsoulis","R. Kaaks","T. Kühn","S. Panico","V. Pala","G. Masala","H.B. Bueno-de-Mesquita","P.H. Peeters","C. van Gils","A. Hjartåker","K. Standahl Olsen","R. Borgund Barnung","A. Barricarte","D. Redondo-Sanchez","V. Menéndez","P. Amiano","M. Wennberg","T. Key","K.T. Khaw","M.A. Merritt","E. Riboli","M.J. Gunter","I. Romieu"],"twitterCount":5,"altmetricId":26354564},{"title":"KEYNOTE-059 cohort 3: safety and efficacy of pembrolizumab monotherapy for first-line treatment of patients (pts) with PD-L1-positive advanced gastric …","googleId":"ViMW45bBJhQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)66220-4/abstract","googleCitationCount":23,"googleAuthor":"VC Daniel"},{"title":"Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and …","googleId":"0B_6P--tdXkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341717","googleCitationCount":16,"googleAuthor":"CA Voltin","doi":"10.1093/annonc/mdy250","elsevierAuthor":"Voltin C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"12","altmetricAuthors":["C.-A. Voltin","H. Goergen","C. Baues","M. Fuchs","J. Mettler","S. Kreissl","J. Oertl","B. Klaeser","A. Moccia","A. Drzezga","A. Engert","P. Borchmann","M. Dietlein","C. Kobe"],"twitterCount":17,"altmetricId":45006236},{"title":"Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of …","googleId":"ytP6KFeYlawJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)66219-8/abstract","googleCitationCount":23,"googleAuthor":"SE Al-Batran"},{"title":"Multi-institutional competing risks analysis of distant brain failure and salvage patterns after upfront radiosurgery without whole brain radiotherapy for brain …","googleId":"Ew02-3G-JAQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350562","googleCitationCount":19,"googleAuthor":"","doi":"10.1093/annonc/mdx740","elsevierAuthor":"McTyre E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"11","altmetricAuthors":[],"twitterCount":0},{"title":"Gene polymorphisms in antioxidant enzymes correlate with the efficacy of androgen-deprivation therapy for prostate cancer with implications of oxidative …","googleId":"ZvUL6KRwalYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319635","googleCitationCount":24,"googleAuthor":"M Shiota","doi":"10.1093/annonc/mdw646","elsevierAuthor":"Shiota M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"19","altmetricAuthors":[],"twitterCount":0},{"title":"Human endogenous retroviruses and their implication for immunotherapeutics of cancer","googleId":"ReeXC9-NowMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318915","googleCitationCount":21,"googleAuthor":"AM Bjerregaard","doi":"10.1093/annonc/mdy413","elsevierAuthor":"Attermann A.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"15","altmetricAuthors":["A.S. Attermann","A -M Bjerregaard","S.K. Saini","K. Grønbæk","S.R. Hadrup"],"twitterCount":6,"altmetricId":48734563},{"title":"Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance)","googleId":"54KbiUmb4h8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324329","googleCitationCount":23,"googleAuthor":"","doi":"10.1093/annonc/mdx109","elsevierAuthor":"Fuchs M.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-06-01","elsevierCoverDisplayDate":"1 June 2017","elsevierCitationCount":"19","altmetricAuthors":["M.A. Fuchs","C. Yuan","K. Sato","D. Niedzwiecki","X. Ye","L.B. Saltz","R.J. Mayer","R.B. Mowat","R. Whittom","A. Hantel","A. Benson","D. Atienza","M. Messino","H. Kindler","A. Venook","F. Innocenti","R.S. Warren","M.M. Bertagnolli","S. Ogino","E.L. Giovannucci","E. Horvath","J.A. Meyerhardt","K. Ng"],"twitterCount":5,"altmetricId":18482492},{"title":"Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for …","googleId":"c0k2nZ9PlW0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321349","googleCitationCount":24,"googleAuthor":"JA Dunn","doi":"10.1093/annonc/mdx173","elsevierAuthor":"Earl H.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-08-01","elsevierCoverDisplayDate":"1 August 2017","elsevierCitationCount":"15","altmetricAuthors":["H.M. Earl","L. Hiller","J.A. Dunn","C. Blenkinsop","L. Grybowicz","A.-L. Vallier","I. Gounaris","J.E. Abraham","L. Hughes-Davies","K. McAdam","S. Chan","R. Ahmad","T. Hickish","D. Rea","C. Caldas","J.M.S. Bartlett","D.A. Cameron","E. Provenzano","J. Thomas","R.L. Hayward"],"twitterCount":17,"altmetricId":19778863},{"title":"A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal …","googleId":"t-dRoNljyh0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931974X","googleCitationCount":38,"googleAuthor":"H Gelderblom","doi":"10.1093/annonc/mdw659","elsevierAuthor":"Wagner A.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"28","altmetricAuthors":["A.J. Wagner","H. Kindler","H. Gelderblom","P. Schöffski","S. Bauer","P. Hohenberger","H.-G. Kopp","J.A. Lopez-Martin","M. Peeters","P. Reichardt","A. Qin","J. Nippgen","R.L. Ilaria","P. Rutkowski"],"twitterCount":2,"altmetricId":16468021},{"title":"Can we trust burnout research?","googleId":"r-Ets0GsUJQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35235-4/abstract","googleCitationCount":23,"googleAuthor":"R Bianchi"},{"title":"Validation of the Complexity INdex in SARComas prognostic signature on formalin-fixed, paraffin-embedded, soft-tissue sarcomas","googleId":"sPCILO20Tw8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341158","googleCitationCount":17,"googleAuthor":"T Lesluyes","doi":"10.1093/annonc/mdy194","elsevierAuthor":"Le Guellec S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"12","altmetricAuthors":[],"twitterCount":0},{"title":"Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or …","googleId":"6y7OCylAkyQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341742","googleCitationCount":16,"googleAuthor":"RL Jones","doi":"10.1093/annonc/mdy253","elsevierAuthor":"Jones R.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"14","altmetricAuthors":["R.L. Jones","G.D. Demetri","S.M. Schuetze","M. Milhem","A. Elias","B.A. Van Tine","J. Hamm","S. McCarthy","G. Wang","T. Parekh","R. Knoblauch","M.L. Hensley","R.G. Maki","S. Patel","M. von Mehren"],"twitterCount":14,"altmetricId":46213186},{"title":"KEYNOTE-427 cohort A: pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC)","googleId":"6w9xRMIoNboJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49260-0/abstract","googleCitationCount":16,"googleAuthor":""},{"title":"Acute liver graft rejection after ipilimumab therapy","googleId":"1TchYA_Nsk0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34924-5/abstract","googleCitationCount":20,"googleAuthor":""},{"title":"Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial","googleId":"Eaow9uIViF8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321593","googleCitationCount":19,"googleAuthor":"A Bamias","doi":"10.1093/annonc/mdx228","elsevierAuthor":"Bamias A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-08-01","elsevierCoverDisplayDate":"1 August 2017","elsevierCitationCount":"11","altmetricAuthors":["A. Bamias","E. Gibbs","C. Khoon Lee","L. Davies","M. Dimopoulos","F. Zagouri","A.-S. Veillard","J. Kosse","A. Santaballa","M.R. Mirza","G. Tabaro","I. Vergote","H. Bloemendal","M. Lykka","A. Floquet","V. Gebski","E. Pujade-Lauraine"],"twitterCount":0,"altmetricId":20469652},{"title":"A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma","googleId":"Hx9MNzhjukEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320496","googleCitationCount":24,"googleAuthor":"E Jonasch","doi":"10.1093/annonc/mdw676","elsevierAuthor":"Vlachostergios P.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-05-01","elsevierCoverDisplayDate":"May 2017","elsevierCitationCount":"3","altmetricAuthors":["E. Jonasch","E. Hasanov","P.G. Corn","T. Moss","K.R. Shaw","S. Stovall","V. Marcott","B. Gan","S. Bird","X. Wang","K.A. Do","P.F. Altamirano","A.J. Zurita","L.A. Doyle","P.N. Lara","N.M. Tannir"],"twitterCount":3,"altmetricId":15221180},{"title":"Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?","googleId":"HSL2uEL21x4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350598","googleCitationCount":18,"googleAuthor":"GD Stewart","doi":"10.1093/annonc/mdx743","elsevierAuthor":"Figlin R.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"12","altmetricAuthors":["R.A. Figlin","B.C. Leibovich","G.D. Stewart","S. Negrier"],"twitterCount":5,"altmetricId":29432510},{"title":"Sacituzumab govitecan (IMMU-132) for patients with pretreated metastatic urothelial uancer (UC): interim results","googleId":"im12lI4fvdsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38131-X/abstract","googleCitationCount":22,"googleAuthor":"B Faltas"},{"title":"Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple negative breast cancer: TONIC-trial","googleId":"kjY_Ybq9LqwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39106-7/abstract","googleCitationCount":22,"googleAuthor":"HM Horlings"},{"title":"Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram","googleId":"W0PksKQk3V8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319568","googleCitationCount":27,"googleAuthor":"F Pietrantonio","doi":"10.1093/annonc/mdw627","elsevierAuthor":"Pietrantonio F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"20","altmetricAuthors":["F. Pietrantonio","R. Miceli","L. Rimassa","S. Lonardi","G. Aprile","A. Mennitto","F. Marmorino","S. Bozzarelli","L. Antonuzzo","E. Tamburini","F. Morano","D. Rossini","F. Battaglin","M. Baretti","R. Berenato","V. Formica","S. Mosconi","F. Petrelli","M. Ghidini","F. Loupakis","D. Spada","S. Cinieri","G. Beretta","A. Falcone","F. de Braud","C. Cremolini"],"twitterCount":3,"altmetricId":13799517},{"title":"A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT# …","googleId":"yzJrJBlWUgEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931957X","googleCitationCount":26,"googleAuthor":"R Salani","doi":"10.1093/annonc/mdw635","elsevierAuthor":"Thaker P.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"23","altmetricAuthors":["P.H. Thaker","R. Salani","W.E. Brady","H.A. Lankes","D.E. Cohn","D.G. Mutch","R.S. Mannel","K.M. Bell-McGuinn","P.A. Di Silvestro","D. Jelovac","J.S. Carter","W. Duan","K.E. Resnick","D.S. Dizon","C. Aghajanian","P.M. Fracasso"],"twitterCount":1,"altmetricId":14908974},{"title":"Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 …","googleId":"W42m9bsjJEkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50429-X/abstract","googleCitationCount":16,"googleAuthor":"P Sharma"},{"title":"Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours","googleId":"x70p9EJt0EQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320447","googleCitationCount":27,"googleAuthor":"","doi":"10.1093/annonc/mdw662","elsevierAuthor":"Leary A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-04-01","elsevierCoverDisplayDate":"1 April 2017","elsevierCitationCount":"17","altmetricAuthors":[],"twitterCount":0},{"title":"A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder","googleId":"KoDrspbUCDAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320484","googleCitationCount":24,"googleAuthor":"","doi":"10.1093/annonc/mdw675","elsevierAuthor":"Obara W.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-04-01","elsevierCoverDisplayDate":"1 April 2017","elsevierCitationCount":"24","altmetricAuthors":["W. Obara","M. Eto","H. Mimata","K. Kohri","N. Mitsuhata","I. Miura","T. Shuin","T. Miki","T. Koie","H. Fujimoto","K. Minami","Y. Enomoto","T. Nasu","T. Yoshida","H. Fuse","I. Hara","K. Kawaguchi","A. Arimura","T. Fujioka"],"twitterCount":6,"altmetricId":15296755},{"title":"Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives","googleId":"bjzEFYI2CpkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319246","googleCitationCount":23,"googleAuthor":"BA Carneiro","doi":"10.1093/annonc/mdw532","elsevierAuthor":"Costa R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"16","altmetricAuthors":["R. Costa","B.A. Carneiro","D.A. Wainwright","C.A. Santa-Maria","P. Kumthekar","Y.K. Chae","W.J. Gradishar","M. Cristofanilli","F.J. Giles"],"twitterCount":1,"altmetricId":12464487},{"title":"Cyclin D mediates tolerance of genome-doubling in cancers with functional p53","googleId":"fypj4BDBu30J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319350","googleCitationCount":25,"googleAuthor":"LP Zalmas","doi":"10.1093/annonc/mdw612","elsevierAuthor":"Crockford A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"18","altmetricAuthors":["A. Crockford","L.P. Zalmas","E. Grönroos","S.M. Dewhurst","N. McGranahan","M.E. Cuomo","V. Encheva","A.P. Snijders","J. Begum","S. Purewal","J. Cerveira","H. Patel","M.J. Renshaw","C. Swanton"],"twitterCount":13,"altmetricId":13846865},{"title":"Introducing whole-genome sequencing into routine cancer care: the Genomics England 100 000 Genomes Project","googleId":"5wKE82e5TP4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)45492-6/abstract","googleCitationCount":21,"googleAuthor":"C Turnbull"},{"title":"Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) …","googleId":"Zoq1NlqiFYEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48485-8/abstract","googleCitationCount":15,"googleAuthor":""},{"title":"Early clinical efficacy of TAS-120, a covalently bound FGFR inhibitor, in patients with cholangiocarcinoma","googleId":"cpOIgVS2IMAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)66171-5/abstract","googleCitationCount":20,"googleAuthor":"JC Soria"},{"title":"Cabozantinib in patients with advanced osteosarcomas and Ewing sarcomas: a French Sarcoma Group (FSG)/US National Cancer Institute phase II collaborative …","googleId":"SBxqqFC1CaQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50473-2/abstract","googleCitationCount":15,"googleAuthor":""},{"title":"PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist?","googleId":"tqhWTdlN128J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31986-6/abstract","googleCitationCount":23,"googleAuthor":""},{"title":"Prediction of pathological response to neoadjuvant treatment in rectal cancer with a two-protein immunohistochemical score derived from stromal gene …","googleId":"3lcq344HU4oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352494","googleCitationCount":19,"googleAuthor":"R Sanz-Pamplona","doi":"10.1093/annonc/mdx293","elsevierAuthor":"Gonçalves-Ribeiro S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"15","altmetricAuthors":["S. Gonçalves-Ribeiro","R. Sanz-Pamplona","A. Vidal","X. Sanjuan","N. Guillen Díaz-Maroto","A. Soriano","J. Guardiola","N. Albert","M. Martínez-Villacampa","I. López","C. Santos","J. Serra-Musach","R. Salazar","G. Capellà","A. Villanueva","D.G. Molleví"],"twitterCount":3,"altmetricId":21839859},{"title":"Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient","googleId":"Vhjkc2v_oAEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35230-5/abstract","googleCitationCount":20,"googleAuthor":""},{"title":"Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the …","googleId":"aYqOwqacxX4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318770","googleCitationCount":13,"googleAuthor":"E Calvo","doi":"10.1093/annonc/mdy398","elsevierAuthor":"Smoragiewicz M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"9","altmetricAuthors":["M. Smoragiewicz","J. Bogaerts","E. Calvo","A. Marabelle","A. Perrone","L. Seymour","A. Shalabi","L.L. Siu","J. Tabernero","G. Giaccone","M. Atkins","U. Banerji","S. Bates","J. Bogaerts","E. Calvo","F. De Braud","J.Y. Douillard","G. Giaccone","P. Keegan","R. Kumar","P. LoRusso","A. Marabelle","A. Perrone","F. Pignatti","R. Plummer","L. Seymour","G. Schwartz","A. Shalabi","G. Shapiro","L.L. Siu","M. Smoragiewicz","J. Tabernero","P. Therasse","A. Yang"],"twitterCount":16,"altmetricId":48064239},{"title":"Three-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)","googleId":"t0F-wBRJfW8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38548-3/abstract","googleCitationCount":25,"googleAuthor":""},{"title":"Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC)","googleId":"T_ZkwSFNi9YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50450-1/abstract","googleCitationCount":16,"googleAuthor":"T Cascone"},{"title":"Drug-induced liver injury in Oncology","googleId":"EWaSsAb4qsgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32132-5/abstract","googleCitationCount":18,"googleAuthor":""},{"title":"Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability–high (MSI-H) colorectal cancer: KEYNOTE-164","googleId":"fum4WBDNkx4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33707-X/abstract","googleCitationCount":16,"googleAuthor":"D Le"},{"title":"Phase II study evaluating trifluridine/tipiracil+ bevacizumab and capecitabine+ bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients …","googleId":"JV5gyM7CEboJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33708-1/abstract","googleCitationCount":17,"googleAuthor":""},{"title":"Tumor regression and preservation of graft function after combination with anti-PD-1 immunotherapy without immunosuppressant titration","googleId":"XLGTvyyhFqEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34591-0/abstract","googleCitationCount":18,"googleAuthor":"CK Wu"},{"title":"An update of the WCRF/AICR systematic literature review and meta-analysis on dietary and anthropometric factors and esophageal cancer risk","googleId":"Oht1iDOv0MUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349427","googleCitationCount":20,"googleAuthor":"","doi":"10.1093/annonc/mdx338","elsevierAuthor":"Vingeliene S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"15","altmetricAuthors":["S. Vingeliene","D.S.M. Chan","A.R. Vieira","E. Polemiti","C. Stevens","L. Abar","D. Navarro Rosenblatt","D.C. Greenwood","T. Norat"],"twitterCount":5,"altmetricId":21445141},{"title":"Different menopausal hormone regimens and risk of breast cancer","googleId":"KoDhSU0EaOQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341304","googleCitationCount":13,"googleAuthor":"N Brusselaers","doi":"10.1093/annonc/mdy212","elsevierAuthor":"Brusselaers N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"10","altmetricAuthors":["N. Brusselaers","R.M. Tamimi","P. Konings","B. Rosner","H.-O. Adami","J. Lagergren"],"twitterCount":5,"altmetricId":43906632},{"title":"Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and …","googleId":"JwXhwsY5A7IJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345922","googleCitationCount":18,"googleAuthor":"","doi":"10.1093/annonc/mdx412","elsevierAuthor":"Berger M.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"16","altmetricAuthors":["M.D. Berger","S. Stintzing","V. Heinemann","D. Yang","S. Cao","Y. Sunakawa","Y. Ning","S. Matsusaka","S. Okazaki","Y. Miyamoto","M. Suenaga","M. Schirripa","S. Soni","W. Zhang","A. Falcone","F. Loupakis","H.-J. Lenz"],"twitterCount":0,"altmetricId":95595267},{"title":"Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy","googleId":"ZF82SFTckCYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349920","googleCitationCount":19,"googleAuthor":"S Jain","doi":"10.1093/annonc/mdx637","elsevierAuthor":"Jain S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"12","altmetricAuthors":["S. Jain","C.A. Lyons","S.M. Walker","S. McQuaid","S.O. Hynes","D.M. Mitchell","B. Pang","G.E. Logan","A.M. McCavigan","D. O’Rourke","D.G. McArt","S.S. McDade","I.G. Mills","K.M. Prise","L.A. Knight","C.J. Steele","P.W. Medlow","V. Berge","B. Katz","D.A. Loblaw","D.P. Harkin","J.A. James","J.M. O'sullivan","R.D. Kennedy","D.J. Waugh"],"twitterCount":11,"altmetricId":27853119},{"title":"Looking beyond drivers and passengers in cancer genome sequencing data","googleId":"eB24NYtlQMQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319982","googleCitationCount":24,"googleAuthor":"S De","doi":"10.1093/annonc/mdw677","elsevierAuthor":"De S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-05-01","elsevierCoverDisplayDate":"May 2017","elsevierCitationCount":"13","altmetricAuthors":["S. De","S. Ganesan"],"twitterCount":18,"altmetricId":14927355},{"title":"Preliminary results of a ph2a study to evaluate the clinical efficacy and safety of erdafitinib in Asian patients with biomarker-selected advanced cholangiocarcinoma …","googleId":"RNuAT5d9ahwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49086-8/abstract","googleCitationCount":14,"googleAuthor":""},{"title":"Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?","googleId":"lkNJ-ZDJGYUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324251","googleCitationCount":21,"googleAuthor":"M Sánchez","doi":"10.1093/annonc/mdx081","elsevierAuthor":"Hierro C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-06-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"0","altmetricAuthors":["C. Hierro","M. Alsina","M. Sánchez","V. Serra","J. Rodon","J. Tabernero"],"twitterCount":1,"altmetricId":18063901},{"title":"Clinic-pathological pattern of hepatocellular carcinoma (HCC) in Egypt","googleId":"J0z1b6T62TcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33755-X/abstract","googleCitationCount":15,"googleAuthor":"H Elghazaly"},{"title":"Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics","googleId":"PfzOf6mXy14J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318903","googleCitationCount":19,"googleAuthor":"","doi":"10.1093/annonc/mdy412","elsevierAuthor":"Ligtenberg K.G.","publicationName":"JAAD Case Reports","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"0","altmetricAuthors":["M. Nikanjam","P.R. Cohen","S. Kato","J.K. Sicklick","R. Kurzrock"],"twitterCount":9,"altmetricId":48372337},{"title":"Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC","googleId":"-TYPnW4rfi0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49776-7/abstract","googleCitationCount":14,"googleAuthor":"C Faivre-Finn"},{"title":"A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head …","googleId":"nKmlcJ_x_tUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49501-X/abstract","googleCitationCount":16,"googleAuthor":"EEW Cohen"},{"title":"Initial results of Phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior …","googleId":"sSIojlFg_bQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50068-0/abstract","googleCitationCount":14,"googleAuthor":"M Heinrich"},{"title":"Long-term safety and clinical outcomes of atezolizumab in head and neck cancer: phase Ia trial results","googleId":"SWjnIPv6N6cJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38316-2/abstract","googleCitationCount":22,"googleAuthor":""},{"title":"Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial","googleId":"3rIlapCVssEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324433","googleCitationCount":22,"googleAuthor":"","doi":"10.1093/annonc/mdx124","elsevierAuthor":"Kollmannsberger C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"3","altmetricAuthors":["A. Necchi","S. Lo Vullo","P. Giannatempo","D. Raggi","G. Calareso","E. Togliardi","F. Crippa","M. Pennati","N. Zaffaroni","F. Perrone","A. Busico","M. Colecchia","N. Nicolai","L. Mariani","R. Salvioni"],"twitterCount":4,"altmetricId":18500692},{"title":"Tracking aCAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor","googleId":"1CsBUKqy9PAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324263","googleCitationCount":20,"googleAuthor":"G Siravegna","doi":"10.1093/annonc/mdx095","elsevierAuthor":"Siravegna G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"40","altmetricAuthors":["G. Siravegna","A. Sartore-Bianchi","B. Mussolin","A. Cassingena","A. Amatu","L. Novara","M. Buscarino","G. Corti","G. Crisafulli","A. Bartolini","F. Tosi","M. Erlander","F. Di Nicolantonio","S. Siena","A. Bardelli"],"twitterCount":10,"altmetricId":18170179},{"title":"Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer","googleId":"8uYTfnNPqJcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320137","googleCitationCount":25,"googleAuthor":"M Schirripa","doi":"10.1093/annonc/mdx035","elsevierAuthor":"Suenaga M.","publicationName":"Annals of oncology : official journal of the European Society for Medical Oncology","elsevierCoverDate":"2017-05-01","elsevierCoverDisplayDate":"1 May 2017","elsevierCitationCount":"21","altmetricAuthors":["M. Suenaga","M. Schirripa","S. Cao","W. Zhang","D. Yang","S. Murgioni","D. Rossini","F. Marmorino","A. Mennitto","Y. Ning","S. Okazaki","M.D. Berger","Y. Miyamoto","R. Gopez","A. Barzi","T. Yamaguchi","F. Loupakis","H.-J. Lenz"],"twitterCount":9,"altmetricId":16420842},{"title":"Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer","googleId":"o4QbMjcrAO8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324330","googleCitationCount":20,"googleAuthor":"I Ray-Coquard","doi":"10.1093/annonc/mdx111","elsevierAuthor":"Pujade-Lauraine E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"1 November 2017","elsevierCitationCount":"18","altmetricAuthors":["A. Poveda","J.M. del Campo","I. Ray-Coquard","J. Alexandre","M. Provansal","E.M. Guerra Alía","A. Casado","A. Gonzalez-Martin","C. Fernández","I. Rodriguez","A. Soto","C. Kahatt","C. Fernández Teruel","C.M. Galmarini","A. Pérez de la Haza","P. Bohan","D. Berton-Rigaud"],"twitterCount":9,"altmetricId":18170350},{"title":"Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2","googleId":"URsX6_3tfgEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342103","googleCitationCount":12,"googleAuthor":"K Chang","doi":"10.1093/annonc/mdy337","elsevierAuthor":"Chang K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"11","altmetricAuthors":["K. Chang","J.A. Willis","J. Reumers","M.W. Taggart","F.A. San Lucas","S. Thirumurthi","P. Kanth","D.A. Delker","C.H. Hagedorn","P.M. Lynch","L.M. Ellis","E.T. Hawk","P.A. Scheet","S. Kopetz","J. Arts","J. Guinney","R. Dienstmann","E. Vilar"],"twitterCount":17,"altmetricId":47085226},{"title":"Overall survival (OS) for first-line crizotinib versus chemotherapy in ALK+ lung cancer: updated results from PROFILE 1014","googleId":"ycDOB8VYG54J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39153-5/abstract","googleCitationCount":22,"googleAuthor":"DW Kim"},{"title":"Phase II study of tepotinib+ gefitinib (TEP+ GEF) in MET-positive (MET+)/epidermal growth factor receptor (EGFR)-mutant (MT) non-small cell lung cancer (NSCLC)","googleId":"-IR_F2bHA5MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49790-1/abstract","googleCitationCount":15,"googleAuthor":""},{"title":"A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors","googleId":"lwi5Pm4ueKMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32724-3/abstract","googleCitationCount":13,"googleAuthor":""},{"title":"Struggling with nutrition in patients with advanced cancer: Nutrition and nourishment—focusing on metabolism and supportive care","googleId":"4JlfDG4yCFcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316813","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdy093","elsevierAuthor":"Arends J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"February 2018","elsevierCitationCount":"9","altmetricAuthors":["J Arends"],"twitterCount":3,"altmetricId":40927523},{"title":"Phase 1 safety and clinical activity of BLU-554 in advanced hepatocellular carcinoma (HCC)","googleId":"SBJR5OdhPfkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37786-3/abstract","googleCitationCount":18,"googleAuthor":"R Kim"},{"title":"Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab","googleId":"Q1Ym5W1uRhcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32164-7/abstract","googleCitationCount":18,"googleAuthor":""},{"title":"Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers","googleId":"DTxfE1-adboJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454872","googleCitationCount":15,"googleAuthor":"NJ Birkbak","doi":"10.1093/annonc/mdy049","elsevierAuthor":"Birkbak N.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"12","altmetricAuthors":["N.J. Birkbak","Y. Li","S. Pathania","A. Greene-Colozzi","M. Dreze","C. Bowman-Colin","Z. Sztupinszki","M. Krzystanek","M. Diossy","N. Tung","P.D. Ryan","J.E. Garber","D.P. Silver","J.D. Iglehart","Z.C. Wang","D. Szuts","Z. Szallasi","A.L. Richardson"],"twitterCount":22,"altmetricId":33510294},{"title":"Training in communication of oncology clinicians: a position paper based on the third consensus meeting among European experts in 2018","googleId":"rpvmicisVyMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342152","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdy343","elsevierAuthor":"Stiefel F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"9","altmetricAuthors":["F. Stiefel","A. Kiss","P. Salmon","S. Peters","D. Razavi","A. Cervantes","A. Margulies","C. Bourquin","Céline Bourquin","Andrés Cervantes","Sarah Dauchy","Vikki Entwistle","Luigi Grassi","Patrick Jermann","Wolf Langewitz","Anita Margulies","Solange Peters","Darius Razavi","Pär Salander","Peter Salmon","Ellen Smets","Wolfgang Söllner","Gilbert Zulian","Jürg Bernhard","Gabriella Bianchi Micheli","Christoph Hürny","Alexander Kiss","Patrick Nemeshazy","Friedrich Stiefel","Brigitta Wössmer"],"twitterCount":2,"altmetricId":51094309},{"title":"Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma","googleId":"KnN6t6zpLQcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320587","googleCitationCount":20,"googleAuthor":"JK Lee","doi":"10.1093/annonc/mdw686","elsevierAuthor":"Chau N.G.","publicationName":"JNCI Cancer Spectrum","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"11","altmetricAuthors":["J.-K. Lee","S. Louzada","Y. An","S.Y. Kim","S. Kim","J. Youk","S. Park","S.H. Koo","B. Keam","Y.K. Jeon","J.-L. Ku","F. Yang","T.M. Kim","Y.S. Ju"],"twitterCount":8,"altmetricId":17035412},{"title":"Prognostic markers for colorectal cancer: estimating ploidy and stroma","googleId":"AEp90PAaGGkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341935505X","googleCitationCount":28,"googleAuthor":"HE Danielsen","doi":"10.1093/annonc/mdx794","elsevierAuthor":"Tijhuis A.E.","publicationName":"Molecular Cytogenetics","elsevierCoverDate":"2019-05-14","elsevierCoverDisplayDate":"14 May 2019","elsevierCitationCount":"10","altmetricAuthors":["H.E. Danielsen","T.S. Hveem","E. Domingo","M. Pradhan","A. Kleppe","R.A. Syvertsen","I. Kostolomov","J.A. Nesheim","H.A. Askautrud","A. Nesbakken","R.A. Lothe","A. Svindland","N. Shepherd","M. Novelli","E. Johnstone","I. Tomlinson","R. Kerr","D.J. Kerr"],"twitterCount":13,"altmetricId":30981443},{"title":"M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients (pts) with advanced SCCHN: Results from a phase I cohort","googleId":"hfyI4X625RsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49505-7/abstract","googleCitationCount":14,"googleAuthor":"A Ravaud"},{"title":"Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG)","googleId":"R7Q2jxfXe6sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454902","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdy052","elsevierAuthor":"MacNeill A.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"22","altmetricAuthors":[],"twitterCount":16,"altmetricId":32843035},{"title":"A randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results …","googleId":"6i5UummQzPYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50049-7/abstract","googleCitationCount":15,"googleAuthor":"JL Pujol"},{"title":"Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of …","googleId":"r7hTrrq6v5cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322495","googleCitationCount":20,"googleAuthor":"D Cunningham","doi":"10.1093/annonc/mdx128","elsevierAuthor":"Pedersen M.Ø.","publicationName":"PLoS ONE","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"5","altmetricAuthors":["A. Kühnl","D. Cunningham","N. Counsell","E.A. Hawkes","W. Qian","P. Smith","N. Chadwick","A. Lawrie","P. Mouncey","A. Jack","C. Pocock","K.M. Ardeshna","J. Radford","A. McMillan","J. Davies","D. Turner","A. Kruger","P.W. Johnson","J. Gambell","A. Rosenwald","G. Ott","H. Horn","M. Ziepert","M. Pfreundschuh","D. Linch"],"twitterCount":5,"altmetricId":18787668},{"title":"Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and …","googleId":"utVCoNNqn0cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319143","googleCitationCount":21,"googleAuthor":"C Massard","doi":"10.1093/annonc/mdw441","elsevierAuthor":"Massard C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"17","altmetricAuthors":["C. Massard","J. Mateo","Y. Loriot","C. Pezaro","L. Albiges","N. Mehra","A. Varga","D. Bianchini","C.J. Ryan","D.P. Petrylak","G. Attard","L. Shen","K. Fizazi","J. de Bono"],"twitterCount":7,"altmetricId":12757781},{"title":"A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck …","googleId":"3rDkwF3nxFMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934949X","googleCitationCount":17,"googleAuthor":"SS Baxi","doi":"10.1093/annonc/mdx346","elsevierAuthor":"Zhang Z.","publicationName":"Toxicology in Vitro","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"2","altmetricAuthors":["L.A. Dunn","M.G. Fury","H. Xiao","S.S. Baxi","E.J. Sherman","S. Korte","C. Pfister","S. Haque","N. Katabi","A.L. Ho","D.G. Pfister"],"twitterCount":1,"altmetricId":22259186},{"title":"Corrections to “Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”","googleId":"W2kW2oceqAcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31701-6/abstract","googleCitationCount":13,"googleAuthor":""},{"title":"Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients …","googleId":"m1FpWm1P458J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)66215-0/abstract","googleCitationCount":19,"googleAuthor":"NH Segal"},{"title":"Phase I–II clinical trial design: a state-of-the-art paradigm for dose finding","googleId":"PMmSXqJi_LQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355061","googleCitationCount":16,"googleAuthor":"PF Thall","doi":"10.1093/annonc/mdx795","elsevierAuthor":"Yan F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"9","altmetricAuthors":["F. Yan","P.F. Thall","K.H. Lu","M.R. Gilbert","Y. Yuan"],"twitterCount":37,"altmetricId":30719776},{"title":"Statistical controversies in clinical research: publication bias evaluations are not routinely conducted in clinical oncology systematic reviews","googleId":"KvYSVQlYeTcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319994","googleCitationCount":19,"googleAuthor":"S Khan","doi":"10.1093/annonc/mdw691","elsevierAuthor":"Ayorinde A.A.","publicationName":"PLoS ONE","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"1 January 2020","elsevierCitationCount":"1","altmetricAuthors":["D. Herrmann","P. Sinnett","J. Holmes","S. Khan","C. Koller","M. Vassar"],"twitterCount":18,"altmetricId":15138783},{"title":"Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic …","googleId":"KzjZjdRKzpwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321088","googleCitationCount":15,"googleAuthor":"L Schwartzberg","doi":"10.1093/annonc/mdy169","elsevierAuthor":"Schwartzberg L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"12","altmetricAuthors":["L. Schwartzberg","E. Roeland","Z. Andric","D. Kowalski","J. Radic","D. Voisin","G. Rizzi","R. Navari","R.J. Gralla","M. Karthaus"],"twitterCount":19,"altmetricId":40523356},{"title":"Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis","googleId":"CzWG6Xi1xe0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319817","googleCitationCount":20,"googleAuthor":"H Abdel-Qadir","doi":"10.1093/annonc/mdw671","elsevierAuthor":"Abdel-Qadir H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"15","altmetricAuthors":["H. Abdel-Qadir","G. Ong","R. Fazelzad","E. Amir","D.S. Lee","P. Thavendiranathan","G. Tomlinson"],"twitterCount":4,"altmetricId":15094937},{"title":"Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer","googleId":"Rw-_3Hq-l-UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341663","googleCitationCount":12,"googleAuthor":"B Basu","doi":"10.1093/annonc/mdy245","elsevierAuthor":"Basu B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"8","altmetricAuthors":["B. Basu","M.G. Krebs","R. Sundar","R.H. Wilson","J. Spicer","R. Jones","M. Brada","D.C. Talbot","N. Steele","A.H. Ingles Garces","W. Brugger","E.A. Harrington","J. Evans","E. Hall","H. Tovey","F.M. de Oliveira","S. Carreira","K. Swales","R. Ruddle","F.I. Raynaud","B. Purchase","J.C. Dawes","M. Parmar","A.J. Turner","N. Tunariu","S. Banerjee","J.S. de Bono","U. Banerji"],"twitterCount":28,"altmetricId":45247921},{"title":"A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD …","googleId":"enJNriCwrKMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37891-1/abstract","googleCitationCount":21,"googleAuthor":"YK Kang"},{"title":"Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","googleId":"Gs_18euEWSYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355024","googleCitationCount":15,"googleAuthor":"AF Herrera","doi":"10.1093/annonc/mdx791","elsevierAuthor":"Herrera A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"9","altmetricAuthors":["A.F. Herrera","J. Palmer","P. Martin","S. Armenian","N.-C. Tsai","N. Kennedy","F. Sahebi","T. Cao","L.E. Budde","M. Mei","T. Siddiqi","L. Popplewell","S.T. Rosen","L.W. Kwak","A. Nademanee","S.J. Forman","R. Chen"],"twitterCount":11,"altmetricId":30741521},{"title":"Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote …","googleId":"vTTAnrfAo-UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49733-0/abstract","googleCitationCount":15,"googleAuthor":"CU Blank"},{"title":"Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-301 …","googleId":"oPZk42tSSQoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350653","googleCitationCount":15,"googleAuthor":"D Cella","doi":"10.1093/annonc/mdx759","elsevierAuthor":"Cella D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"15","altmetricAuthors":["D. Cella","S. Traina","T. Li","K. Johnson","K.F. Ho","A. Molina","N.D. Shore"],"twitterCount":5,"altmetricId":30291451},{"title":"Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in …","googleId":"AePZEsAGOwIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39101-8/abstract","googleCitationCount":21,"googleAuthor":""},{"title":"A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer","googleId":"rRy55OyBl5IJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322203","googleCitationCount":21,"googleAuthor":"","doi":"10.1093/annonc/mdw608","elsevierAuthor":"Belani C.P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"14","altmetricAuthors":["C.P. Belani","B.C. Chakraborty","R.I. Modi","B.M. Khamar"],"twitterCount":1,"altmetricId":13493870},{"title":"Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities","googleId":"Au2SyprlXq4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322598","googleCitationCount":18,"googleAuthor":"","doi":"10.1093/annonc/mdx162","elsevierAuthor":"Pécuchet N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-07-01","elsevierCoverDisplayDate":"July 2017","elsevierCitationCount":"16","altmetricAuthors":["N. Pécuchet","T. Vieira","N. Rabbe","M. Antoine","H. Blons","J. Cadranel","P. Laurent-Puig","M. Wislez"],"twitterCount":2,"altmetricId":19156302},{"title":"Clinical efficacy of atezolizumab (atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: results from the randomized OAK study","googleId":"_EFusNevjhIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38545-8/abstract","googleCitationCount":19,"googleAuthor":"W Zou"},{"title":"Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC)","googleId":"1o27HQJgVNUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49268-5/abstract","googleCitationCount":13,"googleAuthor":""},{"title":"Therapeutic advantage of genetically engineered Salmonella typhimurium carrying short hairpin RNA against inhibin alpha subunit in cancer treatment","googleId":"6C2RUZpSm1AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341614","googleCitationCount":11,"googleAuthor":"","doi":"10.1093/annonc/mdy240","elsevierAuthor":"Yoon W.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"8","altmetricAuthors":["W. Yoon","Y. Yoo","Y.S. Chae","S.-H. Kee","B.M. Kim"],"twitterCount":1,"altmetricId":70381528},{"title":"BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib+ MEK inhibitor binimetinib+ anti–epidermal growth factor receptor antibody …","googleId":"i78V2ZpoX7AJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33713-5/abstract","googleCitationCount":16,"googleAuthor":""},{"title":"Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference","googleId":"YtMetVxVAq4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420346603","googleCitationCount":17,"googleAuthor":"G Stuart","doi":"10.1093/annonc/mdx449","elsevierAuthor":"Bookman M.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"1 November 2017","elsevierCitationCount":"10","altmetricAuthors":["M.A. Bookman","A. Okamoto","G. Stuart","N. Yanaihara","D. Aoki","M. Bacon","K. Fujiwara","A. González-Martín","P. Harter","J.W. Kim","J. Ledermann","E. Pujade-Lauraine","M. Quinn","K. Ochiai"],"twitterCount":2,"altmetricId":31692093},{"title":"Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN)","googleId":"2goHhcDf9kIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341945463X","googleCitationCount":16,"googleAuthor":"JP Machiels","doi":"10.1093/annonc/mdy013","elsevierAuthor":"Machiels J.P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"13","altmetricAuthors":["J.-P. Machiels","P. Bossi","J. Menis","M. Lia","C. Fortpied","Y. Liu","R. Lhommel","M. Lemort","S. Schmitz","S. Canevari","L. De Cecco","M. Guzzo","R. Bianchi","P. Quattrone","F. Crippa","T. Duprez","Y. Lalami","M. Quiriny","N. de Saint Aubain","P.M. Clement","R. Coropciuc","E. Hauben","L.F. Licitra"],"twitterCount":7,"altmetricId":31726438},{"title":"Drug-sensitiveFGFR3 mutations in lung adenocarcinoma","googleId":"3FyZ7o0RSUAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319581","googleCitationCount":20,"googleAuthor":"P Chandrani","doi":"10.1093/annonc/mdw636","elsevierAuthor":"Chandrani P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"14","altmetricAuthors":["P. Chandrani","K. Prabhash","R. Prasad","V. Sethunath","M. Ranjan","P. Iyer","J. Aich","H. Dhamne","D.N. Iyer","P. Upadhyay","B. Mohanty","P. Chandna","R. Kumar","A. Joshi","V. Noronha","V. Patil","A. Ramaswamy","A. Karpe","R. Thorat","P. Chaudhari","A. Ingle","A. Choughule","A. Dutt"],"twitterCount":9,"altmetricId":14894883},{"title":"The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications","googleId":"U4GIn-0DLfAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420346561","googleCitationCount":16,"googleAuthor":"","doi":"10.1093/annonc/mdx445","elsevierAuthor":"Duska L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"1 November 2017","elsevierCitationCount":"13","altmetricAuthors":["L.R. Duska","E.C. Kohn"],"twitterCount":1,"altmetricId":30377990},{"title":"Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC","googleId":"uYSpjXssdI8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50453-7/abstract","googleCitationCount":14,"googleAuthor":""},{"title":"A phase III trial of muparfostat (PI-88) as adjuvant therapy in patients with hepatitis virus related hepatocellular carcinoma (HV-HCC) after resection","googleId":"hosGS95gfBoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37898-4/abstract","googleCitationCount":16,"googleAuthor":""},{"title":"Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in …","googleId":"ZcMyUm9_bLUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349932","googleCitationCount":17,"googleAuthor":"","doi":"10.1093/annonc/mdx638","elsevierAuthor":"Blackwell K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"10","altmetricAuthors":["K. Blackwell","P. Gascon","A. Krendyukov","S. Gattu","Y. Li","N. Harbeck"],"twitterCount":13,"altmetricId":28235600},{"title":"Changes in the use of end points in clinical trials for elderly cancer patients over time","googleId":"27eCLQmryaIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349543","googleCitationCount":16,"googleAuthor":"C Falandry","doi":"10.1093/annonc/mdx354","elsevierAuthor":"Saux O.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"12","altmetricAuthors":["O. Le Saux","C. Falandry","H.K. Gan","B. You","G. Freyer","J. Péron"],"twitterCount":13,"altmetricId":23459177},{"title":"Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative forFLT3-ITD, NPM1-or biallelicCEBPA mutations","googleId":"MIMezPCxcgUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346174","googleCitationCount":18,"googleAuthor":"C Thiede","doi":"10.1093/annonc/mdx500","elsevierAuthor":"Heidrich K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"9","altmetricAuthors":["K. Heidrich","C. Thiede","K. Schäfer-Eckart","N. Schmitz","W.E. Aulitzky","A. Krämer","W. Rösler","M. Hänel","H. Einsele","C.D. Baldus","R.U. Trappe","F. Stölzel","J.M. Middeke","C. Röllig","F. Taube","M. Kramer","H. Serve","W.E. Berdel","G. Ehninger","M. Bornhäuser","J. Schetelig"],"twitterCount":10,"altmetricId":25165628},{"title":"An antisense oligonucleotide targeting TGF-β2 inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages","googleId":"sb7WeCx4H6AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352573","googleCitationCount":16,"googleAuthor":"","doi":"10.1093/annonc/mdx314","elsevierAuthor":"Huber-Ruano I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"11","altmetricAuthors":["I. Huber-Ruano","C. Raventós","I. Cuartas","C. Sánchez-Jaro","A. Arias","J.L. Parra","K. Wosikowski","M. Janicot","J. Seoane"],"twitterCount":1,"altmetricId":26098160},{"title":"CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications","googleId":"EbEPj3dhQLIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454835","googleCitationCount":16,"googleAuthor":"","doi":"10.1093/annonc/mdy039","elsevierAuthor":"Holmes P.M.","publicationName":"Transactions of the Royal Society of South Africa","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"3","altmetricAuthors":["A. Laroche-Clary","C. Lucchesi","C. Rey","S. Verbeke","A. Bourdon","V. Chaire","M.-P. Algéo","S. Cousin","M. Toulmonde","V. Vélasco","J. Shutzman","A. Savina","F. Le Loarer","A. Italiano"],"twitterCount":8,"altmetricId":32701660},{"title":"A randomized, double-blind study of PF-05280014 (a potential trastuzumab biosimilar) vs trastuzumab, both in combination with paclitaxel, as first-line treatment for …","googleId":"ca6bZigFCvYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37662-6/abstract","googleCitationCount":19,"googleAuthor":""},{"title":"Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy","googleId":"AuDPBGBLzzUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932160X","googleCitationCount":18,"googleAuthor":"FT Roncolato","doi":"10.1093/annonc/mdx229","elsevierAuthor":"Frantellizzi V.","publicationName":"Hellenic Journal of Nuclear Medicine","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"1","altmetricAuthors":["F.T. Roncolato","E. Gibbs","C.K. Lee","R. Asher","L.C. Davies","V.J. Gebski","M. Friedlander","F. Hilpert","L. Wenzel","M.R. Stockler","M. King","E. Pujade-Lauraine"],"twitterCount":6,"altmetricId":20965900},{"title":"Phase II multicenter, single arm, open label study of nivolumab in combination with ipilimumab in untreated patients with metastatic uveal melanoma (GEM1402 …","googleId":"fXs_21pmSw8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49702-0/abstract","googleCitationCount":12,"googleAuthor":"JMP Rodriguez"},{"title":"Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus …","googleId":"ueSqddO-8H0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39132-8/abstract","googleCitationCount":19,"googleAuthor":"TK Choueiri"},{"title":"Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2 …","googleId":"p20aovgfKecJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37526-8/abstract","googleCitationCount":18,"googleAuthor":""},{"title":"HPV16 DNA and integration in normal and malignant epithelium: implications for the etiology of laryngeal squamous cell carcinoma","googleId":"cyTFpp9Iq9YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932006X","googleCitationCount":18,"googleAuthor":"","doi":"10.1093/annonc/mdx027","elsevierAuthor":"Chen X.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-05-01","elsevierCoverDisplayDate":"May 2017","elsevierCitationCount":"14","altmetricAuthors":["X. Chen","L. Gao","E.M. Sturgis","Z. Liang","Y. Zhu","X. Xia","X. Zhu","X. Chen","G. Li","Z. Gao"],"twitterCount":11,"altmetricId":19939471},{"title":"Alectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study","googleId":"BndPiJYhfyMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39157-2/abstract","googleCitationCount":18,"googleAuthor":"S Peters"},{"title":"Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population","googleId":"YScanx5D-J8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346113","googleCitationCount":16,"googleAuthor":"S Buti","doi":"10.1093/annonc/mdx492","elsevierAuthor":"Buti S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"0","altmetricAuthors":["S. Buti","M. Puligandla","M. Bersanelli","R.S. DiPaola","J. Manola","S. Taguchi","N.B. Haas"],"twitterCount":5,"altmetricId":26593975},{"title":"Immune checkpoint-associated cardiotoxicity: case report with systematic review of literature","googleId":"05yUc7PNmAsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32154-4/abstract","googleCitationCount":19,"googleAuthor":"A Chauhan"},{"title":"Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice","googleId":"wYOPlx1Qcz0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349890","googleCitationCount":15,"googleAuthor":"D Cunningham","doi":"10.1093/annonc/mdx631","elsevierAuthor":"Moorcraft S.Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"11","altmetricAuthors":["S.Y. Moorcraft","D. Gonzalez de Castro","D. Cunningham","T. Jones","B.A. Walker","C. Peckitt","L.C. Yuan","M. Frampton","R. Begum","Z. Eltahir","A. Wotherspoon","L.S. Teixeira Mendes","S. Hulkki Wilson","A. Gillbanks","C. Baratelli","N. Fotiadis","A. Patel","C. Braconi","N. Valeri","M. Gerlinger","S. Rao","D. Watkins","I. Chau","N. Starling"],"twitterCount":2,"altmetricId":31915530},{"title":"BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in …","googleId":"pPBA7Z-rPYQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320022","googleCitationCount":19,"googleAuthor":"","doi":"10.1093/annonc/mdx022","elsevierAuthor":"Petrella T.","publicationName":"Annals of oncology : official journal of the European Society for Medical Oncology","elsevierCoverDate":"2017-05-01","elsevierCoverDisplayDate":"1 May 2017","elsevierCitationCount":"10","altmetricAuthors":["T. Petrella","C. Copie-Bergman","J. Brière","R. Delarue","F. Jardin","P. Ruminy","C. Thieblemont","M. Figeac","D. Canioni","P. Feugier","B. Fabiani","K. Leroy","M. Parrens","M. André","C. Haioun","G.A. Salles","P. Gaulard","H. Tilly","J.P. Jais","T.J. Molina"],"twitterCount":5,"altmetricId":18040037},{"title":"A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer","googleId":"JhoQkzbrjx8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352391","googleCitationCount":19,"googleAuthor":"I Bondarenko","doi":"10.1093/annonc/mdx275","elsevierAuthor":"Ajani J.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"14","altmetricAuthors":["J.A. Ajani","M. Abramov","I. Bondarenko","Y. Shparyk","V. Gorbunova","A. Hontsa","N. Otchenash","M. Alsina","S. Lazarev","J. Feliu","A. Elme","V. Esko","K. Abdalla","U. Verma","F. Benedetti","T. Aoyama","H. Mizuguchi","L. Makris","G. Rosati"],"twitterCount":5,"altmetricId":23389755},{"title":"Blinatumomab (Blincyto): Lessons learned from the bispecific t-cell engager (BiTE) in acute lymphocytic leukemia (ALL)","googleId":"N0yRvgEPp2cJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32130-1/abstract","googleCitationCount":18,"googleAuthor":"G Friberg"},{"title":"Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment","googleId":"jg3ju11PfBMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319155","googleCitationCount":20,"googleAuthor":"CY Ock","doi":"10.1093/annonc/mdw442","elsevierAuthor":"An E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"14","altmetricAuthors":["E. An","C.-Y. Ock","T.-Y. Kim","K.-H. Lee","S.-W. Han","S.-A. Im","T.-Y. Kim","W.-L. Liao","F. Cecchi","A. Blackler","S. Thyparambil","W.H. Kim","J. Burrows","T. Hembrough","D.V.T. Catenacci","D.-Y. Oh","Y.-J. Bang"],"twitterCount":13,"altmetricId":16462227},{"title":"Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials","googleId":"lodahXmYDscJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32047-2/abstract","googleCitationCount":20,"googleAuthor":"B Gyawali"},{"title":"CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and …","googleId":"1F2oty21kPEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38409-X/abstract","googleCitationCount":16,"googleAuthor":"J Brody"},{"title":"Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic …","googleId":"6tYypZ2h6ZsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454847","googleCitationCount":18,"googleAuthor":"","doi":"10.1093/annonc/mdy040","elsevierAuthor":"Tahara M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"15","altmetricAuthors":["M. Tahara","N. Kiyota","T. Yokota","Y. Hasegawa","K. Muro","S. Takahashi","T. Onoe","A. Homma","J. Taguchi","M. Suzuki","K. Minato","K. Yane","S. Ueda","H. Hara","K. Saijo","T. Yamanaka"],"twitterCount":5,"altmetricId":32543956},{"title":"Atezolizumab+ bevacizumab in hepatocellular carcinoma (HCC): Safety and clinical activity results from a phase Ib study","googleId":"64oxgXJJl6IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43117-7/abstract","googleCitationCount":12,"googleAuthor":""},{"title":"Adding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation …","googleId":"-Qcpwlf8lsgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39124-9/abstract","googleCitationCount":18,"googleAuthor":"MR Sydes"},{"title":"ABVD chemotherapy with reduced radiation therapy rates in children, adolescents and young adults with all stages of Hodgkin lymphoma","googleId":"KJKMJztDuwEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320708","googleCitationCount":16,"googleAuthor":"KJ Savage","doi":"10.1093/annonc/mdx005","elsevierAuthor":"Marr K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-04-01","elsevierCoverDisplayDate":"1 April 2017","elsevierCitationCount":"7","altmetricAuthors":["K.C. Marr","J.M. Connors","K.J. Savage","K.J. Goddard","R.J. Deyell"],"twitterCount":1,"altmetricId":18208955},{"title":"Network-guided modeling allows tumor-type independent prediction of sensitivity to all-trans-retinoic acid","googleId":"8NfagFu1fi8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319751","googleCitationCount":18,"googleAuthor":"E Garattini","doi":"10.1093/annonc/mdw660","elsevierAuthor":"Bolis M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"15","altmetricAuthors":["M. Bolis","E. Garattini","G. Paroni","A. Zanetti","M. Kurosaki","T. Castrignanò","S.K. Garattini","F. Biancardi","M.M. Barzago","M. Gianni’","M. Terao","L. Pattini","M. Fratelli"],"twitterCount":2,"altmetricId":14865513},{"title":"irRECIST and iRECIST: the devil is in the details","googleId":"erFp6c_ZU_gJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32265-3/abstract","googleCitationCount":19,"googleAuthor":""},{"title":"Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib+ trametinib (D+ T) in patients (pts) with resected BRAF V600 …","googleId":"JsQPi7YFWAQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50444-6/abstract","googleCitationCount":13,"googleAuthor":"GV Long"},{"title":"Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK","googleId":"-wnepDaLzEkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38561-6/abstract","googleCitationCount":16,"googleAuthor":"K Syrigos"},{"title":"Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary …","googleId":"mbjEjFym6tIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932174X","googleCitationCount":17,"googleAuthor":"HR Ali","doi":"10.1093/annonc/mdx266","elsevierAuthor":"Liang H.","publicationName":"Thoracic Cancer","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"1 October 2020","elsevierCitationCount":"0","altmetricAuthors":["H.R. Ali","A. Dariush","J. Thomas","E. Provenzano","J. Dunn","L. Hiller","A.-L. Vallier","J. Abraham","T. Piper","J.M.S. Bartlett","D.A. Cameron","L. Hayward","J.D. Brenton","P.D.P. Pharoah","M.J. Irwin","N.A. Walton","H.M. Earl","C. Caldas"],"twitterCount":22,"altmetricId":20300988},{"title":"Intratumoral (it) injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (IPI) triggers durable responses in PD-1 inhibitor refractory …","googleId":"cO0sU3L7qqUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49700-7/abstract","googleCitationCount":11,"googleAuthor":"C Bernatchez"},{"title":"Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trial","googleId":"Oy7HXk1zuqQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454768","googleCitationCount":14,"googleAuthor":"E Itti","doi":"10.1093/annonc/mdy031","elsevierAuthor":"Sobhani I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"10","altmetricAuthors":["I. Sobhani","E. Itti","A. Luciani","I. Baumgaertner","R. Layese","T. André","M. Ducreux","J.-M. Gornet","G. Goujon","T. Aparicio","J. Taieb","J.-B. Bachet","F. Hemery","A. Retbi","M. Mons","R. Flicoteaux","B. Rhein","S. Baron","I. Cherrak","P. Rufat","P. Le Corvoisier","N. de’Angelis","P.-A. Natella","H. Maoulida","C. Tournigand","I. Durand Zaleski","S. Bastuji-Garin"],"twitterCount":61,"altmetricId":32159988},{"title":"YOSEMITE: A 3 arm double-blind randomized phase 2 study of gemcitabine, paclitaxel protein-bound particles for injectable suspension, and placebo (GAP) versus …","googleId":"rGuGA_jEggQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37894-7/abstract","googleCitationCount":16,"googleAuthor":"M Hidalgo"},{"title":"Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer","googleId":"9NlQ6H8tKXQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350604","googleCitationCount":15,"googleAuthor":"DD Yang","doi":"10.1093/annonc/mdx744","elsevierAuthor":"Yang D.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"10","altmetricAuthors":["D.D. Yang","A. Krasnova","K.T. Nead","T.K. Choueiri","J.C. Hu","K.E. Hoffman","J.B. Yu","D.E. Spratt","F.Y. Feng","Q.-D. Trinh","P.L. Nguyen"],"twitterCount":25,"altmetricId":30795661},{"title":"Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: results from two phase II …","googleId":"aT9x-aFNUtAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38594-X/abstract","googleCitationCount":18,"googleAuthor":"T Mitsudomi"},{"title":"Blood first line ready screening trial (B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for …","googleId":"IlOTJ2iRjfQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38628-2/abstract","googleCitationCount":15,"googleAuthor":"ES Kim"},{"title":"Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor","googleId":"aYF3EntCHi0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34107-9/abstract","googleCitationCount":15,"googleAuthor":"V Subbiah"},{"title":"Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors","googleId":"PjjArsRkw-QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49609-9/abstract","googleCitationCount":10,"googleAuthor":"R Leidner"},{"title":"CCTG IND. 231: a phase 1 trial evaluating CX-5461 in patients with advanced solid tumors","googleId":"4uKDHuV3B-QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32636-5/abstract","googleCitationCount":15,"googleAuthor":"DW Cescon"},{"title":"Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials","googleId":"XYWW_J6KU24J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322525","googleCitationCount":15,"googleAuthor":"","doi":"10.1093/annonc/mdx152","elsevierAuthor":"Yerushalmi R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-07-01","elsevierCoverDisplayDate":"July 2017","elsevierCitationCount":"10","altmetricAuthors":["R. Yerushalmi","B. Dong","J.W. Chapman","P.E. Goss","M.N. Pollak","M.J. Burnell","M.N. Levine","V.H.C. Bramwell","K.I. Pritchard","T.J. Whelan","J.N. Ingle","L.E. Shepherd","W.R. Parulekar","L. Han","K. Ding","K.A. Gelmon"],"twitterCount":1,"altmetricId":18549693},{"title":"A phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas","googleId":"40Oc9WgQXiIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32634-1/abstract","googleCitationCount":15,"googleAuthor":"J Abramson"},{"title":"Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus iv paclitaxel in patients with advanced gastric cancer after failure …","googleId":"Hsrby8tNKUsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345296","googleCitationCount":12,"googleAuthor":"YK Kang","doi":"10.1093/annonc/mdy055","elsevierAuthor":"Kang Y.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"9","altmetricAuthors":["Y.-K. Kang","M.-H. Ryu","S.H. Park","J.G. Kim","J.W. Kim","S.-H. Cho","Y.-I. Park","S.R. Park","S.Y. Rha","M.J. Kang","J.Y. Cho","S.Y. Kang","S.Y. Roh","B.-Y. Ryoo","B.-H. Nam","Y.-W. Jo","K.-E. Yoon","S.C. Oh"],"twitterCount":43,"altmetricId":32964700},{"title":"MicroRNA-related genetic variants in iron regulatory genes, dietary iron intake, microRNAs and lung cancer risk","googleId":"lilW3MDj8q8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320198","googleCitationCount":18,"googleAuthor":"L Zhang","doi":"10.1093/annonc/mdx046","elsevierAuthor":"Yang Y.","publicationName":"Ferroptosis in Health and Disease","elsevierCoverDate":"2019-10-10","elsevierCoverDisplayDate":"10 October 2019","elsevierCitationCount":"0","altmetricAuthors":["L. Zhang","Y. Ye","H. Tu","M.A. Hildebrandt","L. Zhao","J.V. Heymach","J.A. Roth","X. Wu"],"twitterCount":3,"altmetricId":19738625},{"title":"Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors","googleId":"OIehBdTihvwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345454","googleCitationCount":14,"googleAuthor":"JR Infante","doi":"10.1093/annonc/mdy076","elsevierAuthor":"Italiano A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"9","altmetricAuthors":["A. Italiano","J.R. Infante","G.I. Shapiro","K.N. Moore","P.M. LoRusso","E. Hamilton","S. Cousin","M. Toulmonde","S. Postel-Vinay","S. Tolaney","E.M. Blackwood","S. Mahrus","F.V. Peale","X. Lu","A. Moein","J. Epler","K. DuPree","M. Tagen","E.R. Murray","J.L. Schutzman","J.O. Lauchle","A. Hollebecque","J.-C. Soria"],"twitterCount":6,"altmetricId":33852406},{"title":"Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced …","googleId":"WLbR1J3w_A0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49163-1/abstract","googleCitationCount":11,"googleAuthor":"T Meyer"},{"title":"Results of a multi-institutional, randomized, non-inferiority, phase III trial of accelerated fractionation versus standard fractionation in radiation therapy for T1 …","googleId":"QtTaE6_4btYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341945480X","googleCitationCount":11,"googleAuthor":"","doi":"10.1093/annonc/mdy036","elsevierAuthor":"Kodaira T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"14","altmetricAuthors":["T. Kodaira","Y. Kagami","T. Shibata","N. Shikama","Y. Nishimura","S. Ishikura","K. Nakamura","Y. Saito","Y. Matsumoto","T. Teshima","Y. Ito","T. Akimoto","K. Nakata","T. Toshiyasu","K. Nakagawa","Y. Nagata","T. Nishimura","T. Uno","M. Kataoka","A. Yorozu","M. Hiraoka"],"twitterCount":5,"altmetricId":32821242},{"title":"(Neo-) adjuvant ipilimumab+ nivolumab (IPI+ NIVO) in palpable stage 3 melanoma–updated relapse free survival (RFS) data from the OpACIN trial and first biomarker …","googleId":"E71XlXHsvx8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38484-2/abstract","googleCitationCount":17,"googleAuthor":""},{"title":"Analytic validation of a next generation sequencing assay to identify tumor mutational burden from blood (bTMB) to support investigation of an anti-PD-L1 agent …","googleId":"FrVzjq4RKsYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37596-7/abstract","googleCitationCount":16,"googleAuthor":"D Lieber"},{"title":"EVITA—a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity","googleId":"boqZl4EOZzoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454653","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdy015","elsevierAuthor":"Hofheinz R.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"14","altmetricAuthors":["R.-D. Hofheinz","S. Lorenzen","J. Trojan","J. Ocvirk","T.J. Ettrich","S.-E. Al-Batran","H. Schulz","N. Homann","H.-P. Feustel","M. Schatz","M. Kripp","N. Schulte","M. Tetyusheva","S. Heeger","S. Vlassak","K. Merx"],"twitterCount":4,"altmetricId":31912508},{"title":"Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the …","googleId":"b6E2Ur4zWawJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355073","googleCitationCount":14,"googleAuthor":"CK Lee","doi":"10.1093/annonc/mdx796","elsevierAuthor":"Friedlander M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"11","altmetricAuthors":["M. Friedlander","J. Rau","C.K. Lee","W. Meier","A. Lesoin","J.-W. Kim","A. Poveda","M. Buck","G. Scambia","M. Shimada","F. Hilpert","M.T. King","P. Debruyne","A. Bologna","S. Malander","B.J. Monk","E. Petru","P. Calvert","T.J. Herzog","C. Barrett","A. du Bois"],"twitterCount":2,"altmetricId":30629433},{"title":"ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly …","googleId":"lbsUPJQO2zYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50426-4/abstract","googleCitationCount":12,"googleAuthor":"F Saad"},{"title":"Prevention of chemotherapy toxicity by agents that neutralize or degrade cell-free chromatin","googleId":"u4obYjMDdwQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352603","googleCitationCount":20,"googleAuthor":"I Mittra","doi":"10.1093/annonc/mdx318","elsevierAuthor":"Mittra I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"13","altmetricAuthors":["I. Mittra","K. Pal","N. Pancholi","A. Shaikh","B. Rane","P. Tidke","S. Kirolikar","N.K. Khare","K. Agrawal","H. Nagare","N.K. Nair"],"twitterCount":2,"altmetricId":25241767},{"title":"Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques?","googleId":"s8cL_m4puMIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35013-6/abstract","googleCitationCount":12,"googleAuthor":"M Fiorentino"},{"title":"Expression III: patients' expectations and preferences regarding physician–patient relationship and clinical management—results of the international NOGGO …","googleId":"KOASZnTMoL0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454811","googleCitationCount":12,"googleAuthor":"S Alavi","doi":"10.1093/annonc/mdy037","elsevierAuthor":"Oskay-Özcelik G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"9","altmetricAuthors":["G. Oskay-Özcelik","S. Alavi","R. Richter","M. Keller","R. Chekerov","S.C. Cecere","G. Cormio","F. Joly","J.E. Kurtz","A. du Bois","M. Maciejewski","M. Jedryka","I. Vergote","E. Van Nieuwenhuysen","A. Casado","C. Mendiola","P. Achimas-Cadariu","C. Vlad","D. Reimer","A.G. Zeimet","M. Friedlander","J. Sehouli"],"twitterCount":3,"altmetricId":32701641},{"title":"Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular …","googleId":"yN4Gc7CnZL8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345909","googleCitationCount":14,"googleAuthor":"L Magnano","doi":"10.1093/annonc/mdx407","elsevierAuthor":"Magnano L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"13","altmetricAuthors":["L. Magnano","O. Balagué","I. Dlouhy","J. Rovira","K. Karube","M. Pinyol","A. Rivas-Delgado","D. Costa","A. Martínez-Trillos","B. González-Farre","A. Martínez-Pozo","E. Giné","D. Colomer","J. Delgado","N. Villamor","E. Campo","A. López-Guillermo"],"twitterCount":4,"altmetricId":25704256},{"title":"Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously …","googleId":"MSJ5QK4RFF8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43122-0/abstract","googleCitationCount":10,"googleAuthor":"F Meric-Bernstam"},{"title":"Why the US Centers for Medicare and Medicaid Services (CMS) should have required a randomized trial of Foundation Medicine (F1CDx) before paying for it","googleId":"YoEFZIdJIZoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35074-4/abstract","googleCitationCount":14,"googleAuthor":"V Prasad"},{"title":"No association between circulating concentrations of vitamin D and risk of lung cancer: an analysis in 20 prospective studies in the Lung Cancer Cohort …","googleId":"I3HqJpuqZmQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934894X","googleCitationCount":12,"googleAuthor":"DC Muller","doi":"10.1093/annonc/mdy104","elsevierAuthor":"Muller D.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"7","altmetricAuthors":["D.C. Muller","A.M. Hodge","A. Fanidi","D. Albanes","X.M. Mai","X.O. Shu","S.J. Weinstein","T.L. Larose","X. Zhang","J. Han","M.J. Stampfer","S.A. Smith-Warner","J. Ma","J.M. Gaziano","H.D. Sesso","V.L. Stevens","M.L. McCullough","T.M. Layne","R. Prentice","M. Pettinger","C.A. Thomson","W. Zheng","Y.T. Gao","N. Rothman","Y.B. Xiang","H. Cai","R. Wang","J.M. Yuan","W.P. Koh","L.M. Butler","Q. Cai","W.J. Blot","J. Wu","P.M. Ueland","Ø. Midttun","A. Langhammer","K. Hveem","M. Johansson","J. Hultdin","K. Grankvist","A.A. Arslan","L. Le Marchand","G. Severi","M. Johansson","P. Brennan"],"twitterCount":48,"altmetricId":35139574},{"title":"Phase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer","googleId":"rXGjs_y8pU4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32638-9/abstract","googleCitationCount":15,"googleAuthor":""},{"title":"Immunomodulation by regorafenib alone and in combination with anti PD1 antibody on murine models of colorectal cancer","googleId":"hWi9eiaerd8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38462-3/abstract","googleCitationCount":16,"googleAuthor":""},{"title":"Statistical challenges posed by uncontrolled master protocols: sensitivity analysis of the vemurafenib study","googleId":"9Rbe3njT4QkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342449","googleCitationCount":8,"googleAuthor":"BP Hobbs","doi":"10.1093/annonc/mdy457","elsevierAuthor":"Hobbs B.P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"5","altmetricAuthors":["B.P. Hobbs","M.J. Kane","D.S. Hong","R. Landin"],"twitterCount":2,"altmetricId":49913950},{"title":"Nivolumab in non-small-cell lung cancer with EGFR mutation","googleId":"CgfPpTQire8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35486-9/abstract","googleCitationCount":13,"googleAuthor":"YH Kim"},{"title":"Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers","googleId":"FQcv3-eYVm8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342115","googleCitationCount":10,"googleAuthor":"","doi":"10.1093/annonc/mdy338","elsevierAuthor":"Chen X.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"6","altmetricAuthors":["X. Chen","Y. Li","T. Ouyang","J. Li","T. Wang","Z. Fan","T. Fan","B. Lin","Y. Xie"],"twitterCount":8,"altmetricId":47169845},{"title":"Updated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up","googleId":"5BzUywwZaEgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49321-6/abstract","googleCitationCount":12,"googleAuthor":""},{"title":"Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer","googleId":"EEZh81WWgJ0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324184","googleCitationCount":16,"googleAuthor":"L Ermini","doi":"10.1093/annonc/mdx074","elsevierAuthor":"Alves J.M.","publicationName":"Nature Communications","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"12","altmetricAuthors":["H. Lote","I. Spiteri","L. Ermini","A. Vatsiou","A. Roy","A. McDonald","N. Maka","M. Balsitis","N. Bose","M. Simbolo","A. Mafficini","A. Lampis","J.C. Hahne","F. Trevisani","Z. Eltahir","G. Mentrasti","C. Findlay","E.A.J. Kalkman","M. Punta","B. Werner","S. Lise","A. Aktipis","C. Maley","M. Greaves","C. Braconi","J. White","M. Fassan","A. Scarpa","A. Sottoriva","N. Valeri"],"twitterCount":76,"altmetricId":16870686},{"title":"Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer","googleId":"7JP9nIFlCLUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341171","googleCitationCount":9,"googleAuthor":"FR Hirsch","doi":"10.1093/annonc/mdy196","elsevierAuthor":"Bonomi P.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"6","altmetricAuthors":["P.D. Bonomi","D. Gandara","F.R. Hirsch","K.M. Kerr","C. Obasaju","L. Paz-Ares","C. Bellomo","J.D. Bradley","P.A. Bunn Jr","M. Culligan","J.R. Jett","E.S. Kim","C.J. Langer","R.B. Natale","S. Novello","M. Pérol","S.S. Ramalingam","M. Reck","C.H. Reynolds","E.F. Smit","M.A. Socinski","D.R. Spigel","J.F. Vansteenkiste","H. Wakelee","N. Thatcher"],"twitterCount":3,"altmetricId":43728956},{"title":"A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two …","googleId":"qlQElXhg-9YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321453","googleCitationCount":16,"googleAuthor":"","doi":"10.1093/annonc/mdx202","elsevierAuthor":"Inhestern J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-08-01","elsevierCoverDisplayDate":"1 August 2017","elsevierCitationCount":"11","altmetricAuthors":["J. Inhestern","H. Schmalenberg","A. Dietz","N. Rotter","G. Maschmeyer","M. Jungehülsing","C. Grosse-Thie","T. Kuhnt","M. Görner","H. Sudhoff","C. Wittekindt","O. Guntinas-Lichius"],"twitterCount":6,"altmetricId":20104760},{"title":"Updated results from a phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with pretreated recurrent or …","googleId":"xMKTts7-O1sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49123-0/abstract","googleCitationCount":11,"googleAuthor":"S Kondo"},{"title":"Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer","googleId":"BJMq0Cpl0u0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341638","googleCitationCount":11,"googleAuthor":"JC Soria","doi":"10.1093/annonc/mdy242","elsevierAuthor":"Soria J.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"10","altmetricAuthors":["J.-C. Soria","S.N. Ho","M. Varella-Garcia","A.J. Iafrate","B.J. Solomon","A.T. Shaw","F. Blackhall","T.S. Mok","Y.-L. Wu","K. Pestova","K.D. Wilner","A. Polli","J. Paolini","S. Lanzalone","S. Green","D.R. Camidge"],"twitterCount":14,"altmetricId":45027879},{"title":"Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular …","googleId":"xrgY8xtpdQ4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39122-5/abstract","googleCitationCount":13,"googleAuthor":""},{"title":"A comparison of matched interim analysis publications and final analysis publications in oncology clinical trials","googleId":"GWZ3oyaCQh4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342346","googleCitationCount":8,"googleAuthor":"C Wayant","doi":"10.1093/annonc/mdy447","elsevierAuthor":"Wayant C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"5","altmetricAuthors":["C. Wayant","M. Vassar"],"twitterCount":6,"altmetricId":49668326},{"title":"Early-drug development in the era of immuno-oncology: are we ready to face the challenges?","googleId":"W-YwwoO5kkoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341390","googleCitationCount":9,"googleAuthor":"M Oliva","doi":"10.1093/annonc/mdy225","elsevierAuthor":"De Olza M.O.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"0","altmetricAuthors":["M. Ochoa de Olza","M. Oliva","C. Hierro","I. Matos","J. Martin-Liberal","E. Garralda"],"twitterCount":3,"altmetricId":44204639},{"title":"Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primaryEGFR mutation plus secondaryMET amplification and a novel acquired …","googleId":"Pv-ZPe7r9eQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34936-1/abstract","googleCitationCount":17,"googleAuthor":""},{"title":"Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine","googleId":"jxXQeWPfPMgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319131","googleCitationCount":18,"googleAuthor":"","doi":"10.1093/annonc/mdw440","elsevierAuthor":"Husseini F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"15","altmetricAuthors":["F. Husseini","J.-P. Delord","C. Fournel-Federico","J. Guitton","P. Erbs","M. Homerin","C. Halluard","C. Jemming","C. Orange","J.-M. Limacher","J.-E. Kurtz"],"twitterCount":1,"altmetricId":16648725},{"title":"Intratumoral heterogeneity in gastric cancer: a new challenge to face","googleId":"aaotkedc5CYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32038-1/abstract","googleCitationCount":16,"googleAuthor":"F Carneiro"},{"title":"Recommendation on testing for dihydropyrimidine dehydrogenase deficiency in the ESMO consensus guidelines for the management of patients with metastatic …","googleId":"j2ZwKY4AmmwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31925-8/abstract","googleCitationCount":18,"googleAuthor":""},{"title":"Phase 1b/2 Study (SCORES) assessing safety, tolerability, and preliminary anti-tumor activity of durvalumab plus AZD9150 or AZD5069 in patients with advanced …","googleId":"k_l-SUFn5-oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38403-9/abstract","googleCitationCount":14,"googleAuthor":"EE Cohen"},{"title":"Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a …","googleId":"mDKlvjyCsmgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934565X","googleCitationCount":10,"googleAuthor":"","doi":"10.1093/annonc/mdy113","elsevierAuthor":"Iacoboni G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"4","altmetricAuthors":["G. Iacoboni","E. Zucca","M. Ghielmini","A. Stathis"],"twitterCount":25,"altmetricId":35730251},{"title":"JNJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): An update on phase I results","googleId":"-Jcm_XzhbzsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49908-0/abstract","googleCitationCount":9,"googleAuthor":"JS Lee"},{"title":"Safety and efficacy analyses of atezolizumab in advanced non-small cell lung cancer (NSCLC) patients with or without baseline brain metastases","googleId":"ekhxv8malSoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33575-6/abstract","googleCitationCount":16,"googleAuthor":"RV Lukas"},{"title":"Nivolumab (nivo) in combination with radiotherapy (RT)±temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated …","googleId":"HNjdgIA-iB4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37748-6/abstract","googleCitationCount":14,"googleAuthor":""},{"title":"Data resources for the identification and interpretation of actionable mutations by clinicians","googleId":"D2jCzpx_UDgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320034","googleCitationCount":15,"googleAuthor":"A Prawira","doi":"10.1093/annonc/mdx023","elsevierAuthor":"Roos A.","publicationName":"Cancer Treatment and Research","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"2019","elsevierCitationCount":"1","altmetricAuthors":["A. Prawira","T.J. Pugh","T.L. Stockley","L.L. Siu"],"twitterCount":7,"altmetricId":18480522},{"title":"Phase III study of gefitinib (G) versus gefitinib+ carboplatin+ pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer …","googleId":"bU4S9l_diEsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49795-0/abstract","googleCitationCount":10,"googleAuthor":""},{"title":"OpACIN-neo: a multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO)","googleId":"FbykJDO-4GwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50443-4/abstract","googleCitationCount":11,"googleAuthor":"CU Blank"},{"title":"The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma","googleId":"fOS_3nB9Y8sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350458","googleCitationCount":12,"googleAuthor":"F Bertucci","doi":"10.1093/annonc/mdx699","elsevierAuthor":"Bertucci F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"11","altmetricAuthors":["F. Bertucci","A. De Nonneville","P. Finetti","D. Perrot","M. Nilbert","A. Italiano","A. Le Cesne","K.M. Skubitz","J.Y. Blay","D. Birnbaum"],"twitterCount":13,"altmetricId":27885093},{"title":"Durvalumab in≥ 3rd-line EGFR mutant/ALK+, locally advanced or metastatic NSCLC: results from the phase 2 ATLANTIC study","googleId":"Pp0NtP49oTkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33576-8/abstract","googleCitationCount":19,"googleAuthor":"MC Garassino"},{"title":"Networking for ovarian rare tumors: a significant breakthrough improving disease management","googleId":"3eKdtuax7AAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324287","googleCitationCount":14,"googleAuthor":"P Pautier","doi":"10.1093/annonc/mdx099","elsevierAuthor":"Chiannilkulchai N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-06-01","elsevierCoverDisplayDate":"1 June 2017","elsevierCitationCount":"13","altmetricAuthors":["N. Chiannilkulchai","P. Pautier","C. Genestie","A.S. Bats","M.C. Vacher-Lavenu","M. Devouassoux-Shisheboran","I. Treilleux","A. Floquet","S. Croce","G. Ferron","E. Mery","C. Pomel","F. Penault-Llorca","C. Lefeuvre-Plesse","S. Henno","E. Leblanc","A.S. Lemaire","G. Averous","J.E. Kurtz","I. Ray-Coquard"],"twitterCount":1,"altmetricId":18742951},{"title":"Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) …","googleId":"YQKTst0WitMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50400-8/abstract","googleCitationCount":10,"googleAuthor":"M Cristofanilli"},{"title":"Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer","googleId":"12cCb0AAurYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350082","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdx688","elsevierAuthor":"Overman M.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"0","altmetricAuthors":["M.J. Overman","L. Adam","K. Raghav","J. Wang","B. Kee","D. Fogelman","C. Eng","E. Vilar","R. Shroff","A. Dasari","R. Wolff","J. Morris","E. Karunasena","R. Pisanic","N. Azad","S. Kopetz"],"twitterCount":1,"altmetricId":27823714},{"title":"Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study","googleId":"0nx7Eh0CSvQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322689","googleCitationCount":14,"googleAuthor":"","doi":"10.1093/annonc/mdx172","elsevierAuthor":"Bourgeois H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-07-01","elsevierCoverDisplayDate":"July 2017","elsevierCitationCount":"14","altmetricAuthors":["H. Bourgeois","F. Grudé","P. Solal-Céligny","O. Dupuis","E. Voog","G. Ganem","F. Denis","M. Zinger","L. Juhel-Voog","C. Lafond","P. Maillart","O. Capitain","R. Delva","P. Soulié","S. Abadie-Lacourtoisie","V. Guérin-Meyer","M.E. Morin-Meschin","J.M. Commer","A. Gangler","B. d’Aillières","A. Zannetti","E. Bourbouloux","D. Berton-Rigault","S. Lebouvier-Sadot","M. Kaassis","J. Baudon","Y.H. Lam","A. Bizieux","M. Marcq","J. Edeline","F. Le Du","C. Lefeuvre","P. Deguiral","V. Delecroix","E. Blot","J. Egreteau","M.J. Goudier","R. Lamy","M. Ferec","X. Artignan","S. Corbinais","H. Morel","A.C. Hardy-Bessard","C. Alleaume","E. Naudeix","O. Cojocarasu","J.P. Metges","C. Riché","E. Gamelin","D. Déniel-Lagadec","F. Marhuenda","P. Ingrand","J.Y. Douillard"],"twitterCount":18,"altmetricId":19852969},{"title":"SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of …","googleId":"DPGsVv6IkmEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354766","googleCitationCount":13,"googleAuthor":"JC Soria","doi":"10.1093/annonc/mdx628","elsevierAuthor":"Soria J.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"10","altmetricAuthors":["J.-C. Soria","A. Fülöp","C. Maciel","J.R. Fischer","G. Girotto","S. Lago","E. Smit","G. Ostoros","W.E.E. Eberhardt","P. Lishkovska","S. Lovick","G. Mariani","A. McKeown","E. Kilgour","P. Smith","K. Bowen","A. Kohlmann","D.J. Carlile","P.A. Jänne"],"twitterCount":15,"altmetricId":27031983},{"title":"Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial","googleId":"ojVym39t45wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345892","googleCitationCount":14,"googleAuthor":"","doi":"10.1093/annonc/mdx406","elsevierAuthor":"Miles D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"7","altmetricAuthors":["D. Miles","Y.-H. Im","A. Fung","B. Yoo","A. Knott","S. Heeson","M.S. Beattie","S.M. Swain"],"twitterCount":10,"altmetricId":28425549},{"title":"CheckMate 227: a randomized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in …","googleId":"4RRO1dMAZIcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33638-5/abstract","googleCitationCount":15,"googleAuthor":"MD Hellmann"},{"title":"Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib+ fulvestrant: results from MONALEESA-3","googleId":"47mR_Vw6Yl4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48711-5/abstract","googleCitationCount":11,"googleAuthor":"FJ Esteva"},{"title":"Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer—a prospective evaluation of circulating tumor cells, 18F …","googleId":"a_rXeNt41CcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322501","googleCitationCount":15,"googleAuthor":"B Ma","doi":"10.1093/annonc/mdx149","elsevierAuthor":"Ma B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-30","elsevierCoverDisplayDate":"30 March 2017","elsevierCitationCount":"12","altmetricAuthors":[],"twitterCount":0},{"title":"A double-blind, placebo-controlled randomized trial of creatine for the cancer anorexia/weight loss syndrome (N02C4): an Alliance trial","googleId":"6gCl_Xz0WiEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321635","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdx232","elsevierAuthor":"Prado C.M.","publicationName":"Journal of Cachexia, Sarcopenia and Muscle","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"1 April 2020","elsevierCitationCount":"27","altmetricAuthors":["A. Jatoi","P.D. Steen","P.J. Atherton","D.F. Moore","K.M. Rowland","N.A. Le-Lindqwister","C.S. Adonizio","A.J. Jaslowski","J. Sloan","C. Loprinzi"],"twitterCount":7,"altmetricId":19944422},{"title":"A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN)","googleId":"QumaJ_MlYZkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932277X","googleCitationCount":17,"googleAuthor":"J Bellmunt","doi":"10.1093/annonc/mdx186","elsevierAuthor":"Bellmunt J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-07-01","elsevierCoverDisplayDate":"July 2017","elsevierCitationCount":"13","altmetricAuthors":["J. Bellmunt","J.M. Kerst","F. Vázquez","R. Morales-Barrera","E. Grande","A. Medina","M.B. González Graguera","G. Rubio","U. Anido","O. Fernández Calvo","E. González-Billalabeitia","A.J.M. Van den Eertwegh","E. Pujol","J.L. Perez-Gracia","J.L. González Larriba","R. Collado","M. Los","S. Maciá","R. De Wit"],"twitterCount":11,"altmetricId":19172620},{"title":"First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma","googleId":"y8LzN8HfCPcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35522-X/abstract","googleCitationCount":11,"googleAuthor":"S Turajlic"},{"title":"Phase I/II, multicenter, open-label study of intratumoral/intralesional administration of the retinoic acid–inducible gene I (RIG-I) activator MK-4621 in patients with …","googleId":"gai3XoXpTL8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50407-0/abstract","googleCitationCount":11,"googleAuthor":"E Calvo"},{"title":"Phase 2 study of neoadjuvant dabrafenib+ trametinib (D+ T) for resectable stage IIIB/C BRAF V600 mutant melanoma","googleId":"zlCUWsnz8HUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38483-0/abstract","googleCitationCount":14,"googleAuthor":"AM Menzies"},{"title":"Second or 3rd line nivolumab (Nivo) versus Nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: updated results of the IFCT-1501 MAPS2 …","googleId":"Ix9hnXD8lB8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39174-2/abstract","googleCitationCount":14,"googleAuthor":"G Zalcman"},{"title":"Efficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the …","googleId":"wrGX6_M83lEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49922-5/abstract","googleCitationCount":9,"googleAuthor":""},{"title":"A phase III study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data","googleId":"d7EHdWetjYsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49080-7/abstract","googleCitationCount":9,"googleAuthor":"YK Kang"},{"title":"Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes","googleId":"cl3P3p3lzecJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32273-2/abstract","googleCitationCount":16,"googleAuthor":"I Beh"},{"title":"How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials","googleId":"IQsfHRSLt8gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352287","googleCitationCount":14,"googleAuthor":"C Borg","doi":"10.1093/annonc/mdx191","elsevierAuthor":"Bonnetain F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"9","altmetricAuthors":["F. Bonnetain","C. Borg","R.R. Adams","J.A. Ajani","A. Benson","H. Bleiberg","B. Chibaudel","E. Diaz-Rubio","J.Y. Douillard","C.S. Fuchs","B.J. Giantonio","R. Goldberg","V. Heinemann","M. Koopman","R. Labianca","A.K. Larsen","T. Maughan","E. Mitchell","M. Peeters","C.J.A. Punt","H.J. Schmoll","C. Tournigand","A. de Gramont"],"twitterCount":1,"altmetricId":19179229},{"title":"Next-generation immunotherapies for lymphoma: one foot in the future","googleId":"9dkmkb6RV1AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355243","googleCitationCount":11,"googleAuthor":"","doi":"10.1093/annonc/mdy032","elsevierAuthor":"Manson G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"10","altmetricAuthors":["G. Manson","R. Houot"],"twitterCount":13,"altmetricId":32083075},{"title":"Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer","googleId":"uOuufzkM6ToJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349622","googleCitationCount":12,"googleAuthor":"J Bellmunt","doi":"10.1093/annonc/mdx400","elsevierAuthor":"Bellmunt J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"9","altmetricAuthors":["J. Bellmunt","B.J. Eigl","E. Senkus","Y. Loriot","P. Twardowski","D. Castellano","N. Blais","S.S. Sridhar","C.N. Sternberg","M. Retz","S. Pal","B. Blumenstein","C. Jacobs","P.S. Stewart","D.P. Petrylak"],"twitterCount":9,"altmetricId":22323706},{"title":"Avelumab treatment of metastatic urothelial carcinoma (mUC) in the phase 1b JAVELIN solid Tumor study: updated analysis with≥ 6 months of follow-up in all …","googleId":"0Fj2u2HE-GoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38129-1/abstract","googleCitationCount":14,"googleAuthor":"AB Apolo"},{"title":"Immunotherapy is not for all comers in chemotherapy-refractory advanced gastric cancer. Better predictive biomarkers are needed","googleId":"8VIe_zPSaEUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34204-8/abstract","googleCitationCount":9,"googleAuthor":"EC Smyth"},{"title":"Results of a phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head …","googleId":"qXp2ni0-4BcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49506-9/abstract","googleCitationCount":10,"googleAuthor":""},{"title":"Phase Ib study (COSMIC-021) of cabozantinib in combination with atezolizumab: Results of the dose escalation stage in patients (pts) with treatment-naïve advanced …","googleId":"DG3nr_4XfrsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49261-2/abstract","googleCitationCount":10,"googleAuthor":"N Agarwal"},{"title":"Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG)","googleId":"41POqI8UiBsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352664","googleCitationCount":18,"googleAuthor":"","doi":"10.1093/annonc/mdx334","elsevierAuthor":"Dabaja B.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"11","altmetricAuthors":["B.S. Dabaja","A.D. Zelenetz","A.K. Ng","R.W. Tsang","S. Qi","P.K. Allen","D. Hodgson","U. Ricardi","R.T. Hoppe","R. Advani","P.M. Mauch","L.S. Constine","L. Specht","Y. Li","S.A. Terezakis","A. Wirth","G. Reinartz","H.T. Eich","B.M.P. Aleman","P. Barr","J. Yahalom"],"twitterCount":2,"altmetricId":21371358},{"title":"Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas","googleId":"yLfzu97XHLAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350690","googleCitationCount":11,"googleAuthor":"LI Gordon","doi":"10.1093/annonc/mdx768","elsevierAuthor":"Karmali R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"7","altmetricAuthors":["R. Karmali","E. Kimby","M. Ghielmini","I.W. Flinn","L.I. Gordon","E. Zucca"],"twitterCount":3,"altmetricId":30290850},{"title":"Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study","googleId":"aC4gGUBb4_cJ","googleLink":"https://vbn.aau.dk/ws/files/306929894/Six_cycles_of_R_CHOP_21_are_not_inferior_to_eight_cycles_for_treatment_of_diffuse_large_B_cell_lymphoma_A_Nordic_Lymphoma_Group_population_based_study.pdf","googleCitationCount":9,"googleAuthor":"JL Biccler","doi":"10.1093/annonc/mdy184","elsevierAuthor":"Wästerlid T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"4","altmetricAuthors":["T. Wästerlid","J.L. Biccler","P.N. Brown","M. Bøgsted","G. Enblad","J. Mészáros Jørgensen","J.H. Christensen","B.E. Wahlin","K.E. Smedby","T.C. El-Galaly","M. Jerkeman"],"twitterCount":2,"altmetricId":42382662},{"title":"Open access to journal articles in oncology: current situation and citation impact","googleId":"TFbriuhi3hsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349609","googleCitationCount":14,"googleAuthor":"F Hua","doi":"10.1093/annonc/mdx398","elsevierAuthor":"Hua F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"12","altmetricAuthors":["F. Hua","H. Sun","T. Walsh","A.-M. Glenny","H. Worthington"],"twitterCount":7,"altmetricId":22537080},{"title":"A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder …","googleId":"2PulFdXf-o0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49584-7/abstract","googleCitationCount":10,"googleAuthor":"A Naing"},{"title":"MEDIOLA: a phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours–new ovarian cancer …","googleId":"YLPWSpAo1kwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48914-X/abstract","googleCitationCount":8,"googleAuthor":""},{"title":"A phase 2b of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180)","googleId":"4OicpOP0gsAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37895-9/abstract","googleCitationCount":12,"googleAuthor":"P Hammel"},{"title":"Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials","googleId":"Z7lSCNBIwzYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50283-6/abstract","googleCitationCount":8,"googleAuthor":"M Mau-Sorensen"},{"title":"Nivolumab and ISA 101 HPV vaccine in incurable HPV-16+ cancer","googleId":"L1-lRbB_dFoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38404-0/abstract","googleCitationCount":13,"googleAuthor":""},{"title":"Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib …","googleId":"v-Niy_nMe2UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49084-4/abstract","googleCitationCount":12,"googleAuthor":"PR Galle"},{"title":"Gougerot-Sjogren-like syndrome under PD-1 inhibitor treatment","googleId":"dm8nOicMgHMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35393-1/abstract","googleCitationCount":12,"googleAuthor":""},{"title":"Phase II trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC)","googleId":"3UH3BEffnpMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49083-2/abstract","googleCitationCount":8,"googleAuthor":"TY Kim"},{"title":"Afatinib (A) vs gefitinib (G) in patients with EGFR mutation-positive (EGFRm+) NSCLC: updated OS data from the phase IIb trial LUX-Lung 7 (LL7)","googleId":"sr3txyXte_kJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33587-2/abstract","googleCitationCount":16,"googleAuthor":"JCH Yang"},{"title":"A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good …","googleId":"fsVN8TFCXfYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324159","googleCitationCount":14,"googleAuthor":"SJ Sarker","doi":"10.1093/annonc/mdx071","elsevierAuthor":"Shamash J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-06-01","elsevierCoverDisplayDate":"1 June 2017","elsevierCitationCount":"8","altmetricAuthors":["J. Shamash","S.-J. Sarker","R. Huddart","S. Harland","J.K. Joffe","D. Mazhar","A. Birtle","J. White","K. Chowdhury","P. Wilson","M.R. Marshall","S. Vinnicombe"],"twitterCount":2,"altmetricId":32758244},{"title":"Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients","googleId":"dxWeF3qG5rUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32758-9/abstract","googleCitationCount":9,"googleAuthor":"K Homicsko"},{"title":"Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: results …","googleId":"GW-Lz2YKnqcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50434-3/abstract","googleCitationCount":8,"googleAuthor":"JA Ledermann"},{"title":"Updated results of phase I study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer","googleId":"fZM3KUUnHG0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49027-3/abstract","googleCitationCount":9,"googleAuthor":"S Takahashi"},{"title":"Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma","googleId":"PQhBzeopOYcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319180","googleCitationCount":15,"googleAuthor":"A Agaimy","doi":"10.1093/annonc/mdw446","elsevierAuthor":"Dieter S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"12","altmetricAuthors":["S.M. Dieter","C. Heining","A. Agaimy","D. Huebschmann","D. Bonekamp","B. Hutter","K.R. Ehrenberg","M. Fröhlich","M. Schlesner","C. Scholl","H.-P. Schlemmer","S. Wolf","A. Mavratzas","C.S. Jung","S. Gröschel","C. von Kalle","R. Eils","B. Brors","R. Penzel","M. Kriegsmann","D.E. Reuss","P. Schirmacher","A. Stenzinger","P.A. Federspil","W. Weichert","H. Glimm","S. Fröhling"],"twitterCount":7,"altmetricId":12362584},{"title":"CARRIE: A randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and …","googleId":"7awphYJB_DUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50422-7/abstract","googleCitationCount":9,"googleAuthor":""},{"title":"Adult weight gain and colorectal adenomas—a systematic review and meta-analysis","googleId":"WwO3viqyf7YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932424X","googleCitationCount":13,"googleAuthor":"L Abar","doi":"10.1093/annonc/mdx080","elsevierAuthor":"Schlesinger S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-06-01","elsevierCoverDisplayDate":"1 June 2017","elsevierCitationCount":"8","altmetricAuthors":["S. Schlesinger","K. Aleksandrova","L. Abar","A.R. Vieria","S. Vingeliene","E. Polemiti","C.A.T. Stevens","D.C. Greenwood","D.S.M. Chan","D. Aune","T. Norat"],"twitterCount":4,"altmetricId":18032742},{"title":"Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease","googleId":"Cd8LHiDHBBkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341389","googleCitationCount":10,"googleAuthor":"A Kamoun","doi":"10.1093/annonc/mdy224","elsevierAuthor":"Kamoun A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"10","altmetricAuthors":["A. Kamoun","G. Cancel-Tassin","G. Fromont","N. Elarouci","L. Armenoult","M. Ayadi","J. Irani","X. Leroy","A. Villers","G. Fournier","L. Doucet","S. Boyault","L. Brureau","L. Multigner","A. Diedhiou","M. Roupret","E. Compérat","P. Blanchet","A. de Reyniès","O. Cussenot"],"twitterCount":36,"altmetricId":44204653},{"title":"Association between immune-related adverse events and efficacy in patients treated with anti-PD-(L) 1","googleId":"Iv32EbsCZC8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49598-7/abstract","googleCitationCount":8,"googleAuthor":"S Champiat"},{"title":"Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials","googleId":"lncf11Y8bjIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321982","googleCitationCount":14,"googleAuthor":"B Gyawali","doi":"10.1093/annonc/mdw549","elsevierAuthor":"Gyawali B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"13","altmetricAuthors":["B. Gyawali","T. Shimokata","M. Ando","K. Honda","Y. Ando"],"twitterCount":52,"altmetricId":12910589},{"title":"Genetic landscape of ultra-stable chronic lymphocytic leukemia patients","googleId":"LiLrQuW9ZC4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454677","googleCitationCount":10,"googleAuthor":"J Wang","doi":"10.1093/annonc/mdy021","elsevierAuthor":"Raponi S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"10","altmetricAuthors":["S. Raponi","I. Del Giudice","M. Marinelli","J. Wang","L. Cafforio","C. Ilari","A. Piciocchi","M. Messina","S. Bonina","S. Tavolaro","M. Bordyuh","P. Mariglia","N. Peragine","F.R. Mauro","S. Chiaretti","S. Molica","M. Gentile","A. Visentin","L. Trentin","G.M. Rigolin","A. Cuneo","F. Diop","D. Rossi","G. Gaidano","A. Guarini","R. Rabadan","R. Foà"],"twitterCount":4,"altmetricId":32083070},{"title":"A phase 1b study of RXDX-105, a VEGFR-sparing potent RET inhibitor, in RETi-naïve patients with RET fusion-positive NSCLC","googleId":"yxdJD4z9aScJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39112-2/abstract","googleCitationCount":13,"googleAuthor":"AE Drilon"},{"title":"Metastasis of cancer: when and how?","googleId":"4kYscleVzb0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35264-0/abstract","googleCitationCount":12,"googleAuthor":"WC Lee"},{"title":"A phase I study of MEDI1873, a novel GITR agonist, in advanced solid tumors","googleId":"_HQWIYeHDY8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49611-7/abstract","googleCitationCount":8,"googleAuthor":"CS Denlinger"},{"title":"Analyzing biomarkers of cancer immunotherapy (CIT) response using a real-world clinico-genomic database","googleId":"_u2r8vSuugMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38407-6/abstract","googleCitationCount":11,"googleAuthor":"G Singal"},{"title":"Adherence to capecitabine in preoperative treatment of stage II and III rectal cancer: do we need to worry?","googleId":"MPfqAgcRSIwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932071X","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdx006","elsevierAuthor":"Font R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-04-01","elsevierCoverDisplayDate":"1 April 2017","elsevierCitationCount":"10","altmetricAuthors":["R. Font","J.A. Espinas","L. Layos","M. Martinez Villacampa","J. Capdevila","M. Tobeña","A. Pisa","C. Pericay","C. Lezcano","E. Fort","I. Cardona","N. Berga","J. Solà","J.M. Borras"],"twitterCount":2,"altmetricId":18066564},{"title":"Cetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy","googleId":"1cOysXW6k6IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50437-9/abstract","googleCitationCount":10,"googleAuthor":"H Mehanna"},{"title":"Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab","googleId":"NaKcqMY10I0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35379-7/abstract","googleCitationCount":12,"googleAuthor":""},{"title":"Preliminary results from subsets of patients (pts) with advanced gastric cancer (GC) and esophageal carcinoma (EC) in a dose-escalation/expansion study of BGB …","googleId":"NyEAuyJsQVIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37806-6/abstract","googleCitationCount":11,"googleAuthor":""},{"title":"IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo)+ nab-paclitaxel (nab-P) vs placebo+ nab-P in treatment-naive …","googleId":"4GqWk8juhtMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50399-4/abstract","googleCitationCount":9,"googleAuthor":""},{"title":"MSR1 repeats modulate gene expression and affect risk of breast and prostate cancer","googleId":"Qn5RhGQtpkcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345478","googleCitationCount":9,"googleAuthor":"","doi":"10.1093/annonc/mdy082","elsevierAuthor":"Rose A.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"6","altmetricAuthors":["A.M. Rose","A. Krishan","C.F. Chakarova","L. Moya","S.K. Chambers","M. Hollands","J.C. Illingworth","S.M.G. Williams","H.E. McCabe","A.Z. Shah","C.N.A. Palmer","A. Chakravarti","J.N. Berg","J. Batra","S.S. Bhattacharya"],"twitterCount":34,"altmetricId":33842672},{"title":"Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO …","googleId":"RQ3aeaGkY-wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354730","googleCitationCount":11,"googleAuthor":"","doi":"10.1093/annonc/mdx547","elsevierAuthor":"de Hosson L.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"6","altmetricAuthors":["L.D. de Hosson","L.M. van Veenendaal","Y. Schuller","W.T. Zandee","W.W. de Herder","M.E.T. Tesselaar","H.J. Klümpen","A.M.E. Walenkamp"],"twitterCount":5,"altmetricId":26597453},{"title":"German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early …","googleId":"yO3vXot4r8AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321465","googleCitationCount":12,"googleAuthor":"","doi":"10.1093/annonc/mdx203","elsevierAuthor":"Möbus V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-08-01","elsevierCoverDisplayDate":"1 August 2017","elsevierCitationCount":"10","altmetricAuthors":["V. Möbus","G. von Minckwitz","C. Jackisch","H.-J. Lück","A. Schneeweiss","H. Tesch","D. Elling","N. Harbeck","B. Conrad","T. Fehm","J. Huober","V. Müller","I. Bauerfeind","A. du Bois","S. Loibl","V. Nekljudova","M. Untch","C. Thomssen"],"twitterCount":1,"altmetricId":19778866},{"title":"Does severe toxicity affect global quality of life in patients with metastatic colorectal cancer during palliative systemic treatment? A systematic review","googleId":"1BVATlv7RFIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319520","googleCitationCount":15,"googleAuthor":"","doi":"10.1093/annonc/mdw617","elsevierAuthor":"Schuurhuizen C.S.E.W.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"11","altmetricAuthors":["C.S.E.W. Schuurhuizen","A.M.J. Braamse","I.R.H.M. Konings","M.A.G. Sprangers","J.C.F. Ket","J. Dekker","H.M.W. Verheul"],"twitterCount":6,"altmetricId":14898924},{"title":"Interim safety and clinical activity of nivolumab (nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable …","googleId":"MB_Vhe6ump0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37945-X/abstract","googleCitationCount":12,"googleAuthor":"YK Kang"},{"title":"PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P)+ trastuzumab (T) with or without chemotherapy both followed by T-DM1 in …","googleId":"CqDBCIlOHewJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48709-7/abstract","googleCitationCount":8,"googleAuthor":""},{"title":"Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO …","googleId":"UV1SvNxckN4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341262","googleCitationCount":8,"googleAuthor":"E Fokas","doi":"10.1093/annonc/mdy205","elsevierAuthor":"Hofheinz R.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"5","altmetricAuthors":["R.-D. Hofheinz","D. Arnold","E. Fokas","M. Kaufmann","T. Hothorn","G. Folprecht","R. Fietkau","W. Hohenberger","M. Ghadimi","T. Liersch","G.G. Grabenbauer","R. Sauer","C. Rödel","U. Graeven"],"twitterCount":13,"altmetricId":43450244},{"title":"Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an …","googleId":"5bgptQfyjK8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345363","googleCitationCount":9,"googleAuthor":"I Bondarenko","doi":"10.1093/annonc/mdy063","elsevierAuthor":"Martin M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"5","altmetricAuthors":["M. Martin","M. Campone","I. Bondarenko","D. Sakaeva","S. Krishnamurthy","L. Roman","L. Lebedeva","J.-C. Vedovato","M. Aapro"],"twitterCount":11,"altmetricId":33152865},{"title":"Phase I expansion of olaparib (PARP inhibitor) and AZD5363 (AKT inhibitor) in recurrent ovarian, endometrial and triple negative breast cancer","googleId":"Ghu8q0D2eMMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37810-8/abstract","googleCitationCount":11,"googleAuthor":"S Westin"},{"title":"Can the FIGO 2000 scoring system for gestational trophoblastic neoplasia be simplified? A new retrospective analysis from a nationwide dataset","googleId":"r-Lug83gR3MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321520","googleCitationCount":13,"googleAuthor":"J IntHout","doi":"10.1093/annonc/mdx211","elsevierAuthor":"Eysbouts Y.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-08-01","elsevierCoverDisplayDate":"1 August 2017","elsevierCitationCount":"6","altmetricAuthors":["Y.K. Eysbouts","P.B. Ottevanger","L.F.A.G. Massuger","J. IntHout","D. Short","R. Harvey","B. Kaur","N.J. Sebire","N. Sarwar","F.C.G.J. Sweep","M.J. Seckl"],"twitterCount":2,"altmetricId":19661277},{"title":"Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia","googleId":"fhEJJB4kmLMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355218","googleCitationCount":9,"googleAuthor":"","doi":"10.1093/annonc/mdy019","elsevierAuthor":"Khoury H.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"8","altmetricAuthors":["H.J. Khoury","C. Gambacorti-Passerini","T.H. Brümmendorf"],"twitterCount":10,"altmetricId":32327211},{"title":"Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance","googleId":"P8XvexqBV7kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319519","googleCitationCount":17,"googleAuthor":"","doi":"10.1093/annonc/mdw615","elsevierAuthor":"Bonavida B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"9","altmetricAuthors":["B. Bonavida","S. Chouaib"],"twitterCount":11,"altmetricId":13870232},{"title":"Efficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced Met+ hepatocellular carcinoma (HCC) previously treated with sorafenib","googleId":"Z7FK_hRE6tAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43119-0/abstract","googleCitationCount":7,"googleAuthor":"C Barone"},{"title":"How can molecular abnormalities influence our clinical approach","googleId":"8MbruARbqEgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420346585","googleCitationCount":9,"googleAuthor":"W Wei","doi":"10.1093/annonc/mdx447","elsevierAuthor":"Wei W.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"1 November 2017","elsevierCitationCount":"9","altmetricAuthors":["W. Wei","F. Giulia","S. Luffer","R. Kumar","B. Wu","M. Tavallai","R.T. Bekele","M.J. Birrer"],"twitterCount":0,"altmetricId":34816175},{"title":"Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern Italy","googleId":"HqdEDhcKhH8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350677","googleCitationCount":9,"googleAuthor":"P Boffetta","doi":"10.1093/annonc/mdx762","elsevierAuthor":"Boffetta P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"0","altmetricAuthors":["P. Boffetta","L. Righi","C. Ciocan","C. Pelucchi","C. La Vecchia","C. Romano","M. Papotti","E. Pira"],"twitterCount":1,"altmetricId":29979868},{"title":"Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib …","googleId":"_VChNlQP92gJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34063-3/abstract","googleCitationCount":10,"googleAuthor":"P Galle"},{"title":"Anti-CC-chemokine receptor 4 (CCR4) antibody mogamulizumab (Moga) and nivolumab (Nivo) combination phase I study in patients with advanced or metastatic …","googleId":"LE03kod8y4cJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39110-9/abstract","googleCitationCount":11,"googleAuthor":""},{"title":"Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial","googleId":"zM44t18gR_sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49393-9/abstract","googleCitationCount":7,"googleAuthor":"IL Ray-Coquard"},{"title":"Preliminary results of a phase 1A/1B study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb), in patients with advanced hepatocellular carcinoma (HCC)","googleId":"SkKTtPGi3QgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)65921-1/abstract","googleCitationCount":10,"googleAuthor":"J Kang"},{"title":"Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study","googleId":"7sVWQyyh4c0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43457-1/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"The landscape of NTRK fusions in Chinese patients with solid tumor","googleId":"sRlNzIBDgwoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48501-3/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant …","googleId":"mvXgIlqnYXQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934606X","googleCitationCount":11,"googleAuthor":"S Ladoire","doi":"10.1093/annonc/mdx487","elsevierAuthor":"Fizazi K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"9","altmetricAuthors":["K. Fizazi","A. Ulys","L. Sengeløv","M. Moe","S. Ladoire","A. Thiery-Vuillemin","A. Flechon","A. Guida","J. Bellmunt","M.A. Climent","S. Chowdhury","H. Dumez","M. Matouskova","N. Penel","S. Liutkauskiene","L. Stachurski","C.N. Sternberg","F. Baton","N. Germann","G. Daugaard"],"twitterCount":2,"altmetricId":27737046},{"title":"Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapies","googleId":"ESFT-2LgA_0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320538","googleCitationCount":15,"googleAuthor":"NA Wages","doi":"10.1093/annonc/mdw681","elsevierAuthor":"Hobbs B.P.","publicationName":"Journal of the National Cancer Institute","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"12","altmetricAuthors":["N.A. Wages","C.L. Slingluff","G.R. Petroni"],"twitterCount":2,"altmetricId":14955397},{"title":"Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine …","googleId":"nrznlVtFY6gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322616","googleCitationCount":12,"googleAuthor":"A Dasari","doi":"10.1093/annonc/mdx164","elsevierAuthor":"Peng F.","publicationName":"Colloids and Surfaces B: Biointerfaces","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0","altmetricAuthors":["C. Shen","A. Dasari","Y. Chu","D.M. Halperin","S. Zhou","Y. Xu","Y.T. Shih","J.C. Yao"],"twitterCount":4,"altmetricId":19627897},{"title":"Characterization of response to nivolumab plus ipilimumab (N+ I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc) …","googleId":"e7iXe_XL5M0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49264-8/abstract","googleCitationCount":10,"googleAuthor":"BI Rini"},{"title":"Dose-finding combination study of niraparib and pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or recurrent platinum-resistant …","googleId":"YlD0FRxHzlMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38411-8/abstract","googleCitationCount":14,"googleAuthor":"PA Konstantinopoulos"},{"title":"Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol","googleId":"FGZ0zLD2CboJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346071","googleCitationCount":10,"googleAuthor":"","doi":"10.1093/annonc/mdx488","elsevierAuthor":"Bernichon E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"10","altmetricAuthors":["E. Bernichon","A. Vallard","Q. Wang","V. Attignon","D. Pissaloux","T. Bachelot","P.E. Heudel","I. Ray-Coquard","E. Bonnet","A. de la Fouchardière","C. Faure","N. Chopin","F. Beurrier","S. Racadot","M.P. Sunyach","C. Rancoule","D. Perol","V. Corset","V. Agrapart","F. Tinquaut","J.-Y. Blay","N. Magné","O. Trédan"],"twitterCount":8,"altmetricId":24614073},{"title":"A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas","googleId":"L7sY3_utSc4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319167","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdw444","elsevierAuthor":"Agulnik M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"11","altmetricAuthors":["M. Agulnik","R.L.B. Costa","M. Milhem","A.W. Rademaker","B.C. Prunder","D. Daniels","B.T. Rhodes","C. Humphreys","S. Abbinanti","L. Nye","R. Cehic","A. Polish","C. Vintilescu","T. McFarland","K. Skubitz","S. Robinson","S. Okuno","B.A. Van Tine"],"twitterCount":8,"altmetricId":12991801},{"title":"Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID studies","googleId":"t75bdl-wglIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321507","googleCitationCount":19,"googleAuthor":"","doi":"10.1093/annonc/mdx207","elsevierAuthor":"Guo L.","publicationName":"Neoplasma","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"2018","elsevierCitationCount":"4","altmetricAuthors":["U.-P. Rohr","P. Herrmann","K. Ilm","H. Zhang","S. Lohmann","A. Reiser","A. Muranyi","J. Smith","S. Burock","M. Osterland","K. Leith","S. Singh","P. Brunhoeber","R. Bowermaster","J. Tie","M. Christie","H.-L. Wong","P. Waring","K. Shanmugam","P. Gibbs","U. Stein"],"twitterCount":4,"altmetricId":21137412},{"title":"A Phase 1/2 trial of intratumoral (it) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-(L) 1-refractory melanoma","googleId":"BXclw3d9kUcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38454-4/abstract","googleCitationCount":11,"googleAuthor":""},{"title":"Statistical controversies in clinical research: Value of adverse events relatedness to study treatment: analyses of data from randomized double-blind placebo …","googleId":"xaz0dx7r1Z8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324135","googleCitationCount":11,"googleAuthor":"","doi":"10.1093/annonc/mdx043","elsevierAuthor":"Le-Rademacher J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-06-01","elsevierCoverDisplayDate":"1 June 2017","elsevierCitationCount":"6","altmetricAuthors":["J. Le-Rademacher","S.L. Hillman","J. Meyers","C.L. Loprinzi","P.J. Limburg","S.J. Mandrekar"],"twitterCount":0,"altmetricId":49946015},{"title":"ESMO Consensus Conference on malignant lymphoma: management of 'ultra-high-risk'patients","googleId":"MiGZJQS89bAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341067","googleCitationCount":7,"googleAuthor":"M Hutchings","doi":"10.1093/annonc/mdy167","elsevierAuthor":"Hutchings M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"5","altmetricAuthors":["M. Hutchings","M. Ladetto","C. Buske","P. de Nully Brown","A.J.M. Ferreri","M. Pfreundschuh","N. Schmitz","A. Sureda Balari","G. van Imhoff","J. Walewski"],"twitterCount":38,"altmetricId":43889263},{"title":"The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients—the …","googleId":"Y3lEWPcLi_YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353888","googleCitationCount":12,"googleAuthor":"S Chauvie","doi":"10.1093/annonc/mdx524","elsevierAuthor":"Carella A.M.","publicationName":"Annals of Hematology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"1 August 2018","elsevierCitationCount":"3","altmetricAuthors":[],"twitterCount":0},{"title":"Initial results from a phase I/IIa trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer","googleId":"XZfS_yDtzlYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48878-9/abstract","googleCitationCount":9,"googleAuthor":"M Voskoboynik"},{"title":"Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic …","googleId":"pBA4_G-SPE4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49507-0/abstract","googleCitationCount":8,"googleAuthor":"EEW Cohen"},{"title":"Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell …","googleId":"EkrCO7XiilQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319702","googleCitationCount":13,"googleAuthor":"BE Chen","doi":"10.1093/annonc/mdw653","elsevierAuthor":"Davison K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"9","altmetricAuthors":["K. Davison","B.E. Chen","V. Kukreti","S. Couban","A. Benger","N.L. Berinstein","L. Kaizer","P. Desjardins","J. Mangel","L. Zhu","M.S. Djurfeldt","A.E. Hay","L.E. Shepherd","M. Crump"],"twitterCount":4,"altmetricId":14865555},{"title":"Informatics for cancer immunotherapy","googleId":"_e7NI8pTSuYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419541503","googleCitationCount":10,"googleAuthor":"J Hammerbacher","doi":"10.1093/annonc/mdx682","elsevierAuthor":"Hammerbacher J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"8","altmetricAuthors":["J. Hammerbacher","A. Snyder"],"twitterCount":2,"altmetricId":45998615},{"title":"Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99","googleId":"Ou-n1yx2_ywJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322288","googleCitationCount":14,"googleAuthor":"D Klingbiel","doi":"10.1093/annonc/mdw622","elsevierAuthor":"Pagani O.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"9","altmetricAuthors":["O. Pagani","D. Klingbiel","T. Ruhstaller","F. Nolè","S. Eppenberger","C. Oehlschlegel","J. Bernhard","P. Brauchli","D. Hess","C. Mamot","E. Munzone","B. Pestalozzi","M. Rabaglio","S. Aebi","K. Ribi","C. Rochlitz","K. Rothgiesser","B. Thürlimann","R. von Moos","K. Zaman","A. Goldhirsch"],"twitterCount":5,"altmetricId":14898919},{"title":"Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer","googleId":"s_qbrsj3-BQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355139","googleCitationCount":8,"googleAuthor":"F Khosrow-Khavar","doi":"10.1093/annonc/mdx822","elsevierAuthor":"Khosrow-Khavar F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"5","altmetricAuthors":["F. Khosrow-Khavar","H. Yin","A. Barkun","N. Bouganim","L. Azoulay"],"twitterCount":1,"altmetricId":31204468},{"title":"The effects of nurses' empathy skills on attitudes towards patients with cancer","googleId":"UGG6AApT6TgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38827-X/abstract","googleCitationCount":10,"googleAuthor":""},{"title":"Development and analytical validation of a plasma-based tumor mutational burden (TMB) score from next-generation sequencing panels","googleId":"97OmJZUbU38J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48557-8/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Coincidence of immunotherapy-associated hemophagocytic syndrome and rapid tumor regression","googleId":"oP_b8NJLFAQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31929-5/abstract","googleCitationCount":12,"googleAuthor":""},{"title":"A phase II study investigating the safety and efficacy of neoadjuvent atezolizumab in muscle invasive bladder cancer (ABACUS)","googleId":"Gg0zJkQzSaoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49288-0/abstract","googleCitationCount":8,"googleAuthor":"I Duran"},{"title":"ARIEL3: a phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC)","googleId":"X_v2ca4mOu0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39134-1/abstract","googleCitationCount":12,"googleAuthor":"J Ledermann"},{"title":"Incidence of second tumors after treatment with or without radiation for rectal cancer","googleId":"6bFFfJLDlcQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319763","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdw661","elsevierAuthor":"Rombouts A.J.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"8","altmetricAuthors":["A.J.M. Rombouts","N. Hugen","M.A.G. Elferink","T. Feuth","P.M.P. Poortmans","I.D. Nagtegaal","J.H.W. de Wilt"],"twitterCount":1,"altmetricId":16166929},{"title":"Revival of PI3K inhibitors in non-Hodgkin's lymphoma","googleId":"CEG4-ej9FiAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35270-6/abstract","googleCitationCount":9,"googleAuthor":""},{"title":"Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck?","googleId":"et0Jlf86iSwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31920-9/abstract","googleCitationCount":14,"googleAuthor":"R Danesi"},{"title":"Mildly elevated serum alpha-fetoprotein (AFP) among patients with testicular cancer may not be associated with residual cancer or need for treatment","googleId":"mSmu7NjsbngJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32077-0/abstract","googleCitationCount":14,"googleAuthor":"S Daneshmand"},{"title":"Tailoring treatment of salivary duct carcinoma (SDC) by liquid biopsy: ARv7 expression in circulating tumor cells","googleId":"sy8X2EDvFd8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32102-7/abstract","googleCitationCount":9,"googleAuthor":"C Reduzzi"},{"title":"A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer","googleId":"y984qFmMw-QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321684","googleCitationCount":11,"googleAuthor":"KL Mahon","doi":"10.1093/annonc/mdx247","elsevierAuthor":"Zhang A.Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-08-01","elsevierCoverDisplayDate":"1 August 2017","elsevierCitationCount":"8","altmetricAuthors":["A.Y. Zhang","J.S. Grogan","K.L. Mahon","K. Rasiah","P. Sved","D.R. Eisinger","J. Boulas","A. Vasilaris","S.M. Henshall","P.D. Stricker","J.G. Kench","L.G. Horvath"],"twitterCount":3,"altmetricId":20212139},{"title":"Methylation in cell-free DNA for early cancer detection","googleId":"qTUhgCxAneQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34910-5/abstract","googleCitationCount":11,"googleAuthor":"FF de la Cruz"},{"title":"Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS)","googleId":"wbzaTQ0J9fIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34064-5/abstract","googleCitationCount":10,"googleAuthor":"K Shitara"},{"title":"Cytoreductive surgery for ovarian cancer: quality assessment","googleId":"Si_wBuKzCKMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420346597","googleCitationCount":10,"googleAuthor":"","doi":"10.1093/annonc/mdx448","elsevierAuthor":"Brand A.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"1 November 2017","elsevierCitationCount":"5","altmetricAuthors":[],"twitterCount":0},{"title":"Phase I study results from an esophageal squamous cell carcinoma (ESCC) cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting …","googleId":"-dvwUuBFYzkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49104-7/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Cancer risk among 21st century blood transfusion recipients","googleId":"EFS7dJWUfUkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322033","googleCitationCount":11,"googleAuthor":"TO Yang","doi":"10.1093/annonc/mdw555","elsevierAuthor":"Yang T.O.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"7","altmetricAuthors":["T.O. Yang","B.J. Cairns","G.K. Reeves","J. Green","V. Beral"],"twitterCount":28,"altmetricId":13661015},{"title":"Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer (CC): Results from phase III ACHIEVE trial as part of the …","googleId":"02T_Qe7j9K4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39117-1/abstract","googleCitationCount":11,"googleAuthor":""},{"title":"Genetic profiling of cell-free DNA from cerebrospinal fluid: opening the barrier to leptomeningeal metastasis in EGFR-mutant NSCLC","googleId":"reiw4tDd1lQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)45491-4/abstract","googleCitationCount":8,"googleAuthor":"IV Bempt"},{"title":"Statistical controversies in cancer research: using standardized effect size graphs to enhance interpretability of cancer-related clinical trials with patient …","googleId":"VOQ_npCBWT8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321246","googleCitationCount":11,"googleAuthor":"ML Bell","doi":"10.1093/annonc/mdx064","elsevierAuthor":"Bell M.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-08-01","elsevierCoverDisplayDate":"1 August 2017","elsevierCitationCount":"8","altmetricAuthors":["M.L. Bell","M.H. Fiero","H.M. Dhillon","V.J. Bray","J.L. Vardy"],"twitterCount":2,"altmetricId":18120327},{"title":"Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors","googleId":"_NHHrFpPaNcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50440-9/abstract","googleCitationCount":7,"googleAuthor":"IM Rodas"},{"title":"A phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: Primary analysis results","googleId":"WF8ShIPo8zgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37996-5/abstract","googleCitationCount":10,"googleAuthor":""},{"title":"Genomic profiling of circulating tumour DNA (ctDNA) and tumour tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC)","googleId":"pkplFhe9OFUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49325-3/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Alectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study","googleId":"4rv899XNrSgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)56555-3/abstract","googleCitationCount":9,"googleAuthor":"S Peters"},{"title":"M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer …","googleId":"exBE5CKpzxsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43120-7/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Larotrectinib efficacy and safety in TRK fusion cancer: an expanded clinical dataset showing consistency in an age and tumor agnostic approach","googleId":"hByNxCw893MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43057-3/abstract","googleCitationCount":6,"googleAuthor":"DSW Tan"},{"title":"Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations","googleId":"FFHoMYpLHiQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49793-7/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Talimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (PTS) with …","googleId":"ILa2QrTyCNYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49701-9/abstract","googleCitationCount":7,"googleAuthor":"H Gogas"},{"title":"Improved survival in metastatic germ-cell cancer","googleId":"WoZ4C1ZU4N0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350574","googleCitationCount":8,"googleAuthor":"J Beyer","doi":"10.1093/annonc/mdx741","elsevierAuthor":"Fankhauser C.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"5","altmetricAuthors":[],"twitterCount":0},{"title":"A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer","googleId":"n76Pxji-3_YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322276","googleCitationCount":11,"googleAuthor":"","doi":"10.1093/annonc/mdw621","elsevierAuthor":"Yoshioka H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"8","altmetricAuthors":["H. Yoshioka","N. Katakami","H. Okamoto","Y. Iwamoto","T. Seto","T. Takahashi","N. Sunaga","S. Kudoh","K. Chikamori","M. Harada","H. Tanaka","H. Saito","H. Saka","K. Takeda","N. Nogami","N. Masuda","T. Harada","H. Kitagawa","H. Horio","T. Yamanaka","M. Fukuoka","N. Yamamoto","K. Nakagawa"],"twitterCount":12,"altmetricId":13613656},{"title":"Encouraging activity of novel pan-KIT and PDGFRα inhibitor DCC-2618 in patients (pts) with Gastrointestinal Stromal Tumor (GIST)","googleId":"H8YSz_xX-ywJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38723-8/abstract","googleCitationCount":12,"googleAuthor":"ARA Razak"},{"title":"Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer","googleId":"_HHU9tNetO8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34581-8/abstract","googleCitationCount":10,"googleAuthor":""},{"title":"A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC …","googleId":"Axnebzzsj1oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49405-2/abstract","googleCitationCount":7,"googleAuthor":"RE O'Cearbhaill"},{"title":"Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project","googleId":"L1EumcapPtQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349877","googleCitationCount":9,"googleAuthor":"U Dafni","doi":"10.1093/annonc/mdx629","elsevierAuthor":"Kerr K.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"7","altmetricAuthors":["K.M. Kerr","U. Dafni","K. Schulze","E. Thunnissen","L. Bubendorf","H. Hager","S. Finn","W. Biernat","L. Vliegen","J.H. Losa","A. Marchetti","R. Cheney","A. Warth","E.-J. Speel","F. Blackhall","K. Monkhorst","E. Jantus Lewintre","V. Tischler","C. Clark","J. Bertran-Alamillo","P. Meldgaard","K. Gately","A. Wrona","P. Vandenberghe","E. Felip","G. De Luca","S. Savic","T. Muley","E.F. Smit","A.-M.C. Dingemans","L. Priest","P. Baas","C. Camps","W. Weder","V. Polydoropoulou","T.R. Geiger","R. Kammler","T. Sumiyoshi","M.A. Molina","D.S. Shames","R.A. Stahel","S. Peters"],"twitterCount":6,"altmetricId":29482446},{"title":"Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)","googleId":"yo2UfzeWQ9QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49164-3/abstract","googleCitationCount":7,"googleAuthor":"T Meyer"},{"title":"Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase I clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with …","googleId":"12CcdXNKCfcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49396-4/abstract","googleCitationCount":7,"googleAuthor":"V Moreno"},{"title":"High eosinophils lymphocyte ratio (ELR) related with subtype of breast cancer in Sanglah General Hospital, Bali","googleId":"oaHWuhNvDssJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43014-7/abstract","googleCitationCount":6,"googleAuthor":"AAW Lestari"},{"title":"A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group","googleId":"FKmi36VbgvQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932023X","googleCitationCount":11,"googleAuthor":"","doi":"10.1093/annonc/mdx050","elsevierAuthor":"Kao C.Y.","publicationName":"European Journal of Cancer Care","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"1 September 2020","elsevierCitationCount":"0","altmetricAuthors":["H. Bleiberg","G. Decoster","A. de Gramont","P. Rougier","A. Sobrero","A. Benson","B. Chibaudel","J.Y. Douillard","C. Eng","C. Fuchs","M. Fujii","R. Labianca","A.K. Larsen","E. Mitchell","H.J. Schmoll","D. Sprumont","J. Zalcberg"],"twitterCount":43,"altmetricId":18483450},{"title":"Identification of a novel crizotinib-sensitive MET–ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing","googleId":"DGLcXY6_vVIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34242-5/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI) …","googleId":"TL0DYpF9zlkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38476-3/abstract","googleCitationCount":10,"googleAuthor":"J Larkin"},{"title":"Use of nivolumab in elderly patients with advanced non-squamous NSCLC: results from the Italian expanded access program (EAP)","googleId":"JeZvimCsZVcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38567-7/abstract","googleCitationCount":11,"googleAuthor":"MR Migliorino"},{"title":"Use of nivolumab in elderly patients with advanced non-squamous NSCLC: results from the Italian expanded access program (EAP)","googleId":"JeZvimCsZVcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38567-7/abstract","googleCitationCount":11,"googleAuthor":"MR Migliorino"},{"title":"A phase II study of durvalumab (MEDI4736) for previously treated patients with stage IV squamous NSCLC (SqNSCLC): Lung-MAP sub-study SWOG S1400A","googleId":"bPE6Iia7I90J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33577-X/abstract","googleCitationCount":13,"googleAuthor":""},{"title":"Phase I studies of the novel carcinoembryonic antigen T-cell bispecific (CEA-CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary …","googleId":"kxdgsEGJ8vUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37820-0/abstract","googleCitationCount":9,"googleAuthor":"NH Segal"},{"title":"Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer","googleId":"PTCfGKQDUqQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352548","googleCitationCount":10,"googleAuthor":"","doi":"10.1093/annonc/mdx303","elsevierAuthor":"Blackwell K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"8","altmetricAuthors":["K. Blackwell","P. Gascon","C.M. Jones","A. Nixon","A. Krendyukov","R. Nakov","Y. Li","N. Harbeck"],"twitterCount":4,"altmetricId":21345604},{"title":"Potent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pre-treated metastatic renal cell carcinoma (mRCC) patients (PTS)","googleId":"mp9K3_U8oL0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49271-5/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer …","googleId":"x9yg4o0qsQ4J","googleLink":"https://www.researchgate.net/profile/Arun_Azad/publication/328455745_792OA_randomized_phase_II_study_of_cabazitaxel_CAB_vs_ABI_abiraterone_or_ENZ_enzalutamide_in_poor_prognosis_metastatic_castration-resistant_prostate_cancer_mCRPC/links/5bdad964299bf1124fb20b99/792OA-randomized-phase-II-study-of-cabazitaxel-CAB-vs-ABI-abiraterone-or-ENZ-enzalutamide-in-poor-prognosis-metastatic-castration-resistant-prostate-cancer-mCRPC.pdf","googleCitationCount":7,"googleAuthor":"KN Chi"},{"title":"A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk","googleId":"YmSRDRzXQkEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322641","googleCitationCount":10,"googleAuthor":"C Bosetti","doi":"10.1093/annonc/mdx167","elsevierAuthor":"Gomez-Rubio P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-07-01","elsevierCoverDisplayDate":"July 2017","elsevierCitationCount":"10","altmetricAuthors":["P. Gomez-Rubio","V. Rosato","M. Márquez","C. Bosetti","E. Molina-Montes","M. Rava","J. Piñero","C.W. Michalski","A. Farré","X. Molero","M. Löhr","L. Ilzarbe","J. Perea","W. Greenhalf","M. O’Rorke","A. Tardón","T. Gress","V.M. Barberá","T. Crnogorac-Jurcevic","L. Muñoz-Bellvís","E. Domínguez-Muñoz","A. Gutiérrez-Sacristán","J. Balsells","E. Costello","C. Guillén-Ponce","J. Huang","M. Iglesias","J. Kleeff","B. Kong","J. Mora","L. Murray","D. O’Driscoll","P. Peláez","I. Poves","R.T. Lawlor","A. Carrato","M. Hidalgo","A. Scarpa","L. Sharp","L.I. Furlong","F.X. Real","C. La Vecchia","N. Malats"],"twitterCount":4,"altmetricId":18585918},{"title":"Copy number alterations assessed at the single-cell level revealed mono-and polyclonal seeding patterns of distant metastasis in a small-cell lung cancer patient","googleId":"O6kGfj98wNcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32274-4/abstract","googleCitationCount":10,"googleAuthor":"P Ferronika"},{"title":"Baseline corticosteroids (CS) could be associated with absence of benefit to immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) …","googleId":"pvhavE_UnJ0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38569-0/abstract","googleCitationCount":10,"googleAuthor":"L Mezquita"},{"title":"Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation …","googleId":"2KintmRMi6cJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50432-X/abstract","googleCitationCount":7,"googleAuthor":"N Colombo"},{"title":"Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC)","googleId":"otu3FOFPhCsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50260-5/abstract","googleCitationCount":6,"googleAuthor":"B Keam"},{"title":"Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA","googleId":"-iQxm-QU-O0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38060-1/abstract","googleCitationCount":10,"googleAuthor":"MS Hofman"},{"title":"Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors","googleId":"N-DJLkVNhUMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35046-X/abstract","googleCitationCount":10,"googleAuthor":"JM Michot"},{"title":"Evaluation of tumour responses and olaparib efficacy in platinum-sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the …","googleId":"o4xYEL7YA7sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38237-5/abstract","googleCitationCount":9,"googleAuthor":"J Ledermann"},{"title":"CTONG 1103: Erlotinib versus gemcitabine plus cisplatin as neo-adjuvant treatment for stage IIIA-N2 EGFR-mutation non-small cell lung cancer (EMERGING): A …","googleId":"hVhx1z_lOTcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50449-5/abstract","googleCitationCount":8,"googleAuthor":""},{"title":"Understanding patterns of pathologic response following neoadjuvant immunotherapy for solid tumors","googleId":"wZRwMlqwP8EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34141-9/abstract","googleCitationCount":7,"googleAuthor":"LM Sholl"},{"title":"Tumor molecular characteristics in patients (pts) with international metastatic renal cell carcinoma database consortium (IMDC) good (G) and intermediate/poor (I/P) …","googleId":"k0CL5401In0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49258-2/abstract","googleCitationCount":6,"googleAuthor":"G Couchy"},{"title":"64Cu-DOTA-trastuzumab PET imaging for HER2-specific primary lesions of breast cancer","googleId":"TjLd3-Ugnq4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32158-1/abstract","googleCitationCount":11,"googleAuthor":""},{"title":"Phase I extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment, in patients with advanced solid tumours","googleId":"uZZBBqJgbtUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43045-7/abstract","googleCitationCount":6,"googleAuthor":"V Subbiah"},{"title":"Phase I experience with rogaratinib in patients with head and neck cancer selected based on FGFR mRNA overexpression","googleId":"zxDOEt4tFjwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49513-6/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Rechallenge with EGFR inhibitors in patients with metastatic colorectal cancer: effect on outcomes","googleId":"P58Phs1avOkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)66092-8/abstract","googleCitationCount":9,"googleAuthor":"S Salvatore"},{"title":"M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated biliary tract cancer: Preliminary results from a …","googleId":"QFDL9MeZUX4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49218-1/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"IMpower150: an exploratory analysis of efficacy outcomes in patients with EGFR mutations","googleId":"iMyptmkb4qAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43458-3/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Statistical controversies in clinical research: comparison of primary outcomes in protocols, public clinical-trial registries and publications: the example of …","googleId":"u088u6fvZ5EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932054X","googleCitationCount":11,"googleAuthor":"AS Perlmutter","doi":"10.1093/annonc/mdw682","elsevierAuthor":"Perlmutter A.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-04-01","elsevierCoverDisplayDate":"1 April 2017","elsevierCitationCount":"11","altmetricAuthors":["A.S. Perlmutter","V.-T. Tran","A. Dechartres","P. Ravaud"],"twitterCount":45,"altmetricId":14957765},{"title":"A new ProTide, NUC-1031, combined with cisplatin for the first-line treatment of advanced biliary tract cancer (ABC-08)","googleId":"SBoGx6_4TE4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49219-3/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"A phase IIa trial to assess the safety and efficacy of BL-8040 and pembrolizumab in patients with metastatic pancreatic adenocarcinoma (PDAC)","googleId":"202ljc2qi_UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49590-2/abstract","googleCitationCount":6,"googleAuthor":"M Hidalgo"},{"title":"A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (rhabdoid tumor cohort)(NCT02601950)","googleId":"uIQHn2fE7OcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50077-1/abstract","googleCitationCount":6,"googleAuthor":"RL Jones"},{"title":"Colon cancer molecular subtype intratumoral heterogeneity and its prognostic impact: An extensive molecular analysis of the PETACC-8","googleId":"zsV_I6ViyJUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48486-X/abstract","googleCitationCount":9,"googleAuthor":"P Laurent-Puig"},{"title":"Short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR): a planned interim analysis","googleId":"7HM5X7gZd8QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48961-8/abstract","googleCitationCount":8,"googleAuthor":""},{"title":"Effects of antibiotics and proton pump inhibitors in NSCLC patients treated with atezolizumab and docetaxel: pooled analysis of the OAK and POPLAR trials","googleId":"ypuHZ3N8lJoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32664-X/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"A phase 2 study of CMB305 and atezolizumab in NY-ESO-1+ soft tissue sarcoma: Interim analysis of immunogenicity, tumor control and survival","googleId":"eh0G7pe7hdAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38730-5/abstract","googleCitationCount":10,"googleAuthor":"BA Van Tine"},{"title":"Modeling individual and relative accuracy of screening tools in geriatric oncology","googleId":"_W6gGBWE-VcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320290","googleCitationCount":10,"googleAuthor":"CA Bellera","doi":"10.1093/annonc/mdx068","elsevierAuthor":"Garcia M.V.","publicationName":"JAMA Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0},{"title":"The US Food and Drug Administration's use of regular approval for cancer drugs based on single-arm studies: implications for subsequent evidence generation","googleId":"AlKpG67mLt0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35517-6/abstract","googleCitationCount":8,"googleAuthor":"V Prasad"},{"title":"TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase …","googleId":"4W7dH3d3dywJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352524","googleCitationCount":10,"googleAuthor":"PM Specenier","doi":"10.1093/annonc/mdx300","elsevierAuthor":"Specenier P.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"12","altmetricAuthors":[],"twitterCount":0},{"title":"Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse …","googleId":"AGT8yDUzRAwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454793","googleCitationCount":5,"googleAuthor":"E Ollier","doi":"10.1093/annonc/mdy035","elsevierAuthor":"Trone J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"4","altmetricAuthors":["J.C. Trone","E. Ollier","C. Chapelle","L. Bertoletti","M. Cucherat","P. Mismetti","N. Magné","S. Laporte"],"twitterCount":10,"altmetricId":32701613},{"title":"An epidemiological insight into epithelioid sarcoma (ES): The open issue of distal-type (DES) versus proximal-type (PES)","googleId":"LGXnbdwGHyYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38736-6/abstract","googleCitationCount":9,"googleAuthor":"L Botta"},{"title":"Adding a new analytical procedure with clinical interpretation in the tool box of survival analysis","googleId":"Djaa9aJh6-0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34561-2/abstract","googleCitationCount":7,"googleAuthor":"H Uno"},{"title":"Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): efficacy and safety data","googleId":"tL0uk_KnP7IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33584-7/abstract","googleCitationCount":10,"googleAuthor":"RS Herbst"},{"title":"COMBI-AD: Adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K–mutant melanoma","googleId":"d8QJxlVJtb4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39146-8/abstract","googleCitationCount":8,"googleAuthor":"GV Long"},{"title":"Updated results of M7824 (MSB0011359C): a bifunctional fusion protein targeting TGF-β and PD-L1, in second-line (2L) NSCLC","googleId":"xtOf0Fm0HWIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49875-X/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment of minal breast cancer. Results of the UNICANCER-eoPAL study","googleId":"vlxBjswJCKQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39100-6/abstract","googleCitationCount":9,"googleAuthor":"P Cottu"},{"title":"Statistical controversies in clinical research: overlap and errors in the meta-analyses of microRNA genetic association studies in cancers","googleId":"l7iIRzX_KpsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324111","googleCitationCount":9,"googleAuthor":"JI Shin","doi":"10.1093/annonc/mdx024","elsevierAuthor":"Park J.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-06-01","elsevierCoverDisplayDate":"1 June 2017","elsevierCitationCount":"6","altmetricAuthors":["J.H. Park","M. Eisenhut","H.J. van der Vliet","J.I. Shin"],"twitterCount":2,"altmetricId":16578653},{"title":"CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence …","googleId":"zwg2g7sIzhkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49244-2/abstract","googleCitationCount":5,"googleAuthor":"M Akce"},{"title":"NCI-MATCH arms N & P: phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (Mut/del) or PTEN protein …","googleId":"WKJaqQzaQlwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48885-6/abstract","googleCitationCount":6,"googleAuthor":"O Jegede"},{"title":"Safety and efficacy of a DKK1 inhibitor (DKN-01) in combination with pembrolizumab (P) in patients (Pts) with advanced gastroesophageal (GE) malignancies","googleId":"Faa6rKSZe2sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49122-9/abstract","googleCitationCount":7,"googleAuthor":"SJ Klempner"},{"title":"Regional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO …","googleId":"iF88J9IDxPYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38485-4/abstract","googleCitationCount":9,"googleAuthor":"D Schadendorf"},{"title":"Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small …","googleId":"gcriKNabDmsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353967","googleCitationCount":7,"googleAuthor":"A Argiris","doi":"10.1093/annonc/mdx534","elsevierAuthor":"Argiris A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"5","altmetricAuthors":["A. Argiris","J.W. Lee","J. Stevenson","M.G. Sulecki","V. Hugec","N.W. Choong","J.N. Saltzman","W. Song","R.M. Hansen","T.L. Evans","S.S. Ramalingam","J.H. Schiller"],"twitterCount":5,"altmetricId":26518067},{"title":"TRIBE2: A phase III, randomized strategy study by GONO in the 1st-and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts)","googleId":"VStRIiT5upgJ","googleLink":"https://www.researchgate.net/profile/Gianluca_Masi/publication/328503649_LBA20TRIBE2_A_phase_III_randomized_strategy_study_by_GONO_in_the_1st-_and_2nd-line_treatment_of_unresectable_metastatic_colorectal_cancer_mCRC_patients_pts/links/5dd2cbc04585156b351e8234/LBA20TRIBE2-A-phase-III-randomized-strategy-study-by-GONO-in-the-1st-and-2nd-line-treatment-of-unresectable-metastatic-colorectal-cancer-mCRC-patients-pts.pdf","googleCitationCount":7,"googleAuthor":"S Lonardi"},{"title":"Population pharmacokinetic analyses for talazoparib (TALA) in cancer patients","googleId":"zdZdSBVbaGQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48898-4/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Not only tumor but also therapy heterogeneity","googleId":"yPEyYUtkJRMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34999-3/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials","googleId":"leJr73uXJtkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48725-5/abstract","googleCitationCount":6,"googleAuthor":"M Elmeliegy"},{"title":"Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor","googleId":"CsokYC2ZV6UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34197-3/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis results","googleId":"HNYnz896378J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50392-1/abstract","googleCitationCount":6,"googleAuthor":"C Hulme"},{"title":"Dietary acrylamide and the risk of pancreatic cancer in the International Pancreatic Cancer Case–Control Consortium (PanC4)","googleId":"AnNwn_WmX-4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322264","googleCitationCount":10,"googleAuthor":"C Pelucchi","doi":"10.1093/annonc/mdw618","elsevierAuthor":"Pelucchi C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"6","altmetricAuthors":["C. Pelucchi","V. Rosato","P.M. Bracci","D. Li","R.E. Neale","E. Lucenteforte","D. Serraino","K.E. Anderson","E. Fontham","E.A. Holly","M.M. Hassan","J. Polesel","C. Bosetti","L. Strayer","J. Su","P. Boffetta","E.J. Duell","C. La Vecchia"],"twitterCount":1,"altmetricId":13555664},{"title":"Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: Results from the ENGOT-OV16/NOVA Trial","googleId":"y3l9KAw-KJYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38201-6/abstract","googleCitationCount":10,"googleAuthor":""},{"title":"Interim analysis of the phase 3 ADAPT trial evaluating rocapuldencel-T (AGS-003), an individualized immunotherapy for the treatment of newly-diagnosed patients …","googleId":"Tfu1ODhXYEMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38405-2/abstract","googleCitationCount":9,"googleAuthor":""},{"title":"Chemotherapy-induced toxicity—a secondary effect caused by released DNA?","googleId":"eGkgK4xB5kEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35268-8/abstract","googleCitationCount":8,"googleAuthor":"T Helleday"},{"title":"30 months relapse-free survival, overall survival, and long-term toxicity update of (neo) adjuvant ipilimumab (ipi)+ nivolumab (nivo) in macroscopic stage III melanoma …","googleId":"uVN0BgNONXAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32759-0/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Pleural mesothelioma: is the surgeon still there?","googleId":"QHIGoicQKRUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934116X","googleCitationCount":6,"googleAuthor":"I Opitz","doi":"10.1093/annonc/mdy195","elsevierAuthor":"Opitz I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"1","altmetricAuthors":["I. Opitz","W. Weder"],"twitterCount":1,"altmetricId":73207186},{"title":"Comparison of tumor mutational burden (TMB) in relevant molecular subsets of metastatic urothelial cancer (MUC)","googleId":"Yg6wxMr9-k0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38123-0/abstract","googleCitationCount":8,"googleAuthor":"SK Pal"},{"title":"Refining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability","googleId":"F9gE0H5vyFUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50279-4/abstract","googleCitationCount":5,"googleAuthor":"J Martin-Liberal"},{"title":"Phase II study of cetuximab rechallenge in patients with RAS wild-type metastatic colorectal cancer: E-Rechallenge trial","googleId":"1b8-qnsI4g8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48947-3/abstract","googleCitationCount":6,"googleAuthor":"E Shinozaki"},{"title":"Role of industry funders in oncology RCTs published in high-impact journals and its association with trial conclusions and time to publication","googleId":"Aiy0S5jwlmkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341948","googleCitationCount":7,"googleAuthor":"L Xie"},{"title":"Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic …","googleId":"88iGymSPyOEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38964-X/abstract","googleCitationCount":9,"googleAuthor":"J Bennouna"},{"title":"Refractory or relapsed aggressive B-cell lymphoma failing (R)-CHOP: an analysis of patients treated on the RICOVER-60 trial","googleId":"4cZ6OGX6KNIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354742","googleCitationCount":9,"googleAuthor":"","doi":"10.1093/annonc/mdx556","elsevierAuthor":"Glass B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"4","altmetricAuthors":["B. Glass","A.J. Dohm","L.H. Truemper","M. Pfreundschuh","A. Bleckmann","G.G. Wulf","A. Rosenwald","M. Ziepert","N. Schmitz"],"twitterCount":5,"altmetricId":27188913},{"title":"Final results of a multi-institutional phase II trial of reirradiation with concurrent weekly cisplatin and cetuximab for recurrent or second primary squamous cell …","googleId":"79wZyRWvoQEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454665","googleCitationCount":7,"googleAuthor":"MJ Awan","doi":"10.1093/annonc/mdy018","elsevierAuthor":"Awan M.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"5","altmetricAuthors":["M.J. Awan","L. Nedzi","D. Wang","V. Tumati","B. Sumer","X.-J. Xie","I. Smith","J. Truelson","R. Hughes","L.L. Myers","P. Lavertu","S. Wong","M. Yao"],"twitterCount":2,"altmetricId":31945538},{"title":"Combined pathologic‐genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay","googleId":"Z3qZ0vRJN_0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345430","googleCitationCount":6,"googleAuthor":"M Rosman","doi":"10.1093/annonc/mdy074","elsevierAuthor":"Gage M.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"3","altmetricAuthors":["M.M. Gage","W.C. Mylander","M. Rosman","T. Fujii","F. Le Du","A. Raghavendra","A.K. Sinha","J.R. Espinosa Fernandez","A. James","N.T. Ueno","L. Tafra","R.S. Jackson"],"twitterCount":3,"altmetricId":33595236},{"title":"Pulmonary sarcomatoid carcinoma—a new hope","googleId":"sOj0Lcn0rQgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32288-4/abstract","googleCitationCount":9,"googleAuthor":"AS Mansfield"},{"title":"Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II","googleId":"z2E74tiDVPgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350471","googleCitationCount":13,"googleAuthor":"I Sestak","doi":"10.1093/annonc/mdx713","elsevierAuthor":"Sestak I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"7","altmetricAuthors":["I. Sestak","S.G. Smith","A. Howell","J.F. Forbes","J. Cuzick"],"twitterCount":27,"altmetricId":30070469},{"title":"A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial","googleId":"J8alWGTBcEQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49798-6/abstract","googleCitationCount":6,"googleAuthor":"S Peters"},{"title":"Circulating tumour DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer","googleId":"rWHYVw3pLmIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35520-6/abstract","googleCitationCount":7,"googleAuthor":"C Abbosh"},{"title":"Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of …","googleId":"WxLMgpabXVYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38119-9/abstract","googleCitationCount":8,"googleAuthor":"MO Grimm"},{"title":"Derived neutrophil-to lymphocyte ratio (dNLR) change between baseline and cycle 2 is correlated with benefit during immune checkpoint inhibitors (ICI) in advanced …","googleId":"CcVG-7Wo73wJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49819-0/abstract","googleCitationCount":5,"googleAuthor":"L Mezquita"},{"title":"Real-world data on nivolumab treatment in Asian patients with advanced hepatocellular carcinoma","googleId":"4QZ2XKqg88EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49160-6/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation …","googleId":"0u6uKKBChdQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37577-3/abstract","googleCitationCount":8,"googleAuthor":"R Gelber"},{"title":"Anti-HER2 therapy efficacy in HER2-negative metastatic breast cancer with HER2-amplified circulating tumor cells: Results of the CirCe T-DM1 trial","googleId":"UPpXznuLn40J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37611-0/abstract","googleCitationCount":8,"googleAuthor":""},{"title":"First-in-human (FIH) study of TAS-120, a highly selective covalent oral fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors","googleId":"EbajW8uk2jAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37792-9/abstract","googleCitationCount":8,"googleAuthor":"K Shitara"},{"title":"A phase I and randomized phase II trial to evaluate the efficacy and safety of nab-paclitaxel (nab-P) in combination with gemcitabine (G) for the treatment of patients …","googleId":"TMnIfTVDadYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37897-2/abstract","googleCitationCount":9,"googleAuthor":"M Hidalgo"},{"title":"Molecular characterization of epithelioid sarcoma (ES) tumors derived from patients enrolled in a phase II study of tazemetostat (NCT02601950)","googleId":"LbLRR1QH8ssJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50329-5/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"Cancer stigma related to beliefs of patients and care providers","googleId":"qEQMHjtaC9IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49997-3/abstract","googleCitationCount":5,"googleAuthor":"H Malhotra"},{"title":"Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: a retrospective analysis of the European Group for Blood and …","googleId":"wX-gArpm9VwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321714","googleCitationCount":9,"googleAuthor":"U De Giorgi","doi":"10.1093/annonc/mdx259","elsevierAuthor":"De Giorgi U.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-08-01","elsevierCoverDisplayDate":"1 August 2017","elsevierCitationCount":"8","altmetricAuthors":["U. De Giorgi","S. Richard","M. Badoglio","E. Kanfer","J.H. Bourrhis","E. Nicolas-Virelizier","K. Vettenranta","B. Lioure","S. Martin","P. Dreger","M.K. Schuler","K. Thomson","E. Scarpi","G. Rosti","F. Selle","G. Mangili","F. Lanza","M. Bregni"],"twitterCount":2,"altmetricId":20298381},{"title":"Phase II efficacy and safety data for the MET inhibitor tepotinib in patients (pts) with sorafenib-treated advanced hepatocellular carcinoma (HCC)","googleId":"IixMObcX2doJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49159-X/abstract","googleCitationCount":5,"googleAuthor":"C Barone"},{"title":"Efficacy of afatinib in the clinical practice: First results of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC in Germany","googleId":"7MAhmurffwgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49861-X/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"Immune checkpoint inhibitors-related orchitis","googleId":"k8ITcS84Td0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32066-6/abstract","googleCitationCount":10,"googleAuthor":""},{"title":"Impact of primary tumour location on survival in patients with metastatic colorectal cancer receiving selective internal radiation therapy and chemotherapy as first-line …","googleId":"3Etu5EQPAWAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)66217-4/abstract","googleCitationCount":10,"googleAuthor":""},{"title":"Association of plasma concentrations of branched-chain amino acids with risk of colorectal adenoma in a large Japanese population","googleId":"tQ2aO8U2j2MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320526","googleCitationCount":9,"googleAuthor":"S Budhathoki","doi":"10.1093/annonc/mdw680","elsevierAuthor":"Budhathoki S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-04-01","elsevierCoverDisplayDate":"1 April 2017","elsevierCitationCount":"9","altmetricAuthors":[],"twitterCount":0},{"title":"Health-related quality of life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib …","googleId":"4SACoEJs7JwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37892-3/abstract","googleCitationCount":9,"googleAuthor":"S Hudgens"},{"title":"Split dosing of daratumumab (D) in a phase 1b study of D plus carfilzomib (K)-based regimens in patients (pts) with multiple myeloma (MM)","googleId":"JVQ3nljZeOoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38269-7/abstract","googleCitationCount":8,"googleAuthor":"SZ Usmani"},{"title":"Comprehensive profiling and molecularly guided therapy (MGT) for carcinomas of unknown primary (CUP): CUPISCO: A phase II, randomised, multicentre study …","googleId":"27Fs3gJtFJsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48911-4/abstract","googleCitationCount":6,"googleAuthor":"A Krämer"},{"title":"Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma …","googleId":"0h-UvuzlqlwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50448-3/abstract","googleCitationCount":6,"googleAuthor":"N Meyer"},{"title":"The effect of loneliness on cancer mortality","googleId":"R_iMZKC-MjsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)34918-8/abstract","googleCitationCount":9,"googleAuthor":"E Ambrosini"},{"title":"Detection of somatic RAS mutations in circulating tumor DNA from metastatic colorectal cancer patients: are we ready for clinical use?","googleId":"zVN3XqkU3XgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34553-3/abstract","googleCitationCount":6,"googleAuthor":"LA Diaz"},{"title":"No benefit from the addition of anti-EGFR antibody in all right-sided metastatic colorectal cancer?","googleId":"MdtGXOMXBTkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32162-3/abstract","googleCitationCount":9,"googleAuthor":"Y Sunakawa"},{"title":"Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape","googleId":"m_HGMp3PJVoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320149","googleCitationCount":9,"googleAuthor":"DJ Vis","doi":"10.1093/annonc/mdx037","elsevierAuthor":"Stevens I.","publicationName":"PLoS Computational Biology","elsevierCoverDate":"2020-10-05","elsevierCoverDisplayDate":"5 October 2020","elsevierCitationCount":"0","altmetricAuthors":["D.J. Vis","J. Lewin","R.G. Liao","M. Mao","F. Andre","R.L. Ward","F. Calvo","B.T. Teh","A.A. Camargo","B.M. Knoppers","C.L. Sawyers","L.F.A. Wessels","M. Lawler","L.L. Siu","E. Voest"],"twitterCount":39,"altmetricId":19738161},{"title":"Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+ I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma …","googleId":"dB6_QWc55DAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49263-6/abstract","googleCitationCount":6,"googleAuthor":"BI Rini"},{"title":"Antibody therapy targeting CD19 for B-cell non-Hodgkin's lymphoma","googleId":"7b7f52cXm1IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34554-5/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Outcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced …","googleId":"2S3PhaN0jG4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49165-5/abstract","googleCitationCount":5,"googleAuthor":"T Yau"},{"title":"Outcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced …","googleId":"2S3PhaN0jG4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49165-5/abstract","googleCitationCount":5,"googleAuthor":"T Yau"},{"title":"Osimertinib treatment for patients with EGFR exon 20 insertion positive non-small cell lung cancer","googleId":"upXe_EbA6AwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49862-1/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"Oncolytic herpesvirus therapy for mesothelioma: A phase I/IIa trial of intrapleural administration of HSV1716 (NCT01721018)","googleId":"ey79iY0JZMUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37787-5/abstract","googleCitationCount":8,"googleAuthor":"S Danson"},{"title":"Phase II clinical trial of gemcitabine plus oxaliplatin combination therapy (GEMOX) in patients with advanced pancreatic adenocarcinoma with a family history of …","googleId":"SnMi6rDf79wJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49192-8/abstract","googleCitationCount":5,"googleAuthor":"S Nomura"},{"title":"Genomic medicine France 2025","googleId":"RDbuA1CJBJoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)45473-2/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Analytic validation of tumor mutational burden as a companion diagnostic for combination immunotherapy in non-small cell lung cancer","googleId":"8_GW3SVfrIMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48482-2/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"Prognostic utility of HPV specific testing in addition to p16 immunohistochemistry in oropharyngeal squamous cell carcinoma","googleId":"ys_QIPbDK_YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34198-5/abstract","googleCitationCount":6,"googleAuthor":"A Santambrogio"},{"title":"Maintenance therapy following induction chemoimmunotherapy in patients with diffuse large B-cell lymphoma: current perspective","googleId":"P-Ks0EaXmAYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345843","googleCitationCount":8,"googleAuthor":"C Thieblemont","doi":"10.1093/annonc/mdx358","elsevierAuthor":"Reddy N.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"3","altmetricAuthors":["N.M. Reddy","C. Thieblemont"],"twitterCount":2,"altmetricId":27685268},{"title":"Chemotherapy in end-of-life care","googleId":"0ijitt8KcDoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32081-2/abstract","googleCitationCount":9,"googleAuthor":""},{"title":"Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer (mCRC): preliminary results from the phase IIIb, international, open-label …","googleId":"86URG_FAnVgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33699-3/abstract","googleCitationCount":6,"googleAuthor":"A Falcone"},{"title":"Navigating the highlights of phase III trials: a watchful eye on evidence-based radiotherapy","googleId":"zrZ_uQm9JgQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934582X","googleCitationCount":7,"googleAuthor":"","doi":"10.1093/annonc/mdx347","elsevierAuthor":"Trone J.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"5","altmetricAuthors":["J.C. Trone","S. Espenel","A. Rehailia-Blanchard","E. Guillaume","N. Vial","C. Rancoule","C. Rodriguez-Lafrasse","M. Ben Mrad","A. El Meddeb Hamrouni","E. Ollier","C. Chargari","E. Deutsch","A. Vallard","N. Magné"],"twitterCount":9,"altmetricId":21904508},{"title":"Adjuvant GEMOX for biliary tract cancer: Updated relapse-free survival and first overall survival results of the randomized PRODIGE 12-ACCORD 18 (UNICANCER GI) …","googleId":"5mMsK0b0gc8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39121-3/abstract","googleCitationCount":7,"googleAuthor":"J Edeline"},{"title":"Plasma cell-free DNA (cfDNA) assays for early multi-cancer detection: the circulating cell-free genome atlas (CCGA) study","googleId":"7eINOEgSKLwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48476-7/abstract","googleCitationCount":5,"googleAuthor":"MC Liu"},{"title":"RAISEing VEGF-D's importance as predictive biomarker for ramucirumab in metastatic colorectal cancer patients","googleId":"ZanpkEJT3NcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35523-1/abstract","googleCitationCount":5,"googleAuthor":"P Carmeliet"},{"title":"The future of UK healthcare: problems and potential solutions to a system in crisis","googleId":"-IzjfJM0DHkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321295","googleCitationCount":9,"googleAuthor":"A Haines","doi":"10.1093/annonc/mdx136","elsevierAuthor":"Dineen-Griffin S.","publicationName":"PLoS ONE","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"17","altmetricAuthors":["H.E. Montgomery","A. Haines","N. Marlow","G. Pearson","M.G. Mythen","M.P.W. Grocott","C. Swanton"],"twitterCount":10,"altmetricId":19737782},{"title":"An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab …","googleId":"0oHUCn9zIS8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346083","googleCitationCount":7,"googleAuthor":"JC Soria","doi":"10.1093/annonc/mdx489","elsevierAuthor":"Temam S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"6","altmetricAuthors":["S. Temam","J. Spicer","F. Farzaneh","J.C. Soria","D. Oppenheim","M. McGurk","A. Hollebecque","J. Sarini","K. Hussain","S. Soehrman Brossard","L. Manenti","S. Evers","P. Delmar","L. Di Scala","C. Mancao","F. Feuerhake","L. Andries","M.G. Ott","A. Passioukov","J.P. Delord"],"twitterCount":3,"altmetricId":28714863},{"title":"Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC) …","googleId":"1Aijnu-5Ks0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49409-X/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Atezolizumab+ bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma: The randomised phase III study IMbrave150","googleId":"MDhk9wDWOy4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49243-0/abstract","googleCitationCount":7,"googleAuthor":"MP Ducreux"},{"title":"Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study","googleId":"PMETrGgHENgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319659","googleCitationCount":8,"googleAuthor":"C Oing","doi":"10.1093/annonc/mdw648","elsevierAuthor":"Oing C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"8","altmetricAuthors":["C. Oing","K. Oechsle","A. Necchi","Y. Loriot","U. De Giorgi","A. Fléchon","G. Daugaard","M. Fedyanin","E. Faré","C. Bokemeyer"],"twitterCount":3,"altmetricId":17853024},{"title":"Analysis of POLE mutation and tumor mutational burden (TMB) across 80,853 tumors: Implications for immune checkpoint inhibitors (ICPIs)","googleId":"FcE-ZlFJ3xsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38437-4/abstract","googleCitationCount":7,"googleAuthor":"AB Schrock"},{"title":"PROCLAIM-CX-2009: A first-in-human trial to evaluate CX-2009 in adults with metastatic or locally advanced unresectable solid tumors","googleId":"FRGL0rbIaSYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37839-X/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors","googleId":"xYQDpFz2FJQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34602-2/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"A phase 3 study of first-line durvalumab vs platinum-based chemotherapy in patients with advanced NSCLC and high PD-L1 expression: PEARL","googleId":"RQphHGK1WZoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38623-3/abstract","googleCitationCount":7,"googleAuthor":"S Clarke"},{"title":"Detection of EGFR T790M in Asia-Pacific patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): circulating tumour (ct) DNA …","googleId":"sJinVWgMwIkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38577-X/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) …","googleId":"medh-4M0SdEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352627","googleCitationCount":8,"googleAuthor":"A Psyrri","doi":"10.1093/annonc/mdx320","elsevierAuthor":"Psyrri A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"6","altmetricAuthors":["A. Psyrri","C. Fortpied","G. Koutsodontis","M. Avgeris","C. Kroupis","N. Goutas","J. Menis","L. Herman","L. Giurgea","É. Remenár","M. Degardin","I.S. Pateras","J.A. Langendijk","C.M.L. van Herpen","A. Awada","J.R. Germà-Lluch","H.R. Kienzer","L. Licitra","J.B. Vermorken"],"twitterCount":0,"altmetricId":23586127},{"title":"Comparative molecular analysis between microsatellite instability-high (MSI-H) tumors with high tumor mutational burden (TMB-H) versus MSI-H tumors with TMB …","googleId":"ZRds5-27lJUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50273-3/abstract","googleCitationCount":6,"googleAuthor":"A Puccini"},{"title":"M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with post-platinum esophageal adenocarcinoma (EAC): Preliminary …","googleId":"CILzF8eBg4QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49105-9/abstract","googleCitationCount":5,"googleAuthor":"A Khattak"},{"title":"TRIUMPH Study: A multicenter phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive …","googleId":"5TuNu7z-q38J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39097-9/abstract","googleCitationCount":8,"googleAuthor":""},{"title":"Kinase fusions in colorectal cancers: a unique biologic subset","googleId":"WUq5GpjCnUkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48923-0/abstract","googleCitationCount":6,"googleAuthor":"F Pietrantonio"},{"title":"Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC)","googleId":"CqE-zjVeDAMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50464-1/abstract","googleCitationCount":6,"googleAuthor":"DS Tan"},{"title":"Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet","googleId":"GNc_h7abBzgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35001-X/abstract","googleCitationCount":6,"googleAuthor":"AJ Armstrong"},{"title":"A large retrospective multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancer with microsatellite instability","googleId":"jM8f4rr55NQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39019-0/abstract","googleCitationCount":7,"googleAuthor":"D Tougeron"},{"title":"Final analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen+/-gonadotropin …","googleId":"PB265SW4nzYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50398-2/abstract","googleCitationCount":4,"googleAuthor":"M Reinisch"},{"title":"Genetic variations in cancer-related significantly mutated genes and lung cancer susceptibility","googleId":"ldcm9ADMJfcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322586","googleCitationCount":7,"googleAuthor":"Y Zhang","doi":"10.1093/annonc/mdx161","elsevierAuthor":"Zhang Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-07-01","elsevierCoverDisplayDate":"July 2017","elsevierCitationCount":"6","altmetricAuthors":["Y. Zhang","L. Zhang","R. Li","D.W. Chang","Y. Ye","J.D. Minna","J.A. Roth","B. Han","X. Wu"],"twitterCount":2,"altmetricId":18583192},{"title":"A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults: Epithelioid sarcoma cohort (NCT02601950)","googleId":"JXEhguGzaDsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50080-1/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"Immunosenescence (iSenescence) correlates with disease progression in advanced non-small cell lung cancer (aNSCLC) patients treated with PD-(L) 1 inhibitors (IO …","googleId":"miDYMwHljw8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49828-1/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Identification of adenosine pathway genes associated with response to therapy with the adenosine receptor antagonist CPI-444","googleId":"95qOOxbOaIAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49594-X/abstract","googleCitationCount":5,"googleAuthor":""}]